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 Abstract 
Lentiviral vectors are increasingly used as delivery methods in gene therapy 
clinical trials due to their high efficiency transducing cells and stability of 
transgene expression. The development of packaging and producer cell lines for 
the production of lentiviral vectors has always been a labour-intensive and 
lengthy process. Sequential introduction of vector components, adaptability to 
suspension cultures, autotransduction and genetic, transcriptional or cell line 
growth instability are some of the limitations that cause significant drops in 
productivity. Improved transcription of self-inactivating vectors leading to high 
titers has been attempted in different ways with the intent to find a high stable 
producer clone. 
In this project, we studied the use of lentiviral vectors as a tool to target and 
identify high-transcribing loci in the genome of our host cells for lentiviral 
packaging cell line development. Third generation lentiviral vectors carrying 
eGFP under the control of an endogenous clinically-tested promoter (short EF1α) 
were produced, containing a variable DNA sequence tag (barcode) in their long 
terminal repeat (LTR). The aim of the barcode is to uniquely tag, identify and track 
a particular clone within the heterologous expressing population. Human 
embryonic kidney cell lines (HEK-293) were transduced with a barcoded 
lentiviral library at a low multiplicity of infection. We demonstrated that 
integration site analysis and next-generation sequencing of lentiviral barcoded 
vector junctions by ligation-mediated PCR (LM-PCR) coupled with RNA-Seq 
allows for quantification of the relative abundance of each barcode variant in each 
specific genomic position. Expression cassettes containing lentiviral vector 
components were then site-specifically integrated into these genomes sites using 
the CRISPR-Cas9 technology. 
 The barcoding lentiviral system allows for rapid and high-resolution high-
throughput screening of gene expression in a large number of genomic positions 
naturally targeted for optimal vector expression but also of lower expressing sites 
in order to meet lentiviral cytotoxicity and stoichiometric constraints.  
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RT   Reverse transcription/reverse transcriptase or room 
temperature (25oC) 
RTC   Reverse transcription complex 
RV    Retrovirus or retroviral  
RVV    Retroviral vectors 
R1 or R2  NGS read1 or read2 dataset  
S   Guanine or cytosine  (G or C in IUPAC nomenclature) 
SA   Suspension adapted 
SBE    Society for Biological Engineering  
SD or s.d.   Standard deviation  
SE   Single end 
seBFP   strongly enhanced BFP 
SFDA    State Food and Drug Administration 
SFFV   Spleen focus-forming virus 
SFV   Semliki Forest virus 
sgRNA   Single guide RNA 
SIN   Self Inactivating 
SINE   Short interspersed elements 
S/MAR  scaffold/matrix attachment region 
SMRT   Single-molecule real-time 
SOC   Super optimal broth with catabolite repression 
SF   Serum free  
SFFV    Spleen focus-forming virus 
SP2/0   Cell line from murine myeloma 
ss    Single stranded 
SU   Surface protein 
SV40   Simian virus 40 
SYNT   Synthetic 
T   Thymine 
TAE   Tris-acetate-EDTA 
TALENs  Transcription activator-like effector nucleases 
TAR   Trans-activation response element 
Tat   Transactivator protein 
Tas   Transactivator of spumavirus 
TCA   Tricarboxylic acids 
TCL   Temperature cycling ligation 
TCR   T-cell receptor 
TE   Transfection efficiency of Tris-EDTA 
Tet   Tetracycline 
Tet   tetracycline repressor 
TK   Thymidine kinase 
TIL   Tumour infiltrating lymphocytes 
TM   Transmembrane protein 
TPA    Tissue plasminogen activator 
tracrRNA  Trans-activating crRNA  
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TRE   Tet regulatory element 
TSS   Transcription start sites 
tTA   Tetracycline-controlled transactivator 
TU    Transducing units 
TV   Transfer vector 
U    Unit 
UCL   University College London 
UCOE    Ubiquitous chromatin opening element 
UCSC   University of California Santa Cruz 
UCLA   University of California Los Angeles 
U3    Unique at 3’ region  
U5    Unique at 5’ region  
UT    Untransduced  
UTR   Untranslated terminal repeat  
UV    Ultraviolet  
V    Volt 
VacV, VV  Vaccinia virus 
VISA   Vector Integration Site Analysis 
vLB    Vegitone lysogeny broth  
Vpr   Viral protein R 
Vpu   Viral protein U 
Vpx   Viral protein X 
v/v   Volume/volume 
VSV-G    Vesicular stomatitis virus glycoprotein  
W   Adenine or thymine (A or T in IUPAC nomenclature) 
WAS   Wiskott Aldrich syndrome 
WHV   Woodchuck hepatitis virus 
WPRE   Woodchuck hepatitis virus posttranscriptional pegulatory 
element 
w/v   Weight/volume  
w/w   Weight/ weight 
X-CGD   X-linked chronic granutomalous disease 
XGPRT   Xanthine-guanine phosphoribosyltransferase 
X-SCID   X-linked severe combined immunodeficiency 
Zeo   Zeocin 
ZFN    Zinc finger nuclease 
ZFP   Zinc finger protein 
+ve   Positive 
-ve   Negative 
-d   Distance (Starcode parameter) 
-r   Ratio (Starcode parameter) 
ψ   Packaging signal 
Ω   Ohms 
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Chapter 1  
INTRODUCTION 
1.1 Lentiviral gene therapy and packaging cell lines 
1.1.1 A brief overview of the history of gene therapy 
Long before the concept of the gene was discovered, the human race has 
intentionally bred animals and plants with the intent of achieving more 
productive specimens and consequently meet the increasing nutritional 
demands.  This early form of genetic engineering (or selection) has persisted over 
generations as discussed in the Sixth International Congress of Genetics in 1932 
in Ithaca1. With the discovery of gene transmission via nucleic acids by Avery et 
al., in 19442 and the posterior discovery of the structure of DNA by Watson, Crick 
(and Franklin) in 19533,4, the use of genetic concepts changed the scope towards 
a potential therapeutic application. As Avery stated in his article: “Biologists have 
long attempted by chemical means to induce in higher organisms predictable and 
specific changes which thereafter could be transmitted in series as hereditary 
characters”. Such chemical means turned out to imply viruses when some authors 
demonstrated their ability to transfer genes into bacterial host genomes (i.e., 
Salmonella and bacteriophages)5. These findings were extended to animal cells 
when Rous sarcoma virus (RSV) and Simian virus (SV40) viral genes were found 
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to be responsible for cell transformation. In 1966, Edward Tatum speculated 
about the potential of this tool affirming that “viruses will be effectively used for 
man’s benefit, in theoretical studies in somatic-cell genetics and possibly in genetic 
therapy…”  
Although the terms ‘gene surgery’ and ‘gene therapy’ were originally coined in 
the early 1960s, the genetic code, recombinant DNA and prokaryotes relegated 
the general interest to the end of the next decade. Nonetheless, a first (and 
premature) early approach of gene therapy was put into practice in the late 1960s 
when Rogers et al., treated hyperargininaemia patients with whole Shope 
papilloma virus arguing that the viral genome contained a copy of the arginase 
gene6,7. However, the experiment did not show any influence on the metabolic 
profile of the patients8. From the 1970s, the recombinant DNA era revolutionised 
the field and provided the tools to feasibly develop conceptual gene engineering. 
The improvement in the knowledge of molecular genetics and gene delivery 
methods such as with calcium phosphate9 and the subsequent proof-of-concept 
in vitro correction of hypoxanthine-guanine phosphoribosyl transferase  (HPRT) 
deficient cells10 (although its efficiency was not sufficient for treating patients) as 
well as the general acceptance that viruses could be used for therapeutic use led 
to a new reconsideration of the potential of gene therapy. A clear reflection of that 
perception was the title of Anderson’s article “Gene therapy in human beings: 
When is it ethical to begin?”11 
In a study that was probably considered ahead of its time, the controversial ‘Cline 
experiment’ demonstrated the first non-viral gene therapy clinical trial published 
in Nature in 1980.  His team transfected bone marrow cells with the beta-globin 
gene using the calcium phosphate technique and transplanted them back into 
patients12. Although the theoretical key principles behind this approach were 
reasonable, the experiment provided no meaningful data and such practices were 
methodologically and scientifically questioned13,14 (costing him his chairmanship 
at UCLA and his NIH funding) and highlighted the important role of regulatory 
agencies on the authorization of such practices in the clinic. Proof of this was the 
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creation of the DNA Advisory Committee of the NIH, in 1974, to specifically 
regulate any activities derived from the use of DNA as a therapeutic tool. 
During the 1980s, and thanks to the advances in the understanding of molecular 
biology of retroviruses (in particular the discovery of RNA polymerase by 
Mizutani Temin and Baltimore in 197015,16), the first retroviral vectors were 
developed and demonstrated efficacy in complementing patient cells defective in 
HPRT17,18 and two years later in ADA-SCID models19. The first attempt to utilise 
vector-mediated gene-modified cells in humans took place in 1998; Rosenberg et 
al., demonstrated safety and feasibility in patients with advanced melanoma that 
were successfully treated using retrovirally marked tumor-infiltrating 
lymphocytes (TIL) with a gene conferring resistance to G418 (a neomycin 
analogue)20. In the 1990s, a better understanding of viral vectors combined with 
the expertise acquired in DNA-manipulating techniques made researchers raise 
expectations that gene therapy would eventually provide a safe and feasible 
alternative to allogeneic bone marrow transplant for the treatment of hereditary 
monogenic diseases (when there is no suitable donor match). Blaese and 
Anderson (NIH, 1990) and Bordignon and Mavilio (HSR-TIGET, 1992) performed 
the first approved clinical trials using retroviral-mediated gene transfer of the 
adenosine deaminase (ADA) gene in T cells and peripheral blood lymphocytes 
(and hematopoietic stem cells), respectively. Both attempts led to short-term 
immune system reconstitution and temporary response although the treatment 
was not completely curative since the patients continued requiring enzyme 
replacement therapy21,22.  
A few years later, the death of 18 year-old patient Jesse Gelsinger (suffering from 
a mild ornithine transcarbamylase deficiency) as a result of adenoviral vector-
associated toxicity and subsequent multi-organ failure struck the gene therapy 
scientific community and caused a great stir in the media. The investigation 
revealed serious violations on the reporting of previous adverse events 
incompatible with the inclusion criteria of the clinical trial and resulted in serious 
fines and other consequences for the leading researchers and institutions23. 
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In the next decade, gene therapy treatment for X-linked severe combined 
immunodeficiency (X-SCID) resulted in the sustained expression of the functional 
IL-2 common γ-chain receptor (IL2RG) followed by consequent successful 
repopulation of the patient’s bone marrow and restoration of the immune 
function24. However, early successes were also accompanied by serious side 
effects derived from the integration properties of gamma-retroviral vectors used 
for the gene delivery. Cavazzana-Calvo’s team reported the onset of leukaemia in 
five of the twenty patients (of whom one died) as a consequence of insertional 
mutagenesis of murine leukaemia gamma-retroviral vector in the LMO2 proto-
oncogene leading to its activation and T-cell proliferation. Similar results were 
obtained in the British clinical trial led by Thrasher and Gaspar25. The Jesse 
Gelsinger case and the lethal case of leukaemia highlighted the need for greater 
vigilance, safety studies and investigation into any potential adverse effects 
associated to viral vectors. 
The monogenic nature of primary immunodeficiencies makes them attractive 
targets for gene therapy. Although allogeneic haematopoietic stem cell 
transplantation provides a curative option and new protocols are reducing the 
effects of conditioning chemotherapy and graft-versus host diseases, gene 
therapy has demonstrated to be an efficacious alternative, especially for patients 
for whom HLA–matching donors are not available. Autologous transplantation of 
stably genetically modified hematopoietic stem/progenitor CD34+ cells has been 
able to treat a sizable number of hereditary rare diseases within the last 25 years. 
In the Italian trial led by Roncarolo and Bordignon, patients with adenosine 
deaminase deficiency (ADA-SCID) with no enzyme replacement therapy available 
responded satisfactorily to engraftment of engineered HSC with non-
myeloablative conditioning and did not present any adverse effects after up to 15 
years of follow-up. Moreover, polyethylene glycol–modified bovine ADA (PEG-
ADA) discontinuation (3 months after reinfusion) favoured the selective 
outgrowth of transduced T lymphocytes, which led to sustained immune function 
restoration26,27. Similar results were observed in the parallel British clinical 
trial28. Diseases affecting the myeloid compartment such as X-linked chronic 
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granulomatous disease (X-CGD) have also been successfully treated; two adults 
received retroviral transfer of gp91phox that restored the oxidative antimicrobial 
activity of phagocytes29. In the case of X-linked adrenoleukodystrophy, a fatal 
brain demyelinating disease, Cartier et al., demonstrated safety and efficacy using 
3rd generation lentiviral vectors to complement the ABCD1 faulty gene and 
maintain ALD protein expression up to 16 month post-infusion30. More prevalent 
inherited diseases like beta-haemoglobinopathies –affecting adult age patients- 
have also benefited from gene therapy. Trials for beta-thalassemia have showed 
promising results after 33 months following HMGA2 gene transfer using lentiviral 
vectors. Recently, two more Phase I/II trials using lentiviral vectors have 
approached the treatment of Wiskott–Aldrich syndrome (WAS)31 and 
metachromatic leukodystrophy (MLD) ex vivo32. ProSavin® vector has been used 
for the in vivo treatment of Parkinson disease (PD)  in a Phase I/II trial33. The 
successful application of retroviral vetors has subsequently led to significant 
milestone of GSK releasing Strimvelis®, a commercial retroviral gene therapy 
product for ADA-SCID primary immunodeficiency34 in 2016. Previously, only 
UniQure’s Glybera®, a variant (Ser447X) of the human LPL gene under the control 
of the CMV promoter transferred using recombinant adeno-associated virus type 
1 (rAAV1) vector, had received market authorisation in 2012 for a subcohort 
group of patients with severe pancreatitis attacks. However, the lack of demand 
forced UniQure to withdraw Glybera® from the market. Other gene therapy 
products approved by Chinese regulatory agencies comprise Gendicine®  (SiBiono 
GenTech) a recombinant adenoviral p53 (rAd-p53) gene-replacement for head 
and neck squamous cell carcinoma or Oncorine® (a recombinant oncolytic human 
adenoviral vector type 5, rAd5) for nasopharingeal carcinoma in 2005 by 
Shanghai Sunway Biotech. Besides the aforementioned products, only the 
Russian Neovasculgen® (intramuscular injection of a plasmid encoding the pCMV-
vegf165 cassette, carrying vascular endothelial growth factor) to treat peripheral 
arterial disease (PAD, including atherosclerotic lower limb ischemia) received 
national marketing authorization in 201235. More recently, BioVex/Amgen 
released OncoVex/T-Vec® (talimogene laherparepvec, an oncolytic HSV) in 2015 
for the treatment of advanced melanoma.  
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1.1.2 Vectors as tools for gene delivery 
Considering the wide range of potential applications with an increasing demand 
that gene therapy is required to address, this technology faces several conceptual 
and technical limitations. Although the efficiency of gene delivery of a therapeutic 
gene to a population of dividing and non-dividing cells remains as the main 
concern, current drawbacks also comprise the sustainability of expression in the 
target tissue, potential adverse events derived from insertional mutagenesis of 
integration vectors (also referred as genotoxicity), the potential host immune 
response and the high costs associated to solve the aforementioned 
complications. In order to provide efficient and safe gene delivery of the 
therapeutic gene in different medical contexts, different types of viral and non-
viral vectors have been engineered and developed to fulfil the conditions of each 
treatment.  
In general, non-viral methods (grouped in naked DNA, cationic lipids and 
molecular conjugates) are easier to produce and scale up36, allow larger genetics 
payloads and present lower immunogenicity and carcinogenesis as no integration 
of the transgene into the host genome occurs. Nonetheless, one of the main 
challenges to overcome in order to augment the current (21%) representation in 
on-going clinical trials is the low gene delivery efficacy together with poor 
nanoparticle stability37. However, as most of the current approaches use viral 
vectors, we will focus the scope of this research study on them. 
Viruses have naturally evolved to target cells and transfer their gene content to 
be replicated. Transduction of viral vectors enables highly efficient gene transfer 
with a lower impact on the cell physiology and viability of the target cells. In 
addition, some viral (and modifiable) surface molecules confer specific tropism. 
Non-essential cis viral components have been replaced with therapeutic cassettes 
for viral delivery. A number of virus families have been explored for gene delivery 
Adenoviruses are linear dsDNA viruses that can infect both dividing and non-
dividing cells and cause common upper respiratory infections in humans. First 
generation replication-deficient adenoviral vectors (ADV, Ad) were first 
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engineered by replacing the E1 protein with the gene of interest and can be 
prepared at concentrations higher than other vectors (1011 - 1012 particles per 
mL)38. Three generations of adenoviral vectors have been generated by deleting 
viral genes (also termed gut-less or gutted) showing higher capacity (up to 36kb), 
extended expression periods and reduced immune response. ADV are 
characterised by being capable of inducing a potent immune response and thus, 
short-term expression, which make them useful for cancer applications. The first 
trial approved using Ad (in which Jesse Gelsinger took part) was for the delivery 
of the OTC (ornithine transcarbamoylase) gene39. 
Vaccinia virus (VV or VacV) is a dsDNA virus, member of the orthopoxviridae 
family that has shown promise in in vivo gene delivery applications. VV remains 
episomal and its arrest of the host protein machinery function allows it to form 
mature virions 4-6 hours post-infection. Its broad tropism, high capacity and 
levels of transgene expression compensate the large size of viral particles and 
make it a good candidate for gene therapy treatment for cancer40. Like 
herpesviruses, poxviruses have been used as oncolytic vectors for the treatment 
of cancer. Oncolytic viruses selectively replicate in cancer cells directly inducing 
their lysis or triggering an immune modulatory response towards cancer cells. 
Moreover, additional selective targeting can be achieved by genetic engineering 
of the vector. Despite the entry pathway driving hepatic tropism of VV has not 
been characterised in detail to date, heparan sulfate proteoglycans have been 
suggested as potential receptors. Oncolytic viral products like JX-594 (by 
Jennerex) armed with granulocyte macrophage colony stimulating factor (GM-
CSF) successfully completed Phase II trials for hepatocellular carcinoma41.  
Herpes Simplex Viruses (HSV) have also been extensively used as gene transfer 
vector. Their broad tropism, very high packaging capacity (the viral genome is 
153kb) and its ability to transduce dividing and quiescent cells (especially 
neurons) have attracted the interest of researchers for the treatment of 
neurological disorders. In addition to that, the vector remains episomally 
recircularised in the nucleus and is thought to replicate as a concatemer via a 
rolling circle-like mechanism42. Different types of HSV-1 vectors exist: (i) 
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replication defective rHSV-1 vectors lack essential replication genes, which are 
provided in trans by the cell line, (ii) attenuated rHSV-1 carry deletions in non-
essential genes that hamper their replication in vivo but not in vitro. (iii) HSV-1-
derived amplicon vectors are a safer approach since the amplicon plasmid only 
contains an origin of viral replication, a packaging signal as well as the cassette of 
interest. Therefore, replication, structural and packaging proteins must be 
supplied in trans by a helper/packaging cell line (lacking packaging signal). The 
historical concern in HSV has been the presence of contaminating helper viruses 
in vector stocks, which can induce immune responses.  
Adeno-associated viruses (AAV) are 25nm, non-enveloped ssDNA virus, members 
of the Parvoviridae family and not currently known to be pathogenic for humans. 
Their genome consists of two ORFs (cap and rep) that contain the genes 
responsible for viral replication (normally replaced with transgene for gene 
therapy applications) flanked by 145-bp inverted terminal repeats (ITRs). 
Cap/rep-deficient AAVs require helper functions to be provided in trans 
(adenovirus or herpes simplex virus) to enable the expression of the cap gene and 
thus synthesis of the capsid proteins43. Recombinant adeno-associated viral 
(rAAV) vector production is commonly achieved by cell lysate harvest 72 hours 
prior to triple transfection into human embryonic kidney (HEK) 293 cells. 
Following promising clinical trials results, type 1 rAAV encoding for the LPLS447X 
gene variant became the first commercially available gene therapy product 
(alipogene tiparvovec or Glybera® by UniQure) in the Western world after the 
approval from the European Union in October, 2012 for the treatment of familial 
lipoprotein lipase deficiency suffering from pancreatitis attacks. rAAVs have also 
demonstrated their clinical efficacy and safety in the treatment of cystic fibrosis44, 
Leber’s congenital amaurosis type 245, choroideremia46, and hemophilia B47 and 
other neurological disorder due to its ability to travers the blood brain barrier. 
However, among their downsides limited capacity (5kb) and the pre-existing 
immunity to some AAV serotypes48. Recently, in a controversial article, insertional 
mutagenesis caused by AAV2 vectors has been shown to result in hepatocellular 
carcinoma49, contrary to the safe profile associated to AAV vectors. 
Chapter 1. Introduction  
 30 
Among retroviruses, gamma-retroviruses are historically the most widely used 
for gene therapy applications, mainly for the availability of cell lines for their 
production. Gamma-retroviruses differ from lentiviruses in several ways. Splicing 
is regulated by the formation of a secondary structure in the RNA upstream of the 
major splice donor, which results in 2 species of mRNA50, rev protein is not 
required to export unspliced mRNA51. In terms of viral integration, gamma-
retroviruses also integrate in gene-rich regions but, unlike lentiviruses, they do 
not interact with LEDGF/p75, which shifts their integration pattern towards the 
body of actively transcribed genes52. Gamma-retroviruses cannot pass through 
the nucleopore and thus require nuclear envelope breakdown to access the cell 
genome. As a consequence, they cannot infect non-dividing cells and integrate 
more frequently in cell cycle-related genes. Gamma-retroviruses display a more 
genotoxic integration profile as a result of the positional effect of the vector 
components. Upon integration of a retroviral vector, the activity of the internal 
promoter or 5’LTR  U3 promoter/enhancer  vector regions (if the vector is not 
self-inactivated) can induce the expression of proto-oncogenes located upstream 
or downstream of the vector 53. Alternatively, the integration of the vector within 
a tumor suppressor gene can disrupt its function might also trigger tumor 
activity. 
Foamy viruses (FV) are members of the Spumaretrovirinae subfamily that owe 
their name to the appearance of cells under cytopathic effect54. Their life cycle is 
particularly different from the other retroviruses because its reverse 
transcription takes place during viral assembly prior to the budding of the viral 
particle55. This allows for longer persistence of infective dsDNA, especially in 
quiescent target cells. However, FV can also transduce non-dividing cells as 
nuclear membrane breakdown is not required for the FV pre-integration complex 
to enter the nucleus56. FVs mediate nuclear export of mRNAs through interaction 
of constitutive transport element with NXF1 and NXT1 transporter proteins and 
the interaction of a viral mRNA element with kariopherin CRM1 via a virus 
encoded protein57. Besides gag, pol and env, FV genome also contains an internal 
promoter located in the env gene driving basal expression of tas (TransActivator 
of Spumavirus, or bel-1) and bet accessory genes. While bet participates in the 
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inhibition of APOBEC3 cell restriction factors58, tas acts as a transactivator of 
transcription59. Vectorisation of FVs includes the removal of tas and bet accessory 
genes and separation of the packaging genes into several helper plasmids60. 
Interestingly, gag and pol can be provided from separate plamids, as they are 
translated from different viral RNAs and its relative expression is not regulated 
by a ribosomal frameshift as in other retroviruses61. 
Alpha-retroviruses mainly differ from lenti- and gamma-retroviruses in their 
integration preferences. The integration profile of alpha-retroviruses is more 
neutral and does not favour gene-rich regions, transcription units or TSS, which 
makes them attractive candidates for gene therapy in the future62. However, a 
model for alpha-retroviral integration or the existence of a tethering protein that 
modulate their integration profile are yet to be discovered.  
Non-HIV lentiviruses such as bovine immunodeficiency virus (BIV), caprine 
arthritis-encephalitis virus (CEAV), feline immunodeficiency virus (FIV), simian 
immunodeficiency virus (SIV) and equine infectious anaemia virus (EIAV) have 
also given rise to lentiviral vector systems. However, only the latter has been used 
by Oxford Biomedica for the treatment of Parkinson’s disease, due to its no-
association to any disease in humans63. The vector contains three genes encoding 
for the critical enzymes involved in the production of dopamine (tyrosine 
hydroxylase, aromatic L-amino acid decarboxylase and guanosine 5'-
triphosphate cyclohydrolase 1). 
From the molecular biology prespective, non-HIV lentiviruses share most of their 
features with HIV, with only a few differences. EIAV possesses three accessory 
proteins (Tat, rev and S2) compared to the seven proteins present in HIV-1. S2 
protein contributes to viral replication and its removal reduces the virulence of 
the infection although its function is poorly understood64. Differences between 
HIV and FIV comprise its cell entry through CD134 receptor instead of CD465 and 
rev gene overlaps and shares reading frame with env (like BIV and CEAV)66. Also, 
unlike primate lentiviruses, FIV infection is not limited by the presence of 
tetherin67; tetherin binds viral particles to the cell membrane to prevent further 
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infection. Another difference found in FIV compared to primate lentiviruses is the 
sequence homology between both polypurine tracts68. SIV follows a different 
pathway to enter the nucleus69 and shares low homology with HIV, reducing the 
risks of recombination. 
Finally, HIV-1 derived lentiviral vectors (derived from lentiviruses and thus 
retroviruses) were used in this study and thus will be explained in more detail in 
the Section 1.1.3.  
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Table 1.1. Characteristics of the main vectors used in gene therapy. 
 
 
*** if rep protein present, into AAVS1 site, chr19 q13.4; ** concentrated; * gutless ADV 1 although no genotoxic events seen; 2 integration pattern more random than 
lentivirus; CNS,  central nervous system; PI, primary immunodeficiencies. 
Vector Gamma-retroviral Lentiviral Vaccinia Adenoviral AAV Herpes viral Naked/plasmid DNA 
Nucleic acid form ssRNA ssRNA dsDNA dsDNA ssDNA dsDNA dsDNA 
Size of the particle 100nm 100nm 360 × 270 × 250nm 90-100nm 25nm 120-300nm 10-100nm 
Maximum insert 
size 
8-10kb 8-10kb 25kb 35kb* 5kb 152-155kb Unlimited 
Enveloped Yes Yes Yes No No Yes NA 
Titer (TU/mL) >109** >109** >109 >1011 >1012 >1012 No limitation 
Transduce non-
dividing cells 
No Yes No Yes Yes Yes Yes 
In/Ex vivo 
applications 
Ex vivo Ex vivo Ex/in vivo Ex/In vivo Ex/In vivo Ex/In vivo Ex/In vivo 
Integration Yes Yes No No No/(Yes***) No No 
Duration of 
expression 
Long Long Short >1year <1year >6 months Short 
Scale up 
adaptability 
Pilot scale up Not tested Easy Easy Difficult  Difficult Easy 
Immunological 
problems 
Few Few Extensive Extensive Not known Few None 
Pre existing host 
immunity 
Unlikely Unlikely Yes Yes Yes Yes No 
Main limitation 
Insertional 
mutagenesis 
Insertional 
mutagenesis1  
Inflammatory 
response, toxicity 
Inflammatory response, 
toxicity of the capsid 
Capacity. Immune 
response in 2nd dose 
Inflammatory response, 
toxicity 
Low efficacy 
Main application PI PI Cancer Cancer Retina, CNS, liver, muscle CNS 
Various (mainly 
cancer) 
Use in clinical trials 18.4% 5% 7.2% 22.2% 6% 2.9% 17.4% 
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1.1.3 Lentiviral vectors 
Lentiviral genome and structure 
Lentiviral vectors are derived from lentiviruses that belong to the Retroviridae 
family. Retroviruses are enveloped 100nm diameter viruses that possess 2 copies 
of +ssRNA in their virion form. Out of the 7 genera of retroviruses comprising 
alpha-, beta- delta-, epsilon-, spuma- gamma- and lenti- (retro)viruses, the latter 
two (detailed in Table 1.1) have been used for gene therapy. The different genera 
differ in morphology, integration profile, genomic complexity and structure. 
Given their use in this study, lentiviral vectors will be covered in detail. 
Lentiviruses, like all other retroviruses, are characterised by their replicative 
strategy, which requires reverse transcription of its viral RNA in order to integrate 
into the host cell genome as a proviral dsDNA fragment. The virus indefinitely 
persists in the host and uses the host’s expression machinery to express viral 
genes. Viral particles are budded using the host cell membrane as envelope. The 
genome of lentiviral virions is composed of 2 molecules of positive strand RNA 7-
10kb in length. Unlike gamma-retroviral vectors, lentiviral pre-integration 
complexes possess the singular feature of being able to actively traverse the 
nuclear envelope and therefore integrate into the genome of dividing and non-
dividing (quiescent) cells70,71. Another distinctive characteristic is the high 
efficiency displayed and the ability to transduce a wider range of cell types. 
The genome of a complex retrovirus can be divided into coding and non-coding 
sequences. The coding sequences contain the group-specific antigen (gag) 
proteins that form the structural components of the virion (capsid CA, matrix MA, 
nucleocapsid NC and p6), the protease (PR) that catalyses gag and pol polyprotein 
cleavage during viral maturation, pol proteins responsible for the viral enzymes 
(integrase IN and reverse transcriptase RT) and env proteins (surface SU and 
transmembrane TM) that confer the virus the ability to enter cells. The functions 
of regulatory proteins encoded by the genes rev (regulator of virion) and tat 
(trans-activator of transcription) and accessory proteins (vpr, vpu, vif, nef) are 
described in more detail the Section 1.1.3 (‘Molecular biology of HIV’ subsection).   
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Non-coding sequences include the long terminal repeats, which in turn are 
subdivided into U3 (unique in 3’), R (repeat) and U5 (unique in 5’) regions 
(named after their exclusivity on one of the ends of the viral RNA). The U3 region 
(455bp) has enhancer/promoter activity for the expression of viral transcripts72. 
The R region (95bp) acts as a polyadenylation signal (AAUAAA) in the 3’LTR, and 
coordinates reverse transcription together with the 5’LTR R region. The U5 region 
(81bp) helps processing the preceding polyadenylation signal73. Following 5’ to 
3’ direction, the primer binding site (PBS) is a cis-regulatory sequence that binds 
18bp in the tRNALys3, which primes extension of the DNA minus strand during 
reverse transcription74,75. The packaging signal (Ψ) allows encapsidation of full-
length RNA transcripts into virions76. The central polypurine tract (cPPT, located 
in the IN region of the pol gene)77 and the polypurine tract (located upstream of 
the 3’LTR) are 16bp-priming regions that enable the extension of the DNA plus 
strand during reverse transcription78.  
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Figure 1.1. Schematic of the structure of a mature HIV-1 virion and expression of lentiviral 
genes. 
Transmembrane glycoprotein (TM); surface glycoprotein (SU); matrix (MA); protease (PR); capsid 
(CA); nucleocapsid (NC); integrase (IN); reverse transcriptase (RT); long terminal repeat (LTR); 
unique in 3’ (U3); repeat (R); unique in 5’ (U5); trans-activator of transcription (tat); regulator of 
virion (rev); negative regulatory factor (nef); viral protein R (vpr); viral protein U (vpu); group-
specific antigen (gag); polymerase (pol); envelope (env); Spacer peptide 1 (SP1); Spacer peptide 
2 (SP2).  
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Molecular biology of HIV-1 
Transcription of integrated proviral DNA 
The 5’LTR U3 region contains enhancer/promoter sequences that enable RNA 
polymerase II to drive the expression of viral transcript from the integrated 
proviral dsDNA. In the absence of Tat, hypophosphorylation of RNApol II79 results 
in transcription of short and unpolyadenylated transcripts. However, 
phosphorylation of the C-terminal of RNA pol II prevents premature transcript 
termination, enabling the expression of regulatory proteins Tat, Rev, Nef80. Trans-
activating factor Tat feeds back the phosphorylation of RNA pol II through its 
binding to transcription factor II H81. In turn, Tat binds to the transactivation-
responsive (TAR) stem-loop in the RNA and recruits cyclin T1 and Cdk9, which 
also hyperphosphorylate RNApolII to mediate elongation of HIV mRNA79. Over 40 
alternative spliced forms of RNA derived from four splice donors and eight splice 
acceptors are translated giving rise to multiple viral proteins. However, they can 
be grouped in unspliced 9kb genomic RNA, the 4kb incompletely/partially spliced 
mRNAs (comprising vif, vpr, env/vpu and tat exon 1) and the 1.8kb completely 
spliced mRNAs (comprising tat exon 1-2, rev and nef). Control over the splicing is 
finely regulated by the strength of splice donors and acceptors and additionally 
by intronic and exonic splicing silencers and enhancers. At this point, lentiviral 
RNA represents about a 1% of the total cellular RNA82. However, expression of 
viral RNA is not detectable if the virus persists latently in a cell reservoir83.  
Latency is a reversibly non-productive state of infection that the virus can 
undergo after infection. Pre-integration latency allows persistence of 
unintegrated forms in the cytoplasm of CD4+ T cells for one day although cannot 
form long-term reservoirs84. Post-integration latency consists of a state of 
reversible blockage of expression of viral genes at a transcriptional level due to 
several potential mechanisms: chromatin structure at the site of integration, 
nuclear architecture/chromosomal disposition, transcriptional interference, 
transcription factors or repressors, concentration of tat, epigenetics85. 
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Several regulatory elements mediate the addition of the polyA tail upon 
recognition of a polyadenylation signal (AAUAAA) located in the R region of the 
LTR. The U3 and 5’ side of nef gene contain a upstream enhancer elements that 
promote recognition by the cleavage/polyadenylation specificity factor86. Binding 
of factors to the secondary structure favour the access to the 3’LTR polyA87. U1 
snRNP splicing factor binds 5’polyA site precluding its use88. 
Nuclear export of viral RNA 
Unspliced mRNA and partially spliced RNA species (4kb transcripts encoding 
accessory proteins), are exported to the cytoplasm in a process mediated by 
Rev89. Cooperative oligomerisation of Rev protein on the Rev responsive element 
(RRE) stem–loop present in the env region of spliced mRNA and mediate nuclear 
export through the nuclear pore complex with the participation of Ran-GTP and 
Cellular exportin-1 (Crm-1)90,91 owing to a 10 amino acid nuclear export signal 
rich in leucines92. Once in the cytoplasm, the GTP of the former is hydrolysed to 
GDP by Ran GAP and Ran BP1, which dissociates the complex and enables return 
of Rev to the nucleus93. Fully-spliced HIV-1 RNAs are not retained in the nucleus 
and follow the cellular RNA export pathway. 
Translation of viral proteins 
Unlike cellular mRNAs, translation of HIV-mRNAs is not initiated at the first AUG 
from the 5’ end due to the presence of secondary structures (TAR, PBS, 5’ polyA 
and packaging signal) precluding it. Initiation of translation can take place either 
via cap- or IRES-dependent mechanism. The cap mechanism requires 12 eIF and 
the interaction of the eIF2 GTP Met-tRNAMeti ternary complex with the complex 
formed by the 40S ribosome and 3 eukaryotic initiation factors (eIFs)94. The IRES 
mechanism relies on the secondary structure of these sequences located in the 
5’UTR and in the gag coding region but also on their interaction with the 40S 
subunit and IRES trans-acting factors95. However, the mechanism of translation 
initiation through IRES is not completely understood96.  
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The env gene is translated from spliced mRNA in the rough endoplasmic 
reticulum and glycosylated to gp160 glycoprotein in order not to be recognised 
by neutralising antibodies97. Unspliced gag mRNA is translated by polyribosomes 
into Gag p55 polyprotein. Gag-pol is also translated from unspliced mRNA and 
also contains reverse transcriptase (RT or p51/p66). Gag-pol polyprotein is 
translated from the same unspliced mRNA as gag at a lower frequency. A slippery 
hexanucleotide followed by a stem-loop pseudoknot at the end of NC protein 
ORF98 increases the chances of frameshift to 5-10%99. The consequent 1:20 
gag:gag-pol ratio is critical for infectivity100. As a result the ribosome reads 
through the gag stop codon and translation of gag-pol polyprotein containing the 
viral enzymes protease (PR or p10), integrase (IN or p32), and reverse 
transcriptase occurs.  
Accessory proteins are also synthesized from spliced mRNA and, among other 
functions, participate in the neutralisation of host restriction factors. The 
dimerization domain of viral infectivity factor (vif) is involved in neutralisation 
of the APOBEC3G host factor101. The function of this host factor is to prevent 
retroviral replication by deaminating cytidine residues during reverse 
transcription, which causes detrimental mutations in the proviral genome. 
Similarly, in HIV-2 and SIV, vpx counteracts the action of SAMHD1 restriction 
factor102. The dNTPase activity of SAMHD1 protects the cells from viral infection 
by reducing the levels of nucleotides in order to inhibit reverse transcription. 
Viral protein R (vpr) has been associated with multiple functionalities involving 
facilitation of reverse transcription, nuclear import of HIV-1 PIC, transcription 
and has also been reported as toxic inducing cellular apoptosis103. Viral protein U 
(vpu) and negative regulatory factor (nef) downregulate the expression of CD4 
cell receptor preventing the interaction between premature envelope protein and 
its receptor104,105. Vpu also interacts with tetherin host restriction factor 
mediating its degradation106.  
Assembly, maturation and budding 
Assembly of immature viral particles lasts approximately 10 minutes107 and is 
mainly mediated by polyprotein Gag, which in turn is cleaved to give rise to Matrix 
Chapter 1. Introduction  
 40 
(MA or p17), Capsid (CA or p24), Nucleocapsid (NC or p7, separated by p2 and p1 
spacer peptides) and p6 proteins108. MA contributes to the assembly via 
myristoylation of Gag N-terminus, which in addition to its membrane binding 
domain triggers its targeting to the cell membrane109. In addition, MA also 
recruits Env protein110. MA and CA mediate protein interaction and virion 
stabilisation111. Highly basic NC recognises the 4–hairpin secondary structure of 
the packaging signal (Ψ) and allows packaging of two molecules of 
polyadenylated and capped full size ssRNA virion genome together with the 
LysRS/tRNALys packaging complex. LysRS interacts with C-terminal domain of 
Gag protein and IN-RT-PR polyprotein, which also interacts with tRNALys3. C-
terminal domains of different Gag and Gag-pol proteins also interact. The 
stoichiometry within the tRNALys packaging complex is 12:4:1:8 Gag:gag-pol: 
LysRS:tRNALys3 112,113. Protein p6 also participates in virion budding by 
interacting with IN-RT-PR polyprotein and mediating incorporation of viral 
accessory proteins like vpr114. Spacer peptides SP1 and SP2 help accommodating 
the conformational changes occurring during these processes115. Mature 
transmembrane Env protein is glycosylated in the Golgi and transported to the 
membrane through the cellular secretory pathway. During this process cleavage 
of the gp160 polyprotein in the Golgi by furin-like proteases gives rise to the 
surface (SU, gp120) and transmembrane (TM, gp41) mature glycoproteins116. SU 
and TM are then delivered to the cell membrane to become part of the viral 
particles. Maturation does not conclude prior to viral budding. When the viral 
particle is budded, dimerisation of the protease causes its activation through a 
mechanism that is not well understood. As a consequence, the nine peptide bonds 
contained in the gag and gag-pol polyproteins are cleaved by the viral protease 
(PR) to give rise to CA, MA, NC, p6 and PR, RT and IN mature enzymes. Polyprotein 
proteolysis is necessary to yield mature infective virions.  
Virion budding is mediated by the host endosomal-sorting complex required for 
transport (ESCRT) machinery. Briefly, p6 binds to ALIX and TSG101 proteins, 
which trigger recruitment of VPS4 ATPases and ESCTR-III complexes creating a 
‘dome’ that induces a fission of the membrane neck110.  
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Viral entry  
Following non-specific interactions with negatively charged heparan sulfate 
proteoglycans and more specific interactions with α4β7 integrin117 or DC-SIGN118, 
viral entry is mediated through the specific interaction between the viral 
envelope protein and the human receptor CD4 in T lymphocytes and 
macrophages. The viral envelope protein is composed of three transmembrane 
(TM) gp41 non-covalently bound to trimeric forms of gp120 surface (SU) 
glycoproteins. Interaction between CD4 receptor and gp120 SU glycoprotein 
induces conformational changes in gp41 and gp120, which allow binding of the 
gp120 variable loop 3 with CCR5 (predominantly found in macrophages) or 
CXCR4 (mainly in hematopoietic progenitor cells) chemokine co-receptors 
binding site119,120. Such interaction triggers rearrangement within gp41 resulting 
in insertion of a fusion peptide into the target cell membrane and the formation 
of a six-helix bundle and ultimately the fusion of the virion and host cell 
membranes121.  
Uncoating and cytosolic transport 
HIV-1 core uncoating occurs in the cell cytoplasm between viral entry and the 
nuclear import of reverse transcribed dsDNA and other proteins of the PIC. The 
stages and mechanism of the uncoating process is not well understood. Three 
models have been proposed to explain the CA disassembly during the uncoating 
process. The early immediate uncoating model supports complete CA 
disassembly right after membrane fusion and virion entry and the migration 
through the nucleopore of a reverse transcription complex (RTC) devoid of CA122. 
The RTC is a transitory structure consisting of MA, CA, NC, IN, Vpr and RT whose 
function is to enable reverse transcription of the viral RNA in the cytoplasm prior 
to transition into pre-integration complex (PIC) for nuclear import and proviral 
integration. The cytoplasmic uncoating model suggests a progressive process 
where CA is removed in the cytoplasm and highlights the role of remaining CA 
associated with the RTC mediating interaction with host factors and nucleopore 
complexes123. The nucleopore uncoating model suggests complete CA removal in 
the nucleopore complex, protecting the RTC from cytosolic DNA sensing pathway 
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proteins124,125. Experimental evidence of CA associated with PIC in the nucleus 
reinforces the two latter models123,126. 
Viral proteins also interact host proteins during the uncoating process; for 
example, peptidyl-prolyl isomerase Cyclophilin A (CypA) binds to CA and protects 
the viral DNA genome enhancing its replication127. The transport of RTC/PIC is 
mediated by the interaction of viral proteins with actin microfilaments and 
microtubules. Diffusion of DNA macromolecules is a slow and random process 
due to the steric hindrance occurring between the molecules present in the 
cytoplasm128. Transport of RTC/PIC structures is actively mediated through actin 
filaments (using myosin VI complexes129) and the microtubules tubuline130 (using 
dynein complexes, mechanism also observed in other viruses)131,132 from the cell 
membrane and to the nuclear envelope  
Reverse transcription 
Reverse transcription constitutes one of the defining features of retroviruses and 
is an essential step in viral replication. This process is carried out by the two 
subunits of the reverse transcriptase heterodimer: p66 subunit, which contains 
two domains that play the catalytic roles and the p51 subunit whose four 
subdomains have structural function. Within the p66 subunit, RNAse H domain, 
that allows degradation of RNA in DNA-RNA hybrids and DNA polymerase domain 
allows DNA synthesis and elongation from RNA and DNA templates133. Within the 
50 molecules of RT present in a virion, RT with defective p66 or p51 activity can 
complement each other and restore the infective phenotype, indicating that they 
interact in a cooperative manner134. 
During uncoating MA, NC, vpr, RT and IN remain associated with the tRNALys3 and 
the viral genome RNA in the RTC while reverse transcription takes place135. 
Reverse transcription of lentiviral vectors is initiated when the host-derived 
tRNALys3 serves as a primer and hybridises the primer binding site (PBS). The 
choice of host tRNA can vary among retroviruses. DNA synthesis creates a short 
(-) single strand of DNA from the PBS in the 5’LTR upstream to the 5’ R136. This 
DNA fragment (tRNALys3-U5-R DNA) undergoes strand transfer and primes the R 
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regions in the 3’LTR for the synthesis of the remaining a full-length (-) genome 
single strand of DNA up to the 5’ end of the viral RNA genome (until the PBS, 
included). RNase H activity of the RT cleaves the RNA from the DNA–RNA hybrid 
except a purine-rich PPT137, which primes initiation of synthesis of the DNA (+) 
strand. Synthesis of the DNA (+) strand commences towards the 3’LTR using the 
(-) strand as a template.  Formation of cPPT DNA-RNA and tRNA-DNA duplexes 
allow the degradation by RNAse H activity138. Then, (+) strand transfer and 
hybridisation of primer binding sites from both strands allow bidirectional 
elongation of both DNA strands ending with U3-R-U5 regions on both LTRs139. 
Renda et al., demonstrated that methylation of the adenosine58 residue in 
tRNALys3 (1-methyladenosine 58, m(1)A58) is required to stop elongation of (+) 
strand during reverse transcription140.  The reverse transcription takes place in 
the cytoplasm and is completed when all RNA has been reverse transcribed to 
dsDNA and the RTC gives rise to pre-integration complexes (PIC). PICs are 
integration competent complexes in vitro 140,141. 
 
Figure 1.2. Schematics of the retroviral reverse transcription process. 
Dark blue line represents DNA and light blue represent RNA. Dashed light blue line represents 
degradation of the RNA strand by RNAse H. primer binding site (PBS); long terminal repeat (LTR); 
unique in 3’ (U3); repeat (R); unique in 5’ (U5); group-specific antigen (gag); polypurine tract 
(ppt); polymerase (pol); envelope (env). Figure extracted from Hu and Hugher 2012135. 
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Nuclear import 
Unlike γ-retroviruses, which require nuclear envelope dismantlement to access 
the nucleus, lentiviral vector PIC can actively enter the nuclear envelope through 
nucleopore complexes and thus can transduce dividing and non-dividing cells. 
The ability of the PIC to traverse the nuclear envelope barrier was thought to be 
due to the IN (through interaction with Nup153 and their nuclear localisation 
sequences, NLS)141,142, Vpr and MA (through two weak NLS)143,144 and the cPPT. 
However, depletion of cPPT145, Vpr (in the third generation lentiviral vectors146) 
and IN and MA nuclear localisation signals proved their role is not essential in 
nuclear entry147. Dispensability of karyophilic components is thus controversial 
since the virus is still able to replicate but nuclear import kinetics are 
considerably affected by the removal of some of  these components148. Instead, 
CA protein has been shown to play a crucial role in nuclear import149; MLV 
CA/HIV-1 chimeras showed significantly impaired nuclear import. However, 
although it is known that TNPO3150 is involved, the mechanism by which this 
occurs is not well understood151. 
Several cellular proteins have also been shown to be implicated in HIV-1 nuclear 
import such as α2 Rch1152, importin 7153 and transportin SR-2 (also called 
TNPO3)154 and several nucleoporines. Nucleoporine 358 (Nup358 358kDa, also 
called RanBP2), Nup153 and Nup98 mediate uncoating and active transport of 
the PIC into the nucleus155. Nup358 has also been implicated with target site 
preference156,157.
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Figure 1.3. Stages of the HIV-1 life cycle.  
CD4, cluster of differentiation 4; CCR5, chemokine receptor type 5; PIC, Pre-integration complex; LTR, long terminal repeat; rev, regulator of virion; nef, negative 
regulatory factor; vpr, viral protein R; vpu, viral protein U; gag, group-specific antigen; pol, polymerase. Modified from Engelman and Cherepanov 2012158.
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1.1.4 Lentiviral integration 
Proviral integration constitutes another essential step in retroviral replication. In 
this step, linear proviral double stranded DNA is covalently inserted into the host 
chromosomal DNA by the viral integrase. Viral DNA serves as a template to 
generate either mRNA and subsequently viral proteins or unspliced genomic RNA 
for future virions. 
Integrase protein 
 Viral integration is catalysed by the integrase in a complex process that involves 
viral and host proteins. Integrase (IN) was first described as a non-specific 
endonuclease in avian myeloblastosis virus159. Its function was confirmed when 
knock-out of certain residues blocked viral replication160. HIV integrase (IN) is a 
32kDa non-specific endonuclease protein whose sequence shares homology with 
the avian sarcoma virus (ASV) reverse transcriptase161 but also RNAse H and 
RuvC resolvase and Mu transposase162.  This protein is encoded and translated 
from the gag-pol open reading frame and processed by the viral protease (PR) to 
its mature form. The 50 amino acid N-terminal is composed of 3 alpha-helixes 
with a HHCC motif that when coordinated with zinc acts as a DNA binding 
domain163,164. The 160-amino acid central core domain is composed of a mixed 
alpha-helix and β-sheet165 and contains the catalytic function. Extensive 
mutational and substitution analysis performed on the catalytic core revealed 
that the D64, D116 and E152 triad (in HIV) is functionally critical166,167. The 80-
amino acid C-terminal domain possesses a nuclear localization signals and a 5-
stranded β-barrel conforming a SH3-like domain whose function is DNA 
binding168,169. Experiments combining truncated C- or N- terminal domains imply 
that all three domains are likely to form dimers independently and that IN acts as 
a dimer or a higher order multimer170,171. Crystallization of the FV IN revealed the 
interaction between the N-terminal and the catalytic core of monomers forming 
a dimer and these in turn homotetramer structures172. 
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Together with the retroviral DNA, viral proteins including matrix (MA)173, reverse 
transcriptase (RT)174 nucleocapsid (NC)175 and cellular proteins like barrier to 
autointegration factor (BAF)176 and high-mobility-group (HMG-I(Y))177, the 
integrase protein (IN) form the pre-integration complex (PIC). HMGs are DNA-
binding proteins that contribute to lentiviral integration in many ways: 
recognising DNA secondary structure, binding to the minor grove, interacting 
with supercoiled, bent and non-B-DNA structures and modulating chromatin 
structure. Pre-integration complexes (which can be isolated from infected 
cells174,178,179) are able to catalyse integration in vitro in the presence of Mg+2 and 
target DNA180–185. PIC is guided to the nucleus due to the nuclear leading 
sequences (NLS), present in MA protein, which together with Vpr and CA, are 
involved in lentiviral nuclear import via the nucleopore and integrate into non-
dividing cells186–188. Other proteins such as the transcriptional co-activator lens 
epithelium derived growth factor (LEDGF or p75) also play a role as co-factors of 
the viral integrase and participate in the target site selection of the HIV pre-
integration complex.  
The integration mechanism 
The integration reaction takes place in two catalytic steps. In the first step, 
referred to as end processing, IN specifically recognises sequences on both ends 
of the long terminal repeats (LTR)179,189–191. Crosslinking and nucleotide 
substitution experiments have confirmed specific interactions between the IN 
and the LTR termini sequence182,192. This way, HIV-1 IN recognises 20bp182 on the 
U5 and U3 ends, murine leukaemia virus (MLV) integrase recognizes 11-12 bp 
and ASV recognises 15bp181. Modification of these recognition sequence was also 
found to affect integration efficiency193. Next, the integrase cleaves a highly-
conserved 5’-GT-3’ dinucleotide resulting in a 5’-CA-3’ overhang  (5’ protruding) 
on both ends of the viral DNA194,195 in an ATP-independent process181. In the 
strand transfer step, the exposed oxygens of the hydroxyl group in the resected 3’ 
viral ends attack the phosphodiester bonds on the host cell target DNA196,197. The 
integration reaction concludes when the host DNA repair machinery fills the gaps 
between the recessed LTR termini and the host DNA198,199. As a result, five 
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nucleotides at the integration site are duplicated on both ends of the integration. 
Circular intermediates containing 1-LTR or 2-LTR, formed as dead-end product of 
reverse transcription reaction, are not integration competent195. 2-LTR forms are 
generated as result of recircularisation events174 in a process that involves the 
non-homologous end joining (NHEJ) machinery200. 1-LTR forms are derived from 
incomplete reverse transcription201 or recombination involving the MRN 
complex202 . Additionally, if not prevented by the host cell protein BAF176,203, HIV 
can target itself (autointegration) yielding a smaller truncated autointegrant (if 
targeting the same DNA strand) or a 2(inverted)-LTR internally arranged circle (if 
targeting a different one)195. 
Integration preferences of HIV and other retroviruses 
Lentiviral vector integration preferences are not random but a complex puzzle for 
which an integral and accurate model has not been described. Integration site 
selection is partially determined and modulated by a combination of interrelated 
factors including accessibility to chromatin204–206, nuclear disposition of 
chromosomes207,208, tethering proteins209–211, topological features and the 
primary sequence via the integrase viral protein212.  
Initial thoughts on retroviral integration suggested it may be driven by a 
particular nucleotide sequence. Withers-Ward et al., revealed no strong 
correlation between integration pattern and host’s DNA primary sequences213. 
However, re-examination by Shih et al., described the existence of integration 
hotspots with specific base pairs214. Integration downstream the local 5’-TpN-3’ 
pattern215 and 5’ G/C residues159 were found more predominant than random for 
HIV and Avian sarcoma leukosis virus (ASLV), respectively. More recently, 
integration base-patterns  [-3]TDG(int)GTWACCHA[7] for HIV, [–
4]DNST(int)VVTRBSAV[7] for MLV and [–4]STNN(int)SNNNNSNAAS[9] for ASLV 
were observed in a 2-fold higher-than-expected frequency. However, the absence 
of a strong consensus sequence indicates that sequence recognition is not a strict 
requirement and only modulates structural features in the integration site 
selection process216. Katz et al., demonstrated that sequences containing inverted 
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repeats were also shown to enhance integration through the formation of a 
hairpin loop184. Loop-forming oligonucleotides were also shown to be preferred 
as integration targets in vitro217. 
 
Figure 1.4. Schematics of lentiviral integration.  
LTR, Long Terminal Repeat; LEDGF, lens epithelium-derived growth factor; IN, integrase; PWWP, 
Pro-Trp-Trp-Pro domain; AT, A/T (adenine/thymidine) DNA hook; IDB, Integrase binding domain.   
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The idea that retroviral vectors preferentially integrate into open euchromatin 
suggested nucleosomes may exert steric hindrance preventing retroviral 
integration218–221. However, early experiments on retroviral integration 
performed with isolated PICs in vitro revealed integration on DNA wrapped 
around the histone octameric core is preferred over naked DNA215,222–224, 
possibly because deformation is needed to complete the strand transfer step172. 
Lentiviral integration was found to be favoured in positions presenting high 
levels of distortion in their chromatin structure215. Integration frequency seem to 
follow 10.4bp periodic windows in A/T-rich regions221 corresponding to the 
number of bases per turn whose phosphates are outwardly exposed in the major 
groove in nucleosomal DNA in vitro215,223 (confirmed also in lentiviruses in recent 
genome-wide analysis225,226). This link between DNA sequence and chromatin 
structure may also explain diminished GC content in lentiviral target sequences 
over short intervals (<2kb)227. Topological preferences correlate with local 
chromatin structure on lentiviral integration targeting. HIV-1 integration was 
found to be disfavoured in centromeric and telomeric regions due to the high 
degree of condensation and poor accessibility of constitutive heterochromatin228 
(same occurs with facultative heterochromatin). 
With the publication of the human genome229 and the arrival of next-generation 
sequencing technologies, integration site selection was analysed at a higher 
throughput level leading to more representative conclusions. Murine leukaemia 
virus (MLV, as a representative of a gamma-retroviridae family) was found to 
integrate within gene enriched regions, highly/actively transcribed genes 
(transcribed by RNA pol-II or protein coding genes) often collocated with CpG 
island-dense regions and is 5 times more likely to integrate near (<2kb) RefSeq 
transcription start sites230–234 showing only a moderate preference for 
transcription units (with respect to HIV). Xenotropic murine leukaemia virus 
showed the same integration features235,236. These results correlate with their 
over representation around annotated CpG islands, conserved transcription 
factors binding sites and non-coding sequences52,237.  
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A genome-wide analysis analyzing 8,250 unique integration sites of avian 
sarcoma-leukosis virus (ASLV) against the UCSC hg19 genome confirmed the 
results of previous studies performed at a lower scale231,238. ASLV (as a 
representative of the alpha-retroviridae family) presents a relatively neutral 
pattern with only a very modest predisposition towards genes and promoter 
regions when compared to SIN-MLV and SIN-HIV-derived vectors239. ASLV 
integration near repetitive or satellite elements was close to random239.  
HIV-1 (and lentiviral vectors in general) instead tend to integrate within active 
transcription units in areas with high gene density (60-70% according to Kursun 
et al.,240), collocated with CpG islands, regions, DNAseI cleavage sites and G/C-
rich regions241. Unlike gamma-retroviruses, more likely to be integrated near 
TSS, lentiviral integration events are evenly distributed over the length the 
gene231,234,242–250. Within genes, more than 90% of the integrations take place 
within introns due to their relative longer proportion. 
Early studies on retroviral integration did not report a preferential integration 
near transcription units or repetitive elements251,252. Leclercq et al., did not 
observe this integration pattern in human T-lymphotropic virus (HTLV)253. In the 
same line, Weidhaas et al., suggested high levels of transcription might interfere 
with avian leukosis virus (ALV) integration254. However, the representation of 
some of these studies was questioned due to the limited number of integration 
events and the fact the human sequence was not available yet and conclusions 
were drawn from a few model genes. In recent studies, MLV integrations are 
under represented around repetitive regions (e.g. LINEs) with the exception of 
SINEs frequently located in transcribed regions and contain PolII 
promoters255,256. Satellite elements were clearly underrepresented. 
As shown before, a number of studies have presented divergences between 
integration profiles depending on genera. Experiments examining integration 
preferences of chimeric HIV-1 containing the MLV integrase showed a gamma-
retroviral-like integration pattern245, narrowing down the determinant factor to 
the viral integrase and specific tethering factors. 
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Tethering proteins and other factors influencing the retroviral integration 
profile 
Contrary to early studies showing that DNA binding proteins blocked the access 
of pre-integration complex to the target DNA, host cellular proteins have been 
demonstrated to play an important role in target site selection. As previously 
mentioned, the lens epithelium-derived growth factor (LEDGF, also known as p75 
protein encoded by the PC4 and SFRS1 interacting protein 1 gene, PSIP 1) binds 
the lentiviral IN and strongly influences the targeting of the proviral DNA. 
LEDGF/p75 was reported to bind lentiviral IN through its integrase binding 
domain (IBD), whose structure was published by Cherepanov et al.,257. 
LEDGF/p75 prevents IN degradation by the proteasome258 and also participates 
in its nuclear import and localisation via the interaction of its integrase binding 
domain (IBD)259 with the N-terminal and core domains of the integrase; its knock-
down prevented their colocalisation in the nucleus260. Integrases of other viruses 
such as MLV, RSV, HTLV did not show this interaction indicating it is specific to 
lentiviruses261. LEDGF/p75 knock-down showed a decrease in infectivity262, 
which identified the LEDGF/p75 as a candidate target for integrase inhibitors263. 
LEDGF/p75 knock-down did not present a biased affinity towards transcription 
units and instead, integrations were more distributed among CpG islands and 
promoter regions identifying ‘LEDGF/p75 islands’243,264. The tethering model 
supports that LEDGF/p75 modulates the integration preferences via the 
interaction of its C-terminal domain with the viral IN and secondly via the 
interaction between two AT DNA hooks (+NLS) with chromatin. In addition, the 
N-terminal of the LEDGF PWWP domain has been shown to interact with 
chromatin. Although this interaction is key for viral replication, fusion proteins 
consisting of LEDGF and LANA or H1 proteins instead of the PWWP domain have 
shown to enable replication265. If theAT hooks and PWWP domains of LEDGF are 
replaced with chromatin binding domains (CBDs), viral replication can still be 
supported and the integration patterns are redirected to those of the CBDs248. 
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However, the mechanism of interaction between the PWWP domain/AT-hooks 
and the chromatin is poorly understood266. In 2013, Eidahl et al., published a 
solution structure of LEDGF PWWP with a peptide of H3K36me3 and examined 
its binding with DNA by nuclear magnetic resonance267. 
Therefore, retroviral vector integration distribution pattern is also consistent 
with their epigenetic marks in different cell types52. MLV-derived vectors are 
more frequently integrated in regions with methylation marks associated with 
active RNA PolII promoters and enhancers (H3K4me1 and me3)241. HIV-derived 
integrations are often found close to epigenetic markers associated with 
transcribed gene bodies (H3K36me3)237,268. SIN-ASLV shows poor correlation 
with epigenetic markers found in transcribed regions and slightly higher than 
random close to regulatory regions. When histone modification mediates gene 
silencing through chromatin conformation (for example via trimethylation of 
H3K9me2 and me3 and HP1 protein269 or H3K27me2 and me3 marks) the 
integration frequency drops in all retroviruses. Histone acetylation (commonly 
linked to active gene expression) located near to TSS is less frequent along the 
HIV targeting sites and vice versa241. Acetylation markers associated with TSS 
and proto-oncogene rich regions are preferentially associated with 
bromodomain and extraterminal (BET) proteins in MLV241. The BET proteins 
(Brd2, -3, -4) were recently identified to play an equivalent role as cellular 
binding partners targeting MLV integrase at the TSS270,271. 
To a lesser extent, the Ini1 protein (integrase-interacting protein 1), part of the 
SWI/SNF ATP-dependent chromatin remodelling complex, was found to enhance 
HIV-1 integration by tethering integration machinery to specific DNA sites and 
increasing the catalytic activity of IN272. Miller and Bushman hypothesized the 
recruitment of this chromatin remodelling complex could facilitate chromatin 
accessibility and thus subsequent retroviral integration273. 
The viral protein CA  may also play a role in integration site targeting of PICs 
through its interaction the cellular splicing factor CPSF6. Variations in proteins 
that interact with CA such as cyclophillin or N74D CA mutant affect its binding to 
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CPSF6 and alters integration preferences although the underlying mechanisms of 
this and the involvement of other cell factors needs to be clarified155. 
Cell type might also be involved in lentiviral integration site selection, probably 
through one of the previously described factors. In Jurkat cells, Lewinski et al., 
showed favoured integration in alphoid repeats typically found in gene deserts 
of centromeric heterochromatin (although its expression is repressed)274. A 
potential explanation could be satellite DNA contains the conserved motif 
(TGGAA)n which attracts nuclear proteins. In general, differential exposure of 
chromatin and the presence of remodelling complexes affect acceptor site 
selection. In post-mitotic/non-dividing/quiescent/resting retinal and neuronal 
cell types, Brady et al., and Bartholomae et al., reported 30% reduced frequency 
of lentiviral targeting into transcription units227,275. Concordant histone 
modifications and decreased levels of associated features such as CpG islands, GC 
content and DNAseI hypersensitive sites corroborate that pattern227. Marshal et 
al., showed that there is a correlation between the levels of integration close to 
transcription units and the endogenous level of tethering protein LEDGF/p75243  
of different cell lines. However, while LEDGF/p75 is the driving force in dividing 
cells and its knock-down leads to a shift towards regions rich in TSS and CpG 
islands, in quiescent cells its effect is less pronounced. In LEDGF/p75 knocked-
down quiescent cells, a decrease in the targeting of transcription units was 
described but integration near TSS and CpG islands was not enhanced276. This 
suggested that small traces of LEDGF/p75 are sufficient to the tethering effect or 
that other factors can also influence the integration preferences. Moreover, in 
their study, in vivo delivery of LVV into brain and eye cells resulted in integration 
in non-expressed genes indicating that target tissue (and possibly the delivery 
method) tune the integration profile.  
1.1.5 Development of lentiviral vectors 
Lentiviral vectors are derived from HIV-1. However, a range of gene delivery 
vectors have also been derived from other lentiviruses such as the HIV-2277, the 
simian278, feline279, bovine280 immunodeficiency or the caprine arthritis-
encephalitis virus281 and equine infectious anaemia virus (EIAV)282  the latter of 
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which has reached clinical trial for the treatment of Parkinson’s disease 
(NCT00627588 and NCT01856439).  
The generation of lentiviral vectors is based on the separation of the viral genome 
into the transfer vector (provided in cis) and genes encoding structural and 
enzymatic functions (provided in trans) in order to reduce the risk of generating 
replication competent lentivirus (RCL) in target/infected cells. While cis-acting 
sequences comprising the LTR, RRE, splice donor and acceptor, Ψ, PBS, PPT and 
cPPT have been maintained in the transfer vector, packaging genes (gag-pol, rev, 
env) have been iteratively separated from the viral genome into several helper 
plasmids or replaced with the objective of producing safer retroviral vectors. The 
vectors are replication deficient (only one round of transduction is observed) and 
the likelihood of generating a replication competent retrovirus (or lentivirus, 
RCR/RCL) from the transduction of target cells is significantly reduced146.  
In the first generation of lentiviral vectors70, the viral components were split in 
three plasmids containing (i) the packaging genes (gag-pol) and genes coding for 
accessory (vif, vpu, vpr and nef) and regulatory (tat, rev) proteins (ii) the transfer 
vector and the packaging signal flanked by long terminal repeats and (iii) the 
replacement of the endogenous envelope env protein with protein G of the 
vesicular stomatitis virus, that has a wider tropism283. Originally, endogenous 
gp41/120 envelope protein limited HIV-derived vector tropism to CD4 expressing 
cells. Other less toxic pseudotypes such as the feline endogenous virus RD114, 
cocal and Gibon ape leukaemia virus (GALV) envelope glycoproteins or chimeras 
using the cytoplasmic domain of the amphotrophic MLV-A glycoprotein 
(RD114/TR, GALV/TR) have shown efficient transduction of CD34+ cells. 
However, their titers are lower than VSV-G and they are not established for GMP 
production. Ross River virus (RRV) and Semliki Forest virus (SFV) envelope 
glycoproteins also reported lower titers284. The development of other 
pseudotypes such as and Venezuelan Equine Encephalitis and Rabies virus 
envelope widened the tropism to neuronal tissues285. 
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Second-generation lentiviral vectors eliminated viral accessory genes vpr, vif, vpu, 
nef from the packaging plasmid. The removal of accessory genes whose functions 
are not essential for early phases of vector transduction was found not to be 
detrimental for transduction efficiency286. 
However, the potential formation of replication competent retroviruses (RCR or 
lentiviruses, RCL)146 still raised safety concerns about the use of LVV for clinical 
applications. Sequences as short as 8 nucleotides have been shown to increase 
the chances of recombination leading to RCR events287. A third generation 
lentiviral vectors, devoid of tat and providing of rev gene in trans as a fourth 
plasmid, was developed in order to further split the vector genome and reduce 
the chances of RCR formation146. As a consequence of the removal of tat, a 
promoter upstream of the 5’LTR driving the expression of the vector is necessary. 
Typically, the Rous Sarcoma Virus (RSV)146 or the cytomegalovirus (CMV)288 
promoters are used in this chimeric promoter configuration (RSV- or CMV–HIV 
5’LTR) also known as pRRL or pCCL, respectively.  
In order to reduce the risk of proto-oncogene activation due to the positional 
effects of insertional mutagenesis caused by the 3’LTR U3 promoter/enhancer 
activity289 observed in gene therapy clinical trials in the early 2000s a vector 
modification was implemented. Self-inactivating (SIN) vectors have reduced the 
LTR enhancer/promoter sequences resulting from the deletion of a 399bp DNA 
fragment (including the TATA box) in the 3´LTR U3 region (-418 to -18 nucleotides 
relative to the beginning of the R region, namely SIN-18). Other SIN vectors have 
been developed by deleting different fragments of the 3’LTR U3289,290. The 
deletion of LTR promoter and enhancer sequences encoded in the 3’LTR is 
transferred to the 5’LTR and requires the presence of an external promoter, which 
is lost after the first round of infection. Additional elements such as enhancers291 
of inducible elements such as the tetracycline 7tetO sequence292 can also be 
added giving rise to conditional SIN lentiviral vectors (cSIN LVV). Additionally, 
this modification reduced the percentage of homology between the transfer 
vector and the viral genome down to 10%. 
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External/heterologous elements have also been useful in order to improve gene 
expression and titers at different levels. Although not essential, reintroduction of 
a central poly purine tract/central termination sequence (cPPT/CTS) is thought 
to improve nuclear import dynamics and improve lentiviral production147. This 
element has also been suggested to enhance reverse transcription as mutations 
in its sequence did not abolish nuclear import but decreased virus infectivity293.   
Post-transcriptional regulatory elements (PRE) are intronless sequences located 
downstream of the env gene -firstly described in hepatitis B virus (HBV)294- that 
have been proposed as an alternative to introns to enhance transcript 
stabilization and gene expression. Such effect is thought to be due to cis-acting 
regulatory element that actively enables RNA export and cytoplasmic localization 
regardless of its relative position (but not its orientation)295. However, 
Higashimoto et al., showed that the PRE sequence from the Woodchuck Hepatitis 
Virus (WPRE) increases viral titers by reducing the readthrough and improving 
the transcript termination296. The WPRE harbours an additional subelement that 
showed higher efficacy in lenti- and gamma-retroviral vector backbones 
irrespective of the promoter driving the expression and the presence of introns 
in the RNA297. LVV containing WPRE reported titers 5-7-fold higher to standard 
lentiviral productions298,299. Although the presence of an enhancer element 
(We1), the WHV X-protein promoter and 180bp of sequence coding for the X-
protein within the WPRE raised some concerns regarding its safety300. This 
enhancer activity is not likely to pose a problem since a second enhancer (We2) 
is needed to drive gene expression301, also in lentivirus302. However, X-proteins, 
and in particular those truncated in the COOH-terminal303,304, might be indirectly 
(as a cofactor) involved in cellular proliferation and anti-apoptotic activity305. 
Such concerns were mitigated with the validation of an equally functional 
mutated derivative with abrogated WHV X-protein translation306.  
Further improvements after the SIN vector configuration comprise optimisation 
of packaging signal in the transfer vector and the gag packaging gene to decrease 
their homology307 or via codon optimisation of packaging genes, which has also 
been reported to reduce the chances of RCL308. The rev-independence of codon 
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optimised HIV-1 gag-pol gene enables the removal of the Rev-responsive element 
(RRE) from packaging plasmids. However, its nuclear export is compromised in 
the absence of rev. Kotsopoulou et al., compensated this with an overexpression 
of gag-pol309. However, most 3rd generation vectors still incorporate rev/RRE in 
trans as a fourth plasmid since rev independence resulted in lower titers. Other 
sequences such as constitutive transport elements (CTEs)310,311 have shown not 
to be as efficient as rev312 although less cytotoxic. Clontech claimed to have 
developed the fourth generation by further splitting the gag-pol cassette onto two 
cassettes (gag-pro and vpr-pol) although their system is not tat independent313. 
Precursor Pr55Gag polyprotein has been shown to play an important role in 
several processes of viral replication.  Replacement of the Matrix protein (p17) 
myristoylation signal with phospholipase C-d1 pleckstrin homology (PH) domain 
has been shown to enhance viral production314.  
 
The choice of promoter to drive the expression of the internal cassette has also 
been optimised depending on the stemness of the target cell population and the 
genetic context. Cytomegalovirus (CMV) promoter is stronger than Spleen focus-
forming virus (SFFV), phosphoglycerate kinase (PGK) and EF-1α in differentiated 
cells315. Nonetheless, all the aforementioned provide robust stable gene 
expression and have been used in clinical trials.  
The chicken beta-globin insulator sequences (cSH4) have been introduced in 
order to neutralise the potential positional effect resulting in silencing of the 
expression cassette or activation of neighbouring genes. Inclusion of highly 
repetitive insulating sequences results in a reduction in titer and transgene 
expression and do not seem to compensate a questionable reduced risk of 
genotoxic effects316,317. The bovine growth hormone polyadenylation sequence 
has showed improved efficiency compared to the 3’ LTR U5 region318. 
Other modifications include the mutation of the catalytic domain of lentiviral IN 
(D64V) to prevent integration. Episomal expression from integration deficient/ 
non-integrating lentiviral vectors (IDLV/NILV) offers an alternative as a delivery 
vehicle to support transient transgene expression. Despite IDLV titers are 
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comparable to those of integrating lentiviral vectors, expression per copy has 
been shown to be 10-fold lower319,320. Background integrations were detected at 
a low frequency (10-4) due to non-homologous end joining of lentiviral episomes 
into chromosomal double strand breakage sites321. Nonetheless, IDLVs may 
represent a safer transient viral mediate gene delivery system for transient 
expression322. When integration is required, hybrid vectors benefiting from the 
Sleeping Beauty transposon system provide a more neutral and thus potentially 
safer integration pattern323,324.  
Figure 1.5. Lentiviral generations of packaging constructs and transfer vectors. 
(A) (i) Non-SIN lentiviral transfer vector. (ii) Self-inactivating (SIN) lentiviral transfer vector; U3 
is replaced by the Tat-independent promoter (usually CMV, cytomegalovirus or RSV Rous Sarcoma 
virus promoters) (iii) Conditional self-inactivating (SIN) lentiviral transfer vector: expression is 
dependent on the presence or lack of inducer molecule. (B) Envelope plasmid containing the VSV-
G pseudotype. (C) Different generations of packaging constructs (i) first generation: viral 
accessory and regulatory proteins are present. (ii) Second generation packaging constructs: genes 
encoding for accessory proteins are depleted. (iii) Third generation. Gag-pol and rev are split into 
two different plasmids. VSV-G, vesicular stomatitis virus glycoprotein (VSVg), usually driven by 
the CMV promoter; Ψ, packaging signal; polyA, polyadenilation signal, RRE, rev sesponsive 
element. LTR, long terminal repeat; U3, unique in 3’; R, repeat; U5, unique in 5’; tat, trans-activator 
of transcription; rev, regulator of virion; nef, negative regulatory factor; vpr, viral protein R; vpu, 
viral protein U; gag, group-specific antigen; pol, polymerase; env, envelope. 
Chapter 1. Introduction  
 60 
1.1.6 Lentiviral vector production 
Retroviral vectors have been used in the clinic for therapies against HIV/AIDS325 
and rare primary immunodeficiencies32. More recently, cancer immunotherapies 
have shown promising results from lentiviral-modified autologous T cells326. 
Production of infective lentiviral vector particles has been historically achieved 
by transfection of packaging genes and transfer vector for transient expression 
and is still today the most used method. Titers around 107 TU/mL are typically 
achieved with most protocols and can be increased to 109 TU/mL after 
ultracentrifugation. 
Transient transfection 
Transient transfection is the main method to produce LVV and relies on the 
delivery of gag-pol, rev (and tat if not using 3rd generation packaging systems), 
envelope protein and transfer vector to yield non-sustained expression of viral 
components and produce vector. Transient transfection saves the time-
consuming cell line development of producer cell lines and allows expression of 
viral cytotoxic proteins. Transfection efficiency depends on the quality of the 
DNA, the method employed, the target cells and the size of the transfer vector 
(dropping significatively from 9 to 13kb)327.  
However, the main limitations of lentiviral production using transient 
transfection come from (i) the low adaptability of transient systems for large-
scale production328, (ii) the high cost of GMP plasmids (iii) contamination of the 
harvested vector with transfection plasmids329 (iv) the difficulty in the 
optimisation of transfection conditions. Lentiviral vector production is still 
limited to a research setting using cell factories rather than large volume 
industrial bioreactors. Current transient transfection batches yield sufficient 
vector to treat one or a few patients (109-1011 TU330,331) limiting the 
reproducibility between patients in large clinical trials. Large-scale industrial 
batches (listed in Merten et al.,332) have achieved the 1011 TU threshold by 
Chapter 1. Introduction  
 61 
optimising cell type, density media supplementation, and plasmid delivery. 293T 
cells are normally used for large-scale LVV production given their faster growth 
and enhanced productivity although 293 have also been used when traceability 
was not certain for GMP industrial productions333. Some protocols use adherent 
cultures, FBS and calcium phosphate334, others use  serum free-media with 
Ca3(PO4)2335 or PEI336. Segura et al., used HEK 293 suspension cells transfected 
with PEI and protein-free media supplemented with Pluronic®337. Broussau et al., 
and Co te et al., isolated and established a HEK293 clone (HEK 293SF-3F6) for 
suspension culture338,339. 108 TU/mL have also been achieved using 3L stirred 
tank bioreactors using HEK 293SF-3F6 suspension adapted cells and serum-free 
media340. 
Packaging and producer cell lines 
The development of packaging cell lines to produce lentiviral vectors potentially 
solves the aforementioned disadvantages, may produce higher amounts of vector 
and reduces the batch-to-batch variability. A lentiviral packaging (or helper) cell 
line (PCL) stably expresses the packaging and/or the envelope genes (gag-pol, env 
and rev) in trans. The packaging cell line becomes a producer cell line when the 
transfer vector is also provided to produce the packaged lentiviral vector particle. 
The ideal packaging (or producer) cell line should be stable in growth and vector 
production, produce high amounts of infective lentiviral vector and be adapted to 
serum-free and suspension conditions. Historical limitations of packaging cell 
lines are low vector titer (105 -107 TU/mL) and cytotoxicity of the lentiviral 
proteins leading to reduced stability over generations. Standard cell line 
development processes from initial cloning until master cell banking including 
the sequential integration and selection of all the vector components typically 
take from 6 to 12 months.   
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Choice of host cell line 
More than 70% of the biopharmaceutical products in the market are produced in 
a few host cell lines: Chinese hamster ovary (CHO) cells, human embryonic kidney 
(HEK 293) cells, baby hamster kidney cells (BHK) and cells derived from mouse 
myeloma (NS0).  
CHO cells were isolated by Theodore Puck in 1957 from a biopsy from Cricetulus 
griseus341 and are currently the most widespread and well understood cell line in 
the industry for protein production342. CHO DG44, and DUK-B11 cells lack DHFR 
and are used in combination with MTX, which enables gene amplification of 
expression cassettes343. Instead, CHO-K1 cells use the GS/MSX system with 
methionine sulphoximine  (MSX) concentrations above 3μM, enough to inhibit 
endogenous glutamine synthetase (GS)344. CHO cells are good secretors and 
produce proteins with a human-like glycan profile345. 
NS0 are murine myeloma cell lines derived from BALB/c mouse plasmacytoma 
cell line and due to their origin they are able to synthesize high levels of Ig346. NS0 
express low levels of GS and consequently the GS/MSX system is mostly used for 
gene amplification347. Baby hamster kidney (BHK) cells were derived from 
subclone 13 of a parental cell line fibroblast from 5 unsexed 1-day old Syrian 
hamsters (Mesocricetus auratus) by Macpherson and Stoker in 1962348. All these 
cell lines have been adapted to grow in serum-free and suspension conditions at 
high densities and their glycosylation pattern is compatible with humans. 
However, lentiviral vectors have not been transiently produced in cell lines with 
rodent origin given that they are less susceptible to infection by human viruses 
due to the restriction factors349. 
Initially, retroviral vectors derived from MLV were produced in NIH 3T3 murine 
cell lines350, which are strictly adherent. However, endogenous retrovirus could 
lead to potential mobilisation of vector genomes and generation of replication 
competent retroviruses raised safety concerns287. Another reason for the 
transition towards human cell lines is the fact that murine cell lines add a non-
Chapter 1. Introduction  
 63 
human sugar residue onto N-glycans (Galα1-3Gal) of the envelope protein and 
other membrane proteins351. Retroviral particles with this glycosylation pattern 
are neutralised by the human complement system in 20 minutes post-
injection352,353. However, (Galα1-3Gal)-positive retroviral vectors (produced by a 
brain derived cell line, Mustela putorius furo, Mpf) are immune to human 
immunity indicating that other epitopes could participate in the immune system 
recognition354. Therefore, vector produced for in vivo applications must be 
produced in monkey or human-derived cell lines. 
PerC6 cells were originally derived from healthy human embryonic retina and 
were immortalised by Crucell via transfection of the Ad E1 gene instead of viral 
transduction for biopharmaceutical production of proteins and Ad vectors355. 
PerC6 cell lines were explicitly designed for biopharmaceutical production and 
its traceability is extensively documented. The main advantage of PerC6 cell lines 
is their ability to grow to high cell densities in suspension, which results in higher 
product titers. Although their glycosylation pattern is slightly different from that 
of humans (fewer mannoses and hybrid structures) it is not immunogenic356. No 
amplification systems are needed since stable levels of expression are obtained 
from low copy number transfection355.  In 2011, the acquisition of Crucell by 
Johnson&Johnson caused the discontinuation of the distribution of commercial 
licenses for biopharmaceutical manufacture. 
Human embryonic kidney cell lines were originally isolated from a healthy 
aborted female foetus in 1973 in the laboratory of Alex van der Eb in Leiden357. 
During his 293rd experiment (which gave them their current name), Frank 
Graham transformed them using the mechanically sheared fragments of human 
adenovirus 5 (hAd5) using the calcium phosphate co-precipitation transfection 
technique358. Analysis of the HEK 293 genome by Louis et al., 4,344 bp showed 
the DNA fragment corresponded to the 11% far 5’ end of the Ad genome. This 
fragment contains the E1A, E1B and IX early hAd5 genes, which were integrated 
in the human pregnancy-specific beta-1-glycoprotein 4 (PSG4) gene located in 
chr19q13.2359. A genomic study of the cell line by Lin et al., revealed that the hAd5 
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integrated fragment had undergone genome amplification resulting in 5-6 
copies360.  
HEK 293 cells (available at the non-profit American Type Culture Collection 
repository under the catalog number CRL-1573) are dynamic cells and changes 
have been observed over passages. Growth rate increases more than twice in 40 
passages (from 0.29/day at passage 43 to 0.74/day at passage 70-80) and cell 
size diminishes361. Their tumorigenicity also varies from being negligible in early 
passages (up to 21) to cause solid tumours (after passage 65) in two weeks when 
injected in nude mice362. Therefore, it is critical to maintain cells in early passages 
to limit their variability for any application. Although they were termed human 
embryonic kidney cells and were originally thought to have fibroblastic, 
endothelial or epithelial origin, their response to neuronal signalling, the 
presence of neuron-specific voltage channels and susceptibility to infection by 
neurotropic viruses suggest that they belong to neuronal lineage in the kidney363. 
HEK 293 cells are cultured in adherent cultures typically with DMEM and 
supplemented FBS but can adapt to suspension cultures in the absence of serum 
in low calcium ion concentration media350. HEK 293 cells are pseudo (or hypo) 
triploid, meaning that their genome has less than three sets of chromosomes with 
a modal number of 64 chromosomes. However, their abnormalities include four 
copies of chromosome 17 and 22 three copies of chromosome X and no traces of 
Y chromosome (the latter as expected)360. 
HEK 293 cells have given rise to several derivatives such as HEK 293T, HEK 293E 
and HEK 293FT and have been used for AAV, Ad, MLV and LVV production364. HEK 
293T cells (originally referred to as 293tsA1609neo) (ATCC CRL-3216) were 
obtained by DuBridge et al.,365 in the laboratory of Michele Calos upon stable 
transfection of standard HEK 293 with 2 plasmids a pRSV-1609 plasmid366 
containing a temperature sensitive SV40 T-antigen coding sequence driven by the 
RSV promoter. The other plasmid, which is no traceable in the literature, contains 
a neomycin resistance gene as a selectable marker for stable integration, thus 
293T are resistant to neomycin. They are easily transfectable and grow faster 
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than standard HEK 293 as T antigen interacts with several proteins and inhibits 
replication control367.   
HEK 293FT adherent cells (Invitrogen R700-07) were obtained after transfection 
of standard HEK 293 with pCMVSPORT6Tag.neo by Life Technologies in 1988 and 
are traceable since then. These cells also constitutively express the SV40 T-
antigen (Ag) under the CMV promoter and have a similar growth rate to HEK 
293T. SV40 T antigen allows amplification of transfected plasmids with a 
compatible origin of replication365, which leads to higher production rates368. 
However, as with HEK 293T cells, the association of SV40 with cancer (T Ag 
complexes and p53, which inhibits its tumour suppressor function)369 raises 
concerns on the utilisation of these cell lines for biopharmaceutical production. 
Nevertheless, the adenoviral E1 region was used to immortalise HEK 293 cell line 
and such cell line has been validated for clinical grade biopharmaceutical 
products370 and no adverse events associated with the T antigen have been ever 
reported.  Moreover, millions of people were accidentally inoculated with SV40 
detected as a contaminant of the polio vaccine between during the 1950s in the 
USA and Denmark; follow up studies found no increase in the cancer incidence371. 
HEK 293EBNA-1 (or HEK293-E cells, ATCC CRL-10852, R620-07, Life 
Technologies) were established by inserting the Epstein Barr virus (EBV) nuclear 
antigen-1 (EBNA-1), from pCMV/EBNA. EBNA acts as a transcriptional 
enhancer372 and allows episomal replication and maintenance of plasmids 
containing the EBV oriP origen of replication (oriP) in cis373, which increases 
protein yield374. HEK293-E cells are also neomycin resistance as a result of the 
stable expression of the neomycin resistance gene driven by the Rous Sarcoma 
Virus long terminal repeat promoter from pRSV4neo375. 
HEK 293EBNA-1 6E cells (originally from the National Research Council of 
Canada, NRC file 11565) also termed or 293-6E cells376 stably express a truncated 
version of the EBNA-1, lacking Gly-Gly-Ala domain. Expression of this truncated 
form is more stable and less cytotoxic and cell lines show higher growth rates and 
increased transient gene expression compared to full length EBNA1377. 
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Construct design and mode of expression 
Stability of production is one of the main hurdles due to cytotoxicity derived from 
prolonged expression of toxic vector components. The toxicity of the envelope 
protein (and other potential viral proteins) dictates the strategy employed for its 
expression. Packaging cell lines can be divided in two categories (constitutive and 
inducible) depending on the mode of expression of its viral proteins.  
Constitutive expression 
Several groups have generated packaging cell lines that constitutively express 
viral proteins378–383 on occasions reaching titers >107 TU/mL. Given the inherent 
toxicity of VSV-G protein and some elements of p24Gag, constitutive packaging 
cell lines use other non–cytotoxic envelope pseudotypes and thus can 
constitutively express viral proteins for prolonged periods. Feline endogenous 
virus envelope RD114 protein has wide range of cell tropism but shows 
preferential tropism for hematopoietic CD34+ stem cells384,385, a therapeutic 
target for gene therapy; Gibbon ape leukaemia virus has preferential tropism for 
hematopoietic progenitor cells and peripheral blood lymphocytes386,387 and has 
been used in clinical trials carried out with γ-retroviral vectors388.  The STAR389 
packaging cell line developed by Ikeda et al., was the first using this mode of 
expression. In that study, three potential host cell lines (HT1080, HeLa and 293T) 
were tested with three different envelope proteins (RD114-Pro with a protease 
site at the R cleavage site; MLV 4070A and GALV with a cytoplasmic MLV domain). 
In addition, Ikeda’s approach was novel because viral genes were introduced by 
transduction (instead of transfection) using a 2nd generation MLV vector. 
However, although titers were >107 TU/mL for 12 weeks, the use of non-SIN 
vectors to generate the PCL specifically impeded STAR cell lines could progress 
for clinical applications385. WinPac381 packaging cell line used the same principle 
to insert gag-pol but provided a modular approach (already used in γ-retroviral 
PCLs390–392) in which viral transduction was used as a platform to 
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deliver/retarget other viral components via recombinase mediated cassette 
exchange (RMCE). However, site-specific insertion does not completely eliminate 
interclonal variation in expression and therefore screening of clones is still 
required. In addition, the lower titers (>106 TU/mL) could be associated to the 
toxicity from integration of gag-pol into high transcribing sites. 
RD2-MolPack developed by MolMed is another example of a constitutive 
packaging cell line expressing RD114-TR envelope protein (containing the 
cytoplasmic domain (TR) of MLV-ampho 4070)393. Interestingly, the packaging 
genes were transduced using a baculo-AAV vector previously transfected with 
AAV Rep78 to target their integration. However, the safety profile of this cell line 
was not optimal since co-expression of gag-pol and rev were driven from the same 
plasmid and the transfer vector was not self-inactivating. RD3-MolPack corrected 
the issue using SIN vectors but titers remained at approximately 106 TU/mL in 
both cases382. Despite its cytotoxicity, the use of VSV-G is still generalised due to 
its multiple advantages (broad tropism, stable particles upon 
ultracentrifugation283) and none of the other pseudotypes has gained FDA 
clearance for gene therapy with lentiviral vectors394. In any case, an ideal 
producer cell line platform should be able to support any pseudotype.  
Inducible expression: Inducer-Off 
Inducible expression systems are meant to regulate expression of cytotoxic viral 
proteins in cells e.g. VSV-G and protease amongst others. The VSV-G pseudotype 
has been extensively used due to its wide tropism (mammalian and non-
mammalian cells) and its stability against ultracentrifugation shearing forces. 
However, it has been shown to be toxic through the formation of syncytia and 
subsequent cell death when constitutively expressed in packaging cell lines283. 
Vpr accessory protein, although dispensable in SIN-LVV have also been shown to 
be toxic395–397. In order to overcome these limitations, inducible systems using the 
Tetracycline (Tet) regulatory system292,398–404 or the ecdysone405,406 regulatory 
system have been assessed. When using the Tet-Off system, tetracycline (or its 
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analogue doxycycline) is used to block the binding of the tetracycline 
transactivator (tTa) to the Tet responsive element (TRE), which supresses the 
expression of the gene. The tetracycline transactivator (tTa) is a chimeric protein 
resulting from the fusion between the DNA binding domain (N-ter) of the 
tetracycline repressor (TetR) and the activation domain (C-ter) of the Herpes 
Virus V16 protein (HV-VP16) transactivator407. Initially, Yu et al., used the Tet-Off 
system in HeLa cells that constitutively expressed tTa (HtTA-1 cell line) to 
regulate the expression of rev and the latter indirectly that of packaging genes408. 
Kafri et al., developed a 1st generation LVV cell line with Tet-off inducible 
expression of VSV-G yielding acceptable titers (>106 TU/mL) for 3-4 days398. 
Second generation lentiviral vectors demonstrated that accessory proteins are 
redundant for lentiviral vector transduction286,312,409. Consequently, in the 
following years, packaging cell line designs did not include vpr, vif, vpu and nef 
complementing in trans399,400,402,405,408. Kaul et al., still reintroduced viral 
accessory proteins in trans with the objective of boosting the titers402. Following 
Kafri’s approach, Farson et al., independently developed 2nd generation packaging 
cell lines and achieved similar titers399,400. However, the design of this cell line (2nd 
generation LVV) was not considered sufficiently safe. Klages et al., achieved >106 
TU/mL in the absence of tat and rev was stably cotransfected as a fourth plasmid 
under the control of TRE, increasing system biosafety and reducing percentage of 
homology with the HIV genome to 40%399. This way gag-pol mRNA nuclear 
export was regulated by rev in a 2-step regulation system. 
With the arrival of the third generation of lentiviral vectors146, the removal of rev 
and tat  regulatory genes was attempted by replacing them with complementary 
systems. The regulatory protein Tat is responsible for transcription of the full-
length vector genomic RNA in HIV (and up to 2nd generation LVV). Elimination of 
this dependence and reduction of the viral homology was achieved by replacing 
the HIV 5’ U3 region with a constitutive heterologous promoter e.g CMV or RSV 
promoter405.  
Xu et al., introduced a novelty in the PCL design consisting of the replacement of 
the third generation LVV 5’ LTR U3 promoter/enhancer region with seven copies 
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of the Tet responsive element (TRE) giving rise to conditional self-inactivating 
lentiviral vector system (cSIN)404. Unlike standard SIN vectors, cSIN design allows 
delivery of transfer vector via transduction and yielded titers of >106 TU/mL.  
In 2006, Cockrell et al., combined the Tet-Off system with further splitting of the 
gag-pol construct into gag–pro and vpr–RT–IN401 and a standard SIN LVV 
configuration to reduce the risk of production of replication competent lentivirus 
and yet obtain relatively high titers (>107 TU/mL). Despite being a transient 
packaging system but in line with this concept, Westerman et al., used a 7-plasmid 
(non-cSIN) system where, besides plasmids encoding VSV-G, tat, rev and the 
transfer vector plasmid, up to three constructs for the gag-pol (Gag + Vpr-PR + 
Vpr-RT/IN) were used. However, titers dropped from the >106 TU/mL using the 
5 plasmid system to the >105 TU/mL using the 6 and 7 plasmid system410. 
Ni et al., at Virxsys developed a 3-step regulation system that avoids constitutive 
expression of cytotoxic viral proteins and also toxicity present in the tetracycline 
transactivator (tTA). In their work, the tTA is under an inducible system, which 
upregulates itself upon induction. This system also included expression of codon 
optimised tat and rev, which in turn regulates codon optimised gag-pol and VSV-
G transcription403. Their strategy yielded 3.5x107 TU/mL for 11 days but 
leakiness of p24Gag expression resulted in silencing after 2-3 months. Gene 
silencing was confirmed not to be caused by gene loss but at an expression level. 
Methylation of ERVs, transposons or even at a post-transcriptional level has been 
observed among other mechanisms411 in eukaryotic cells as a defence mechanism 
to the expression of foreign DNA412,413.   
Throm et al. used SIN-MLV to deliver gap-pol and rev (and tat) genes into a 3rd  
(and 2nd) generation GPRG (and GPRGT) packaging cell line regulated by the Tet-
Off system. Unlike Ikeda’s work in which LTR-MLV were used to deliver packaging 
genes414, the use of SIN-MLV reduced the risk of cross-packaging of MLV genomes 
in lentiviral particles and allowed clinical applications. Interestingly, Throm et al., 
also used a concatemeric array of vector genomes to enhance the expression of 
vector genomes, which yielded 5x107 TU/mL292. 
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The Tet-Off system represents an advantage from the downstream processing 
point of view compared to the Tet-On system, as no inductor molecule is present 
in the culture during vector production. However, complete elimination of 
repressor to promote the induction of the system requires a full media change 
and represents a challenge for large volume bioreactors. Morover, cells need 
several days to reach peak of production, which makes the Tet-Off system not 
optimal for large-scale production. The regulation of these inducible systems is 
not always tight and stability is compromised due to the leakiness of VSV-G 
expression in the off-state. As a result, genetic and transcriptional instability was 
shown after 2-3 months of culture when using this method400,403. In addition, 
there is a delay between the removal of doxycycline and the induction.  
Inducible expression: Inducer-On 
In the Tet-On mechanism, the binding of the inducer molecule to the tetracycline 
transactivator (rtTA) promotes the binding of the TRE and thus switching on 
expression of the gene. Stewart et al., (Oxford Biomedica) developed a EIAV-based 
packaging cell line to generate ProSavin® for the treatment of Parkinson’s 
disease415.  The cell line was based on codon optimised TetR (coTetR) enhancing 
its expression and the two obtained clones (PS46.2 and PS5.8) achieved a tight 
regulation and stable titers (<106 TU/mL) for 7 weeks63. Further modifications of 
the Tet-On system include the Tet repressor devoid of the VP16 protein, which 
has been suggested to be toxic for cellular transcription407. Location of the two 
copies in tandem of the TetO 10bp downstream of the CMV immediate early 
promoter TATA box allow blockage of expression by TetR homodimers in absence 
of inducing agent416. Using this strategy, Stewart et al., reported stable (although 
low titers, mid <106 TU/mL) for 16 weeks in absence of selective pressure63,415. 
Recently, other Tet On inducible systems have been developed by Clontech. The 
Tet On 3G system achieves a x25,000 induction factor by constitutively expressing 
the transactivator 3G molecule under the PGK promoter, which activates 
transcription (in trans) of the gene of interest, downstream the TRE3G promoter 
in the presence of doxycycline417.  
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Similarly, regulation of viral protein expression using the ecdysone system was 
used as an alternative to the Tet system since it is less leaky and more rapid in the 
induction (3-5 days instead 14 days) and clearance418. The insect hormone 
ecdysone (or its analogue ponasterone A) promotes the binding of this molecule 
to the ecdysone receptor (VgEcR)-retinoid X receptor (RXR) heterodimer and 
thus activation of transcription. Since this protein is not endogenous, basal levels 
are considered negligible. However, packaging genes under the control of one405 
or separate406 ecdysone promoters only yielded 105 TU/mL (before 
concentration).  
Another example of inducible Tet-On system is the work of Broussau et al., in 
2008, who combined a reverse transactivator (rtTA2S-M2) of the tetracycline 
system with a cumate switch (CymR from Pseudomonas putida) for rev and VSV-
G expression (and constitutive expression of gag-pol) achieving stable suspension 
cell lines for 18 weeks and induction/production cycles of 7 days in absence of 
selective pressure338 and promising titers (3.4x107 TU/mL). Cumate and 
doxycycline can be removed after ultracentrifugation419.  However, despite 
controlled expression of cytotoxic genes upon induction, their effects cannot be 
mitigated in long-term cultures.  
Nonetheless, cytotoxicity is not the only limitation that impedes high titers. A 
correlation between titers and the amount of transfer vector copies introduced in 
producer cell lines was identified by Sheridan et al.,420. As previously mentioned, 
Throm et al., corroborated the insufficient expression of SIN LVV transfer vector 
genome as a limitation for vector production, already confirmed by Ikeda et al.,389 
and proposed a new approach based on the transfection of >200 copies in tandem 
(as a concatemeric array) of transfer vector292 yielding >107 TU/mL. 
A different strategy to approach the limiting factor is that followed by Sanber et 
al. In their study, MLV vectors were used to target recombinase recognition sites 
into actively transcribed sites in a controlled way. Gag-pol genes were then 
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retargeted using recombinase-mediated cassette exchange (RMCE) and the env 
and rev genes were finally stably transfected yielding titers higher than 106 
TU/mL381. 
Finally, inducible systems based on light-switchable promoters have been 
suggested as innovative mechanisms to regulate LVV production.  The change of 
conformation (trans to cis) of azobenzene upon reversible induction with UV light 
(300-400nm) allows activation with short pulses of light421,422. Similarly, when 
excited with far-red light, photoresponsive phytoreceptor interacts with PIF3 
phytochrome and mediates transcription of downstream genes421,423. 
To date, only two lentiviral packaging cell lines have been exploited for 
production of SIN-LVV for clinical trials. Two of them are derived from GRPG/T 
cell line generated by Throm et al., with titers >107 TU/mL: (i) GPRGT-derived 
650MNDhWASp1 packaging cell line by Wielgosz et al., expressing WAS protein 
for the clinical trial treating Wiskott Aldrich Syndrome at the St. Jude Children’s 
Research Hospital424 and (ii) GPRG-CL204i-EF1α-hγcOPT by Greene et al., 
expressing IL-2Rγc for SCID-X1292,425.  
Stoichiometry 
As addressed in previous sections, lentiviral vector genes are split into several 
expression cassettes to avoid the generation of RCL. However, as a consequence, 
the stoichiometry is disrupted as each vector gene is expressed separately. In 
addition, accessory proteins, removed after the second generation of LVV, cannot 
participate in its modulation. Viral gene expression and splicing dictate the 
efficiency of assembly in lentiviral vectors. Unspliced RNA gives raise to gag-pol 
polyprotein and full length viral RNA and spliced RNA giving rise to envelope 
protein among others. Katz et al., showed the amount of unspliced:spliced RNAs 
follows a 1:2 ratio in physiological conditions426. In turn, such unspliced RNA 
proportions must be in conjunction with the gag:gagpol frameshift rate (20:1)427. 
The introduction of mechanisms to finely control viral gene expression via stable 
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transfection and (MOI-regulated) transduction, often used in PCL development, 
is cumbersome. Therefore, achieving such proportions of RNA species becomes a 
challenge to replicate the normal physiology of the virus. 
Yap et al., demonstrated that the effect of gag-pol overexpression depends on the 
amount of envelope protein used in viral particle formation. The interaction 
between the premature envelope protein and its receptor within the cell 
constitutes a limitation and compromises its availability for the packaging of viral 
particles428. In normal circumstances, vpu viral accessory protein prevents the 
interaction between the viral envelope protein and the premature receptor by 
down-regulating the expression of CD4 receptor. In gamma-retroviral vectors, 
devoid of vpu, envelope protein is overexpressed to compensate for the 
interaction. This, together with the existence of a threshold level of env protein 
for packaging of MLV viral articles highlights the relevance of the env protein in 
viral production429.  Low levels of receptor could have a positive effect and 
prevent the entry of viruses. Despite studies of stoichiometry by Katz et al., and 
Yap et al., the issue had never been considered in the context of a packaging cell 
line. However, when expression of envelope protein was not a limitation, they 
observed a large number of empty particles suggesting the expression and/or 
packaging of vector genome was compromised. This limitation, already identified 
by Sheridan et al., was also corroborated in part by Lei and Andreadis430. In their 
study, ecotropic envelope producer cell lines showed a large number of empty 
non-infectious viral particles, while this trend was not seen with amphotropic 
producers. In 2007, Carrondo et al., used the Flp/FRT system to mediate cassette 
replacement and assess the influence of each of these components on vector 
production. Interestingly, they found gag-pol expression is pivotal since a 2-fold 
variation in its content could impact titers by one or two orders of magnitude431. 
Its balance with env expression was also shown to be critical for viral infectivity, 
identifying a 100-fold margin between balanced and unbalanced gag-pol/env 
expression. Their study also showed stability of the infective particles remains 
unaltered if conditions are suboptimal although transduction efficiencies can 
dramatically drop. But more interestingly, by firstly integrating the transfer vector 
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and selecting clones with no limitation in the amount of RNA expression and 
secondly preserving an optimal of gag-pol/env balance on those clones, they 
showed titers were not significantly increased. These findings confirm that there 
is room for improvement in encapsidation of viral genomes when the 
stoichiometry is balanced and expression of the viral genome is not a limitation.  
In conclusion, each packaging cell line presents different limitations depending 
on differential expression of viral components, which rely on integration site, 
copy number or silencing. In the event of correct balance between gag-pol and 
env, limitation coming from vector genome can reside either on insufficient 
expression or on packaging efficiency. 
Delivery and selection of lentiviral components 
Transduction 
Delivery of packaging plasmids can be achieved using either transfection or viral 
transduction. Transduction has shown to produce more stable expression and 
higher titers than transfection using second generation packaging plasmids, 
despite having only one copy of the transgene when a low multiplicity of infection 
is applied (MOI, ratio of viral particles to cells)389. That is explained by the ability 
of retroviral vectors to integrate genes into the host cell genome providing more 
stable expression. Integration catalysed by the viral integrase may contribute to 
genetic stability compared to stable plasmid transfection, which relies on double 
strand breaks and thus a potential selection of genetically unstable loci. Many 
groups have used this method to deliver packaging genes338,398–401,403–406. 
Interestingly, Ikeda et al., also reported enhanced probability of high-producing 
clones when using this method389. Second generation LTR- γRV and third 
generation SIN γRV have been used for permanent delivery of packaging genes 
for example in STAR and GPRG-TL-20 packaging cell lines (with the exception of 
env, which was delivered using transfection389). However, delivery of full SIN-LVV 
transfer vector (containing the ΔU3 deletion) is not recommended. This is 
because once transcribed, the 5’LTR no longer has promoter/enhancer activity 
and the transferred U3 from the 5’ LTR during reverse transcription is inactivated 
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as it contains the ΔU3 deletion. Therefore, plasmid delivery for generation of SIN 
transfer vector has to be done by transient DNA transfection.  
Transfection 
Plasmid transfection protocol typically involves delivery of an stoichiometrically 
optimised mix of plasmids to a monolayer of cells, change of media a few 
hours/one day post-transfection (if transfection method is cytotoxic) and media 
harvest two days post-transfection followed by 0.45 μm filtration prior to an 
optional ultracentrifugation. Physical and chemical transfection methods are 
generally versatile, rapid, non-cell type dependent and reproducible. 
Physical methods require sophisticated equipment although they avoid many of 
the undesirable effects of chemical and viral transduction. Physical methods 
include methods like high-velocity biolistic transfection of nucleic acid tungsten 
or gold-coated microparticles432, laserfection-mediated permeabilisation of 
membranes (also known as optofection or phototransfection)433 or 
magnetofection, which is particularly attractive for primary cell lines given its 
mildness and can be performed in the presence of serum434. However, 
electroporation, first used by Wong and Neumann et al., in 1982435, is the physical 
method par excellence. It is based on the application of electric fields to cells and 
tissues, which causes the appearance of transient aqueous pores, which results in 
an increase of the permeability of the cell membranes and tissue to extracellular 
DNA435. Interestingly, electroporation technology has been improved to enable 
continuous transfection of large volumes of flowing high density cultures436. This 
method is compliant with current regulations437, requires 33% less DNA than 
other transfection methods and can be used at a bioprocessing scale for lentiviral 
vector production with titers 8.8x107 TU/mL437. 
In general, chemical methods are inexpensive, non-mutagenic, and adaptable to 
high-throughput applications. In addition, unlike viral delivery they do not 
present limitations on the amount of nucleic acid loaded and can be easily used 
in many cell types with varying efficiencies. Among chemical methods, calcium 
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phosphate is sensitive to pH variations and cells require low concentration of BSA 
or FBS to reduce the cytotoxicity. Liposomes and cationic lipids or polymers are 
relatively expensive to scale up although they require less DNA than calcium 
phosphate438. Polyamidoamine dendrimers (like PEI) are less expensive, their 
efficiency is similar to that of calcium phosphate and they require less DNA.  
However, DNA-PEI complexes are relatively cytotoxic and require change of 
media a few hours post-transfection439. Key parameters to be optimised not to 
hamper their efficiency include the nucleic acid:chemical agent ratio, serum 
concentration, pH, exposure to the transfection or permeabilising reagent. There 
is no ideal method suitable for all application. The choice of a delivery method is 
dictated by the inherent properties, its manufacturability and target application.   
An inherent disadvantage of stable plasmid transfection is the introduction of 
antibiotic resistance in the packaging cell line to select for stable expressers in 
each round of transfection. When not co-transfected along with the transgene in 
separate plasmids, antibiotic resistances are advised not to be in the same 
expression cassette for clinical applications440 as their unmethylated CpG islands 
can induce innate immune response via the Toll-like receptor 9441.  
Suspension adaptation, scale up and upstream process improvements in 
lentiviral production  
Unlike murine NIH 3T3 cell lines, used as gamma-retroviral vector producer cells, 
HEK 293 cells can adapt to suspension conditions media devoid of serum and 
containing low Ca+2 concentrations442. Calcium is involved in cell to cell adhesion 
through cadherins, transmembrane calcium-dependent proteins443. This makes 
their scalability much easier, as they can be cultivated in different suspension 
systems such as spinner flasks, fixed bed, fluidized bed or stirred tank bioreactor 
(with optional perfusion). For cell lines that require cell adhesion, such as 293Ts, 
lentiviral productions can be scaled-up to using cell factories or stacks, units of 
up to 40 layers of plates or chambers providing a culture surface of 25,280 cm2. 
Using this method, large-scale LVV production (250mL with 2x109 TU/mL) have 
been achieved for the treatment of ex vivo immunodeficiencies444. HYPERflasks 
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have shown a >9x106 TU/cm2 improvement in surface productivity compared to 
normal T-flasks, possibly attributed to a better gas exchange445. Other alternatives 
comprise fixed bed reactors, hollow fiber reactors and micro- or macrocarriers 
(also used for gamma-retroviral or adenoviral production) although titers do not 
show an increase in productivity446. 
LVV production using suspension HEK 293E cell lines was first achieved in 3L 
stirred tank bioreactors yielding >106 TU/mL447. More recently, Witting et al., 
reported titers >108 TU/mL using bag bioreactors, GMP-compliant closed 
systems that are easily scalable448.  
Increases in productivity of producer cell lines have been attempted at different 
levels. In upstream process, addition of sodium butyrate (NaBu) has been one of 
the most widely used strategy449. NaBu inhibits HDACs and promotes 
hyperacetylation of histones and other nuclear proteins450, which translates into 
an increase in chromatin accessibility remodelling and transcriptional 
stimulation leading to higher titers. Lei et al., reported 2-3-fold increase of 
retroviral p30 protein with 2-20mM of NaBu430. However, NaBu effects seem to 
be linked to the envelope protein pseudotype451; the enhancement of LVV titers 
pseudotyped with VSV-G is controversial63. Other authors have shown an increase 
in titers using chloroquine452 and caffeine453. The former acts by increasing the 
pH of lysosomes and thus preventing degradation of transfected DNA (although 
it is highly dependent on the delivery method with which it is combined454) while 
the mechanism of action of the latter remains unclear. 
Another phenomenon observed during culture of lentiviral packaging cell lines 
using VSV-G is autotransduction, as producer cells do not usually have 
superinfection interference455. Reverse transcriptase inhibitors such as 
azidothymidine455 and tenofovir456 have been used to prevent autotransduction 
of packaging cell lines and their consequent increase in vector copy number. 
However, this components need to be removed during downstream processing, 
which presents further complications. Table 1.2 summarises the main feature of 
all the packaging cell lines reported in the literature to date. 
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Table 1.2. Packaging and/or producer cell lines (PCL) for lentiviral vector production developed and published to date. 
Author Year Vector/SIN?  
Envelope 
protein 
Pack/ 
Prod 
Mode of 
expression 
PCL name 
Parental   
cell line 
Construction method (and comments) Titre (TU/mL) Ref 
Carrol 1994 HIV non-SIN HIV-1 env Pack Constitutive D3.2/B4.7 Vero Stable transfection of a plasmid containing all the packaging genes and 
hygro resistance (only 5’LTR). Ψ, PPT and 3´LTR provided in trans 
102(SupT1 
cells) 
457 
Poeschla 1996 HIV non-SIN  HIV-1 env/VSV-
G 
Pack Constitutive n.s. HeLa T4 Cotransfection of one ΔΨ plasmid containing all the packaging genes, 
env and LTR and a transfer vector. 
>104 (HeLa T4 
cells) 
378 
Corbeau 1996 HIV non -SIN HIV-1 env  Pack Constitutive n.s. phi422 Co-transfection of one ΔΨ plasmid containing all the packaging genes, 
env and LTR and a transfer vector. 
105(CD4+ cells) 379 
Yu 1996 HIV non -SIN HIV-1 env Pack Inducible  (Tet-
Off) 
#69 (HtTA-
1) 
HtT4 
(HeLa) 
Sequential transfection of 2 plasmids containing gag-pol and rev+env 
and eventually the transfer vector. 
7.3x103 (HeLa 
T4 cells) 
408 
Srinivasa
-kumar 
1997 HIV non-SIN HIV-1 env Pack Constitutive 2A.22 B4.14 
5BD.1 
CMT3 Cotransfection of gag-pol+rev, then env and eventually transfer vector. 
Evaluation of the Mason-Pfizer monkey virus (MPMV) constitutive 
transport element (CTE) instead of rev 
103-104 (HeLa 
CD4 cells) 
380 
Haselhor
st 
1998 HIV non -SIN HIV-1 env Pack Constitutive n.s MDS/ 
SW480 
Sequential transfection of gag-pol, rev, then env and finally transfer 
vector  
101-102 (HeLa 
T4 cells) 
458 
Kafri 1999 HIV non -SIN VSV-G Prod Inducible  (Tet-
Off) 
SODK1CG1 293T.tA 
(SODK0) 
Co-transfection of 2 plasmids containing VSV-G and gag-pol, rev and 
subsequent transduction of transfer vector.  
3x106 398 
Kaul 1998 HIV non -SIN HIV-1 env Prod Inducible  (Tet-
Off) 
B16 clone HeLa.tT4  Sequential transfection with 3 plasmids: rev-env, then gag-pol-tat and 
finally transfer vector 
2.9x104 (HeLa 
T4 cells) 
402 
Klages  2000 HIV non-SIN VSV-G Prod Inducible  (Tet-
Off) 
LVG-1/GFP 293 
(TRE.VSV
-G.tTA) 
293 sequentially cot-ransfected with 4 plasmids: tTA+tet/VSV-G and 
then Gag-pol/Rev. Resulting LVG packaging cell line then transduced with 
a transfer vector.  
3.5x106 (HeLa 
cells) 
399 
Farson 
 
2001 HIV non-SIN VSV-G Prod Inducible  (Tet-
Off) 
Lentikat 293G 293G cells were transfected with aplasmid containing gag-pol, rev, tat 
and then sequentially transduced with an inducible VSV-G cassette and 
a transfer vector.  
5x106 400 
Pacchia 2001 HIV non-SIN VSV-G Prod Inducible 
(Ecdysone) 
REr1.35 293T Sequential transfection with3 plasmids: gag-pol-rev (deletions in other 
accessory genes) or CTE, VSV-G and finally the transfer vector 
1.2x105 405 
Sparacio 2001 HIV non-SIN VSV-G Pack Inducible  
(Ecdysone) 
293-Rev 
/Gag/Pol 
293 Sequential co-transfection with tat-rev or rev and gag-pol. 293-gag-pol 
transiently transfected with transfer vector and VSV-G 
3.0x105  (HeLa 
cells) 
406 
Xu 2001 HIV cSIN VSV-G Prod Inducible  (Tet-
Off) 
SODk1 
cSCG 
293T.tTA 
(SODk1) 
Transduction of transfer vector using cSIN and subsequent co-
transfection of 2 plasmids: gag-pol, tat, rev (no nef vif, vpr) and VSV-G  
2.0x106             
(293T cells) 
404 
Kuate 2002 SIV non-SIN VSV-G Prod Inducible  
(Ecdysone) 
SgpG109 293 Sequential transfection with VSV-G and gag-pol and finally transduced 
with transfer vector (containing tat and rev) 
2x105 459 
Ikeda 2003 HIV non-SIN MLV 4070A, 
GaLV, RD114-PR 
Prod Constitutive STAR 293T LTR-γRV transduction of gag-pol genes. RD114 env and rev genes are 
integrated by plasmid transfection. 
1.0x107  (SIN-
LVV)  
389 
Ni 2005 HIV non-SIN VSV-G Pack Inducible  (Tet-
Off) 
17B-5 293 Co-transfection of 3 plasmids containing VSV-G+RRE, gag-pol+TAR and 
TRE-tTA and TRE-rev+tat. Transduction of transfer vector 
3.5x107 (on 
HeLa-tat cells) 
403 
Strang 2004 HIV non-SIN HIV env Prod Constitutive SFV E2E1 
RRV E2E1 
STAR 
(293T 
from389) 
STAR cells (expressing Gag, Pol, Rev, and Tat) were transfected with HIV 
env and transduced with a transfer vector 
>105 (293T + 
polybrene) 
460 
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Cockrell 2006 HIV cSIN VSV-G Prod Inducible  (Tet-
Off) 
SODk3 SODk0 
or 293T 
Transfection with TRE-VSV-G. Subsequent cot-ransfection with gag–
pro and vpr–RT–IN. Transduction of cSIN transfer vector 
1.0x107 (293T) 401 
Muratori 2006 HIV non-SIN? VSV-G Prod Inducible 
(Ecdysone) 
293-Rev 
/Gag/Pol  
18-4406 
(293T) 
293-Rev/Gag/Pol express gag-pol and rev separately and were 
transfected with transfer vector and subsequently with VSV-G 
n.s 461 
Broussau 2008 HIV SIN VSV-G Prod Inducible (Tet-
On/cumate 
switch) 
293SF-
PacLV 
293SF 2 strategies. One-shot: Co-transfection of 3 plasmids: gag-pol, rev and 
VSV-G. Second transfection with transfer vector. Two step: first co-
transfection with 1 plasmid rev, gag-pol; second with 2 plasmids rev and 
VSV-G 
3.4x107 338 
Throm 2009 HIV SIN VSV-G Prod Inducible  (Tet-
Off) 
GPRG-TL20-
GFP 
293T/17 Serial transduction gag-pol, rev+tTA, VSV-G and finally a concatemers of 
transfer vector  
5.0x107 292,42
5 
Stewart 2009 EIAV SIN VSV-G Prod Inducible  (Tet-
On) 
PS5.8, and 
PS46.2 
293T Sequential transfection with coTetR, gag-pol, VSV-G, and transfer vector  <106 63 
Lee 2012 HIV SIN  SVGmu Prod Inducible  (Tet-
Off) 
DC-LV GPR 
cells292 
(293T) 
GPR (expressing gag-pol and rev) transduction with Tet-off/SVGmu 
(env). Transfection of a concatemers of transfer vector 
>107 (293T 
cells) 
462 
Storna-
iuolo 
2013 HIV SIN  RD114-TR  Prod Constitutive RD2-
MolPack-
Chim3 
293T Serial load of HIV gag-pol, rev with baculo/AAV vector to give rise to PK-
7 cell line tat and RD114-TR genes introduced by VSV-G pseudotyped 
SIN LVV. 
1.0x106 393 
Wielgosz 2015 HIV SIN VSV-G Prod Inducible  (Tet-
Off) 
650MNDh
WASp1 
HEK 
293T/17 
Transfection of GRPG or GRPT-G from Throm et al., 2009292 with transfer 
vector concatemer 
>1.0x107 (HeLa 
cells) 
424 
Hu 2015 HIV (IDLV) SIN VSV-G Prod Inducible  (Tet-
Off) 
n.s PVG3  
(293) 
Cells constitutively express tTA and inducible VSV-G expression. Stable 
transfection with gag-pol, tat/rev. Transfer vector transduction with 
cSIN vectors* and transfection**.  
*5x106 
**2x108 
463 
Sanber 2015 HIV SIN  RD114-PR Prod Constitutive WinPac-RD 293FT 293T MLV transduction tagging = 2G; 2G RMCE with gag-pol Subsequent 
transfection of rev, RD114 and transfer vector 
1.0x107 381 
Marin 2016 HIV SIN RD114-TR Prod Constitutive RD3-
MolPack 
PK-7 
from393 
(293T) 
Transduction of PK7 cell lines (expressing gag-pol and rev) with SIN LVV 
with RD114-TR and subsequently transfection of SIN transfer vector 
1.8x106 (CEM 
A3.01 cells) 
382 
Humbert 2016 HIV SIN Cocal Prod Constitutive eGFP2-12 
and C4 1-9 
HEK 
293T 
Serial stable transfection of 293T cells with cocal envelope, gag-pol, rev 
and LV transfer vector (hygro, puro, blast, zeo resistance genes, 
respectively) 
>106 (HT1080 
cells) 
383 
n.s. non-specified; Ref, reference; Pack, packaging cell line; Prod, producer cell line. Titers before concentration.  
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1.2 Cell line development and genome editing 
1.2.1 The conventional cell line development workflow 
Since the approval of the first recombinant therapeutic protein (tissue 
plasminogen activator, tPA) in 1986, ‘biologicals’ have gained presence in the 
pharmaceutical market. According to the FDA, biologicals are medical products 
obtained from natural sources; they are typically large complex molecules 
compared to chemical drugs. Vaccines, therapeutic proteins, tissues or organs and 
cell and gene therapiey products are examples of biologicals. Most of these 
products are typically manufactured in cells deriving from the same cell and with 
a homogeneous phenotype that can be sustained for prolonged periods in culture 
with denominated cell lines. Cell line development consists of the optimisation of 
each of the steps involved in the production of a biological in order to achieve 
scalable, stable (in growth rate, genetically and protein levels) and high yield 
production processes. The cell line development strategy for biopharmaceutical 
production follows an established workflow464: an expression cassette containing 
a gene of interest is introduced into (preferably suspension adapted, serum free) 
a suitable host cell line together with a selectable marker that will confer 
advantage to cells expressing the transgene. After that, selection is applied to 
avoid growth of cells that have not up taken any DNA. Gene amplification 
strategies are often introduced at this stage to increase the number of transgene 
copies. Selected and amplified clones are isolated and its specific productivity 
evaluated using high through put systems. The best performing clones are then 
scaled-up to fed-batch cultures and monitored for long-term productivity and 
stability as well as other factors (proliferation, viability, folding, and secretion) 
prior to cell banking. In this section of the Introduction chapter, potential 
problems typically encountered during the cell line development process will be 
extensively covered. 
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1.2.2 Problems in cell line development and their potential solutions 
Low expression of the transgene of interest 
High levels of expression of heterologous proteins suppose a burden for the host 
cell metabolism. Expression cassettes used for biopharmaceutical production 
usually contain a strong cellular or viral promoter to drive the expression of the 
cDNA of the gene of interest465, terminated with strong polyA signals. In order for 
the mRNA to be more stable and exported to the nucleus for transcription, an 
intronic sequence is normally included between the promoter and the beginning 
of the coding sequence466. Other common modifications include the codon 
optimisation of the DNA sequence to enhance the use of tRNA codons abundant 
in the species467, removal of cryptic splice sites or a more balanced GC content468. 
The selectable marker, can either be expressed under a different promoter or 
under the same promoter as a polycistronic mRNA using an internal ribosomal 
entry site (IRES)469; this way selection or amplification is linked to the transgene 
expression. However, expression of downstream genes in gene fusions separated 
by IRES is lower. Alternatively, 2A peptide sequences allow expression of different 
proteins from a single ORF separated by a picornavirus auto-proteolytic1 18aa 
motif470.  
Silencing of transgene expression 
Although often attributed to cytotoxicity derived from viral proteins, instability 
of vector production has been a common problem associated with transfection, 
mainly due to gene loss or gene silencing460. Some authors claim gene loss 
becomes a problem in sustained cultures471. Nonetheless, other studies have 
shown both instability of expression despite stable copy numbers thus 
attributing instability to gene silencing403, an eukaryotic mechanism to defend 
from foreign DNA471. Selection and maintenance of cells with packaging function 
can be accomplished by expressing packaging genes alongside with a selectable 
                                                        
1  Ribosomal skip mechanism (cis-acting hydrolase elements) has been proposed instead of 
autocleavage813.  
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marker gene. In the development of FLY retroviral packaging cell lines, Cosset et 
al., optimised the distance (74nt devoid of any ATG) between the stop codon of 
the stop codon of the pol gene and the start codon selectable marker in order to 
allow reinitiation of translation. This enabled higher expression of mRNA and a 
better selection of cells expressing viral proteins, leading to higher-titer vector472. 
Optimisation of expression systems can be further achieved by adding elements 
that protect the expression cassette from the effects derived from genetic 
elements located in regions proximal to the integration site. These positional 
effects are often associated with gene silencing occurring as a consequence of the 
methylation of the DNA in heterochromatic regions. Cis-acting elements such as 
chicken lysozyme473, beta-globin474, beta-interferon475, scaffold/matrix 
attachment regions (S/MAR), insulators or ubiquitous chromatin opening 
elements (UCOE)476 can be employed to maintain active chromatin. S/MARs are 
genomic DNA attachment points to the nuclear matrix477, which also act as 
binding sites for CCCTC-transcription factor and nuclear matrix proteins478,479. 
S/MARs create a loop that maintains chromatin transcriptionally active. UCOE 
consists of a methylation free CpG island that keeps chromatin open in 
housekeeping genes480 and showed increased levels of antibody production481 
and restore wild type phenotype when used in SIN LVV in mouse models of SCID-
X1482. UCOE (commercialised by Merck-Millipore) not only increased protein 
titers up to 5-fold483 but also the proportion of high producing clones481. 
Limitations in the cell metabolism 
Increasing demands in protein production pose a metabolic and viability 
limitation for the host cells484. Protein and vector yields have also been increased 
through engineering host cell line homeostatic processes at different levels. Such 
changes have been applied to CHO cell lines for antibody production but could 
feasibly be applied to HEK 293 cell lines for lentiviral production. Anti/pro-
apoptotic regulating factors such as Bcl2 family proteins have been expressed in 
host cells to delay apoptosis485. Type II programmed cell death (or autophagy) 
can also be delayed by overexpression of Bcl-xL or constitutive expressing Akt in 
conditions of nutrient exhaustion486,487. These modifications extend the 
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productive phases of the cell cycle increasing the yield of protein production. 
Overexpression of p27KIP1 and p21CIP1 have shown to arrest the CHO cell cycle in 
the most prolific phase (G1)488 although lentiviral vector production does not 
depend on cell cycle449. Metabolic engineering has also been explored to reduce 
the amounts of ammonia and lactate accumulated in culture, which are toxic for 
the cell489. Cells expressing high levels of glutamine synthetase can convert 
ammonia into glutamine in the presence of glutamate490. Modifications in the TCA 
cycle such as overexpression of pyruvate carboxylase491 or knock-down of LDH-A 
with iRNA492 have also been attempted. Folding, secretion and glycosylation 
profiles can also be optimised although their application is more focused to 
antibody development. 
Other strategies such as directed evolution consist of the application of selective 
pressure to force selection and mutation (mimicking Darwinian engines of 
evolution) and ultimately improve the performance of host cell lines. Cell culture 
at lower temperatures (32°C) has shown increased cell volumes and higher 
productivities (also in HEK 293 cells)493. Prolonged exposure to hydrogen 
peroxide can be applied to enhance the tolerance to genomic instability effect494. 
Low efficiency of integration 
The non-viral integration of heterologous DNA in the host cell genome can be 
achieved by plasmid DNA transfection. Upon exposure of foreign DNA, 10-3 cells 
(depending on the cell type) will insert that into their genome via homology 
dependent or independent mechanisms495. For an ideal DNA transfection, cells 
are generally recommended to be low passage (<20), high viability and mid-high 
confluency (40-80%). Once inside the cell, most nucleic acid molecules are 
degraded in the cytoplasm and only 10% of them reach the nucleus496. 
Microtubules seem to play a role in the intracellular trafficking of plasmids to the 
nucleus497 but the mechanism is not clearly understood. Transfection leads to 
random integration or non-homologous recombination and generation of stable 
transfectants with a frequency of 10-3-10-5 cells498. DNA remains mainly 
episomal467. Under the same conditions of density and media, expression levels 
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were reported to vary over time depending on the number of copies together, the 
site of integration, silencing due to chromosomal rearrangements or methylation 
and the phase of cell cycle can provide heterogeneity in the clonal fitness and 
expression of each clone. The cell cycle is also relevant; cells transfected during 
the S-phase were reported to have maximum uptake and expression499. 
Regarding the quality and type of DNA, contamination of prokaryote DNA with 
lipopolysaccharide endotoxin carryover has been shown to be toxic for the cell500. 
Similarly, integrated DNA can also influence expression of neighbouring 
sequences254.  
Transfection of linearised plasmid is often advised for stable transfection of 
plasmid DNA as free ends are more recombinogenic501. However, this depends on 
the site of linearisation. In addition, linearisation of the plasmids adds digestion 
and inactivation steps with further purifying complications.  
Alternatively to transfection, another non-sequence specific way to efficiently 
integrate plasmid DNA into host cells is using transposon systems. DNA 
transposons are natural genetic elements residing in the genome as repetitive 
sequences that translocate from a specific chromosomal location to another 
through a direct ‘cut-and-paste’ non-replicative mechanism. This mechanism 
maintains a stable copy number, is independent of cellular repair pathways, 
displays low immunogenicity and gene silencing and makes DNA transposons 
very attractive as delivery tools for gene therapy. Transposons naturally contain 
the transposase gene flanked by inverted terminal repeat sequences (ITR). A two-
plasmid system containing the gene of interest (GOI) and selectable markers 
flanked by ITRs and a separate transposase is necessary to avoid uncontrolled 
lateral transfer of the GOI. Several systems have been used for transgenesis and 
mutagenesis across a wide variety of organisms from yeast to mammals: 
Tc1/mariner-like element, Sleeping Beauty502; the Medaka fish-derived system 
Tol2, a member of the hAT family503 and the PiggyBac system504. Transposon 
based system present a more neutral (and safer) integration profile with a slight 
preference for active genes. For this reason, this technology has been combined 
with efficient viral delivery to generate hybrid tools for gene therapy324,505. 
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Cell line development has benefited from transposon technology. The PiggyBac 
system reported high frequency of stable integration and enhanced productivity 
in CHO cells compared to conventional transfection506. Balasumramanian et al., 
reported 3-4-fold increase in volumetric productivities for a Fc-fusion and a 
monoclonal antibody using the same system and cells507. Inducible systems have 
also been developed with PB systems to minimise the effect ot protein 
overexpression on cell stress and growth508. Ley et al., showed that MAR and 
transposons could be combined to improve transgene expression also in CHO 
cells, which turns useful in low copy number expression cassettes or in cassettes 
lacking selectable marker509. 
Transduction is considered the most efficient (95-100% efficiency, calculated as 
the proportion of cells expressing the gene delivered by the virus) means of stable 
gene transfer as vectors possess the inherent ability to deliver the transgene into 
the nucleus. The presence of large portions of human genome occupied by human 
endogenous retroviral vectors (hERVS) reflects that viruses have successfully 
evolved to stably integrate into genomic positions suitable for their propagation. 
Far from the safety concerns such as the potential insertional mutagenesis 
leading to cellular transformation or the patient immune response seen in the 
clinic510, in cell line development the drawbacks are theoretically limited to 
permissiveness of the cell line and the potential cytotoxicity. However, tropism 
can be modified by pseudotyping vectors with proteins to target a specific subset 
of cells. Several alternatives are available for different approaches depending on 
the tropism, intended duration of the expression and gene size.  
Positional effects derived from illegitimate integration 
Illegitimate integration 
The majortity of exogenous DNA integrated into the host chromosome will follow 
a non-homology–based mechanism, also known as illegitimate integration. Upon 
the occurrence of a double strand break, the ratio between homology directed 
repair to non-homologous end joining ratios range from 4:1 to 1:106, being 
typically around 1:103-104 511, although these ratios are subject to cell type and 
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(possibly related) cell cycle. As previously mentioned, and their outcome in terms 
of sequence is less predictable than in homologous directed repair given that 
there is no repair template. Several studies have attempted to clarify the nature 
of this process as a better understanding of the factors that govern this process 
can provide insight for more efficient intergation. DNA that does not degrade in 
the cytoplasm can be modified extrachromosomally either via homologous 
recombination with sequences that share homology512, mutated (indels or 
rearrangement)513 or concatamerised by NHEJ mechanisms (which mutate the 
last 25 nucleotides of each side)514.  
The Non-Homologous End Joining (NHEJ) repair system is more common and 
ligates both ends of the DSB. NHEJ repair enzymes act in any order, and can 
function independently of one another at each of the two DNA ends being joined. 
NHEJ is likely to introduce indels (insertions and deletions), which can sometimes 
impact gene expression. For gene editing purposes, the impreciseness of NHEJ is 
often used to generate a frameshift mutation that disrupts gene expression and 
knockout (or knockdown) genes for the study of their function. 
Modification can also occur once DNA has been integrated. Typically, foreign DNA 
integrates into a few sites displaying a 1-6bp microhomology region between 
copies of transgene in random orientation integrated in tandem by NHEJ515. The 
quantity depends on the genetic instability of the cell type. For example, 
transformed cell types show more complex integration patterns than normal cell 
lines or human cell lines are 30-100 times less likely to integrate exogenous DNA. 
Accessibility to chromatin is another key factor; 15% of illegitimate integration 
were reported in coding sequences, which represent not more than 2-3% of the 
human genome516,517. Interestingly, a study showed that the vast majority of 
illegitimate integration events occurred in AT-rich regions and close to 
topoisomerase recognitions sites, indicating bent regions are integration 
‘hotspots’518. After the integration event, the recipient DNA sequence has also 
been found to be modified516,517,519. Generally the consequences of integration 
comprise the disruption of recipient gene expression but incorporation of 
telomeric regions that could potentially induce chromosomal rearrangements 
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have been described after integration of linearised DNA520. Methylation patterns 
can be also altered although their consequences are not well understood521. 
Instability can also be induced in recipient genomic loci if pericentromeric 
regions are introduced522. In addition, genomic stability is feature specific and 
thus is not constant accross the human genome, varies among cell types and 
external stimuli can also interact with unstable sites523. The probability of a DNA 
fragment to integrate into a locus that already harbours an illegitimate 
integration event was shown to be 100-450 times higher than in a random 
genomic site524. 
The idea of introducing genetic modifications in situ offers unique benefits: not 
only allows modification/restoration of the phenotype525 but also eliminates the 
concerns regarding dose effect and the regulation of expression526. Genome 
editing, defined as the precise nucleotide modification of the genome, provides 
several distinct means for addressing the limitations of previous gene therapy 
approaches. Genome editing is a means of controlled mutagenesis of the genome, 
whether it is done through non-homologous end-joining or homologous 
recombination.  This technology can be employed for therapeutic use by 
efficiently disrupting and inactivating a gene525, precisely fixing a detrimental 
point mutation527, or integrating a correct or useful genetic sequence into the cell 
genome528.   
The ideal gene-editing tool should feature the following characteristics: (i) high 
frequency of desired sequence changes in the target cell population; (ii) no off-
target mutations; (iii) rapid and efficient engineering and assembly of molecules 
that target any site in the genome at low cost; (iv) capability for fine-tuning and 
regulation and (v) amenable to a packaging and delivery approach that will allow 
therapeutic dosing of cells and target tissues both ex vivo and in vivo. 
Homologous recombination  
Upon introduction of DNA into the cell, this can be integrated either by 
homologous recombination or illegitimate integration. Besides canonical HR, 
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small fragment homologous recombination techniques529 are based on 
homologous recombination, allow knock-out or knock-in of DNA fragments. 
Although targeting of specific region of the genome has been achieved for many 
years through homologous recombination, its frequency is low (10-5-10-7 events 
per cell)530 since it relies on naturally occurring double strand breaks and it had 
not been contemplated as a therapeutic alternative531.  
Homologous recombination, also called homologous (directed) repair (HR, HDR) 
is a less common mechanism than non-homologous end joining (NHEJ) in 
mammalian cells (although very common in yeast) given that the repair template 
(a sister chromatid) is only available during mitosis. Unlike HDR, NHEJ is not cell 
cycle dependent. Unlike NHEJ repair mechanism, which introduces insertions and 
deletions (indels), HDR maintains the sequence fidelity; the repaired DNA 
sequence is identical to that before the double strand break532,533. Normally, the 
sister chromatid (and rarely the homolog chromosome) is used as a template to 
repair the DSB but gene targeting exploits the use of external DNA to serve as a 
template and incorporate external or corrected DNA into the cell. Therefore, gene 
addition can be accomplished at in a site-specific manner if donor DNA is 
provided upon the generation of a DSB. In this modality, recombination of a 
cassette (flanked by homology arms) into desired loci of interest, typically safe 
harbours534–536 enables functional gene correction, heterologous transgene 
knock-in or targeted transgene insertion without target gene disruption. Some 
groups have used this strategy to introduce tags when the cohesive sequence 
generated by the nuclease were known537,538. Chen et al., also used this 
mechanism to generate animal models by precisely introducing point 
mutations539. Genome editing tools have also been shown to enable large 
chromosomal rearrangements540,541. However, serious concerns surround this 
approach since off-target DSB are susceptible to causing cancer542.  
In the context of cell line development, successful events must be favoured using 
antibiotic selection until stable pools can be further screened for expression. 
Homologous recombination has been extensively used to modify the genome of 
CHO cell lines to overexpress endogenous genes by the insertion of promoter 
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sequences543, produce antibodies devoid of fucose residues544 and site-
specifically integrate MAR to enhance protein production545. Capecchi and 
Smithies won the Nobel Prize in 2007 for their work on homologous 
recombination, which enabled the generation of transgenic mice, indispensable 
as models for medical research546. 
 
Figure 1.6. Schematic of the proteins and processes involved in DNA repair pathways. 
HDR, Homologous directed repair. Initially, DNA that has suffered from a double strand break 
(DSB) is sensed by the Mre11-Rad50-Nbs1 (MRN) complex, which recruits host DNA repair 
factors through the action of ATM mediators (as in NHEJ). Then, Mre11 processes the 3’ DNA ends 
to generate cohesive ends, and ssDNA fragments are temporarily protected from degradation by 
RPA coating (replication protein A). In the strand invasion step, Rad51 (together with Rad52, 
Rad54 and BRCA2) invades the undamaged homologous DNA creating a displacement loop, which 
serves as a template to synthesise the missing DNA from the 3’ end. Finally, the structure is 
unravelled and resolved by the action of anti-recombinases and resolvases such as RTEL-1 
(regulator of telomere elongation helicase 1), MUS81 (crossover junction endonuclease), EME1 
(Essential Meiotic Structure-Specific Endonuclease 1) and GEN1 (Holliday Junction 5' Flap 
Endonuclease) and the generated strand gets replicated to generate the second strand. 
 
NHEJ, Non-homologous end joining. The DSB is sensed by KU70–KU80 heterodimer complex 
which recruits p53-binding protein 1 (53BP1) and DNA-dependent protein kinase (DNA-
PKcs)547,548. These proteins as well as Ataxia telangiectasia mutated (ATM)-mediated DNA 
stabilisation via phosphorylation of histone H2A.X (also recruited in the HDR pathway)549 
prevents degradation of DNA ends. End processing is by Artemis and subsequently DNA ligase 4 
(LIG4), X-ray repair cross-complementing protein 4 (XRCC4) and XRCC4-like factor (XLF) 
participate in the final ligation of both ends.  
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Nuclease based approaches 
Nuclease based approaches pursue the introduction of DSBs, which increases the 
efficiency of recombination by more than two orders of magnitude550. After 
nucleases cut the DNA, the host’s DNA repair machinery (NHEJ and HDR, always 
active in eukaryotic cells) is employed to enact repairs that can be combined with 
integration of donor genetic material. In the last years, a number of easily 
accessible, relatively simple and highly specific tools have emerged to enable 
genome engineering in many ways for multiple applications. Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR), Zinc Fingers Nucleases 
(ZFN)551,552, MegaNucleases (MN)553,554, Transcription Activator-Like Effector 
Nucleases (TALENs)555 are novel technologies that have changed the paradigm of 
genome editing/engineering for multiple applications. In the frame of cell line 
development, ZFNs have been used to double knockout of the DHFR556, GS and 
FUT8557 gene to maximise genetic amplification or for the disruption of Bak and 
Bax pro-apoptotoc proteins558. Cell line development applications using TALEN 
genome editing technology are less numerous due to its relatively complex 
assembly and longer timelines. Knockout of α(1,3)-fucosyltransferase (FucT) and 
the two β(1,2)-xylosyltransferase (XylT) plant genes is an example of potential 
applications of this technology to generate proteins with a more mammalian 
glycosylation pattern559. However, In this project we have used the CRISPR system 
(that will be discussed in more detail but the reader is referred to the following 
reviews on the other genome engineering technologies560,561. 
 Clustered Regularly Interspersed Palindromic Repeats / CRISPR-associated 
protein (CRISPR/Cas)  
CRISPR/Cas proteins naturally function as an adaptive immunity system in 
bacteria and archaea, to defend the organism against foreign nucleic acid 
sequences562–566. The bacterial immunity function observed in the CRISPR/Cas 
systems can be divided in two phases: (i) adaptation, where a segment of the 
foreign DNA is excised and incorporated in the CRISPR array as a protospacer 
(mainly carried out by Cas1 and Cas2)567,568 and (ii) effector, where the pre-crRNA 
(Crispr RNA) is expressed, processed to mature crRNA569–572 and mediates 
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complex with the Cas9 protein that will cleave foreign sequences573,574. This 
second phase encompasses several CRISPR systems according to the composition 
of their effector function575,576. Type I and type III (as well as the putative type IV) 
belong to class 1 CRISPR systems and mediate their interference through multiple 
proteins and Csm/Cmr effector complexes575,577. Unlike class 1 systems, class 2 
systems employ a single effector (Cas) protein  to cut foreign DNA and include 
type II and type V CRISPR Cas systems570,578,579. Cas9 protein (950-1,600aa 
depending on the species) is the effector protein of class 2 type II CRISPR system 
and possesses a RuvC-like and a HNH nuclease domains580.  
 
Figure 1.7. Schematic of the RNA-guided genome editing CRISPR-Cas9 nuclease system. 
REC, recognition subunit; NUC, nuclease subunit; PAM, protospacer adjacent motif; HNH and RuvC 
are endonuclease domains named due to the critical His-Asn-His residues and E.coli DNA repair 
protein, respectively. 
 
S.pyogenes CRISPR-Cas9 system was engineered to induce site-specific DSB into 
the host genome and enable DNA edition using the host cell DNA repair 
machinery. The SpCRISPR-Cas system consists of the Cas9 nuclease and a single 
guide RNA (gRNA). Guide RNA is composed of a tracrRNA (transactivating) and 
the crRNA. In 2012, Jinek et al., showed successful fusion of these two 
components into a single-chain guide RNA (sgRNA), which simplified the system 
even further579. The sgRNA hybridises with a complementary 20bp sequence of 
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the sgRNA (known as the protospacer), which is preceding a species-specific 
protospacer adjacent motif (PAM) and directs the nuclease to introduce a DSB 
between the 17th and 18th position of the sgRNA complementary sequence. This 
will trigger the host cell DNA to edit the DNA via NHEJ (error prone, introducing 
indels) or HDR (precise repair, used to integrate sequences).  
In terms of design, CRISPR-Cas9 system allows targeting of virtually any sequence 
in the host genome. The ability to redirect the CRISPR/Cas system to new target 
sites by only swapping the 20 base pair targeting sequence of the gRNA is a 
significant advantage compared to MN, MegaTAL, ZFN and TALEN systems due to 
its simplicity of design, inexpensiveness and multiplexing potential. The only 
constraint is that the desired cleavage site must be located immediately upstream 
from PAM (protospacer adjacent motif). These three nucleotides are specific to 
each bacterial species from which the Cas9 and gRNA are derived.  In the case of 
the standard CRISPR-Cas9 system, derived from Streptococcus pyogenes, the 
sequence typically used is ‘NGG’. SpCas9 also cuts upstream a ‘NAG’ PAM, although 
cutting efficiency is reduced to one fifth581. 
Despite being a recent editing system, the CRISPR-Cas9 has been used for 
multiple application such as high through put functional screening582, labelling of 
several loci (CRISPRainbow)583. Knock-in approaches have been used to add 
foreign DNA into the genome of mouse and human embryonic stem cells584,585, 
mouse embryos586,587 or stem cells to generate transgenic animal models588 or 
even CHO cells for cell line development589. Interestingly, CRISPR-Cas9 system has 
also been used to prevent HIV proviral replication. However, while some indels 
block viral replication others mutate the sgRNA recognition of target sequence 
and allow the virus escape contributing to the generation of resistant viruses590. 
Like other nucleases, CRISPR-Cas9 is able to promote genome rearrangement and 
could be used as a tool to study cancer540.  
In June 2016, the first CRISPR clinical study received approval by the NIH advisory 
committee for treatment of cancer. The ex-vivo treatment, manufactured by 
University of Pennsylvania, consists of a triple edition of patient T cell genome591. 
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Examples of CRISPR-Cas9 in cell line development include the knock-in of a 3.7kb 
reporter cassette containing mCherry gene and a neomycin selectable marker 
into the COSMC locus589 or a FUT8 knockout case study by WuXi Biologics592. 
Recombinase based approaches 
Alternatively to HDR or nuclease-based methods, which are triggered by the 
presence of DSB in the DNA, recombinases catalyse cleavage and reunion between 
specific sequences or recognition sites of the target DNA molecule and can lead 
to insertion, deletion or inversion of DNA fragments depending on the orientation 
of the recombinase recognition site593. According to whether their active 
nucleophilic aminoacid residue in the catalytic domain is a Tyr or a Ser, 
recombinases can be classified in two families (serine and tyrosine 
recombinases). Serine recombinases (or resolvases) catalyse irreversible 
reactions and can be further splitted into small (excision, identical recognition 
sites) and large (excision, inversions, integration, non-identical recognition sites). 
Tyrosine recombinases can be uni- or bi-directional and both can catalyse 
excision, inversion and integration although the former acts on identical 
recognition sites and its recombination is reversible and the reaction catalysed 
by the latter is irreversible and acts on non-identical recognition sites593.    
Although the basis of the recombination is a series of transesterification 
reactions, the mechanism of recombination differs between serine and tyrosine 
recombinases594. Serine recombinases cleavage and strand transfer occurs at the 
same time with all four ends bound to the protein. Cleavage of DNA strands by 
tyrosine recombinases occurs and intermediate structures are resolved via the 
Holliday junction pathway595. Most of the recombinase-mediated cassette 
exchange (RMCE) strategies performed in the last years employ one of the 
following systems:  
The ΦC31 (or R4) /attB-attP system is an example of a large serine recombinase 
and mediates recombination between distinct recombinase recognition sites. 
Attachment sites (att) in phage and bacterial sequences (or 34bp attB and 39bp 
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attP)596 allow unidirectional irreversible recombination by the Streptomyces 
phage ΦC31 or the R4 integrases (serine recombinases597) generating attL (left) 
and attR (right) sites in human and mouse cells598. In addition, the existence of 
endogenous attP-like sequences or ‘pseudo’ attP sites599,600 opened the door to 
gene therapy although it also raises concerns for their potential genomic 
rearrangement.  
The Cre/loxP system derived from the bacteriophage P1601,602 is composed of a 
38kDa protein that ‘causes recombination’ and a 34bp target sequence  (locus of 
X-over of P1) consisting of a 8bp spacer sequence flanked by 13bp inverted 
repeats (or palindromic arms). This system has been exploited for recombinase-
mediated cassette exchange (RMCE), which follows two steps: (i) random 
integration or site-specific HR-mediated introduction of the recombinase 
recognition site (a landing platform) and (ii) retargeting of the initially targeted 
site with the cassette of interest flanked with recombinase recognition sites. 
Efficient integration was achieved using this strategy603,604. Cre and ΦC31 
recombinases, toxic for the cell605,606, were only expressed transiently. 
Nevertheless, the first generation of these strategies suffered from reversibility 
and incorporation of bacterial sequences in the host chromosome. The 
composition of the recombinase recognition site was studied to give rise to 
mutants that allow unidirectional and irreversible607–609. The most common 
Cre/loxP spacer mutants (lox511 and lox2272610,611) and arm mutants (lox61612 
and lox71607) supress the ability of the recombinase to revert (excise) the 
integration. Not only mouse transgenesis613 but also antibody (anti-RhD in 
CHO)614 and retroviral vector production (2x107 TU/mL in HEK 293)391,392 also 
have benefited from the second generation RMCE. The S.cerevisiae Flp/FRT 
system615 (or its thermostable improved version Flpe/FRT616) is also a 
bidirectional tyrosine recombinase. Similarly to the Cre/loxP system, the second 
generation RMCE using F3 and F5 showed reduced excision of recombined 
sequences617.  
Kameyama et al., and later Obayashi et al., perfected the Cre/loxP system by 
allowing irreversible serial accumulative and unidirectional retargeting of 
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cassettes after targeting of two and one (respectively) loxP sequences614,615. 
However, these heterologous recombinases rely on the pre-existing recombinase 
recognition sites (previously introduced via HR) and as a consequence, the 
number of potentially targeted genomic positions is limited.  
Custom hybrid recombinases can be generated by combining a catalytic domain 
with invertase/resolvase function with a ZFP or a TALE domain618. The catalytic 
domain of the recombinase recognises a 20bp core sequence that is flanked by 2 
ZFP or TALE binding sites. Given the cooperative nature of the enzyme specificity, 
different recombinase catalytic domain variants (Gin α, β, γ, δ, ε, and ζ, with 
different specificities619) from bacteriophage Mu DNA invertase Gin that contact 
with DNA dimers have been identified and can be modularly ‘mixed and matched’ 
(using plasmid assembly systems such as OPEN620 or CoDA621) to yield 
recombinase variants with  distinct specificities. 
Wide range of productivities of selected cells 
Growth rates and specific productivities of clones resulting from random 
integration are highly heterogeneous. Intrinsic interclonal variation combined 
with acquired drift after isolation are thought to explain this phenomenon622. A 
higher stringency can augment the effect of selectable marker and reduce the 
number of subsequent screening. Stringency is the degree of selective pressure 
applied to cells post-transfection (or transduction) with the objective of killing 
clones that have not taken up any copies of transgene DNA. Stringency can be also 
understood as the ratio between antibiotic uptaken vs detoxifying counteracting 
measure taken by the cell. Thus, low producers can be also eliminated by 
increasing the stringency. However, despite increasing productivity, an increase 
in the stringency of selection can affect cell growth if antibiotic concentrations 
are too high623. Stringency can be increased during antibiotic selection if the 
selectable marker is attenuated. This way, the expression of the GOI and 
selectable marker has to be higher to overcome the selection process and 
stringency can be increased at lower concentrations. This can be achieved by 
using AU-rich elements (AREs) to promote selectable marker mRNA degradation 
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or polypeptide regions rich in proline (P), glutamic acid (E), serine (S), and 
threonine (T) (PEST) regions (from the C-ter murine ornithine decarboxylase), 
which destabilise selectable marker proteins624. Selection stringency can be also 
improved by using a weak promoter such as the SV40 early or non-optimal IRES 
can be used in combination with the selectable marker. Alternatively, codon 
deoptimisation625 or mutation of the selectable marker have also been attempted 
reporting the latter a 10-fold increase in recombinant protein titer626. For 
example, clones mutated neomycin phosphotransferase II display reduced 
affinity for the antibiotic, which promotes overexpression of the selectable 
marker to survive627. In addition, the probability of isolating a high producer has 
also been demonstrated to be higher if the selectable marker is attenuated. 
Positioning of the selectable marker downstream of the gene of interest is also 
critical to colocalise selection events and mitigate the effects of gene 
fragmentation of bicistronic cassettes, a phenomenon that occurs upon stable 
transfection628. 
Low copy number of integrated vector 
As a result of illegitimate integration derived from transfection, expression of the 
gene of interest driven by an uncontrolled low number of copies may be 
unsufficient for production goals. Alternatively, low levels of expression can be 
due to recombination-mediated reduction of the number of ‘head-to-tail’ 
integrated copies of transgene. Mammalian cell lines have the ability to undergo 
genomic rearrangements and increase the copy number of resistance genes upon 
increasing concentrations of selectable marker. This phenomenon, known as 
genetic amplification, was first observed in cancer cells treated with increasing 
concentrations of a chemotherapeutic drug (methotrexate, MTX)629 and can be 
used in cell line development to increase the copy number of integrated vector. 
Gene amplification strategies are based on the co-transfection of the gene of 
interest alongside a selectable marker i.e. dihydrofolate reductase (DHFR). DHFR 
is an endogenously produced protein, which can be blocked by MTX630,631. 
However, after 2-3 weeks of culture with the drug in auxotrophic conditions 
(GHT-minus media) that prevent synthesis of thymidylic acid and purines 
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through alternative pathways, surviving cells contain several hundreds of copies 
of the DHFR gene integrated in the chromosomes alongside the gene of 
interest632, resulting in 10-20 fold increase in the specific productivity633.  
Adenosine deaminase (ADA)/ 2-deoxycoformycin system634 or the glutamine 
synthetase/methionine sulfoximine (GS/MSX) system work in a similar 
fashion347. Knock-out of endogenous copies of these genes has been successfully 
attempted to enhance the effect of the gene amplification635. 
High analytical burden of screening clones 
The frequency of high producing clones is rare (10-3)636, as insertion into a high 
transcribing site is not common and usually expression imposes a metabolic 
burden for the clones. Therefore, hundreds or thousands of clones are typically 
screened, which involves a labour-intensive process that can take up to 6-12 
months355,637. Often clones with higher productivity also show slower growing 
rates638,639. Ideally, high productivity and growth but also stable production is 
desired for scale up.   
Traditional screening methods 
Limiting dilution cloning (LDC) is typically used to isolate clones because of its 
simplicity, reliability and cost640. A few hundreds individual clones are 
individually seeded at low densities so that each well only contains a single cell. 
The best producer clones are assayed for specific productivity by ELISA and a 
second round of cloning is required to ensure clonality since statistical analysis 
indicates it may not be guaranteed641. Imaging systems can assist with this on that 
matter. Therefore, a process like this is highly resource- and time-consuming 
given that it can take several months and only a few hundred clones can be 
screened. 
FACS-based methods 
Flow cytometry and cell sorting is a relatively inexpensive high-throughput 
alternative that can help increase the number of screened clones and can be 
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combined with LDC. Briefly, a laser interrogates the florescence of the protein or 
cell and an electric charge is applied to the droplet to segregate different 
subpopulation. Cell sorters can reach speeds up to 108 cells per hour642. Clone 
productivity can be screened by analysing the expression of a surface antibody or 
proteins on the cell membrane 643. Alternatively, bicistronic expression of the 
gene of interest and CD20 ligand (a protein that is not normally expressed in the 
cell membrane) separated by IRES can be used to assess gene expression. When 
independently translated, fluorescent antiCD20 allowed accurate correlation of 
antibody production644. Nevertheless, the ligand production is a metabolic 
burden for the cell and heterogeneity in the fluorescence levels. If the product is 
not expressed in the membrane, GFP can be used as a reporter gene. Meng et al., 
and Mancia et al., and others demonstrated that a correlation exists between the 
level of GFP fluorescence and the expression of heterologous recombinant protein 
when co-expressed using two promoters645,646. These findings led to the use of 
GFP as a reporter gene for generating stable, high-expressing cell lines and 
proteins by gating for high eGFP producers by FACS644–646. Yoshikawa et al., 
described a method based on intracellular fluorescently labelled methotrexate 
that can quantitatively penetrate the membrane and bind DHFR647. Resistance to 
MTX is proportional to dhfr copy number, which was expressed along with the 
gene of interest.  
Secretion-based assays 
Unlike previously described methods, gel microdrop technology directly 
evaluates protein expression at a single cell level. A cell sorter distributes 
individual cells into a gel microdrop of biotinylated agarose that is linked using 
avidin bridge to an antibody that specifically recognises the secreted protein. 
Once the protein of interest is bound to the capture antibody, a fluorescently 
labelled antibody binds it and allows detection of the secreted protein648. The 
main pitfall is the reduced capacity of this method as only 10% of the droplets 
contain a single cell649.  
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Affinity matrix-based reaction assays follow the same principle as the gel 
microdrop technology although cells are biotinylated and bridged to a capture 
antibody. Secreted proteins are then sandwiched between capture and detection 
antibody (with a FITC molecule conjugated). Cells are cultured in high-viscosity 
low permeability medium and high producers can be subsequently sorted and 
isolated. Reduced timelines and 5-fold increase in titers were reported using this 
method650. 
Automated systems 
Laser-enabled analysis and processing LEAPTM (Cyntellect) is a high-throughput 
automated screening technology that picks adherent and suspension cells651 
immobilised in a capture matrix based on secretion using a specific antibody. The 
laser is used to eliminate undesired neighbouring cells and reduce heterogeneity 
resulting in a 20-fold increase in productivity652. The main drawback of this 
method besides its cost is the potential damage occasioned to the cell636. The Cell 
Xpress system combines the LEAP technology with multicolour live imaging, 
specific detection reagents and a fully automated close contained environment to 
minimise the risk of contamination652. 
Other systems such as CellCelectorTM (Aviso) and Clone PixTM (Genetix) also use 
semi-solid medium to immobilise cells and limit diffusion of the secreted protein, 
which immunoprecipitates with the fluorescently labelled capture antibody and 
forms a halo653. The CelloTM closed system (TAP Biosystems) integrates automatic 
cell culture, microscopy and analytic devices (Sonata, Piccolo, CElloSellecT) 
combined with high-throughput robotics and advanced software. Transfected 
cells are introduced into the system, which automatically seeds them into plates. 
Although the sophistication of this system is translated into expensive equipment, 
up to 800 plates can be processed in parallel636. 
Most high through put selection methods reviewed in this section rely on the use 
of fluorescent antibody and semisolid media combined with sophisticated 
automated systems, which increases screening costs. The publication of the 
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human229 and the CHO genome654 boosted comparative genomics to identify 
genes associated with cell growth and productivity. Predesigned cDNA 
microarray CHIPS655,656 allow high through put determination of expression 
levels although commercial arrays are only able to detect certain standard genes. 
Recently, whole transcriptome analysis opened the door to high-throughput 
screening of expression levels at a genomic level. However, expression values are 
gene-specific and the position effect of the integration of the transgene is not 
always reflected in this analysis.  Therefore, there is a need for a simple high-
throughput system with higher accuracy than FACS that can account for 
expression and site of integration and correlate this to transgene expression 
levels. 
As stated before, in the context of cell line development, the analytical burden is 
intense given the heterogeneity of the clones even though selection strategies are 
employed. In an academic setting, where most gene therapy projects originate, 
large amounts of screening resources may not be available. The integration 
properties of lentiviral vector, enhancing site-specific integration into pre-defined 
loci could also help to bring production of high-performing clones within the 
reach of academic laboratories. This project presents a potential solution to this 
problem using barcode-mediated selection of high producing clones.  
1.2.3 A solution for simple high-throughput screening: a barcode-based 
method 
Screening based on genetic tags (i.e. ESTs) was originally accomplished using 
DNA microarrays657,658, but became progressively replaced with next-generation 
sequencing657,659–662. The latter allows for more quantitative, high-throughput 
and accurate data analysis. However, at that time, high through put sequencing 
technology also presented inherent limitations in terms of costs and number of 
low complexity samples sequenced in parallel (capacity). Physical segregation of 
samples into different lanes allows limited multiplexing and limits the number of 
conditions to be tested and involves higher processing times and costs. 
Parameswaran and Meyer introduced the barcode technology (also known as bar 
codes or bar-codes) that enables efficient tagging multiple samples run in 
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parallel663. DNA barcoding is an innovative technology that consists of marking 
samples with a specific DNA sequence tag so that they can be pooled together in 
the same sequencing lane/run. Although barcoding was initially applied to enable 
routine parallel processing of multiple sequencing datasets, multiple groups 
implemented the barcode system to specifically tag and retrieve samples of 
different biological origin (cells, lineages, tissues) maximising the multiplexing 
potential of this technology. In this study, sequencing barcoding will be referred 
as indexing, in order to distinguish it from clonal cell marking barcodes or cellular 
barcoding.  
In the last years, cellular barcoding has been used for efficient and quantitative 
monitoring of clonal dynamics and spatial distribution of integration sites during 
gene correction of hematopoietic stem cells in clinical trials661,664. In this context, 
vector-host chromosome junctions are retrieved using integration site analysis 
techniques such as ligation-mediated PCR (LM-PCR). DNA barcoding has been 
consolidated as an inexpensive, relatively simple and powerful method that 
allows sample multiplexing and has been used in multiple applications including 
not only characterisation of clonal dynamics of hematopoietic, bacterial 
populations665 and discernment of cell lineages but also to label different sources 
of RNA for Cap Analysis of Gene Expression (CAGE)666 or even for the 
identification of rare HIV drug resistance mutations667. 
Barcode library design, quantification of complexity and error correction  
Although the construction of DNA libraries is reported to be a slow and laborious 
process due to the relative inefficiency of ligation based methods, the library can 
be used for several applications668–671. The construction of a nucleotide library 
appears to be a simple and inexpensive task consisting of subcloning a string of 
“N”s into a vector backbone.  Nonetheless, several aspects need to be taken into 
account when generating a randomized sequence tag. 
The number of possible combinations makes multiplexing practically limitless, if 
one considers the number of variants equivalent to the fourth power of each 
random nucleotide in the DNA stretch. However, the length of the variants also 
influences the complexity or theoretical diversity of the library. The number of 
Chapter 1. Introduction  
 102 
edits needed to transverse or transit from a barcode variant to its nearest 
neighbour is a critical. This parameter is known as the Hamming distance (if 
insertions and deletions are not considered, in which case would be Leveinshtein 
distances). In the case of libraries with low Leveinshtein distance, false barcodes 
can be more easily generated from polymerase or next-generation sequencing 
errors, leading to misrepresentation of the actual library complexity. The mean 
number of dissimilarities between variants is a trade-off and can be modulated 
when playing with two of parameters: sequencing depth and length of the 
barcode. Higher sequencing depths enable the analysis of longer barcodes and, in 
theory, higher complexity libraries. However, they are directly linked with a larger 
number of misreads, which contributes towards less dissimilarities, making the 
clusters less differentiated and distinguishable and thus decreasing the library 
complexity. The length of the barcode can also play an important role in the 
library design and is dependent on the throughput of the application. Shorter 
barcode lentghs reduce the entropy introduced in the system and diminish the 
mean number of dissimilarities observed between the variants of a library. 
Different transduction protocols have been described to minimise the chance of 
biasing the fate of progenitor cells. While cell fate does not pose a problem in this 
study, multiple integration of barcodes into one cell and repeat usage should be 
considered. Integration of multiple barcodes into one cell can be minimised by 
using lower transduction efficiencies/multiplicity of infection and evaluated by 
vector copy number qPCR. In general, it does not influence the outcome since 
each integration site can be individually retrieved even in the same cell. 
A more significant concern arises if multiple cells or integration sites have the 
same barcodes, which is known as repeat usage of barcode variant. This issue 
might have been originated during the library preparation, transduction or 
intrinsically in the number of cells or the library size. This will result in 
ambiguous assignments and the loss of a biological relevance and constitutes an 
experimental parameter that requires to be optimised.  In theory, the probability 
of a barcode variant tagging two different cells is negligible. However, it is 
generally considered best to limit the number of cells to be tagged to be 10% of 
the library sample space672. 
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Similar approaches 
Semiquantitative information can be extracted from barcode quantification 
derived from sequencing or microarray data. Contribution to lineages can be 
extrapolated from the read representation of a particular barcode variant, 
although those variants with less counts can be underestimated662. However, 
quantification of expression derived from barcode integration in a specific locus 
constitutes a different approach. Filion’s laboratory recently introduced the TRiP 
technology, which combines Sleeping Beauty transposase to drive the integration 
of plasmid library (generated by barcoding PCR) containing a reporter gene673. 
Co-transfected cells express the reporter gene and barcode at different levels 
subject to their integration site and the barcode allows for correlation of barcode 
counts with their position in the genome. Barcoded plasmid integration sites are 
analysed by inverse-PCR and coupled to mRNA transcripts, which contain the 
barcode within the GFP ORF to measure their individual expression by 
quantitative high-throughput sequencing. The application of this technology in 
their lab is to study expression in different chromatin context. 
The CellTracker® technology released in 2013 by Cellecta, Inc (when this project 
was initiated) also shares some of the same principles with this project. A library 
consisting of 50 million barcodes is stably integrated into a starter founder 
population of cells using lentiviral vectors674. The tag is passed onto the cell 
progeny upon cell replication; and a red fluorescent protein (RFP) and puromycin 
marker are also included in the lentiviral vector to help maintain selection of 
barcoded cells. This system has been applied to cancer cells to monitor 
differentiation over the course of drug treatment216, 217. However, the location of 
the barcode (in the middle of the lentiviral vector backbone, Appendix A) does 
not enable any association of barcode counts to a particular integration site.  
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Hypothesis and objectives 
This project intends to prove the following scientific hypothesis: 
“It is possible to use cellular barcoding as tools to identify high transcribing 
regions derived from lentiviral integration in host cell lines. Such loci can 
prove useful to insert lentiviral components for packaging cell line 
development.” 
In order to address this hypothesis, a lentiviral vector library containing multiple 
DNA sequence tags (barcodes) will be generated. HEK 293 host cell lines will be 
transduced at a low MOI to allow integration of the barcoded provirus into their 
genome. Chromosome-vector junctions containing the barcode will be identified 
using ligation-mediated PCR (LM-PCR) and next-generation sequencing. In 
parallel, barcoded RNA reads from transduced cells will be analysed via RNA-Seq.  
The RNA reads with higher number of barcode counts will be correlated to a 
genomic position. Finally, a donor plasmid containing a lentiviral transfer vector 
will be specifically targeted into such loci using CRISPR-Cas9 genome editing 
technology and titers of the resulting packaging cell lines assessed.   
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Chapter 2  
MATERIALS and METHODS 
2.1 Materials 
2.1.1 General reagents 
Table 2.1. List of general reagents used in this study. 
Reagent    Manufacturer 
Restriction enzymes   Thermo Fisher Scientific (Waltham, MA, USA) 
1kb Plus DNA ladder    Thermo Fisher Scientific  
SYBR Safe DNA gel stain  Thermo Fisher Scientific 
Agar      Sigma-Aldrich (Dorset, UK) 
Vegitone lysogeny broth  Sigma-Aldrich 
Tryptone    Sigma-Aldrich  
Yeast extract    Sigma-Aldrich 
Agarose     Sigma-Aldrich 
Molecular biology grade water Sigma-Aldrich 
10x Orange G DNA loading buffer BioVision (Milpitas, CA, USA) 
Ultra Pure 10x TAE buffer  Thermo Fisher Scientific 
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DNA polymerase I large                       New England Biolabs (Ipswich, MA, USA) 
(Klenow) fragment 
dNTP Mix    Promega (Manheim, Germany) 
Dimethyl sulfoxide (DMSO)   Sigma-Aldrich 
Ampicillin     Stratagene  (La Jolla, CA, USA) 
Kanamycin     Sigma-Aldrich  
FastAP thermosensitive alkaline       Thermo Fisher Scientific 
Phosphatase     
Gey’s balanced salt solution  Sigma-Aldrich 
Hank’s balanced salt solution Sigma-Aldrich 
Trypan Blue    Sigma-Aldrich 
S.O.C medium    Thermo Fisher Scientific 
Platinum quantitative PCR                  Thermo Fisher Scientific 
Supermix–UDG with ROX  
T4 DNA ligase    Thermo Fisher Scientific 
Polyethylene glycol (PEG) 4000 Thermo Fisher Scientific 
Glycerol (≥99%)   Sigma-Aldrich 
Ethanol (≥99%)   Sigma-Aldrich 
Isopropanol (≥99%)   Sigma-Aldrich 
Polyethylenimine (PEI)  Sigma-Aldrich 
T4 Polynucleotide kinase (PNK) Thermo Fisher Scientific 
Disposable scalpels   Swann-Morton (Sheffield, UK) 
Cloning rings    Sigma-Aldrich 
PIPES2 (≥99%)    Sigma-Aldrich 
Calcium chloride (CaCl2, ≥93%)  Sigma-Aldrich 
Potassium chloride (KCl, ≥99%) Sigma-Aldrich 
Sodium azide (NaN3, ≥99%)  Sigma-Aldrich  
Manganese dichloride (MnCl2,           Sigma-Aldrich 
 ≥99%)  
                                                        
2 1,4-Piperazinediethanesulfonic acid, piperazine-1,4-bis (2-ethanesulfonic acid), piperazine-N,N′-bis (2-
ethanesulfonic acid) 
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Potassium hydroxide (KOH, ≥85%) Sigma-Aldrich 
Sodium chloride (NaCl, ≥99%) Sigma-Aldrich 
Magnesium chloride (MgCl2, ≥99%)  Sigma-Aldrich 
Magnesium sulphate                            Sigma-Aldrich 
(Mg2SO4, ≥99%)  
2.1.2 Reagents for PCR and qPCR 
Table 2.2. List of reagents used for PCR and qPCR in this study. 
Reagent       Manufacturer 
Q5 High-Fidelity DNA polymerase    New England Biolabs 
One-Taq DNA polymerase     New England Biolabs 
Oligonucleotide primers     Thermo Fisher Scientific 
Oligonucleotides probes                       Thermo Fisher Scientific 
2.1.3 Kits 
Table 2.3. List of kits used in this study. 
Kit        Manufacturer 
Cell line Nucleofector Kit V      Lonza (Slough, UK) 
DNeasy Blood and Tissue Kit                  Qiagen (Manchester, UK) 
EndoFree Plasmid Maxi Kit      Qiagen  
QIAprep Spin Mini prep Kit      Qiagen 
QIAquick Gel Extraction Kit     Qiagen  
QIAEXII Gel Extraction Kit     Qiagen 
QIAquick PCR Purification Kit     Qiagen  
RNeasy Plus Mini Kit                  Qiagen 
Topo-TA PCR Cloning Kit      Thermo Fisher Scientific 
Profection Mammalian Transfection Calcium Phosphate    Promega (Madison, USA) 
DNA-free DNA removal Kit                             Thermo Fisher Scientific 
RNA Clean & Concentrator-5                                         Zymo Research  
 (Cambridge, UK) 
Chapter 2. Materials and Methods  
 109 
2.1.4 Parental plasmids 
Third generation lentiviral vector pRRL.SIN.cPPT.PEW was originally obtained 
from Didier Trono’s laboratory677. The third generation lentiviral plasmid 
originally included the enhanced GFP reporter gene (eGFP) under the control of 
the phosphoglycerate kinase (PGK) promoter and contained the Woodchuck 
hepatitis virus post-transcriptional regulatory element (WPRE) downstream of 
eGFP. Plasmid map is shown in Appendix A. 
The EF-1 alpha short promoter (EFS) was obtained from a third generation 
lentiviral vector expressing human alpha-iduronidase, pCCL EFS hIDUA, from 
Axel Schambach and Chris Baum’s group. Plasmid map is shown in Appendix A. 
The zeocin resistance cassette cloned in the AvrII site of the pRRL.SIN. 
SyntLTR.cPPT.EEW was obtained from pcDNA3.1Zeo(+) (Thermo Fisher 
Scientific, V860-20). Plasmid map is shown in Appendix A. 
GeneArt constructs for CRISPR-Cas9-mediated knock-in contain two 800bp 
homology arms (for genomic positions described in Chapter 5) and recombinase 
recognition sites (attB, loxP and FRT) flanking a multi-cloning site. Unlike the 
parental plasmid for EMX1 donor, the plasmid that gives rise to the EGFEM1P and 
CUL5 donor constructs contains a blue fluorescent protein gene under the control 
of the CMV promoter and upstream the SV40 early polyA signal. Plasmid map is 
shown in Figure 5.1. 
pTelo plasmid was obtained from GSK Cell and Gene Therapy Lab and was used 
as the plasmid only contains pBR322, Kanamycin resistance gene, a lacZ reporter 
gene and a short non-coding human telomerase amplicon was used as a qPCR 
standard. The plasmid map is shown in Appendix A. 
CRISPR-Cas9 plasmids were obtained from Sigma-Aldrich. For EMX1 genomic 
position, two separate plasmids (pCMV-cas9 and pU6-gRNA, both with 
Kanamycin resistance) encoded the expression of the Cas9 protein and the EMX1 
sgRNA, respectively. In the case of EGFEM1P and CUL5 genomic positions, the 
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sgRNA+Cas9 were expressed from the same plasmid pCMV-Cas9-RFP (the Cas9 
downstream of the sgRNA). Expression of Cas9 can be assessed by RFP 
fluorescence as this marker is fused with the Cas9 protein using a 2A element. 
Plasmid maps are shown in Figure 5.2. 
2.1.5 Bacterial strains (E. coli) 
Stbl3 cells       Thermo Fisher Scientific 
 
Genotype: mcrB mrr hsdS20 (rB-, mB-) recA13 supE44 ara-14 galK2 lacY1 proA2 
rpsL20(StrR) xyl-5 λ- leu mtl-1 F 
DH10-beta cells  (Dong Hanahan laboratory) New England Biolabs 
Genotype: Δ(ara-leu) 7697 araD139  fhuA ΔlacX74 galK16 galE15 e14-
ϕ80dlacZΔM15  recA1 relA1 endA1 nupG  rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-
mcrBC) 
2.1.6 Mammalian cell lines 
Table 2.4. List of host cell lines used in this study. 
Cell line  Description 
HEK 293T               Human Embryonic Kidney cell line (adherent culture)  
HEK 293 SA RIX  Human Embryonic Kidney cell line (suspension culture) 
HEK293-6E               Human Embryonic Kidney cell line (suspension culture) 
 
HEK 293T cells678 were obtained from the Institute of Child Health/UCL, London, 
UK. HEK293 SA RIX cells were obtained from GSK vaccines, Rixensart (Belgium). 
HEK293 6E cells were originally obtained from National Research Council of 
Canada (#L-11266)376.  
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2.1.7 Media and supplements 
Table 2.5. List of media and supplements used in this study. 
Medium or supplement     Manufacturer 
OPTI-MEM        Thermo Fisher Scientific 
Dulbecco’s Modified Eagle Medium (DMEM)   Thermo Fisher Scientific 
CD293        Thermo Fisher Scientific 
Freestyle 293       Thermo Fisher Scientific 
GlutaMAX       Thermo Fisher Scientific 
Pluronic F-68 (100X)                  Thermo Fisher Scientific 
HyClone G418 solution     Thermo Fisher Scientific 
Dulbecco’s Phosphate Buffered Saline (DPBS)  Thermo Fisher Scientific 
TrypLE Express Enzyme, no phenol red    Thermo Fisher Scientific 
Fetal bovine serum (FBS)     Thermo Fisher Scientific 
Zeocin                    Thermo Fisher Scientific 
Antibiotic-Antimycotic (100x)    Thermo Fisher Scientific 
Dimethyl sulfoxide (DMSO)     Sigma-Aldrich 
0.05% Trypsin-EDTA (1X) (TE)    Thermo Fisher Scientific 
 
2.1.8 Equipment 
Table 2.6. List of equipment used at GSK in this study. 
Piece of equipment (GSK)   Manufacturer 
Nanodrop ND-2000 spectrophotometer  Thermo Fisher Scientific 
BioDoc-It Imaging system    UVP (Cambridge, UK) 
JB1 Unstirred Waterbath   Grant Instruments 
Infors HT Minitron    Infors HT (Bottingem, Switzerland) 
Heraeus Biofuge pico (molecular biology) DJB Labcare (Milton Keynes, UK) 
Heraeus Multifuge X3R (molecular biology) Thermo Fisher Scientific  
Heraeus Multifuge 3S (tissue culture) Thermo Fisher Scientific 
C1000 Touch Thermal Cycler   BioRad (Hemel Hempstead, UK) 
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PowerPac Power Supply   BioRad 
Heraeus HeraCell Air-Jacketed                        Thermo Fisher Scientific 
 CO2 Incubator  
Evos FL Cell Imaging System   Thermo Fisher Scientific 
BD Accuri c6     BD Biosciences (San Diego, CA, USA) 
Lab-Therm LT-XC Shaker-incubator  Kuhner (Birsfelden, Switzerland) 
Axiovert 25 inverted bright field                     Zeiss (Cambridge, UK) 
microscope  
TK100 cryostorage Unit   Taylor-Wharton (Elstree, UK) 
Nucleofector 2b                                                 Lonza 
INCell 2000                                                         GE Healthcare (Hatfield, UK) 
 
Table 2.7. List of equipment used at UCL/ICH/MCI in this study. 
Piece of equipment (UCL/ICH/MCI)    Manufacturer 
Nanodrop ND-1000 spectrophotometer    Thermo Fisher Scientific 
Uvitec DOC-CF08-TFT. Gel Documentation System              UviTec 
Eppendorf Mastercycler® Pro Thermal Cycler  Eppendorf 
Gene Pulser II Electroporation System   BioRad 
IX70 inverted bright field microscope   Olympus 
FACSAria III       BD Bioscience 
Cyan ADP Analyzer      BD Bioscience 
ABI Prism 7000 Sequence Detection System                Thermo Fisher Scientific 
Sorvall Discovery 100SE Ultracentrifuge   Thermo Fisher Scientific 
Sorvall Legend Mach 1.6R Tabletop centrifuge  Thermo Fisher Scientific 
 
2.1.9 Bioinformatic software and scripts 
The analysis pipeline described in this study include several Perl and Bash scripts 
and should work on standard UNIX-based operating systems. The procedures 
described in this section were written by an external collaborator, Yilong Li, under 
specified criteria and require the following software to be installed and 
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executable from the terminal (for example through aliases or through symbolic 
links in a directory that is in $PATH). The scripts listed below can be consulted in 
the Appendix B. 
Table 2.8. List of programs required to run bioinformatic pipelines in this study. 
Program Version Download link 
BWA 0.7.12-
r1039 
http://sourceforge.net/projects/bio-bwa/files/ 
BEDtools 2.20.1 https://github.com/arq5x/bedtools2/releases 
ssearch36 36.3.8b http://faculty.virginia.edu/wrpearson/fasta/CURRENT/ 
FastQC 0.11.4 http://www.bioinformatics.babraham.ac.uk/projects/down
load.html#fastqc 
Blat 36x1 http://hgdownload.cse.ucsc.edu/admin/exe/macOSX.x86_
64/blat/blat 
R 3.2.1 https://cran.r-project.org/src/base/R-3/ 
Starcode 1.0 https://github.com/gui11aume/starcode 
2.2 Methods 
2.2.1 Maintenance and long term storage of E. coli 
Escherichia coli (E. coli) cells were cultured in vegitone lysogeny broth (vLB) at 
37C with shaking at 250rpm (in an Infors HT Minitron incubator) containing the 
appropriate antibiotic. Bacterial colonies were selected on vLB agar plates (1.5% 
(w/w) agar dissolved in vLB by heating) with the corresponding antibiotic (100 
μg/mL of ampicillin or 50 μg/mL of kanamycin). For long-term storage of bacterial 
stocks, liquid cultures of bacteria in the exponential growth phase were 
resuspended in vLB with 15% (v/v) of glycerol and stored at -80C. 
2.2.2 Plasmid DNA preparation 
E. coli cells containing the desired plasmid were cultivated in vLB with the 
appropriated antibiotic for selection (usually 100μg/mL ampicillin or 50μg/mL 
kanamycin) at 37C with shaking at 250 rpm overnight. DNA was extracted using 
a plasmid DNA Miniprep Kit or Endofree plasmid Maxi Kit following 
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manufacturer’s instructions and resuspended in molecular grade water. DNA 
concentration was measured on a Nanodrop ND-1000 or ND-2000 
spectrophotometer and samples were stored at -20C. 
2.2.3 Restriction digests of plasmid DNA 
For plasmid digestion, 0.5-2µg of plasmid DNA was incubated with 5U/µg of the 
appropriate restriction enzymes and 10% (v/v) of suitable 10X enzyme buffer in 
a final volume of 20µL per reaction. Double digests were performed sequentially, 
purifying DNA between reactions using QIAquick PCR purification column 
(Section 2.2.7), when a compatible buffer was not available. When not present in 
the enzyme buffer, BSA was added to a final concentration of 0.1mg/mL in order 
to stabilize enzymes during incubation. Reaction mixture was incubated for 1-2 
hours at the recommended temperature. 
2.2.4  Phosphorylation and dephosphorylation of DNA fragments 
Dephosphorylation was carried out by adding 10% (v/v) of 10X FastAP buffer 
and 1U FastAP thermosensitive alkaline phosphatase to linear DNA (up to 1µg); 
The reaction was spun briefly, incubated for 10 minutes at 37C and stopped by 
heating 5 minutes at 75C. 
For phosphorylation of annealed oligonucleotides, 10-50 pmol of 5’ termini were 
incubated with 10% (v/v) of 10X T4 polynucleotide kinase buffer, 10mM ATP and 
10U of T4 polynucleotide kinase at 37C for 20 minutes. The reaction was heat 
inactivated at 75C for 10 minutes.  
2.2.5 DNA elongation and blunting of overhanging DNA ends 
Digested plasmid DNA (1-2 μg) was combined with 10% (v/v) 10X Klenow DNA 
polymerase buffer and 1U/μg Klenow enzyme together with 50μM of each dNTP 
in order to fill in 5’-overhangs and resect 3’-overhangs. Reaction components 
were mixed and incubated at room temperature for 10 minutes. The reaction was 
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stopped by heat inactivation for 10 minutes at 75°C in a PCR machine and 
fragments were purified as indicated in Section 2.2.7. 
2.2.6 PCR amplification of DNA fragments 
Amplification of DNA fragments was performed using 0.625 units/reaction of 
OneTaq polymerase, 1X OneTaq standard reaction buffer, 200μM of dNTPs, 0.2µM 
of forward and reverse primers, a variable amount of DNA template and nuclease-
free water in a total volume of 25µL. 
Thermocycling conditions comprised an initial denaturation step at 94C for 30 
seconds followed by 20-35 amplification cycles consisting of denaturation at 94C 
for 30 seconds, primer annealing at 50-60C for 30 seconds and extension at 68C 
for 1min/kb and a final extension step of 5minutes at 68C. 
When high fidelity was required for the amplification of subcloning, fragments 
were amplified using Q5 High-Fidelity DNA polymerase. In that case, reactions 
were set up using 0.5µM of primers and 0.5U/reaction of Q5 High-Fidelity DNA 
polymerase.  
Thermocycling conditions for Q5 High-Fidelity DNA Polymerase consisted of an 
initial denaturation step at 98C for 30 seconds followed by 20-25 amplification 
cycles consisting of denaturation at 98C for 10 seconds, primer annealing at 50-
60C for 20 seconds and extension at 72C for 2 minutes and a final extension 
step of 2 minutes at 72C. 
2.2.7  Purification of DNA fragments 
When separated by restriction digest and gel electrophoresis, DNA bands were 
rapidly marked under low intensity UV light and isolated from agarose gels using 
a scalpel. The specific identified DNA bands were extracted from the gel using a 
QIAquick Gel Extraction Kit according to the manufacturer’s instructions. When 
the size of the insert or plasmid backbone was not between 70bp to 10kb, a 
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QIAEXII Gel extraction Kit was used because it allows purification of a wider 
range of DNA fragment sizes (40bp to 50kb). 
 QIAquick PCR Purification Kit columns were used in order to purify DNA after 
ligations or digestions when suitable as per manufacturer’s instructions. 
2.2.8 Agarose gel electrophoresis 
0.5-2% (w/v) agarose was added to 1X TAE buffer (40mM Tris acetate, 5mM 
EDTA) and heated until the mixture was completely dissolved. 0.5μg/mL 
ethidium bromide or SYBR Safe Gel Stain (0.1μL/mL of gel) was added when the 
agarose was cooled to approximately 55C and then poured into the appropriate 
gel casting mould with an inserted comb. 
10x Orange G DNA loading buffer was used as a loading dye for DNA samples and 
1kb Plus DNA ladder was loaded as a molecular weight marker. Samples were run 
together with a 1kb plus DNA ladder (for determination of DNA fragment size) in 
a gel electrophoresis tank in 1X TAE buffer using a voltage of 80-120V. The DNA 
was visualized under UV light and photographed with a UV-gel documentation 
imaging system. 
2.2.9 Ligation of DNA fragments 
Ligations were performed with 1U of T4 DNA ligase, 1X T4 DNA ligase buffer 
(10% v/v), 100ng of plasmid backbone and 1:1 to 1:10 molar ratios of 
insert:vector in a final volume of 10-20µL. Reactions were incubated at 16C, 4C 
or room temperature (25C) for 1-2 hours, 6-8 hours or overnight (depending on 
the conditions tested) and were transformed into chemically or electro-
competent E.coli bacterial cells. 
When required, 10% (v/v) of 50% PEG 4000 Solution was added to the ligation 
mix in order to promote intermolecular binding (only if followed by chemical 
transformation).  
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Alternatively, temperature-cycle ligations (TCL) described by Lund679 were 
carried out for 12–16 hours in Eppendorf Mastercycler® Pro Thermal Cycler 
programmed indefinitely to cycle between 30 seconds at 10°C and 30 seconds at 
30°C. 
2.2.10 Topo TA ligation-independent cloning 
According to Thermo Fisher Scientific instructions, 1μL of A-tailed PCR product 
was mixed with 1μL of water, 0.5μL of Salt Solution and 0.5μL of pCR4 TOPO TA 
vector (volumes per single reaction) and incubated for 1 hour at room 
temperature to undergo topoisomerase-mediated ligation of DNA termini.  The 
reaction was then transformed into Stbl3 competent cells (Section 2.2.12).  
2.2.11 Preparation of Chemically Competent cells 
Chemically competent E. coli cells were prepared according to the Inoue 
method680. A single colony Stbl3 E. coli was used to prepare an initial 3ml 
inoculum in vLB broth at 37°C with vigorous shaking at 250rpm overnight. 
250mL SOB were inoculated (2% tryptone, 0.5% yeast extract, 10mM NaCl, 
2.5mM KCl autoclaved and 10mM MgCl2 and 10mM Mg2SO4 sterile-filtered and 
added before use) and cultured with moderate shaking at RT to an OD600 of 0.6. 
The culture was chilled on ice for 15 minutes and centrifuged at 2500g for 5 
minutes at 4°C. Cells were gently resuspended in 80mL ice-cold Inoue 
transformation buffer (10mM PIPES, 15mM CaCl2, 250mM KCl, 55mM MnCl2, 1M 
KOH to pH6.7) for 10 minutes, and centrifuged as before. The resulting pellet was 
resuspended in 20mL 7% DMSO in Inoue Transformation Buffer, placed on wet 
ice for 10 minutes, and dispensed into aliquots previously snap frozen in liquid 
nitrogen and stored at -80°C. 
2.2.12 Transformation of competent E. coli 
When using chemically competent cells, 1-5µL of ligation mix was added to 100µL 
of competent cells previously thawed on ice. The transformation mix was 
incubated for 30 minutes on ice before undergoing heat shock for 30 seconds at 
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42C (depending on manufacturer recommendations) and placed on ice for 2-5 
minutes afterwards.  
When using electroporation, 50μL of electrocompetent cells were transferred 
into a pre-chilled 0.2mm gap electroporation cuvette. Electroporations were 
performed using a Gene Pulser II Electroporation System at 25µF, 2.5kV, 200Ω. 
In both cases, up to 1mL of pre-warmed (37C) SOC medium (SOB medium with 
10mM MgCl2 or 20mM MgSO4 and 20mM glucose) was added to the cells and 
incubated for 1 hour at 37C with vigorous shaking (200-250rpm). Bacteria were 
then plated out to pre-warmed (37C) vLB agar plates containing the appropriate 
antibiotic and incubated overnight at 37C. 
The next day, 1mm colonies were picked using sterile pipette tips and cultured in 
3-5mL of vLB with the appropriate antibiotic overnight at 37C with agitation 
(200-250rpm).  
2.2.13 Sanger-sequencing of PCR amplicons and subcloned plasmids 
Sanger sequencing of PCR amplicons or subcloned plasmids (and libraries) was 
performed in-house at GSK, by UCL DNA Sequencing services or externally by 
Source Bioscience. 
2.2.14 Construction of barcoded vector libraries 
1% (v/v) single strand oligonucleotides (100µM) obtained from Invitrogen at 
25nmol, desalted purity (5’-TATGAGTAANNNATCNSGATNNAAANNG 
GTNWAACNNTGANNNTGGTAACACCGACTAGGATCCTGAT-3’; 5’-CTAGATCAG 
GATCCTAGTCGGTGTTACCANNNTCANNGTTWNACCNNTTTNNATCSNGATNNNTT
ACTCA-3’; note they create overhangs compatible with XbaI and NdeI) were 
combined in water with 1X ligase buffer and allowed to gradually cool (1C/min) 
to 16C from after an initial 5-10 min temperature hold at 95C. Double stranded 
DNA adapters were then carefully resuspended, aliquoted and stored at -20C for 
subsequent use. 
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50-150ng of vector backbone was diluted to 20µL with 400U T4 DNA ligase and 
the annealed oligonucleotides were added to 10-, 100-, 1000 or 10000-fold molar 
excesses to the vector (Section 2.2.9). A reaction without oligonucleotides was 
included for comparison. After 1-2 hours, 6-8 hours or overnight ligation at 16°C 
4°C or room temperature, 1-5µL of ligation mix were transformed into competent 
cells (Section 2.2.12). 
Dephosphorylation of backbone, phosphorylation of the paired oligonucleotides 
(Section 2.2.4), addition of PEG 4000 (5% (v/v) ligation mix volume), heat 
inactivation after ligation (ligation mix incubated at 65°C for 20 minutes in order 
to inactivate T4 DNA ligase) or other insert:backbone molar ratios were also 
tested parameters in the optimization process for the creation of a barcoded 
plasmid library. 
2.2.15 Propagation of cell lines 
Adherent human embryonic kidney (HEK) 293T cells were seeded into 175cm2 
T-flasks and maintained as a monolayer in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% foetal calf serum (FCS).  
Suspension human embryonic kidney 293 SA RIX were cultured in CD293 
medium and supplemented with 4mM GlutaMAXTM. Cell lines were incubated in 
75cm2 T-75 flasks (upright position) in static incubators, although shaking 
incubators (not available at UCL/ICH/MCI) enable higher viabilities.  
Human embryonic kidney 293 cells 6E (HEK 293 6E) were cultured in Freestyle 
293 medium and supplemented with 10mL of 10% Pluronic F-68 (100x) and 500 
µL of 50mg/mL HyClone G418.  
All cultures were incubated at 37C in the presence of 5% CO2, in 70% relative 
humidity conditions. Suspension cell lines were incubated in conical flasks in 
shaking incubators at 140 rpm in a Kuhner Lab-Therm LT-XC. Suspension cells 
were passaged by diluting 1:10 with fresh medium and transferring them to a 
new flask. Adhered cells were detached by incubating them with TrypLE 
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ExpressTM (1X) or 0.05% (v/v) Trypsin-EDTA (1X) for 5 minutes at 37C (after a 
wash step with PBS). Cells were diluted down to the desired concentration with 
fresh medium when they started to detach. Cells were passaged twice a week 
down to a 0.3x106 cells/mL cell density. Cell density and viability were quantified 
by exclusion method using Trypan blue. 
2.2.16 Production of integrating lentiviral vectors  
Lentiviral vectors were produced using polyethylenimine (PEI, Sigma-Aldrich, 
USA), HEK 293T cells and the four-plasmid system that a third generation 
lentiviral vector requires, following the procedure described by Naldini et al., 
1996681. 1.5x107 cells were seeded 24 hours prior to transfection in a T-175 flask 
in 15-20mL DMEM with 10% FBS. The next day cells were co-transfected with 
sterile-filtered plasmids in Opti-MEM® media: 45µg/plate vector construct, 
17.5µg/plate of pMD.G2 (containing VSV-G env gene682), pMDLg/pRRE 
32.5µg/plate (containing gag and pol genes677) and 12.5µg/plate of pRSV Rev 
(containing Rev gene146) and 1µL of 10mM polyethylenimine (PEI) solution. 
Medium was replaced 4-6 hours post-transfection to remove PEI and cells were 
incubated at 37C 5% CO2 for 48 hours. 
When transfected with calcium phosphate technique, 5µL of pMDL/RRE, 2.5µL of 
pRev, 3.5µL of VSV-G and 14µL of transfer vector (or pTelo) plasmids (all of them 
at a 1µg/µL concentration) were mixed with 62µL of CaCl2 2M and 413 µL of 
water (amounts required for transfection in 10cm2 plates). 500µL of 2x Hepes 
phosphate buffer saline (HBS) was added in 15mL tubes and air was bubbled 
through the solution with a 1mL plastic pippete attached to a pippete pump to 
form the DNA precipitates while the DNA mix is progressively added dropwise. 
Complexes were then incubated 20 minutes at room temperature and 
subsequently added to the cells. Medium was replaced 14-16 hours post-
transfection and cells were incubated at 37C 5% CO2 for 48 hours. 
In both cases, the medium was then harvested and flasks were replenished with 
fresh medium. Harvested media was cleared using a 0.22µm filter to remove cell 
debris and was centrifuged at 98,000g in a Sorvall Discovery 100SE 
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Ultracentrifuge for 2 hours at 4C. Supernatant was discarded after centrifugation 
and viral particles were resuspended in Opti-MEM® media, aliquoted and stored 
at -80C. Centrifugation was repeated 72 hours post-transfection for a second 
harvest following the same procedure. 
2.2.17 Flow cytometry analysis of transduced cell lines 
The proportion of transduced cells positive for eGFP fluorescence was analysed 
after being cultivated for 72 hours at 37C and 5% CO2. Cells were cultured to a 
semi-confluent phase in 6-well plates and the medium was removed, cells washed 
with PBS, treated with 250µL of TrypLE ExpressTM (1X) or 0.05% (v/v) Trypsin-
EDTA (1X) in PBS for about 3 min at room temperature, and pelleted by 
centrifugation at 1200xg for 5 minutes in a Thermo Fisher Scientific Sorvall 
Legend Mach 1.6R Tabletop centrifuge or a Heraeus Multifuge 3S. The cell pellet 
with 0.1-1x106 cells as then resuspended in 300µL of ice cold PBS and kept on ice 
in polypropylene tubes until analysis. 
Flow cytometry analyses were done at Great Ormond Street Hospital Flow 
Cytometry Core Facility (UCL-Institute of Child Health/Great Ormond Street 
Hospital for Children) using a CyAn ADP Analyzer (Dako, Glostrup, Denmark) 
with an argon laser (excitation at 488nm; filter at 491nm and emission at 530nm; 
filter at 530±20nm) according to the procedure recommended by the 
manufacturer. Ten thousand cells were analysed for each sample. Data was 
analysed using FlowJo version 7.6.5 (TreeStar, Stanford University). When 
performed at GSK, a BD Accuri c6 was used (excitation at 488nm; filter at 491nm 
and emission at 530nm; filter at 533±30nm). Data was analysed using BD 
CSampler version 1.0.264. 21. 
2.2.18 Determination of viral vector titer by flow cytometry 
Functional lentiviral vector titer can be assessed by flow cytometric evaluation of 
transduction rates (Section 2.2.17). At 24 hours prior to infection 1x105 cells 
(HEK 293T, HEK 293 SA RIX or HEK 293 6E) were seeded in a 24-well plate and 
in 1mL of media. The next day the media was replaced by 1mL of 10-fold serial 
Chapter 2. Materials and Methods  
 122 
dilutions starting with 10µL of virus in the appropriate media. At day 3 post-
infection, 250µL of TrypLE ExpressTM (1X) or 0.05% (v/v) Trypsin-EDTA (1X) was 
added to cells and the dissociation reagent was inactivated by resuspending them 
in 1mL of DMEM with 10% FBS. Cells were pelleted and resuspended in 500µL of 
FACS buffer (1% FCS, 0.05% sodium azide in PBS) to perform flow cytometric 
analysis to determine the percentage of GFP positive cells. The infecting or 
transducing capacity (titers) of the lentiviral vector produced was calculated by 
multiplying the number of seeded cells by the percentage of GFP positive cells and 
dividing by the volume of lentiviral vector used for the infection. 
Titrations were also performed on different HEK 293 cells since the number of 
transducing units per millilitre (TU/mL) can vary among cell lines284,398,683. Cells 
were cultured in 24-well plates and were trypsinized with TrypLE ExpressTM (1X) 
or 0.05% (v/v) Trypsin-EDTA (1X). Suspension cells were spun in a 24-well plate 
at 1200xg (in a Thermo Fisher Scientific Sorvall Legend Mach 1.6R Tabletop 
centrifuge) for 5 minutes in order to change the media.  
2.2.19 Transduction of host cell lines 
HEK293 cells were seeded at a density of 0.3x106 cells/mL per condition in a 6-
well plate with the appropriate culture medium (as previously described). 
Alternatively, 1,000 and 10,000 HEK293 6E cells were seeded in a 96 well plate 
(100,000 cells were transduced in a 24well plate). Cells were infected with 
different desired MOIs according to the transducing units of titrated lentiviral 
vector 24h after seeding and were incubated for 72 hours incubation at 37C and 
5% CO2. Half of the media was replaced 24 hours post-infection. 
2.2.20 Fluorescence microscopy 
Images of transduced or transfected 293 cells were captured using an Olympus 
IX70 microscope or an EVOS FL Cell Imaging System (ocular magnification: 10x, 
objective magnification 4x, 10x or 20x) after 72 hours incubation at 37C and 5% 
CO2. 
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2.2.21 Isolation of genomic DNA  
Medium from up to 5x106 HEK 293 cell lines was removed, the cells were washed 
twice with PBS and genomic DNA extraction from and HEK 293 cell lines was 
performed using the DNeasy Blood and Tissue Kit as per manufacturer 
instructions. DNA was eluted in AE buffer (10 mM Tris-Cl, 0.5 mM EDTA; pH 9.0) 
and stored at -20˚C.  
2.2.22 Measurement of nucleic acid concentration  
Concentration and purity of plasmid DNA was determined using a Nanodrop ND-
1000 or ND-2000 spectrophotometer with a 0.2mm path to measure the 
absorbance at 260nm because nitrogen rich bases absorb light at this wavelength. 
Nucleic acid concentration can be determined once known that the extinction 
coefficient of dsDNA, ssDNA and RNA is 50, 33, 40 µg/mL, respectively. The ratio 
absorbance at 260nm and 280nm was used to assess the purity of DNA. A ratio of 
~ 1.8-2.0 was accepted as sufficiently pure DNA.  
Prior to next-generation sequencing runs, DNA and RNA sample concentration 
and purity were measured pre- and post-library preparation using an Agilent 
2100 Bioanalyzer or a 2200 Tapestation. DNA peaks were expressed in 
fluorescent units between 10,380bp and 35bp high DNA sensitivity markers; 
28S/18S ratios was used to assess quality of total RNA samples 
2.2.23 Long term storage and revival of mammalian cell lines 
For long-term storage, 1-5x106 cells were pelleted at 1200xg (in a Thermo Fisher 
Scientific Sorvall Legend Mach 1.6R Tabletop centrifuge or Heraeus Multifuge 3S) 
for 5 minutes, resuspended in 1mL of cryopreservation medium (suitable media 
according to Section 2.2.15 with 10% dimethyl sulfoxide, DMSO) and transferred 
to cryovials. Cells were gradually frozen (1C/minute) using an isopropanol-
freezing container before being transferred to liquid nitrogen.  
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In order to revive cells, frozen aliquots were thawed by hand, resuspended in 9mL 
of pre-warmed medium and pelleted at 1200xg for 5 minutes (in a Thermo Fisher 
Scientific Sorvall Legend Mach 1.6R Tabletop centrifuge or Heraeus Multifuge 3S). 
Supernatant (with DMSO) was removed and cells resuspended in 10mL and 
transferred to a 125mL shake flask or T-175 in a suitable tissue culture flask for 
at least 48 hours prior to be seeded for experiments. Revived host cell lines were 
passaged twice (Section 2.2.15) prior to experiments involving transfection 
(Section 2.2.39) or transduction (Section 2.2.19).  
2.2.24 Cell sorting of transduced cell lines 
120x106 HEK 293 cells were transduced in bulk with the lentiviral library 
(RRL.SIN.cPPT.EEW+Barcode) at an MOI of 0.5. After 1 week post-transduction, 
cells were pelleted, washed and resuspended in Gey’s balanced salt solution at a 
concentration of 10-20x106 cells/mL. Media for cell recovery after sorting 
consisted of 1:1 of fresh media and conditioned media (filtered, non-exhausted 
previously used media which supplies growth factors and metabolites) and 
antibiotic-antimycotic at a 1x final concentration to prevent bacterial or fungal 
contamination. Cells were analysed and sorted by Clare Mudd at Labstract 
(Stevenage Bioscience Cayalyst) on a fluorescence-activated cell sorter 
FACSAriaIII using FACSDiva software (BD Biosciences). The fluorochromes were 
excited at 488-nm and green fluorescence was detected using a 530/20 filter. 
Prior to sorting, the nozzle, sheath, and sample lines were sterilized with 70% 
ethanol. A 100-μm ceramic nozzle (BD Biosciences), sheath pressure of 
20 pounds per square inch (PSI) and an acquisition rate of 5,000-10,000 events 
per second was used to sort cells at 4°C into 3 different pools based on the level 
of eGFP-specific fluorescence (top 2.5% high, 2.5% mid and 2.5% low GFP 
producers) in aseptic conditions. GFP- and GFP+ populations were also sorted as 
a control. 
When performed at Labstract (The Catalyst building, Stevenage), 50,000 cells 
were sorted per intensity condition (100,000 for GFP+ and GFP-) into eppendorfs 
containing 200μL of recovery media under the following conditions: serum free, 
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4°C, 100-μm nozzle, continuous agitation and a sorting speed of 2,000-4,000 
events per second. In any case, cells were transferred to V-shaped 96 well plates 
for recovery and expanded when reached maximum confluency.  
2.2.25 Determination of lentiviral vector copy number by quantitative real-
time PCR (qPCR) 
Lentiviral vector copy number was determined by quantitative real-time PCR 
(qPCR) using the absolute quantification method at Institute of Child Health, UCL. 
Reactions were performed in triplicate using approximately 250ng of genomic 
DNA as a template per reaction, 0.9 μM of each primer, 0.2 μM of fluorescent 
probe, and the Platinum qPCR SuperMix-UDG with ROX mastermix. 
Real time PCR was performed as follows: 1 cycle of 50°C for 2 minutes, 1 cycle of 
95°C for 10 minutes followed by 40 cycles of [95 °C for 15 seconds; 60°C for 1 
minute] using an ABI Prism 7000 Sequence Detection System.  
pMKRQ BTW2R  plasmid DNA (Appendix A) containing 106-103 copies/5 μl the 
Woodchuck hepatitis virus enhancer element sequence (WPRE), kindly gifted by 
John Counsell, although originally cloned by Conrad Vink (both Institute of Child 
Health/UCL, London, UK), was used as standard for lentiviral copy number 
quantification. WPRE qPCR primers and probes were kindly provided by John 
Counsell: 
Forward primer: 5’-TGGATTCTGCGCGCGGGA-3’ 
Reverse primer: 5’-GAAGGAAGGTCCGCTGGATT-3’ 
Probe (5’-3’): FAM-CTTCTGCTACGTCCCTTCGGCCCT-TAMRA 
Vector DNA copy number was calculated using the genome mass and the mass of 
DNA employed in the qPCR. Copy numbers per cell are calculated dividing the 
extrapolated copy numbers by the number of cells present in the sample. Cell 
Chapter 2. Materials and Methods  
 126 
number is calculated as the ratio between the mass of template DNA used in each 
reaction divided by the mass of a single host cell genome. The mass of the host 
cell genome is calculated using number of chromosomes, the ploidy, their length 
in bp and the mass of 1bp of DNA. This method of normalisation has been used in 
the literature for absolute quantification of transcripts684.  
2.2.26 Extraction and isolation of cellular and viral RNA 
Cellular RNA was extracted from 0.1-1x107 cells per condition using the RNeasy 
Plus Mini Kit following manufacturer’s instructions. When extracting RNA from 
lentiviral vectors, 40µL of concentrated (ultracentrifuged) viral vector were 
treated using a QIAamp Viral RNA Mini Kit following manufacturer’s instructions. 
In both cases, RNA was eluted in 50µL of RNAse-free water, measured on a 
Nanodrop ND-1000 or ND-2000 spectrophotometer (Section 2.2.22) and samples 
were stored at -80C. 
2.2.27 Elimination of residual DNA in RNA samples 
Residual DNA was eliminated from RNA preparations using DNA removal with 
DNA-free Removal Kit or the RNA Clean & Concentrator Kit following 
manufacturer’s instructions. Samples were eluted in 25µL of RNAse-free water 
and stored at -80C prior to generation of cDNA.  
2.2.28 Generation of Barcoded cDNA from viral/ cellular RNA 
Synthesis of cDNA and amplification of a specific barcoded region was achieved 
in a single step using the SuperScript® III One-Step RT-PCR System with 
Platinum® Taq DNA Polymerase. A cDNA/RNA hybrid was generated by the 
SuperScriptIII reverse transcriptase from 100ng of viral or cellular RNA. The 
reaction was carried out in a 30-minute incubation at 59C. Specific amplification 
of barcoded regions was performed using, 1µL of 10µM forward and reverse 
primers (RNAbc_150ups-fwd 5’-ACGAGTCGGATCTCCCTTTG-3’ (annealing at the 
3’ end of the WPRE and thus only amplifying barcode from the 3’LTR); Barcode-
PBS-rev 5’-GGATCCTAGACGGTGTTACC-3’) and reaction buffer (1x) containing 
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50µM each dNTP under the following cycling conditions: 1 cycle of 94°C for 2 
minutes (which deactivates the reverse transcriptase and activates the Taq DNA 
polymerase) followed by 25 cycles of [94 °C for 30 seconds; 60°C for 30 seconds 
and 68°C for 15 seconds] and a final extension 5min step at 68°C. Reactions were 
further purified using the QIAquick PCR purification Kit (Section 2.2.7) prior to 
submission for next-generation sequencing. A comprehensive diagram showing 
the fragment of reverse transcribed vector RNA amplified after reverse 
transcription can be consulted at Figure 3.9F. 
2.2.29 Integration site analysis of barcoded integrated lentiviral vectors by 
Ligation-mediated (LM-PCR) 
Lentiviral vector – host chromosome junctions were retrieved by using a linker 
cassette that provides a known sequence to specifically amplify target sequences 
when ligated to fragmented genomic DNA. 
Linker cassette was generated by mixing 12.5 pmol of each linker oligo (Linker 
fwd: 5’-GTAATACGACTCACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGT-3’ and 
Linker rev 5’Phos-ACCAGCCCGGGCCGT-3’SpC3, compatible with blunt end 
restriction enzymes such as DraI) in a 50μL final volume (to a 25μM final 
concentration) with 10% T4 DNA ligase buffer as described in Section 2.2.9. The 
mixture was heated at 95C for 2 minutes and gradually cooled to room 
temperature.  
The linker cassette reverse oligonucleotide contains a modification in order to 
prevent the PCR-suppression effect685.  This effect occurs upon extension of the 
linker cassette reverse oligonucleotide, which results into a full-length linker 
cassette that can form linker concatemer and serve as a template for end-to-end 
amplification. Under the annealing and extension temperature conditions, 
intramolecular annealing is strongly favoured over the annealing of a shorter 
primer to the linker cassette, which leads to a ‘panhandle’ structure, which 
hampers PCR amplification.  A three-carbon spacer (C3-Spacer or 3-SpC3) was 
added to the 3’ terminus to impede extension of the linker cassette reverse oligo 
and thus ligation of any molecule on the 3’ end. 
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2.5μg of genomic DNA were digested with 80 units of restriction enzyme (in this 
study DraI, NlaIII, BsuRI and HpyCH4v) for 2h at 37C, column-purified with the 
QIAquick PCR purification kit and ligated to 1.9μL (47.5pmol) of linker cassette 
at 16C over night. The reaction was stopped at 70C for 5 minutes and diluted 5 
times with distilled water prior to 2 rounds of PCR using 5μM primers, 2mM 
MgCl2 and 0.05 units of TrueStart Hot Start Taq DNA polymerase with the 
following thermocycling conditions: 7 cycles at [94C for 25 seconds and 72C for 
3 minutes]; 32cycles at [94C for 25 seconds and 67C for 3 minutes] and 1 cycle 
at 67C for 7 minutes.  
LVVP1 (lentiviral vector primer1): 5’- GCTTCAGCAAGCCGAGTCCTGCGTCGAG -3’ 
LCP1 (linker cassette primer1):   5’- GTAATACGACTCACTATAGGGC -3’ 
LVVP1 anneals at a sequence immediately downstream the LVV 5’LTR so that 
amplification from both LTRs is avoided. A comprehensive scheme of the 
locationof the binding site of the primers can be consulted in Figure 4.1. 
The second PCR round was carried out using the same master mix composition 
and 1/50 (diluted with molecular grade water) of the first PCR product with the 
following thermocycling conditions: 5 cycles at [94C for 25 seconds and 72C for 
3 minutes] and 32cycles at [94C for 25 seconds and 67C for 3 min]. 
LVVP2 (lentiviral vector primer2):  5’- GGATCCTAGTCGGTGTTACCA -3’ 
LCP2 (linker cassette primer2):  5’- ACTATAGGGCACGCGTGGT -3’ 
1μL of the 2nd PCR product was ligation-independent cloned into a pCR4 
backbone following the instructions of the using the TOPO-TA Cloning Kit for 
1hour at room temperature and the resulting mixture transformed into Stbl3 
chemically competent cells section and validated by Sanger-sequencing.  
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Once the technique was validated on low-throughput, 2nd PCR products 
containing the Illumina adapter sequences and individual indexes to allow 
sample identification were column-purified with the QIAquick PCR purification 
Kit and sent to Genewiz (South Plainfield, NJ, USA) or UCL Genomics (London, UK) 
for Next-Generation Sequencing using the a MiSeq and 300bp Paired End strategy. 
2.2.30 Next-Generation Sequencing 
Generation of the sequencing libraries and sequencing runs were carried out by 
Genewiz (South Plainfield, US) or UCL Genomics (London, UK) using the following 
primers: 
Plasmid (Uppercase for Illumina compatible sequences) 
P5fwd-upstream-barcode:  
5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTccttcgccctcagacgagtcggatctc-3’ 
 
bio-P7rev-downstream-barcode (also used for the generation of a custom 
barcoded library from total RNA):  
5’-[bio]GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTcaaaaagcatctagatcaggat 
cctagtcggtgttacca-3’ 
 
LM-PCR 
P5_FWD-LentiXASP2: 5’ ACACTCTTTCCCTACACGACGCTCTTCCGATCTactataggg 
cacgcgtggt 
P7_REV-LentiXPBS2: 5’-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTggatccta 
gtcggtgttacca-3’ 
When performing integration site analysis, LM-PCR host genome-vector 
junctions were sequenced using Illumina MiSeq sequencer 2x300bp (paired-end) 
configuration and a v3 Kit in order to increase cluster density, maximise read 
length as well as improve quality scores. 
Chapter 2. Materials and Methods  
 130 
When performing barcode expression analysis or whole transcriptome analysis, 
RNA-Seq expression was performed using NextSeq500 (UCL genomics) and 
HiSeq2500 (Genewiz) on libraries prepared from total RNA.  
2.2.31 Paired-end joining (and reverse complementing sequences) 
R1 and R2 datasets (per sample) were output from the sequencing in fastq format 
when using paired end configuration. Regarding paired-end joining of plasmid 
PCR reads, the read length from MiSeq 300bp PE configuration was higher than 
the length of the PCR product and thus the reads often tend to sequence ‘into’ the 
primers outside the amplified target product. Therefore, all reads were first 
trimmed down to 240bp. LM-PCR reads were trimmed down to 150bp to obtain 
the optimal amount of merged reads in subsequent steps. 
Subsequently, the actual read pair merging was done using BWA. The appropriate 
value for parameter -Q, optimised through trial and error.  
No merging was performed on RT-PCR samples HiSeq2500 100bp PE because the 
barcode was entirely found in R2. Instead, a simple script called ‘rc_fastq.pl’ 
(Appendix B) was written for reverse-complementing FASTQ R2 files. In the case 
of finding low quality scores towards the 3’ end of the read (represented as Ns), 
the scrip would also remove reads with ≥5Ns. 
2.2.32 Manipulation of sequences using Galaxy 
Next-generation sequencing data manipulation involving sequence trimming, 
sorting, selection or replacement as well as combination or subtraction of 
datasets, operations with columns and data storage was performed using Galaxy, 
a web-based platform for high throughout genomic analyses686–689. 
2.2.33 Quality control 
FastQC690 (Babraham Bioinformatics) was applied on the merged fastq files to in 
order to assess quality statistics, GC content, sequence length distributions and 
duplication and overrepresentation levels. 
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2.2.34 Extraction of barcodes (and host integration sites) 
A custom Perl script, that uses Ssearch36 software, was adapted to different read 
configurations in order to extract barcodes from the merged reads in different 
experiments.  
The script ‘extract_library_barcode.pl’ (Appendix B) was used to extract barcodes 
from the plasmid library. The script specifically identifies the following pattern: 
20bp sequence upstream the barcode (5’-GACAAGATCCATATGAGTAA-3’)- 
barcode sequence (5’-NNNATCNSGATNNAANNGGTNWAACNNNTGANNN-3’)-
20bp downstream the barcode (5’-TGGTAACACCGACTAGGATC-3’). No 
mismatches or insertions/deletions are allowed in matching this pattern.  
The extraction of barcodes and integration site sequences from LM-PCR merged 
reads (sequenced with a MiSeq 300bp PE strategy) was performed using perl 
script version ‘extract_viral_insertion_barcodes.pl’ (Appendix B) meeting the 
following criteria: (1) Alignment to linker ended at the last 5 bases (bases 32-36) 
on the reference linker sequence. (2) The sequence identity was > 80%.  
The script ‘extract_viral_insertion_barcodes.pl’ was modified to ‘extract_rt-
pcr_barcodes.pl’ in order to extract barcodes from viral and cellular RT-PCR 
amplicons sequenced under a HiSeq2500 100bp PE.  
All the scripts mentioned in this Section 2.2.34 were written by Yilong Li (external 
collaborator, Wellcome Trust Sanger Institute, Cambridge, UK). 
2.2.35 Barcode clustering 
Barcode variants with insufficient dissimilarity and low relative representation 
were pooled together using Starcode clustering software691. Clustering 
parameters ‘size absorbing ratio’ (-r) and ‘editing or Leveinshtein distance’ (-d) 
were optimised in agreement with their frequency of dissimilarities. 
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2.2.36 Plotting barcode distributions 
Cumulative density of variant frequencies pre- and post-clustering treatment 
were plotted using the following script in R ‘plot_plasmid_library_ distributions.R’ 
(Appendix B).  
Frequencies of dissimilarities between barcoded variants were calculated using 
the script ‘MHB08-059_check_and_assign_pSYNT’ and the resulting tables were 
plotted in R using the ‘Barcode_error_correction.R’ script (Appendix B). The latter 
two scripts were kindly given by Martijn H Brugman (Leids Universitair Medisch 
Centrum (LUMC), Germany). 
2.2.37 Length filtration and mapping 
Host sequences were filtered to be at least 20bp long and subsequently converted 
into fasta format before being mapped against the human genome using Blat692. 
Integration sites were plotted using the UCSC Genome Graphs tool693 together 
with CpG islands and RefSeq gene annotation tracks. Homo sapiens GRCh37 
assembly (NCBI) Reference genome version used was Homo_sapiens 
(GRCh37/hg19):  
ftp://ftp.ensembl.org/pub/release75/fasta/homo_sapiens/dna/Homo_sapiens.
GRCh37.75.dna.primary_assembly.fa.gz 
2.2.38 Feature annotation 
BEDtools was used to assign intersect, merge, count and genome annotation 
features to genomics intervals or positions retrieved during the integration site 
analysis694. Initially, gene coordinates and symbols were obtained from Ensembl 
BioMart, available at the following link:  
http://grch37.ensembl.org/biomart/martview/f828296ee921fd33b715b6aea8
d521aa). Only genes and transcripts with a CCDS ID (Consensus Coding Sequence 
ID) were included.  
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CpG island annotations, based on Homo sapiens (GRCh37/hg19) assembly Feb. 
2009, were downloaded from the UCSC table browser as a BED file 
(https://genome.ucsc.edu/cgi-bin/hgTables).  
The raw downloaded annotation data were processed using the code in Bash 
script ‘make_ucsc_gene_txs.sh’ (Appendix B) in order to prepare annotation (bed) 
files of genomic features such as genes, transcription start sites and CpG islands 
that were used in the analysis. 
Custom tracks containing annotation for repetitive elements were obtained from 
UCSC Table browser, which uses data from ‘Repbase update library of repeats’ 
from the GIRI (Genetic Information Research Institute)695. 
2.2.39 Nucleofection of host cell lines with CRISPR-Cas9 constructs 
Stable integration of donor constructs into the genome of HEK 293 6E cell lines 
was achieved by co-transfection of separate plasmids containing sgRNA and Cas9. 
2x106 cells per condition were pelleted and washed with Hank’s balanced 
solution prior to nucleofection using the Amaxa Nucleofector Kit V. Cells were 
resuspended in 82μL of Solution V supplemented with 18μL of Supplement 1 and 
mixed with 2μg of each plasmid. The mixture was transferred into an 
electrocuvette and nucleofected using a Nucleofector 2b device (Lonza) using the 
program S-018. Cells were resuspended with pre-warmed media and gently 
transferred into a 6-well plate statically incubated at 37C and 5% CO2 for at 48 
hours before any selective pressure was applied. Transfection efficiency was 
assessed 48 hours post-transfection by flow cytometry.  
Reactions were performed in triplicates and negative controls (no DNA and single 
plasmid controls) were performed alongside. 
2.2.40 Selection and isolation of host cell line colonies 
HEK 293 transfected cell pools were kept in 6-well plates for 48 hours post-
transfection without antibiotic selection. The transfection efficiency of donor 
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construct and sgRNA and Cas9 plasmids was assessed by FACS (Section 2.2.17) 
since plasmids contained an eGFP and RFP fluorescent marker, respectively. The 
media was then replaced by media containing the appropriate antibiotic (300-
500μg zeocin/mL) and cells were cultured for 1-2 weeks under selection 
(changing the media every 3-4 days) until cell colonies became visible. Individual 
cell colonies were transferred to individual 24-well plate using cloning cylinders 
and keeping selective pressure. Alternatively to cloning rings, media was replaced 
with PBS containing 5-10% of TrypLE ExpressTM (1X) or 0.05% (v/v) Trypsin-
EDTA (1X) and incubated for 5 minutes at room temperature. Colonies could then 
be directly and individually pipetted to 24-well plate. Once cells were expanding, 
they were readapted to suspension cultures.  
2.2.41 Scale up of host cell line colonies 
HEK 293 6E eGFP positive colonies from pools successfully transfected with 
donor construct according to FACS (Section 2.2.17) were transferred from a 24-
well plates to a 6-well plates and 125mL shake flasks when they reached 90% 
confluency. Media with selective pressure (300-500μg Zeocin/mL) was replaced 
every 3-4 days. Clones were screened for eGFP intensity by FACS, vector copy 
number by qPCR (Section 2.2.25), viral titer (Section 2.2.18), off-target 
integration (Section 2.2.42) and integrity of the junction by PCR and Sanger 
sequencing (Section 2.2.6 and 2.2.13). 
2.2.42 Determination of off-target integration of donor constructs 
In order to assess random integration of donor construct, a blue (BFP) fluorescent 
cassette was downstream of the right homology arm. If recombination events 
were successful on both homology arms, no blue signal should be detected. Since 
strongly enhanced blue fluorescent protein (seBFP) emission and excitation 
wavelengths is not within the rank of detection of the BD Accuri c6, an IN Cell 
Analyzer 2000 (GE Healthcare Life Sciences, UK) was used instead to detect BFP 
(excitation at 350nm; emission at 470nm); RFP (excitation at 596nm; emission at 
515nm); GFP (excitation at 490nm; emission at 525nm). Overlapping signal was 
compensated with single-fluorochrome controls (pmaxGFP, pMA-RQ HA-MCS-
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HA2-BFP CUL5 and pCMV-Cas9-U6-sgRNA-RFP for GFP, BFP and RFP, 
respectively). Images were taken at a 20x magnification and percentages of BFP, 
GFP and RFP positive cells were quantified with Columbus software using a 
custom script written by Toral Jakhria (GSK) (Appendix B) to quantify the 
proportion of GFP+ve/BFP-ve cells. 
Alternatively, images of cells bright field or expressing BFP and/or GFP were 
taken using a confocal fluorescence microscope Leica TCS SPS II with an Argon 
laser with a Alexa Fluor 488nm detection filter for GFP and a 405nm laser and 
DAPI detection filter for BFP. 20x (HC PL APO 20x/0.70 CS) and 40x (CX PL APO 
40x/0.85 CORR) magnification objectives were used and photomultiplier I and II, 
respectively for GFP and BFP.  
2.2.43 Confirmation of integrity of donor construct-host genome junctions 
by PCR 
Genomic DNA from HEK 293 6E host cell lines generated upon nucleofection of 
donor construct and sgRNA+Cas9 plasmids was extracted (Section 2.2.21) and 
junction sequences were amplified by PCR (Section 2.2.6) both sides of the 
insertion for each candidate using the following primers: 
Control position EMX1 (right junction) (Tm=55C) 
Zeonestedfwd2:  5’-gtcgagacgtacccaattcg -3’ 
EMXrightrev4:  5’-atcctcccctttcctctggt -3’ 
EGFEM1P (left junction) (Tm=64.5C) 
Leftfwdnew1:  5’-cgttcccttcttcccttcct -3’ 
Gagrev2:   5’-gtaagaccaccgcacagcaa -3’ 
CUL5 (right junction) (Tm=57C) 
Zeonestedfwd2:  5’- gtcgagacgtacccaattcg-3’ 
CUL5rightrev1:  5’-caagctcatcactgcacctc -3’ 
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PCR amplicons were TOPO cloned into a pCR5 backbone (Section 2.2.10), 
transformed into Stbl3 competent cells, plated out in LB agar plates with the 
appropriate antibiotic and incubated overnight at 37C. The next day, colonies 
were picked and liquid bacterial cultures were set up for plasmid DNA extraction 
(Section 2.2.2) and Sanger sequencing using the M13 reverse primer (5’-
CAGGAAACAGCTATGAC -3’) (Section 2.2.13). 
2.2.44 Statistical analysis 
One-way Anaysis of Variance (ANOVA) was used to discern whether differences 
between mean±SD obtained from three replicates for each condition were 
significantly different. A post hoc Dunnett’s test was used to compare multiple 
treatments to a ‘fixed’ negative control. A post hoc Tukey’s test was used in 
conjunction to one-way ANOVA to determine significance between treatments, 
conditions or groups without a control. Groups of related samples were analysed 
using the Friedman’s test analysis of variance.  
In Chapter 4, Chi-squared tests were performed to determine the probabilities 
that integration sites are significantly close to RefSeq genes and other genomic 
annotation features compared to randomly generated integration sites using 
VISA696. The total number of observed frequencies is multiplied by the expected 
ratio (obtained from randomly generated IS) to determine the expected number 
of events assumed under the null hypothesis. The Chi-square statistics were 
calculated using the formula (O-E)2/E where E is the number of expected events 
and O is the number of observed events. The statistic obtained and the number of 
degrees of freedom where then used to calculate the p-values. Yate’s correction 
was applied in the case of a 2x2 contingency table and 1 degree of freedom. 
Statistical analysis was performed in GraphPad Prism version 5.0 (San Diego, CA, 
USA). In all cases, levels of significance were established as follows: * p<0.05, ** 
p<0.001, *** p<0.0001. 
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Chapter 3  
RESULTS: Generation, characterisation and 
delivery of lentiviral barcoded vector libraries  
3.1 Introduction 
The development of biopharmaceutical producer cell lines requires a 
considerable investment of time and resources. Low-throughput methods for 
cloning, screening and selection despite being simple, reliable and inexpensive 
are time-consuming and significantly limited by the number of clones that can be 
feasibly screened. On the other hand, higher-throughput (HTP) strategies present 
the opposite characteristics: automated and sterile closed system albeit 
expensive and highly sophisticated. A high resolution, high-throughput, 
biologically driven method for selection of high expression clones applicable to 
multiple cell lines seems an attractive concept to shorten cell line development 
timelines and reduce associated costs.  
Assays currently used to identify high titre clones (e.g. ELISA, qPCR) cannot be 
performed on polyclonal populations, which creates a requirement for arduous 
generation of thousands of single clones. In this project, we propose a strategy 
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that could take advantage of the simplicity and inexpensiveness of the lower 
throughput methods but can be applied in a HTP scheme. The hypothesis utilises 
the natural ability of lentiviruses to integrate into high-transcribing regions 
within human cell genomes. Lentiviral vectors carrying a reporter gene are used 
as a tool to target and identify those defined loci. Beforehand pre-identification 
of genomic positions could reduce screening workloads and contribute to 
generate cell lines in a more reproducible manner.   
In addition to this semi-targeted approach, the system is coupled to a reliable 
method of clonal labelling and detection based on cellular barcoding. The barcode 
system consists of inserting a partially random DNA sequence tag into viral 
vectors. Upon transduction, the tag is stably integrated into the genome of a target 
cell and is inherited by its progeny. Expression values derived from barcode 
counts upon integration are ranked and correlated to the genomic position of 
integration. This way, site-specific expression can be measured in parallel in 
polyclonal populations avoiding the need to generate and screen thousands of 
clones. Next, transfer vector backbone is site-specifically integrated into these 
well-expressed candidate loci via CRISPR-Cas9 and co-transfected with the rest 
of packaging plasmids to assess viral titers.  
The aim of this results chapter is to develop a pool of unique third generation 
lentiviral vector particles, namely a vector library, with tags incorporated in a 
suitable position of the vector that facilitates post-integration retrieval.  
3.2 Aims 
The specific aims for this chapter are: 
- To engineer a lentiviral transfer vector expressing eGFP carrying a unique 
identifiable DNA tag (barcode) that enables integration site tracking. 
- To construct a barcoded plasmid and viral barcoded library with sufficient size 
and complexity to screen integration sites at high-throughput sequencing scale.  
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- To characterise the complexity and composition of such barcoded libraries at a 
plasmid and viral vector stage. 
- To determine whether the addition of a foreign DNA sequence tag into the 3’LTR 
of the lentiviral vector has effect on functional titers. 
- To establish a transduction protocol able to deliver a single copy of barcoded viral 
vector into host cell lines. 
3.3 Construction of lentiviral barcoded libraries 
3.3.1 Cloning of pRRL SIN cPPT EFS eGFP WPRE 
Firstly, a third generation lentiviral vector146 was engineered to contain a reporter 
gene under the control of an internal promoter. The self-inactivating vector pRRL 
SIN cPPT PEW (Appendix A), a gift from Didier Trono’s laboratory, contains a 
chimeric 5’LTR formed by the U3 of the Rous sarcoma virus (RSV) region joined 
to the HIV-1 R and U5 region (Figure 3.1A). The vector also contains a central 
polypurine tract (cPPT) and a reporter gene (enhanced GFP) under the control of 
the phosphoglycerate kinase promoter (PGK). The woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) present downstream of the eGFP 
reporter gene has been reported to improve vector titers and expression levels of 
the transgene298. 
The original aim of this project was to use the lentiviral barcoding strategy to 
identify genomic sites able to support high levels of antibody production. The 
EF1alpha promoter was cloned into the vector given that stable expression of 
high levels of protein has been achieved with this promoter in CHO cells697. 
However, an intron-deleted version of the promoter region from the human 
translation elongation factor 1 α subunit (EF1α) (EFS, EF1α short form) was used 
in order to prevent inefficient splicing of the EF1α intron from the lentiviral 
genomic RNA698, leading to differentially spliced vector products. The EFS version 
has successfully been used in the context of SIN lentiviral vectors by a number of 
academic laboratories and presents a safer insertional mutagenesis safety 
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profile698–701. In addition, it has been observed that levels of transgene expression 
associated to the EF1α promoter are higher than PGK702. 
The aforementioned vector was double-digested with XhoI and BamHI in order to 
replace the original PGK promoter with the intron-deleted (short) version of 
promoter region from the human translation elongation factor 1 α subunit (EF1α) 
(EFS). This was previously PCR-amplified adding both restriction sites from pCCL 
EFS hIDUA (Appendix A), kindly provided by Maria E Alonso-Ferrero (Institute of 
Child Health/UCL, London, UK), with the following primers (fwd 5´-
TCAGTctcgagGATTGGCTCCGGTGCCCG-3’; rev 5’-ggatccCGCGTCACGACAC-3’; 
restriction sites highlighted in lowercase). The resulting plasmid, pRRL SIN cPPT 
EFS eGFP WPRE (Figure 3.1), as well as parental plasmids were test-digested and 
fully sequenced to verify the integrity of its sequence and components (data not 
shown). 
The resulting vector (pRRL SIN cPPT EFS eGFP WPRE) was then cut with AvrII 
and Acc65I in order to replace the original 3’LTR fragment with one including two 
unique restriction sites within the U3 region in the 3’LTR (XbaI and NdeI, 
separated by 6bp) in a position where Somers et al., had previously integrated 
loxP sequences with no effects in viral integration and expression in 2010703. This 
position corresponds to 1bp downstream from the 400bp U3 deletion that gave 
rise to the SIN generation of lentiviral vectors by Zufferey et al.,288  (Figure 3.1C). 
Such modification was introduced to allow directional sticky-end cloning of 
barcodes within the U3 region of the 3’LTR. The modified or ‘synthetic’ LTR 
sequence was synthesised by GeneArt (Invitrogen, Thermo Fisher Scientific) 
delivered in plasmid DNA, pMK-RQ KpnI-LTR-AvrII, subsequently digested with 
AvrII and Acc65I and ligated into a pRRL SIN cPPT EFS eGFP WPRE backbone to 
give rise to pRRL SIN SyntLTR cPPT EFS eGFP WPRE  (Figure 3.1B). 
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Figure 3.1. Vector maps of third generation lentiviral vector plasmids expressing GFP and 
their subsequent modifications.  
(A) Parental plasmid. RSV U3, Rous sarcoma virus U3 long terminal repeat promoter regions; 
5’LTR, HIV-1 5’ long terminal repeat; Ψ, HIV-1 RNA packaging signal; SIN, self-inactivating (U3-
deleted) HIV-1 long terminal repeat; cPPT, central polypurine tract; Gag, HIV Gag gene; RRE, Rev 
responsive element; eGFP, enhanced green fluorescent protein; WPRE, woodchuck 
posttranscriptional regulatory element. (B) Intermediate plasmids generated in this study. (C) 
Diagram of the 3’ LTR and the SIN lentiviral vectors 400bp deletion. Modified (synthetic) LTR with 
NdeI and XbaI sites indicated in lowercase (D) Lentiviral barcoded library containing the semi-
random variable sequence tag (barcode) in the ΔU3 3’LTR. Schematic of the barcode. PBS, primer 
binding site. W is the nucleotide code for A/T; S is the nucleotide code for G/C.  
pRRL SIN Synt LTR cPPT EFS eGFP 
WPRE 
pRRL SIN cPPT PGK eGFP WPRE 
pRRL SIN cPPT EFS eGFP WPRE 
pRRL SIN Synt LTR cPPT EFS eGFP 
WPRE barcode - pSYNT 
 
Chapter 3. Results  
 142 
The barcode system is based on a synthesized variable non-coding DNA sequence 
tag or ‘barcode’, formed by a semi-random 68mer non-coding DNA barcode 
library, with the purpose of uniquely and individually tagging and tracking 
integrated proviral vector genomes in host cell lines. On stable chromosomal 
integration, each vector will introduce a unique, identifiable and heritable mark 
into the host cell genome. The barcode consists of a semi-random 34bp sequence 
followed by a 20bp common ‘anchor’ sequence and it is based on a previous 
barcode construct by Gerrits et al.,659. The Gerrits et al., design alternates triplets 
of known nucleotides with variable positions and labels each cell while the latter 
acts as primer binding site (PBS, not related to the viral primer binding site). This 
way, the occurrence of erroneous restriction sites within the barcode is 
minimised and barcode-positive and negative clones can be easily distinguished 
by PCR. Downstream bioinformatics analysis after integration site analysis and 
RNA-Seq is also facilitated by this barcodes configuration (Figure 3.1D). 
The semi-random variable sequence tag design used in this study consists of 14 
positions with 4 potential nucleotides and 2 positions with 2 potential 
nucleotides which theoretically make up to 1,073,741,824 ~ 109  (414 x 22) 
possible combinations or variants of barcode sequences  (Figure 3.1D). However, 
the complexity is limited in practice by other steps such as the viral titer or the 
size of the subcloned plasmid library (number of bacterial clones generated on 
transformation). This configuration was chosen in order to maintain a balanced 
GC content across the barcode as well as to prevent the formation of secondary 
structures and the accidental generation of restriction sites. The fixed triplets 
included within the variable nucleotides allow unambiguous sample 
identification and are also meant to facilitate the analysis of sequencing results 
by providing an internal standard to evaluate the quality of each sequence trace. 
In terms of nucleotide composition, the signature of each vector particle needs to 
be sufficiently distant to be able to distinguish it from other similar signatures or 
‘false’ signatures originated from sequencing errors. 
As an initial test to assess feasibility of oligonucleotide cloning, equimolar 
amounts of individual strands of barcode were dissolved in 0.5x ligation buffer at 
a final concentration of 10μM, heated at 95C, annealed gradually at decreasing 
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temperature (1C/min), phosphorylated and ligated to column-purified NdeI and 
XbaI-digested pRRL SIN SyntLTR cPPT EFS eGFP WPRE backbone. The ligation 
product was transformed into Stbl3 competent cells and cultured in agar plates 
with the appropriate antibiotic. The resulting plasmid was named pRRL SIN 
SyntLTR cPPT EFS eGFP WPRE barcode (Figure 3.1B).  
The following day, 97 colonies had grown and 8 and 0 colonies were observed in 
backbone-only and insert-only control ligations, respectively. The presence of 
another BamHI site 1.5kb away from the barcode BamHI site revealed >90% of 
the clones contained the barcode (Figure 3.2). DNA from 10 positive clones was 
extracted and Sanger-sequenced with the primer (5’-
TGTGTTGCCACCTGGATTCTG-3’) demonstrated that all clones contained a 
different barcode variant and all nucleotides were evenly represented in the 
variable positions (Figure 3.2A and Figure 3.2C). These results demonstrate a 
successful cloning strategy for barcode oligonucleotide cloning and barcode 
detection. 
 
Figure 3.2. Confirmation of barcoded oligonucleotide library cloning into a lentiviral 
backbone. 
(A) Pictogram of relative frequencies of nucleotides in sequenced barcodes (resource available at: 
weblogo.berkeley.edu.logo.cgi704). Adenine (A) is shown in green; cytosine (C) in blue; thymidine 
(T) in blue and Guanine (G) in yellow. (B) Diagnostic digest of individual minipreps (clones 1-14) 
with BamHI to check the subcloning of barcode. The 1 kb plus ladder is used in agarose gels as 
molecular weight standards (Life Technologies, ThermoFisher Scientific, Appendix B). (C) 
Barcode sequences obtained by Sanger-sequencing of 10 clones. Nucleotides highlighted in 
yellow represent the variable positions within the barcode sequence.  
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3.3.2 Construction of a lentiviral barcoded library 
Once the barcode was demonstrated to be cloned into the lentiviral backbone, the 
next step was to provide it with sufficient barcode variants in order to allow high-
throughput screening of host cell line genomes. To generate the barcoded library, 
double stranded inserts containing the barcode (Barcode_top 5’Phos-
TATGAGTAANNNATCNSGATNNAAANNGGTNWAACNNTGANNNTGGTAACACCGA
CTAGGATCCTGAT-3’ and barcode_bottom 5’Phos-CTAGATCAGGATCCTAGTCGG 
TGTTACCANNNTCANNGTTWNACCNNTTTNNATCSNGATNNNTTACTCA-3’) were 
synthesized by annealing two pools of phosphorylated oligonucleotides. 
Although the designed barcode is theoretically capable of harbouring a barcode 
population of 414 x 22 = 1,073,741,824 > 109 variants, the size of the barcoded 
library will be limited at different stages due to technical limitations such as the 
transformation efficiency of annealed barcodes into competent bacteria or the 
number of viral particles generated in a lentiviral vector preparation. Several 
conditions were tested including insert:backbone molar ratio, ligation times and 
temperatures in order to increase transformation efficiency (Figure 3.3). 
A common issue described in the literature is the ligation of repeated copies of 
oligonucleotide insert forming concatemers. However, no concatemers were 
observed in any of the colonies sequenced after barcode cloning. The different 
number of overhanging base pairs in the restriction site may have contributed 
towards the absence of concatemers, which was also confirmed by gel 
electrophoresis (data not shown) and next-generation sequencing (Section 
3.4.1). 
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Figure 3.3. Optimisation of different parameters to generate the barcoded pSYNT library. 
(A) Number of obtained clones using increasing amounts of lentiviral backbone plasmid DNA. (B) 
Number of obtained clones increasing insert:backbone ratios using 100ng of lentiviral backbone. 
(C) Number of colonies obtained using different times and temperatures for ligation (100ng 
backbone and 1:100 backbone:insert ratio). Temperature-cycle ligation (TCL) method described 
by Lund et al., 1996 for oligonucleotide library cloning consists of 12-16h ligations, alternating 30 
seconds at 10C and 30 seconds at 30C at a frequency of 10 cycles/h679. (D) Number of colonies 
obtained using varied methods reported in bibliography. Colonies were obtained after ligation 
100ng of backbone with 1:100 ratio of oligonucleotide for 1-2h at room temperature. Different 
ligation protocols suggested in bibliography: HI, heat inactivation of T4 DNA ligase; PEG, addition 
of polyethylene glycol 10% (v/v) of 50% (w/v); Scale up, 10x scale up ligation reaction; Scale 
down, 2x scale down reaction; deP Backbone and P insert, standard ligation carried out with 
dephosphorylated backbone and phosphorylated oligonucleotide; conditions suggested by L. 
Bystrykh comprise a 2h ramp from 22C to 18C followed by an overnight incubation at 18C; 
backbone negative control, only backbone ligation; Insert negative control, only insert ligation. All 
transformations were performed using homemade Stabl3 chemically competent cells 
(transformation efficiency 1.5x107) prepared following Inoue protocol680. All results presented 
(means ± SD; * p<0.05, ** p<0.001, *** p<0.0001, compared to backbone only negative control, 
one-way ANOVA and the Post hoc Dunnett’s test) correspond to 3 technical replicates.  
A 
B 
C D 
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Optimization experiments showed that a backbone:insert ratio of 1:100 of 
reported the best results when ligated for 1 hour at room temperature (Figure 
3.3A, B and C). Several methods and protocols found in the literature (e.g. PEG, 
heat inactivation, scale up, de/phosphorylation, etc.) were also tested after having 
established optimal amount of vector backbone and insert ratio as well as ligation 
conditions (Figure 3.3D). 
Polyethylene glycol (PEG) is an additive that can be added to blunt ligations to 
improve its efficiency by acting as a condensing agent and favouring 
intermolecular and intramolecular binding705. However, most manufacturers 
recommend not combining PEG when using electrocompetent cells or heat 
inactivation unless the ligation product is dialysed. The number of colonies 
obtained using 10% (v/v) of 50% (w/v) PEG was equivalent to that of the 
standard protocol. A 2-fold concentrated ligation reaction (50% reduction in 
volume) was performed also with the aim to create a more condensed 
environment and facilitate the approach between molecules but did not report a 
major improvement in the number of clones. In contrast to this, a 5x scaled up 
ligation was performed in parallel using a final volume of 100µL and resulted in 
a 7-fold increase in the number of clones. Heat inactivation or purification of the 
ligation reaction prior to transformation did not exhibit any effect in the 
transformation efficiency. Alternatively, an oligonucleotide library preparation 
protocol suggested by Leonid Bystrykh (University of Groningen, Netherlands) 
(consisting of a 2 hour ramp from 22C to 18C followed by an overnight 
incubation at 18C) was also tested.  
Another factor that might limit transformation efficiency is the amount of fully 
double-stranded insert caused by mismatches in the variable sequence of the 
barcode that impair proper oligonucleotide annealing. Three strategies involving 
extension of the second strand over a single strand of barcode template were 
tested in order to address that potential problem (Figure 3.4).  
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Figure 3.4. Cloning strategies for construction of the barcoded plasmid library. 
(A) Standard strategy of oligonucleotide cloning. Annealing of a pair of oligonucleotides 
containing the complete barcode sequence resulting in a fragment with compatible ends to be 
ligated into the vector backbone (B) Alternative strategy for oligonucleotide library cloning 
consisting in the annealing of a pair of oligonucleotides not comprising the variable barcode 
region. The 3’ ends of the vector backbone were recessed to increase the number of overlapping 
nucleotides and thus transformation efficiency. (C) Second alternative strategy for oligonucleotide 
library cloning. Annealing of a pair of oligonucleotides not comprising the variable region of the 
barcode followed by the extension of the barcode variable sequence and consequent digestion of 
both ends and ligation into the vector backbone. (D) Third alternative strategy differing from (C) 
only in a ligation of an annealed oligonucleotide fragment end prior to strand extension, digestion 
and ligation of the other compatible end. 
 
 
However, none of the alternative cloning strategies previously described (Figure 
3.4) reported a significant increase in the number of colonies achieved (data not 
shown) and thus were discarded due to their added complexity. Eventually, a 10x 
scaled up ligation reaction was prepared following the same stoichiometric 
proportions with a final volume of 200µL. The whole reaction was transformed 
using 2mL of Stbl3 chemically competent cells and the estimated number of 
A D 
B 
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colonies was 120,000 (based on a 10-3 diluted culture, assuming 100% plating 
efficiency) representing a 10-fold increase in respect to the previous scale up 
reaction. In all cases, insert and backbone (recircularisation) negative controls 
remained low with close to 10 and 25 clones, respectively.  
Clones were screened for the presence of barcode by restriction digest and 
sequencing resulting in 85-90% of positive clones harbouring different variants 
in all cases. No concatemerisation of the barcode was observed. The barcoded 
plasmid library was named pSYNT. Although a library size of 105 clones is far from 
the initial expectations to reach the 109 potential variants (theoretical sample 
space), it is sufficiently high to represent a better alternative to current high-
throughput clone selection methods (screen capacity of 103-104 clones636). 
The pool of colonies was grown overnight in 125mL of vLB in the presence of 
50μg/mL of ampicillin in order to generate a plasmid library glycerol stock (124 
x 1mL aliquots) stored at -80C. After overnight culture, an aliquot was streaked 
out on agar plates containing the appropriate antibiotic and colonies were 
screened for the presence and composition of barcode. Plasmid DNA from each 
picked bacterial clone was isolated and Sanger-sequenced and analysed in order 
to pre-validate the library prior to next-generation sequencing. 90% of the 
colonies presented barcode, no concatemers were observed and all barcode 
variants were different. The four nucleotides were equally represented in the 
variable positions (data not shown). 
3.4 Characterisation of barcoded lentiviral libraries 
3.4.1 Barcoded plasmid library validation by next-generation sequencing 
Next-generation sequencing was performed on the barcode fragment to assess 
the library size and complexity of the pSYNT barcoded plasmid library. Aliquots 
11 and 49 of the plasmid barcoded library (124 aliquots) were randomly selected 
for plasmid preparation (named pSYNT11 and pSYNT49). A 187bp fragment 
containing the barcode sequence was amplified from pSYNT11 and pSYNT49 
with primers containing Illumina compatible sequences (highlighted in 
uppercase): (P5fwd-upstream-barcode 5’-ACACTCTTTCCCTACACGACGCTC 
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TTCCGATCTccttcgccctcagacgagtcggatc tc-3’; bio-P7rev-downstream-barcode 5’-
[bio]GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTcaaaaagcatctagatcaggatcctag
tcggtgttacca-3’). The 220bp PCR product was submitted to UCL Genomics for 
next-generation sequencing with the MiSeq using a 300bp paired-end (PE) 
configuration.  
Fastq files of the two PCR products (named Plasmid_PCR11 and 49), obtained 
from pSYNT11 and 49 barcoded regions, were analysed using FASTQC tool690 in 
Galaxy686 yielding 1,752,655 and 1,135,377 reads, respectively. R1 and R2 reads 
were merged with BWA pemerge yielding 1,578,532 (90%) and 1,004,241 
(88.5%) successful merges for PlasmidPCR11 and PlasmidPCR49, respectively. 
Quality control of merged reads revealed an optimal mean quality of the reads 
across the bases of the PCR amplicon, including an average size of nucleotide 
(after merging), balanced GC content and a high amount of repetitive sequence as 
expected by the low complexity of the regions surrounding the barcode (Figure 
3.5). 
Barcodes were extracted from merged reads using a custom Perl script, 
‘extract_library_barcode.pl’ (Appendix B). This script detects a DNA string 
consisting of a defined 20bp sequence upstream of the barcode followed by the 
barcode itself and a defined 20bp sequence downstream. The efficiency of vector 
barcoding (or the number of vectors with barcodes) was 88% according to deep 
sequencing, confirming results obtained at low throughput by enzymatic 
digestion and Sanger sequencing (8% unbarcoded vectors). 1,392,401 and 
892,174 barcodes (88.2 and 88.8% of the sequences from the previous step, 
respectively) were extracted from Plasmid_PCR11 and Plasmid_PCR49, which 
have a total of 89,207 and 65,410 variants (6.4 and 7.3% of the sequences from 
the previous step respectively), of which 12,019 overlapped between the two 
replicates (Figure 3.6A).    
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Figure 3.5. Summary of quality control statistics for barcoded Plasmid_PCR11 and 49 
libraries. 
 (A) 1% agarose gel electrophoresis showing a 320bp barcoded plasmid PCR products. 1kb plus 
DNA ladder (Life technologies, ThermoFisher Scientific, Appendix B). (B) Distribution of quality 
values per base. The yellow boxes represent the inter-quartile range (25-75%). The upper and 
lower whiskers represent the 10th and 90th percentiles; the blue line represents the mean quality. 
The background of the graph divides the y-axis into good quality calls (green), calls of 
intermediate quality (orange), and calls of poor quality (red). (C) Peaks of DNA obtained during 
DNA quality assessment by micro chip-based capillary electrophoresis using Agilent Bioanalyzer. 
Results given in fluorescence units (FU). Peaks at 35bp and 10,380bp are internal controls. (D) 
Distribution of sequence length over all sequences. Equivalent results obtained for 
PlasmidPCR_49 (data not shown). (E) GC distribution over all sequences for PlasmidPCR_11. 
Equivalent results obtained for PlasmidPCR_49 (data not shown).  
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In both replicates, only 11% of the barcode variants (10,249 and 7,260, 
respectively) were recurrent (presented >1 replicate or copy) and thus, the 
majority were singletons (barcodes with a single variant). However, these 
singletons only contribute 6% to the total barcode population. This can mean that 
either a vast majority of recurrent barcodes show very low complexity and/or 6% 
of barcodes (those that are singletons) provide 90% of complexity to the library, 
although this complexity is falsly generated by sequencing errors. Interestingly, 
the error rate of Illumina NGS technology ranges between 1-5%. 
A similar proportion of the 4 nucleotides was observed in all 14 variable positions 
except the 2 positions with W and S (IUPAC nomenclature) where only A/T and 
G/C were equally found, respectively (Figure 3.6B). These results contribute to 
establish a maximal nucleotide dissimilarity (based on Hamming distances706,707) 
in the barcode population thus enabling efficient barcode retrieval and clustering 
correction in subsequent bioinformatics analysis. Major biases in the nucleotide 
composition of the barcode can affect sequence complexity and yield (depending 
on the technology). However, the addition of a balanced and diverse PhiX DNA 
library allows real time control quality metrics and creates a more diverse set of 
clusters to normalize for the low diversity of the amplicons.  
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Figure 3.6. Characteristics of the pSYNT barcoded plasmid library analysed by next-
generation sequencing. 
(A) Number of reads obtained by high-throughput sequencing using a MiSeq 300bp paired-end 
strategy, successfully merged reads, extracted barcodes and unique barcode variants present in 
the two replicates analysed. (B) Pictogram of relative frequencies of nucleotides in sequenced 
barcodes Resource available at: weblogo.berkeley.edu.logo.cgi704. Adenine (A) is shown in green; 
cytosine (C) in blue; thymidine (T) in blue and Guanine (G) in yellow. Top pictogram 
corresponding to PlasmidPCR_11; bottom pictogram corresponding to PlasmidPCR_49. (C) Mean 
number of nucleotide differences between all the sequenced pSYNT11 (left) and pSYNT49 (right) 
barcodes.  
 
Authors differ in the way quality criteria are applied to correct for low frequency 
barcode noise (different criteria detailed in Table 3.2). Arbitrary removal of low 
frequency variants (i.e. variants occurring <2 and up to <10 times) biases the real 
library complexity by underrepresenting the number of ‘true’ singletons (non-
false variants occurring once/non-recurrent in the population). 
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Alternatively, the degree of dissimilarity could be used to discard variants close 
in sequence. The number of nucleotide differences between the barcode variants 
present in the vector library was also evaluated using a script kindly provided by 
Martijn H Brugman (Leids Universitair Medisch Centrum (LUMC), Germany) 
(Appendix B). A peak of dissimilarity around 11 nucleotides can be observed in 
both replicates (Figure 3.6C). This value provides the average variation expected 
between barcodes and could serve as a reference to establish the threshold for 
background noise removal. However, the hierarchy in number of counts needs to 
be considered not to discard predominant variants with this approach.  
A potential way to minimize this bias is to integrate low frequency variant counts 
into the counts of their parental counterparts by clustering correction. Clustering 
correction aims for compensation for the appearance of false positives derived 
from sequencing errors. The algorithms group together sequences based on 
biological relationship or error threshold and assign to a mother/stem barcode. 
Its principle is based on the number of single-character edits necessary to change 
one sequence into another708. The Levenshtein (or editing) distance is computed 
between all the sequence pairs in a sequence population yielding as an output a 
canonical sequence (with minimal distance) and a set of several DNA sequences 
whose metrics are below the established threshold. Read counts of barcode 
variants different by less than a particular number of nucleotides (threshold) are 
pooled together and pictured as a network of nodes linked by edges whose 
distance is proportional to the number of dissimilarities between sequences. 
Barcode clustering consists of a computationally intense ‘matching’ phase in 
which a graph is displayed (typically resembling a star shape), followed by a 
cluster detection phase. Several clustering algorithms exist in the literature to 
correct sequencing errors from random sequences (or sequences of unknown 
source) when a reference library or genome is not available. 
Starcode carries out an all-pair search for the number of Leveinshtein distances 
between sequences to construct the clustering diagram691. Matching is performed 
using lossless filtration but what makes Starcode novel is the ‘poucet’ algorithm 
search strategy, which significantly reduces time compared to other clustering 
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algorithms. Input sequences are prefixed and these intermediates sorted and 
stored in alphabetical order in the edit matrix according to their prefix 
redundancy so that less computational effort is required to process the next 
search.  
As discussed before, distribution of barcode frequencies shows an accumulation 
of low frequency barcodes up to 60% of the total populations. In other words, the 
majority of the population is composed of barcodes variants with a few or a single 
copy (singletons). Starcode clustering (using default parameters) was applied for 
correction on Plasmid_PCR11 and 49 and as result, the consensus showed a more 
even distribution of low frequency barcodes (Figure 3.7). This confirms that a 
fraction of barcode variants had less than 2 distinct nucleotides and less than a 
fifth of relative frequency compared to their corresponding ‘mother’ barcode 
(default parameters for Starcode clustering) and were likely to be originated due 
to sequencing errors. 
After clustering correction of barcode sequences, 39,954 and 28,173 unique 
barcodes (or variants) were identified in clustered barcode populations, of which 
3,078 overlapped. In this case, only 3,053 and 3,046 were recurrent. The profile 
and peak number of dissimilarities is maintained when the barcodes of the 
plasmid library are clustered confirming their variant proportions (data not 
shown).  
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Figure 3.7. Density plot showing the cumulative frequency of barcode variants before (left) 
and after (right) clustering correction. 
Barcode variant frequencies of plasmid libraries 11 (A) and 49 (C) expressed as cumulative 
percentage of the total barcode population. Starcode clustering eliminates low frequency variants 
(sequencing errors) in PlasmidPCR_11 (B) and Plasmid_PCR_49 (D). 
 
Determining the library size or the number of possible barcode variants in a 
library is an essential step for library characterisation. The throughput or 
screening capacity of the lentiviral system will be dictated by the total number of 
distinct variants found in the library, therefore population size values under 103 
would not signify an improvement over current non-parallel high-throughput 
screening procedures. 
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The Lincoln-Petersen estimate709 was used in order to determine the size of the 
pSYNT library. The Lincoln-Petersen estimate is used in ecology to study 
population sizes based on the number of capture and recapture events. This 
model assumes the population is constant i.e. the population size remains the 
same between the time of the capture (mark) and the recapture implying that no 
individuals are born, die or migrate (which obviously does not apply in this 
study). Another premise of the model is that the sample is random and that all 
individuals have the same chances of being captured in the second sample 
regardless whether they were captured in the first place (independent 
recapture). Given the previous premises, the model predicts that the population 
size (N) can be calculated as follows: 
𝑁 =
𝑀 𝑆
𝑅
 
Where M is the number of events marked in the first ‘capture’, S is the number of 
events captured in the second sample or re-capture and R is the number of 
marked events (from the first sample) captured in the second sample. One of the 
strengths of the Lincoln-Petersen estimate is that it remains asymptotically 
unbiased at large sample sizes (which is the case and reason why it is used in this 
case over the Chapman estimator)710. However, despite its simplicity, population 
sizes calculated using the Lincoln-Petersen index tend to be overestimated, 
especially in samples with high heterogeneity whose spatial distribution is not 
uniform711,712. Some authors use the Schnabel index, which share the same 
principle but allows for multiple mark and recapture events. Applying these 
calculations, the population size of the pSYNT barcoded library is comprised 
between 485,484 and 365,700 variants (Table 3.1), which shares the same order 
of magnitude as the estimated number of bacterial colonies obtained in the 
plasmid library cloning.  
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Table 3.1. pSYNT library size and diversity details pre- and post-Starcode clustering 
correction.  
 Non-clustered Clustered (Starcode) 
PlasmidPCR_11 barcode variants 89,207 39,954 
PlasmidPCR_49 barcode variants 65,410 28,173 
Overlapping variants 12,019 3,078 
Recurrent variants PlasmidPCR_11 11.5% 7.6% 
Recurrent variants PlasmidPCR_49 11.1% 10.8% 
Population size (Lincoln-Petersen) 485,484 365,700 
 
Libraries with random oligonucleotides represent a source of entropy useful to 
exploit high-throughput screening. Nevertheless, often the amount of diversity 
observed is only a small proportion of the total number of possible sequences in 
the sampling space. The following argument intends to estimate the real number 
of variants there are in a given library and also the theoretical size of a library to 
be 95% confident for example it contains all possible variants. 
Regarding the number of physical molecules present in the sequencing reaction, 
typically, 600μL of a 12-20pM DNA library are sequenced under this 
configuration, which represents between 4.3-7.2 x 109 300bp molecules. This 
number is higher than the theoretical number of potential barcode variants in the 
library and also sufficiently high to be 95% sure a complete library could be fully 
sequenced; however, sequencing using the HiSeq technology still offers higher 
throughput number. Therefore, this step does not represent a bottleneck for the 
library size and/or complexity. 
According to Patrick et al.,713, given a library with L number of observed clones 
and providing all the variants in a library are equally represented, the mean 
number of occurrences of a sequence variant in the library (λ) can be defined as   
λ= L/V, where V is total number of possible distinct sequence variants. When 
λ<<L, the number of occurrences of a single sequence variant follows the Poisson 
distribution: 
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 𝑃(𝑥) =  
𝑒− 𝜆  𝜆𝑥
𝑥!
 
where P(x) denotes the probability of a library to be present x times in a library. 
From the previous expression, the probability of a variant not occurring in the 
population or occurring once can be expressed as: 
P (0) = e- λ 
P (x≥1) = 1 – P (0) = 1 - e- λ = 1 – e L/V 
Therefore, the expected or real number of different variants (C) can be described 
using the expression C = V P, where V represents all the possible combinations of 
the complete library and P is the probability of a variant to be expressed one or 
more times. In the case of this study, V would correspond to 14 and 2 positions 
with 4 and 2 possible nucleotides, respectively (414 x 22), which results in 
1,073,741,824 ~109 possible combinations. 
C = V P (x ≥ 1) = V (1 – e L/V) 
The probability of a barcode variant to occur one or more times, P (x ≥ 1),  can 
also be understood as the fractional completeness of the library (F) or C/V. For 
example, a library with a completeness of 95%: 
0.95 = (1 – e L/V) 
L = -V ln0.05 = 3 V 
This means a 3-fold degeneracy is expected in a library to contain 95% of the 
clones. In our case, that would mean a library containing 3x109 barcode variants 
should be constructed for it to contain 95% of the expected variants.  
Approaching this question the other way around, we can deduce that the different 
barcodes sequenced in this library provide evidence that there are approximately 
L/3 = 400,000 clones according to Lincoln Petersen estimate divided by 3 equals 
133,333 different variants in the library with 95% fractional completeness. This 
number actually defines the throughput of the library for further screening 
purposes.  
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Library calculation softwares are based on the assumption that all base 
substitutions and barcode variants are equiprobable. In reality, inherent to PCR 
amplification is the fact that some sequences are more easily amplified than 
others. As a consequence, the number of theoretically expected sequences (V) is 
greater than obtained sequences (sub-library size, L). If L >>V then, most variants 
are likely to be sampled unless the bias is very strong. 
As seen in Figure 3.7, false low frequency barcode variants generated from errors 
in the amplification of barcoded sequence during NGS for library validation can 
represent an important proportion of the barcode population. Error rates (f) are 
calculated using the following formula: 
𝐸𝑟𝑟𝑜𝑟 𝑟𝑎𝑡𝑒(𝑓) =  
𝑛
𝑆
 
where n is the number of mutations observed and S = (bp sequenced  x d), d  being 
the average number of doublings occurred in a reaction, which can be calculated 
from the expression below: 
2𝑑 =  
𝑛𝑔 𝐷𝑁𝐴 𝑎𝑓𝑡𝑒𝑟 𝑃𝐶𝑅
𝑛𝑔 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝐷𝑁𝐴 𝑖𝑛𝑝𝑢𝑡
 
Analytical error introduced by commercial polymerases in the sequencing 
process ranges from 10-5-10-7errors/bp714 based on 15-20 doublings and 5kb 
sequenced. Adjusting the values to the 1.5M reads of 2 strands of 300bp, 35 cycles 
and assuming the polymerase used has an error rate of 10-5 (most error-prone 
case scenario), the total number of mutations per sequenced sample oscillates 
around 315,000. The probability of one of these mutations to occur in one of the 
16 variable positions of the barcode is 16/300 = 2% (otherwise would have been 
discarded), which means 6,300 reads out of the initial 1.5M (0.42%) might 
contain a false barcode originated by polymerase error, a minimal proportion of 
the global barcode population.  
In addition, errors in the barcode sequence are also introduced by the cellular 
RNA polymerase on transcription of plasmid molecules. These errors are not 
Chapter 3. Results  
 160 
analytical but real mutations introduced in the barcode sequence that contribute 
to generate complexity in the library. However, since their rate is as low as those 
of analytical origin, the frequency and nucleotide dissimilarity of RNA-pol 
generated (real) barcodes would probably be underestimated by clustering 
algorithms.  
3.4.2 Barcoded vector library validation by next-generation sequencing 
Two aliquots of plasmid library (#11 and #49, randomly chosen) were amplified 
in vLB containing the appropriate antibiotic at 37°C overnight. Bacterial cells 
were pelleted and DNA was isolated to be transfected along with third generation 
lentiviral vector packaging plasmids as indicated in Materials and Methods 
(Section 2.2.16).  
Ultracentrifuged lentiviral vector containing the barcoded library (vSYNT11 and 
49) was prepared and titrated reporting titers comparable to a standard lentiviral 
preparation (Figure 3.8). No significant differences were observed between 
different vectors when titrated in different cell lines. These results indicate that 
the addition of a foreign sequence does not interfere with functional titers. 
Figure 3.8. Functional lentiviral vector titration by flow cytometry on different cell lines. 
All results presented (means ± SD; * p<0.05, ** p<0.001, *** p<0.0001, grouped per cell type, 
Friedman’s test analysis of variance) correspond to 3 technical replicates. Values were similar for 
vSYNT49 (data not shown). 
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Viral vector genomic RNA was extracted from viral vector supernatant and DNA 
contaminants were removed by column purification or DNaseI. Reverse 
transcription and amplification of the desired barcoded sequence were 
performed in a single step using SuperScript® III One-Step RT-PCR System with 
Platinum® Taq DNA Polymerase and P5fwd-upstream-barcode RNAbc_150ups-
fwd 5’-ACGAGTCGGATCTCCCTTTG-3’ and Barcode-PBS(BamHI)-rev 5’- 
GGATCCTAGACGGTGTTACC-3’ primers. A 220bp product was cloned into a TOPO 
backbone and successful retrieval of barcodes was confirmed by Sanger 
sequencing prior to submission of PCR product for deep sequencing (data not 
shown). NGS using a 100bp paired-end strategy with the HiSeq2500 sequencer 
yielded 12,267,014 and 11,641,759 reads for vector libraries 11 and 49, 
respectively. 12,235,295 (99.7%) and 11,611,553 (99.7%) R2 reads passed the 
criterion of having five or fewer Ns. Quality control showed good quality along all 
the basepairs of the 101bp reads and balanced GC content (Figure 3.9). 
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Figure 3.9. Summary of quality control statistics for barcoded vectorPCR_11 and 49 library. 
(A) 1% agarose gel electrophoresis showing a 320bp barcoded plasmid PCR products. 1 kb plus DNA 
ladder (Life technologies, ThermoFisher Scientific, Appendix B).  (B) Distribution of sequence length 
over all sequences. Equivalent results obtained for vectorPCR_49 (data not shown). (C) Peaks of DNA 
obtained during DNA quality assessment by micro chip-based capillary electrophoresis using Agilent 
Bioanalyzer. Results given in fluorescence units (FU). Peaks at 35bp and 10,380bp are internal 
controls. (D) Distribution of quality values per base. The yellow boxes represent the inter-quartile 
range (25-75%). The upper and lower whiskers represent the 10th and 90th percentiles; the blue line 
represents the mean quality. The background of the graph divides the y-axis into very good quality 
calls (green), calls of intermediate quality (orange), and calls of poor quality (red). (E) GC distribution 
over all sequences for vectorPCR_11. Equivalent results obtained for vectorPCR_49 (data not shown). 
(F) Location of the primers used to amplify barcoded regions from lentiviral vector RNA transcripts.  
LTR, HIV-1 long terminal repeat; Ψ, HIV-1 RNA packaging signal; SIN, self-inactivating (U3-deleted) 
HIV-1 long terminal repeat; cPPT, central polypurine tract; Gag, HIV Gag gene; RRE, Rev responsive 
element; eGFP, enhanced green fluorescent protein; WPRE, woodchuck posttranscriptional regulatory 
element; PBS, primer binding site. W is the nucleotide code for A/T; S is the nucleotide code for G/C.  
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For barcoded vector library 11 and 49 (vSYNT11 and 49), 5,061,108 (41.4%) and 
4,688,154 (40.8%) barcodes were extracted from sequences containing the 
barcode regular expression (no flanking sequences) and 545,185 (10.8%) and 
483,700 (10.3%) variants were counted, respectively, of which 105,261 
overlapped. The number of singleton counts dropped from 90% in the plasmid 
library to 10-15% in the vector library; in other words, 458,841 (84.2%) and 
403,001 (83.3%) variants had more than one copy in the vector library 11 and 
49, respectively. This drop in the proportion of barcodes with a unique signature 
can be explained by the higher number of reads obtained by HiSeq sequencing. 
Sequencing errors are more likely to be repeated with 10 times more reads.  
After clustering correction (using Starcode), the number of variants was reduced 
to 88,052 and 75,946, of which 3,211 overlapped between vector library 11 and 
49 replicates (Figure 3.10A). This represents a 1.74% and 1.63% of the initial 
selected barcodes and a reduction of 80.8% and 81.1% in the number of variants, 
respectively. Despite the number of reads being 10 times higher, pSYNT and 
vSYNT retrieved Starcoded variants have the same order of magnitude and the 
difference between replicates remains consistent (pSYNT11 x 0.71 = pSYNT49; 
vSYNT11 x 0.86 = vSYNT49; calculations based on Starcode-clustered variants), 
confirming no major biases occurred during the lentiviral library preparation. 
The fact that the number of retrieved variants in the vector libraries doubled 
those obtained in the plasmid libraries could be attributed to the sampling 
difference.  
The proportion of the four nucleotides in the library remains balanced (Figure 
3.10B). This indicates again that no major biases were introduced during vector 
production.  According to the dissimilarities plot, most barcodes differ from each 
other by 11 nucleotides (also at viral level) (Figure 3.10C), which contributes to 
a sufficient library complexity and eases the discrimination between true 
biological variants and variants originating from sequencing errors.  The profile 
and peak number of dissimilarities is maintained when the barcodes of the vector 
library are clustered confirming their variant proportions (data not shown). 
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Figure 3.10. Characteristics of the vSYNT barcoded vector library analysed by next-
generation sequencing. 
(A) Number of reads obtained by high-throughput sequencing using a HiSeq 2500 100bp paired-
end (PE) strategy, successfully merged reads, extracted barcodes and unique barcode variants 
present in the two replicates analysed. (B) Pictogram of relative frequencies of nucleotides in 
sequenced barcodes Resource available at: weblogo.berkeley.edu.logo.cgi.704 Adenine (A) is 
shown in green; cytosine (C) in blue; thymidine (T) in blue and guanine (G) in yellow. Top 
pictogram corresponding to PlasmidPCR_11; bottom pictogram corresponding to 
PlasmidPCR_49. (C) Barcode comparison plot showing the number of nucleotide differences 
between all the sequenced barcodes. (D) Barcode comparison plot showing the number of 
nucleotide differences between all the sequenced vSYNT11 (left) and vSYNT49 (right) barcodes.  
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3.5 Delivery of barcoded lentiviral libraries 
3.5.1 Transduction of the barcoded vector library into HEK293 host cell 
lines 
Once the lentiviral barcoded library was produced and characterised, barcodes 
were delivered to cell lines in order to identify integration site preferences and be 
able to quantify their transcript expression relative abundance.  
The distribution of vector particles across cells is a random process; the 
probability of cells receiving k number upon transduction at different MOIs is 
expected to follow a Poisson distribution P(k) = e-m mk / k!, where m is the MOI 
and k is the number of integration events715,716. 
Figure 3.11. Poisson distribution describing the expected effect of MOI on the proportion 
of cells receiving k proviruses. 
The green line represents the percentage of cells with no lentiviral proviruses (k=0), the blue and 
red line represent single (k=1) and multiple (k>1) integration events, respectively. 
 
 
The highest proportion of cells containing only one copy of the barcode is 
achieved at a MOI of 1. A lower MOI could reduce the number of cells labelled with 
>1 barcode but would also reduce the number of uniquely labelled cells (Figure 
3.11). In lineage tracking experiments, this would represent a critical issue since 
additional clonal populations could be found if cells have multiple tags (>1 
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barcode and lentiviral vector genome per cell) and is the reason why some 
protocols recommend using MOIs of <0.3 so that >90% of the transduced cells 
only contain one barcode717–719. In the event of measuring transgene expression 
by flow cytometry (not via barcoded RNA quantification), the presence of a 
majority of cells with a single provirus is also critical. However, in the barcode 
approach (expression measurement relying on barcoded RNA quantification) 
cells harbouring more than a single provirus do not pose a limitation for the 
analysis. As the sample space (the total number of possible barcode variants) is 
large, the chances of a cell harbouring two proviral genome copies with the same 
barcode variant are very low. Therefore, in this study, multiple integration of 
barcodes into the same cell is not a critical problem. 
Suspension adapted (SA), serum-free HEK 293 cells from GSK vaccines in 
Rixensart (Belgium), from now on named HEK 293 SA RIX, were initially used as 
candidates for lentiviral vector packaging. Serum free cultures present a lower 
risk of adventitious viruses or prions and also for good manufacturing practices 
(GMP). Cell banks are available for this cell line. The barcode library was delivered 
to 120x106 HEK 293 RIX cells by transduction at a MOI low enough (MOI of 0.5)  
so that most cells receive only a single barcode in order to screen the genome for 
high transcribing sites. Cells were kept in culture for three weeks before cell 
sorting in order to avoid any silencing of the gene expression720. The number of 
cells was estimated so that 5% windows containing 50,000-100,000 cells. Each 
could be sorted depending on the percentage of GFP+ when transduced with a 
MOI of 1 and also the reduced viability (60-70%) of HEK 293 SA RIX cells when 
cultured in upright flasks (due to the lack of shaking platforms for suspension 
cultures). 
Low growth rates and relatively low titers obtained in transient transfection 
experiments done by others at GSK (data not shown) showed HEK 293 SA RIX cell 
lines are not an optimal host for vector production. Instead, HEK293 6E cell lines 
originally from the National Research Council of Canada were used due to their 
increased recombinant protein production374,721. HEK 293 6E express a truncated 
Epstein Barr virus nuclear antigen 1 (EBNA), which increase recombinant protein 
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production in the presence of plasmids carrying Epstein Barr Virus (EBV) oriP 
sequences. Transient production of scFV-FC antibodies was found to be 10-fold 
higher than in HEK 293Ts722. In addition, this cell line is suspension adapted, 
serum-free can be combined with a family of pTT expression vectors for stable or 
transient expression and possess cumate and coumerycin for expression switches 
during production376.  
In a second experiment, 103, 104, 105 HEK 293 6E cells were transduced at a MOI 
of 1 and HEK293 6E cells were harvested (for integration site analysis and RNA-
Seq) after shorter culture (7 days) to prevent fast-growing clones taking over. In 
terms of timing, wild type HIV particles are released as early as 18 hours post-
infection in T cells, integration takes place 8.5 hours and all transcriptional 
species are expressed after 15 hours post-infection indicating that this selection 
method could theoretically be applied 24 hours post-transduction719. 
3.5.2 Cell sorting of HEK293 cell lines transduced with the barcoded vector 
library  
Flow cytometric analysis and fluorescence-activated cell sorting (FACS) was 
carried out on HEK 293 SA RIX to provide separation of cellular populations 
based on fluorescent labelling (Figure 3.12). In this study, 4 HEK 293 SA RIX 
subpopulations with significantly different GFP intensities: top 5% (H), 5% mid 
(M), low 5% GFP expressers, as well as GFP (+ve) and GFP (-ve) were sorted, 
expanded and harvested for further analysis of viral integration sites.  
The viability of the H sorted subpopulation dramatically dropped within 7 days 
after the cell sorting (Figure 3.13B). Repeated rounds of sorting changing the flow 
rate, along with different sorting solutions (PBS vs Hank’s balanced solution) and 
recovery media did not solve viability problems for the highest expressers. This 
could be potentially attributed to the toxic effects of an accumulation of GFP722.  
The sorting strategy was modified to address this problem. Cells were segregated 
into 5 different subpopulations based on GFP intensities: top5% (H6) / high-
medium 10% (HM5), mid-high 10% (MH4), mid 10% (M3 or M), low 10% (L) GFP 
expressers, as well as GFP+ve and GFP(-ve) (Figure 3.12). 156,900, 273,251, 
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267,992, 270,992 cells were recovered for HM5, MH4, M3 and L groups, 
respectively. All HEK 293 subpopulations were successfully expanded after cell 
sorting except from the top 5% (H6) group (Figure 3.13B). Several repeats of this 
experiments with similar outcome confirmed this phenomenon, which suggests 
the loss of viability is due to a cytotoxic effect caused by excessive accumulated 
GFP.  
 
Figure 3.12. Cell sorting of HEK 293 SA RIX populations based on GFP intensity.  
(A) Fluorescence-activated cell sorting (FACS) diagram corresponding to separation of HEK 293 
SA RIX transduced with a barcoded lentiviral vector library. P6 corresponds to high GFP 
producers, P5 is mid-high GFP producers, P4 is mid GFP producers and P3 is low GFP producers. 
GFP (+ve) and GFP (-ve) cells, were also isolated as a control. P2 gate excludes duplets of cells and 
P1 corresponds to the initial population of live cells. (B) Mean fluorescence intensity values 
normalized by MFI of untransduced cells. All results presented (means ± SD; *** p<0.0001, 
compared between groups using one-way ANOVA and the Post hoc Tukey’s test) correspond to 3 
technical replicates. 
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Interestingly, the duplication times of the different sorted cell populations 
increased with GFP intensity (Figure 3.13A) possibly due to the metabolic burden 
on HEK 293 imposed by GFP production. 
 
Figure 3.13. Cell line viability and duplication times of 293 SA RIX subpopulations after cell 
sorting. 
(A) Duplication times of different HEK293 RIX sorted subpopulations. HM5, MH4, M3 and L 
correspond to HEK 293 SA RIX cells sorted into GFP high-medium, medium-high, medium, low. 
All results presented (means ± SD; * p<0.05, ** p<0.001, *** p<0.0001, ns non-significant, 
compared to unsorted negative control, one-way ANOVA and the Post hoc Dunnett’s test) 
correspond to 3 technical replicates.  (B) Viability percentages in different HEK293 RIX sorted 
subpopulations. 
 
 
Duplication times are significantly lower in HEK293 SA RIX HM5 (and in HEK293 
SA RIX MH4 and M3) in respect to other sorted subpopulations. No significant 
differences were observed between HEK293 SA RIX L and HEK293 RIX cells. This 
trend reinforces the hypothesis that an excessive content of GFP is deleterious for 
cells.    
3.5.3 Lentiviral library vector copy number on transduced host cell lines 
In order to normalise the expression per integrated vector copy derived from a 
particular integration site to a particular barcode, integration needs to be coupled 
with vector copy number determination by qPCR. A week after transduction 
genomic DNA was harvested and vector copy number was analysed by qPCR to 
compare the number of lentiviral genomes per cell (measured with primers and 
probes annealing to the WPRE sequence) to those of a housekeeping gene 
(endogenous beta actin) (Figure 3.14). 
A B 
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Figure 3.14. Barcode lentiviral vector copy number on different cell populations.  
Samples labelled 6E3, 4, 5 stand for 103, 104, 105 HEK 293 6E cells, respectively transduced at an 
MOI~1.  NTC, non-template control 1. RIX HM5, MH4, M, L, +, - correspond to HEK 293 SA RIX 
cells sorted into GFP high-medium, medium-high, medium, low, GFP+ and GFP- expressers. 
Results expressed as means ± SD. 
 
 
These results indicate that cells possess a single copy of lentiviral vector 
integrated in their genome. Interestingly, sorting for high GFP levels may enrich 
for cells containing multiple proviruses. GFP is a reporter gene that has been 
described to quantitatively correlate its intensity with the MOI723,724, and thus 
indirectly with the number of integrated vector genomes (obeying a Poisson 
distribution, Figure 3.11). The fact of having observed this phenomenon only in 
the HEK293 SA RIX HM5 population might have been caused by the concentration 
of the fraction of cells containing an average of 4 copies of vector, which according 
to the Poisson distribution is 1.5%. However, this finding does not suppose a 
limitation for the purpose of this project because (i) it is only observed in this 
particular subpopulation (ii) the probability of this 4 barcode copies in the same 
cell to have the same variant is negligible as it is the probability of picking the 
same barcode variant or one differing by only 1 nucleotide (potentially attributed 
to sequencing errors) based on calculations done in libraries with smaller library 
sizes by Bystrykh et al., in 2014725.  
3.6 Summary of results and concluding remarks 
- A lentiviral vector was successfully engineered to harbour a DNA variable 
sequence tag (barcode) within a region that enables its transcription 
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during transgene expression in target cells and allows for its retrieval 
during integration site analysis.  
- A barcoded plasmid (4x105 clones) and vector library (pSYNT/vSYNT) 
was constructed after optimizing the amounts of backbone, stoichiometry 
and ligation conditions.   
- Validation of both libraries by NGS revealed a sufficient size and 
complexity to screen 105 integration sites.  
- Functional titers were not affected by the presence of a foreign 70bp DNA 
sequence within the U3 region in the 3’ long terminal repeat. 
- Duplication times of cell sorted subpopulations correlate with their GFP 
intensity.  
- Vector copy number analysis by qPCR confirmed the presence of one copy 
in MOI-1 transductions (HEK293 6E) and all the sorted cell pools (HEK293 
RIX), except for the highest producers (4 copies). 
In this chapter, barcoded vector libraries were prepared and validated to 
efficiently deliver unique tags into thousands of genomic positions in host cell 
lines. One of the main challenges faced in this chapter was to achieve sufficient 
number of clones to guarantee a large initial sample space and minimise library 
diversity and size bottlenecks in subsequent stages of the project. Unlike previous 
reports, concatemerisation of annealed barcodes was not observed as revealed 
by gel electrophoresis and next-generation sequencing. Worthington et al., 
hypothesised that an excess of 5’unphosphorylated oligonucleotides would 
prevent one vector end finding another due to a mass competition effect726. 
Strategies preventing mismatching did not report an increase in the 
transformation efficiency either.  
However, in order to improve ligation efficiency, a possible improvement would 
be to use a cohesive end restriction enzyme with 4 overlapping nucleotides rather 
than the 2bp of NdeI727. 
Commercial oligonucleotide synthesis uses equimolar ratios of the four 
nucleotides to create primers with degenerate positions. However, biases in the 
Chapter 3. Results  
 172 
stock mixes could affect the nucleotide representation in these positions. In order 
to minimize this source of bias, some companies (i.e. TriLink Biotechnologies) 
have done extensive research to develop a 1:1:1:1 ratio randomers. Although in 
this study the 4 nucleotides were quite evenly represented in the variable 
position, implementing an exact 25% of each-compositon would prevent 
potential biases from being magnified either at the bacterial subculture, viral 
preparation stage or during the detection step by PCR amplification. 
The GC content range of the barcode design proposed in this study (including the 
alternated fixed position) was found to be skewed towards a low GC content. In 
the theoretical case of all the variable positions being occupied by Gs and Cs, the 
global GC content would be 61.8%, a suitable upper limit. In the most AT rich 
scenario, the global GC content drops to 20.6%. Although the GC content did not 
represent a major concern in this study, a range between 40-60% range would 
have been the advisable. A balanced GC range avoids the formation of secondary 
structures that hamper denaturation and annealing of oligonucleotides728. In the 
current barcode design, a more balanced GC content could be achieved some of 
the fixed nucleotides within the barcode sequence or in the surrounding 
nucleotides by switching from W (A or T) to S (G or C). 
In line with the previous proposed optimisation, the design of the barcode could 
be modified to increase the current GC content of the current fixed triplet AAA 
(flanked by NN). Variants in which the current AAA triplet is flanked by AAs (A7) 
may pose a challenge for some sequencing technologies sensitive with 
homopolymer-length sequencing error (i.e 454 Ion Torrent)729. 
The number of clones obtained in the library described in this study is 
comparable (and in most cases higher) to those reported in the literature for 
analysis of clonal dynamics (Table 3.2). 
The position of the barcode within the lentiviral vector backbone is also relevant 
to the retrieval strategy and can be varied according to application. While in some 
publications731,734 the barcode is located between the WPRE and the 3’LTR, 
CellTracker® technology locates it before the cPPT right in the middle of the 
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lentiviral vector backbone. This location allows tracking dynamics of starter 
founder but does not facilitate integration site recovery. The library presented in 
this study not only allows cell labelling (if delivered at a low MOI) but also enables 
recovery of host-vector junctions.    
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Table 3.2. List of lentiviral and gamma-retroviral barcoded libraries recently published in the literature. 
Article Library name Barcode pattern  Size  (# of 
variants) 
Quality control Application 
Cheung et al., 2013730 MNDV-PGK-GFP N2ATC N2 GAT N2 AAA N2 GGT N2 AAC N2  ~2x105 Perfect match of viral vector sequences (length?) and barcode 
allowing up to 3 mismatches and q=20 
Analysis of clonal dynamics in HSCs 
Grosselin et al., 2013731 pLentilox3.4 (N8-(SW5))5-N8 50 Not specified Analysis of clonal dynamics in HSCs 
Verovskaya et al., 
2013732 
pMIEV and pGIPZ GTACAAGTAAGG N3 AC N3GTN3CG N3TA 
N3CA N3TGN3 GACGGCCAGTGAC 
800 and 
450 
Removal of low quality sequences and sequences only 
occurring once 
Analysis of clonal dynamics in HSCs 
Hoffman et al., 2007733 -  N4 (barcoded primers) 7 Perfect match to the barcode and primer regions and <1 N Identify HIV drug resistance mutations 
Cornils et al., 2014 733 LeGO N2ATCN2GAT N2AAA N2 GGT N2AAC N2 >7 x105 Only sequences with a frequency >10 and a perfect match in 
the 22 variable positions were included in the analysis 
Analysis of clonal dynamics in cancer 
Lu et al., 2012734 No specific name N6 (library ID)- N27 >8 x104 Removal of reads with mismatches and indels up to 2bp in the 
27nt random stretch. No mismatches tolerated in the 6bp ID 
library. Barcodes whose copy number is below a background 
noise threshold (algorithm) are excluded 
Analysis of clonal dynamics in HSCs 
Cellecta, Inc674 CellTracker ® (WS)15 5x107 Not specified Multiple 
Schepers et al., 2008657 pLentiLox3.4-GFP2 
and pMX-GFP-bc 
(N8-(SW5))5-N8 ~5x103 and 
~3.3x103 
Barcodes present above background were selected based on 
the probability that a signal differed from an artificial 
background distribution 
T cell lineage analysis 
Brugman et al., 2015735 pTGZ GG N3AC N3 GT N3 CG N3TA N3 CA N3 TG N3 
GA 
485 Bioperl script filtering barcodes with desired barcode regular 
expression including surrounding sequences (length?). 
Application of clustering analysis to reduce sequencing errors 
(dissimilarity <2) 
T cell lineage analysis 
Nolan-Stveaux et al., 
2011717 
CellTracker ® (WS)15 ~27.5 x103 Minimum Hamming distance between barcodes in the set is 4, 
so up to 3 mutations in an 18-nucleotide sequence can be 
detected 
Analysis of clonal dynamics in cancer 
Porter737 et al., 2014 No specific name Not specified >12,000 Removal reads with >3 mismatches or >3Ns. Doping 
experiment to determine lower detectable limit. 
Analysis of clonal dynamics 
Gerrits et al., 2010659 HC (retroviral) N2ATCN2GAT N2AAA N2 GGT N2AAC N2 800 and 
450 
Not specified Analysis of clonal dynamics in HSCs 
This study  pSYNT N3 ATC NS GAT N2 AAA N2 GGT NW AAC 
N2 TGA N3 
~4x105 Exact match for the barcode and a region comprising 20nt 
flanking the barcode. Application of clustering analysis to 
reduce sequencing errors (dissimilarity < 11) 
Lentiviral packaging cell line 
development 
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Another useful improvement to the current design could be to clone barcode tags 
flanked by sequences complementary to Illumina next-generation sequencing 
primers into the transfer vector. This strategy, already applied by Porter et al., in 
2014736, would have helped to reduce the number of amplification steps 
necessary to prepare libraries for sequencing, thus reducing potential handling 
errors, PCR bias and mutations introduced by the DNA polymerase.  
Grosselin et al., remarks the importance of an ‘arrayed’ lentiviral barcoded library 
in order to overcome bias introduced by restriction enzymes, PCR and random 
ligand attachment731. An ‘arrayed’ lentiviral barcoded library involves a known 
library size and complexity, which helps to interpret the linkage between a 
particular barcode variant and the target cells. However, in order to control the 
exact number of variants in a library, each of them should be individually 
annealed and equitably pooled, which can limit the throughput of the library.  
An alternative to that would be to add ‘spike-in’ reference controls to normalize 
or calibrate for the aforementioned bias, in other words, known numbers of cells 
(for instance 50, 500 and 1000 cells) with a known single barcode variant (with 
sufficient Hamming distance). This would also help evaluate loss in sequence 
complexity as a result of sequencing errors. 
An MOI between 0.5-1 was chosen because we believed this to yield the relatively 
highest proportion of single transduced cells following Poisson distribution. The 
single integration of a lentiviral vector genome in the host cell line genome is 
more relevant for the FACS-LM PCR approach, since these cells will not be 
distinguished from those containing more than one integration event. 
Nevertheless, the barcode system enables the RNA-Seq approach to determine 
the relative abundance of integrated barcode, regardless of the number of 
integrated viral genomes. 
FACS sorting would pool cells according to fluorescence intensity regardless of 
the number of integrated viral genomes the cell harbours. Ideally, site-specific 
expression to quantify the relative abundance of barcodes would be performed 
by RNA-Seq. This way, even though high fluorescent intensity pooled cells contain 
more than one vector copy, sequencing of barcode-containing transcripts would 
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allow an individual assessment of their expression profile. Nevertheless, cell 
sorting of polyclonal populations based on the GFP intensity upon transduction 
with the lentiviral library was performed as an alternative to RNA-Seq due to the 
following reasons: (i) to back up the measurement of gene expression in case the 
barcode system did not work; (ii) to validate the barcode system if it works 
(correlate number of barcode counts with average GFP intensity in the sorted 
populations) and (iii) to screen for sites within high GFP expressers with high 
number of RNA counts, which will confirm translatability of integrated cassettes 
(not confirmed with the RNA-Seq approach). 
In this study, high levels of GFP (associated with multiple copies of the provirus) 
were shown to compromise the viability of host cells. However, other factors may 
also contribute to cytotoxicity and a number of alternative strategies are 
available. Relatively low viability rates (60%) were observed in static cultures in 
comparison to agitated suspension cultures (>95%) (data not shown). Non-
agitated cells tend to clump together and grow forming patches or aggregates, 
which limits oxygen supply to central cells737,738. These cell aggregates that occur 
due to environmental stresses can accelerate the rate of cell death within the 
sample, resulting in the release of "sticky" DNA molecules from the dying cells 
that can facilitate further clumping of neighbouring cells739. This phenomenon 
leads to high content of cell debris (with necrotic factors) that could induce 
further cell death740 and problems during cell sorting. Adding endonuclease 
deoxyribonuclease I (DNase I) into the sample can minimize the presence of free-
floating DNA fragments and cell clumps741 
The addition of EDTA is also recommended because it acts as a Ca+2 ions chelator, 
preventing calcium protection of intracellular domains of adhesion molecules 
against proteolytic activities742,743. Although FCS can increase cell viability, it is 
important to note that these cell lines ideally would not be supplemented with 
FCS for safety issues (i.e. prions, adventitious bovine viruses) and manufacturing 
reasons such as (scalability, batch to batch variation and supply chain 
limitations). Serum-free media contains fewer undefined components, offers 
better lot-to-lot consistency and facilitates subsequent purification processes.  
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Additional bias can be introduced by splitting cells after transduction (or during 
the sorting), which skews cell populations containing different barcode variants. 
Experiments to evaluate the extent of this sampling bias must be designed to 
ensure adequate barcode representation. 
Finally, there are currently no guidelines or standard pipelines for barcode 
analysis. The criteria ranges from various minimal read qualities combined with 
the exclusion of reads with lower frequencies (specific threshold for each case). 
Filtering protocols also discard reads not matching the expected barcode pattern. 
All together, around 10% of the reads are usually excluded from further analysis. 
However, this should depend on the error rate of the sequencing platform used. 
Illumina-based sequencing has a 1-5% error rate mostly caused by 
substitution744,745. In contrast, PacBio (third generation or single-molecule 
sequencing) reports up to 15% error rate mostly due to insertions and 
deletions746.  Reference libraries provide a characterised control for these 
parameters and help distinguish sequencing errors from less frequent real 
variants. In the absence of reference libraries, astringent criteria can be applied 
in detriment of low frequent bona-fide barcodes. Porter et al., performed a doping 
experiment to determine the lower detection limit for barcode representation 
(set to 0.0002% of the reads in their study)736.  
In conclusion, we generated, characterised and delivered a lentiviral barcoded 
library with enough complexity to support high throughout genomic site-specific 
expression. The next chapter describes the application of the barcode library to 
find genomic loci that support high transgene expression. 
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Chapter 4  
RESULTS: Integration site analysis and 
correlation with barcode expression 
4.1 Introduction 
Typical strategies for the selection of high producing clones involve their 
individual segregation and high-throughput screening of their performance 
(reviewed in Section 1.22 High analytical burden of screening clones). Selection 
methods such as limiting dilution cloning are simple and inexpensive but often 
laborious and time consuming. FACS-based approaches benefit from high-
throughput capacity but, on occasion, fluorescence results in toxicity to the cell747, 
which limits the ability to select high producers. Secretion-based assays require 
handling expertise and are limited by the fragility of the cells and the costs of 
detection antibodies. These disadvantages are overcome by closed, automated 
sophisticated systems although the associated costs are considerably higher.  
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In this study, we propose the use of lentiviral vector integration preferences as a 
guide to target the insertion of therapeutic cargo genes in genomic positions with 
relatively high expression. Once the barcoded vector library (previously 
introduced in Section 3.3) is generated, most cell types (due to wide tropism of 
VSV-G748) can be transduced with the vector particles. The system relies on the 
evolutive ability of lentiviruses to pick stable sites with light burden on cell 
fitness. Highly laborious screening of individual clone titers (by qPCR, ELISA) is 
substituted with molecular tagging of RNA molecules and parallel screening by 
next-generation sequencing. However, this presents a new challenge in terms of 
bioinformatics. While initial concerns in Chapter 3 regarded size and complexity 
of barcoded libraries, in this chapter retrieval and discrimination of ‘real’ 
barcodes at a genomic and transcriptomic level will be assessed. Although 
multiple online tools to retrieve viral integration sites exist (QuickMap749, 
Mavric750, VISA696, VISPA751), none of them facilitates the retrieval of a barcoded 
sequence in the vector LTR. Similarly, recovery of a reduced portion of barcoded 
traces from whole RNA typically fragmented in relatively short length libraries is 
a challenge this approach faces. In this chapter, these questions will be 
investigated to develop and prove an alternative approach for selection of high 
producing clones. Despite integration properties (efficiency, payload and copy 
number) would be those of the method chosen for targeted-insertion (Chapter 5), 
as reviewed in Chapter 3, the use of lentiviral barcoded libraries for cell line 
development constitutes a unique approach for packaging cell line development 
due to its high-resolution genomic screening and its quantitative site-specific 
expression analysis.  
4.2 Aims 
The specific aims of this chapter are: 
- To show evidence of the retrieval of lentiviral barcode library-host cell line 
junctions containing the barcode. 
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- To generate a bioinformatics integration site analysis pipeline to analyse barcoded 
junctions at a high through put scale. 
- To quantify the abundance of RNA encoding each barcode variant delivered by the 
lentiviral library. 
- To assess the complexity of the barcoded library at different stages of the process 
(integrated provirus, expression levels via barcode counts). 
- To compare expression derived from lentiviral integration in particular loci with 
basal gene expression levels of host cell lines. 
- To correlate location and relative abundance using the barcode in order to select 
biologically relevant candidate position which can stably harbour lentiviral vector 
packaging components. 
4.3 Integration site analysis and RNA expression on 
vSYNT-transduced HEK 293 SA RIX  
4.3.1 Retrieval of lentiviral barcoded vector library – host chromosome 
junctions in HEK 293 SA RIX cells by LM-PCR 
Typically, in cell line development, the expression of integrated transgenes is 
screened based on the mean fluorescence intensity of a fluorescent protein in the 
clone or by antibody-derived methods as described in Section 1.2.2. In this study, 
4 subpopulations were isolated by cell sorting based on GFP intensity and the 
genomic position of integration analysed by ligation-mediated PCR (LM-PCR) to 
identify sites associated with high transgene expression. Alternatively, the 
barcoded approach suggested in this study investigates the use of barcodes 
present in viral vector transcripts as a quantitative method to link clonal 
expression to a particular integration site. Although, it is not required, the 
barcode approach is performed in populations sorted by FACS in order to 
compare their outcome and complement the former in case it is not functional.  
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In order to recover vector integration sites, genomic DNA from host cell lines with 
a low vector copy number per cell was harvested and analysed using ligation-
mediated PCR. Following from Section 3.5, 1.2x108 HEK293 SA RIX cells were 
transduced with the vSYNT11 library at an MOI of 0.5 to deliver the barcode. As 
described in Section 3.5, cells were kept in culture for three weeks to obtain 
expression only from integrated provirus and sorted into 4 subpopulations 
displaying differential GFP intensities (high-medium 10% (HM5), mid-high 10% 
(MH4), 10% mid (M3 or M), low 10% GFP expressers) as well as GFP+ve and 
GFP(-ve) (Figure 3.12). Genomic DNA was extracted from subpopulations HM5, 
MH4, M3 and L and digested with DraI. A linker cassette with compatible ends 
was ligated in order to provide a known region to specifically amplify junctions 
by nested PCR (Figure 4.1A). In contrast to the standard LM-PCR approach, which 
uses 3’LTR-specific primers, this version of LM-PCR is performed on the 5’ 
junction and allows amplification of the barcode within the junction (Figure 
4.1C). This modification is designed to enable longer (and better quality) reads 
into host chromosome given that the deltaU3 (where the barcode is located) is 
closer to the end of the provirus so reverse primers can be positioned 
immediately downstream of the barcode. In addition, primers only binding 
regions proximal to the 5’LTR enable specific amplification of upstream junctions 
and prevent the formation of by-products (often used as control bands). A faint 
DNA smear of chromosome-vector junctions was observed in all HEK 293 SA RIX 
samples (Figure 4.1B). Amplified junctions were ligation-independently cloned 
into pCR4-TOPO TA vector backbone. 8 colonies per group were Sanger-
sequenced and the presence of LTR-chromosome junctions was confirmed prior 
to NGS (Figure 4.1D and E) 
Retrieved sequences were manually mapped against the hg19/GRCh37 
(UCSC/NCBI) version of the human genome using BLAT. In all groups, 1-3 out of 
8 colonies picked per group contained an integration site that could be mapped 
(data not shown), making the retrieval efficiency consistent across all groups.   
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 Figure 4.1. Retrieval of integration junctions between barcoded vector library and HEK 
293 host chromosomes by ligation-mediated PCR. 
(A) Schematics of the LM-PCR performed in this study. Primer names and sequences are detailed 
in Section 2.2.29, Materials and Methods. (B) 2% agarose gel electrophoresis of vector library-
host cell chromosome obtained by LM-PCR. 1kb plus DNA ladder (Appendix B). (C) Schematics of 
the LM-PCR performed on a hypothetical 3’LTR-host DNA junction. (D) Alignment of traces 
obtained by Sanger sequencing showing 5’LTR barcoded U3 on the right and chromosome 
junction on the left. (E) Traces recovered in reverse orientation contain the barcode on the left 
side of the alignment and the linker on the right.  
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4.3.2 Next-generation sequencing of integration sites in HEK 293 SA RIX 
Once LM-PCR retrieval of integration sites was confirmed by shotgun cloning and 
Sanger sequencing (Section 4.3.1), LM-PCR products generated from sorted 
HEK293 SA RIX subpopulations with vSYNT11 (RRL EEW barcoded library) were 
purified and submitted to Genewiz and UCL genomics for high-throughput 
sequencing with Illumina MiSeq using a 300bp paired-end (PE) strategy. The aim 
of this choice was to extend the retrieval of long junctions to 600bp. Around 2 
million (M) R1 and R2 reads per sample were obtained. 50% of the reads were 
successfully merged using Burrows-Wheeler Aligner (BWA) pemerge tool in 
HEK293 SA RIX HM5 and MH4 samples; however, rates were lower for M and L 
samples (37 and 16%, respectively). Further optimization including trimming of 
read ends, error threshold or number of overlapping base pairs did not result in 
higher merging rate.  
Quality control of LM-PCR SA RIX merged reads showed good (green) quality 
score values in most of the reads (Figure 4.2E) and along the length of the read 
(Figure 4.2B). Merged reads have a GC content ratio distribution of around 50% 
as expected (Figure 4.2D) and show a peak of frequency around 330-340bp of 
length although read lengths up 530bp were obtained (Figure 4.2C). Capillary 
electrophoresis of LM-PCR products prior to indexing is comparable with the 
agarose electrophoresis gel (Figure 4.1B) and did not show a high degree of 
polyclonality or diversity in 2HM5 and 2MH4 samples (compared to 2M and 2L) 
(groups’ nomenclature defined in Section 3.5.2), which can be deduced from the 
presence of just a few strong bands (Figure 4.2A). These results confirm the good 
quality of most sequences and discard any potential errors originated during the 
library preparation.   
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Figure 4.2. Summary of quality control statistics by FastQC for LM-PCR performed on HEK 
293 SA RIX HM5 subpopulation. 
(A) DNA quality assessment of vector-chromosome junctions by microchip-based capillary 
electrophoresis using Agilent Bioanalyzer; results given in fluorescent units (FU). Peaks at 15bp 
and 1,500bp are internal controls.  (B) Distribution of quality scores across all 100bp of the read 
(Sanger/Illumina 1.9 encoding). The yellow boxes represent the inter-quartile range (25-75% of 
the score values per bp). The upper and lower whiskers indicate the 10th and 90th percentiles; the 
blue line represents the mean quality. The background of the graph divides the y-axis into very 
good quality calls (green), calls of intermediate quality (orange) and calls of poor quality (red). 
(C) Frequency of read lengths after trimming 3´ends and merging with BWA pemerge. (D) GC 
distribution (mean GC%) over all sequences. (E) Mean sequence quality distribution over all 
sequences. Similar results were obtained for LM-PCR 2MH4, LM-PCR 2M and LMPCR 2L also 
sequenced using MiSeq 300bp PE (data not shown).  
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A custom script called ‘extract_library_barcode.pl’ (AppendixB) was used to 
extract barcode sequences and host integration sites. The script detects the 
barcode and 46nt and 39nt LTR sequences flanking it and removes the linker 
sequence as long as all of the following criteria are satisfied: 
- Alignment to linker ends at the last 5 bases (bases 32-26) on the reference linker 
sequence (5’-ACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGT-3’). 
- The sequence identity of the linker sequence is >80%. 
Additionally, host sequences <20nt in length (minimum required to 
unequivocally map an integration site) were filtered out. Around 160,000-
200,000 extracted IS/barcodes passed the filter for HEK293 SA RIX HM5, MH4. 
HEK293 SA RIX M, L counts were reduced down to nearly 30,000 sequences. 
Integration sites were mapped against the human genome (H. sapiens UCSC 
hg19/GRCh37) using Blat. Blat was used instead of Blast because it is indexed in 
a different manner allowing for less usage of RAM memory and an easier 
mirroring than BLAST. Despite having less homology depth, Blat enables to run 
simultaneous queries at a higher speed with increased output options as well as 
different links to UCSC tools such as custom tracks and genome browsers.  
A .psl file was output from Blat and was converted to bed format using a custom 
script (‘get_best_hit_from_psl.pl’, Appendix B) following the criteria below: 
- The identity metrics set by default 1-(#mismatches/length) were replaced 
with the expression: 1 - (#mismatches + insertions + deletions / query + 
insertions + deletions). This way, insertions and deletions are included in the 
total number of mismatches, which contributes to accurate retrieval of 
sequences providing that long sequences with a high number of mismatches 
and gaps are not expected.  
- Blat parameters were optimized, -minMatch=2 (default number of tile 
matches) and -minScore=20 instead of the default 30 in order to retrieve 
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integration sites between 20 and 30 nucleotides in length (still unambiguously 
mappable).  
-Use of –fastMap parameter; –fastMap works for alignments with high identity 
(>90%) and increases the speed when gaps are not expected. 
- Only sequences with an exact match in the last position (the closest to the 
LTR) must be retrieved. 
- The minimum identity threshold of host genomic sequences (-
minIdentity=N) was set to 99% to enhance highly specific alignments (default 
is N=90%)  
- Integration sites with ambiguous alignments (alignments with >1 position 
retrieved) were discarded (the filter command was not included in the script 
but performed separately).  
The aforementioned criteria were established after manually mapping 100 
random integration sites using Blat web tool. The results obtained were used as 
a reference/standard to adjust the mapping parameters and default criteria of the 
pipeline. 
Out of the 142,749; 157,558; 21, 817 and 22,698 raw alignments with various 
scores output by Blat, 116,048 (81%); 127,476 (68%); 14,873 (68%) and 16,099 
(71%) non-ambiguous reads containing integration sites were retrieved for 
2HM5, 2MH4, 2M, 2L HEK 293 SA RIX cells, respectively (Figure 4.3). Since psl 
files contained repeated hits retrieved with different restriction enzymes, the 
different loci retrieved were counted based on the expression ‘endposition_chr’ 
and 310, 385, 414, 30 different IS (1,149 in total) were obtained out of the 2HM5, 
2MH4, 2M, 2L HEK 293 SA RIX psl files, respectively. Providing the theoretical 
maximum complexity of the barcoded vector library (discussed in Section 3.4.1) 
and taking into account the MOI of 1 at which the >250,000 sorted were 
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transduced (and being the NGS no limitation in screening throughput) values 
lower than 103 variants represent a substantial decrease in complexity. 
Figure 4.3. Frequency of sequences throughout the integration site analysis pipeline.  
Number of reads obtained from MiSeq 300bp paired-end PE sequencing configuration, 
successfully merged reads with less than 5N, sequences with a complete barcode and IS, IS with a 
length >20 nucleotides, filtered using optimised Blat parameters and alignments with >1 genomic 
position retrieved. IS, integration sites. 
 
 
The drop in the complexity of the library could be explained by the bias 
introduced at several levels: internal population dynamics during 3 weeks of cell 
culture (i.e. some clones overgrowing others) and the cell population drift 
introduced in consecutive rounds of passaging.  
4.3.3 Distribution of integration sites and annotation features in HEK293 
SA RIX 
In order to understand the integration profile of lentiviral vectors, the 310, 385, 
414, 30 different integration sites extracted from 2HM5, 2MH4, 2M, 2L HEK 293 
SA RIX psl files, respectively were analysed. Unexpectedly, a major proportion 
(>70%) of the different integration sites recovered in all four groups were located 
in a few regions in the host genome within a window of a 100-200 base pairs 
(Table 4.1). The bias concerning reduced number of integration sites, also 
translated to the barcode diversity where a large part of the populations’ 
polyclonality was depleted, limiting the throughput of the approach and the 
chances of finding a corresponding barcode in the RNA-Seq analysis (Figure 4.4). 
Chapter 4. Results  
 188 
Table 4.1. Clusters of integration sites retrieved from HEK 293 SA RIX cells by LM-PCR.  
 
Positions in bold were found in different subpopulations. This table shows the genomic positions 
retrieved with a higher proportion of the LM-PCR reads (95.7% of 2HM5, 92% of 2MH4, 87.1% 
2M and 36.7% in 2L subpopulations). The remaining proportions are constituted by reads 
containing a more varied representation of loci. 
 
 
These results could be explained due to the bias introduced during prolonged 
periods of culture.  A small number of fast-growing clones may have formed an 
increasing proportion of the population. Alternatively, it may have been 
originated due to the accessibility to the vector-chromosome junction, dependent 
Subpopulation Chromosome 
Genomic 
position 
Number of reads (%) Gene 
2HM5 
chr1 240504150 38 (12.3) FMN2 
chr12 85450800 17 (5.4) LRRIQ1 
chr3 152185950 60 (19.4) Downstream MBNL1 
chr5 88071754 84 (27.1) MEF2C 
chr6 76538100 10 (3.2) MYO6 
chr7 4730550 61 (19.7) FOXK1 
chr8 71354775 17 (5.4) Downstream NCOA2 
chrX 117405680 10 (3.2) Upstream WDR44 
2MH4 
chr1 240504085 50 (13.0) FMN2 
chr2 216556664 53 (13.8) LINC00607 
chr3 152185920 107 (27.8) Downstream MBNL1 
chr5 88071734 83 (21.6) MEF2C 
chr7 4730521 61 (15.8) FOXK1 
2M 
chr1 178838231 40 (9.7) RALGPS2 
chr1 87493018 49 (11.8) HS2ST 
chr12 84905305 42 (10.1) - (in 100kb) 
chr13 73000938 34 (8.2) - (in 100kb) 
chr18 67970581 22 (5.3) SOCS6 
chr5 91734199 14 (3.4) AK0568485 
chr6 72120260 33 (8.0) LINC00472 
chr6 101103750 51 (12.3) ASCC3 
chr8 57589988 15 (3.6) - (in 100kb) 
chrX 24003100 61 (14.7) KLHL15 
2L Chr7 4730521 11 (36.7) FOXK1 
Chapter 4. Results  
 189 
on the restriction site chosen in the LM-PCR step. The composition of the 
barcoded library retrieved by LM-PCR also showed a strong bias towards certain 
variants. However, the percentage of most represented variants (Figure 4.4) does 
not correspond to the most represented retrieved integration sites (Table 4.1), 
indicating that vectors with different variants integrated in the same genomic 
position. 
 
 
 
 
 
 
 
Figure 4.4. Relative abundance of barcode variants retrieved by LM-PCR on HEK 293 SA RIX 
cells transduced with vSYNT11. 
 
However, since the chances of two lentiviral vector particles to integrate within a 
region separated by a few base pairs are very low, the clustering of multiple reads 
around certain positions with slightly different coordinates is likely due to the 
generation of chimeric PCR products. This phenomenon was first described by 
Saiki et al., 1988 and describes an apparent recombination between different 
sequences with a high degree of similarity during PCR amplification752. The 
formation of chimeric PCR products is due to insufficient extension times that 
lead to incomplete extension of primers during the elongation phase of the PCR. 
These incomplete sequences cross-prime a different (but similar) molecule of 
template in the next cycle and complete the extension generating a strand 
consisting of fragments from two different parental templates. Since lentiviral 
junctions possess similar sequences between templates (the lentiviral LTR) and 
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their length is variable, extension times may not be sufficient for complete 
amplification of certain junctions favouring the generation of chimeric sequences. 
As a consequence, no conclusions regarding integration preferences could be 
drawn from this experiment.  
As shown in Table 4.1, the same integration sites were retrieved in different 
sorted populations. This could be explained by the variegation of expression in 
overgrown clones so cells containing the same IS were sorted into different 
subpopulations.  
Alternatively to LM-PCR, high frequency unique integration sites could be 
retrieved by linear amplification mediated (LAM) PCR or its restriction digest-
free variation non-restrictive (nr) LAM-PCR.  
4.3.4 Determination of the relative abundance of barcode RNA variants by 
RNA-Seq on a custom sequencing library in HEK 293 SA RIX 
Initially, relative abundance of barcode variants in sorted HEK 293 SA RIX HM5, 
MH4, M and L subpopulations was evaluated by whole transcriptome analysis. 
Whole RNA from the subpopulations mentioned above was submitted for 
sequencing using the Illumina HiSeq2500 1x (single-read) 50bp reads 
configuration in the Rapid Run mode. Results demonstrated quality scores >30 
for more than 90% of the sequence in most reads (Figure 4.5C) all files along 
with balanced GC (Figure 4.5D). However, only a few tens of barcodes per sample 
were retrieved from fastq files containing >20M reads. Providing that RNA was 
extracted from 107 cells and that a single cell contains an average of 200,000 
mRNA molecules (1-5% whole RNA)753, a total of 1012 RNA molecules per RNA 
preparation should be expected. Under the assumption that the expression of the 
vector only constitutes a 0.1% of the overall protein production (to 109 
hypothetical vector RNA molecules) and considering 20M reads per sample were 
obtained, the 5-log difference between the initial number of reads and the tens of 
barcodes eventually retrievedwhose is not difficult to explain. Lack of coverage or 
excessive fragmentation could explain the origin of this problem. In order to test 
the latter, reads containing half of the barcode pattern were extracted; 17 
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nucleotides following a known pattern are sufficiently specific not to retrieve 
unspecific sequences. Ten times more reads were retrieved in all samples 
suggesting 50bp fragments might be too short to integrally retrieve a sequence of 
34bp (the size of the semirandom stretch of the barcode).  
Alternatively, a custom library preparation was tested in order to retrieve 
barcoded transcripts more efficiently. In a standard library preparation for RNA-
Seq (using the TruSeq RNA Sample Prep kit form Illumina), mRNA is purified, 
fragmented and captured with polyA magnetic beads prior to polymerisation of 
the first strand of cDNA. Then, the second strand is synthesised, ends are 
repaired, 3’ ends are adenylated, adapters are ligated and indexed and P7 
sequences are added by PCR prior to library validation, normalization and pooled 
for sequencing. The objective of the custom library preparation was to maximise 
barcode retrieval by (i) decreasing the RNA fragmentation time during the library 
preparation step and (ii) pulling down only barcoded transcripts to ease 
posterior bioinformatics analysis. Accordingly, fragmentation times were 
reduced from the standard 8 minutes to 3 minutes. Libraries significantly longer 
than the standard insert size (~500bp instead of ~150bp) were obtained. An 
additional step was included after the ligation of the adapters consisting of a 
selective amplification of the library by PCR using biotinylated primers 
specifically annealing flanking the barcode followed by an enrichment of 
biotinylated DNA. Custom-made libraries were sequenced using the v3 2x300bp 
(paired-end) MiSeq kit at UCL genomics. The ~25M reads of the flow cell were 
divided into 9 samples (>2M each) including HEK 293 HM5, MH4, M, L among 
other 5 other samples (from a different study).   
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Figure 4.5. Summary of quality control statistics by FastQC from HEK SA RIX HM5 from a 
custom sequencing library. 
(A) RNA quality assessment by microchip-based capillary electrophoresis using Agilent RNA 600 
Nano; results given in fluorescent units (FU). Peaks at 25bp, 35bp and 10,380bp are internal 
controls. Top  and bottom left diagram shows total RNA profile with peaks corresponding  to 18S 
and 28S ribosomal RNA; bottom right diagram shows extracted barcoded RNA. (B) Distribution 
of quality scores across all 300bp of the read (Sanger/Illumina 1.9 encoding). The yellow boxes 
represent the inter-quartile range (25-75% of the score values per bp). The upper and lower 
whiskers indicate the 10th and 90th percentiles; the blue line represents the mean quality. The 
background of the graph divides the y-axis into very good quality calls (green), calls of 
intermediate quality (orange) and calls of poor quality (red). (C) Mean sequence quality 
distribution over all sequences. (D) GC distribution (mean GC%) over all sequences. Similar 
results were obtained for 2MH4, 2M and 2L, also sequenced using MiSeq 300bpPE (data not 
shown). (E) Diagram showing the use of biotinylated primers (left) as opposed to the first step of 
a conventional RNA-Seq library preparation workflow (right). Diagram from Corney et al., 754.  
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Close examination of reads from both orientations revealed barcodes could 
successfully be extracted from R2 reads. 2-3M input R2 reads per sample were 
reverse-complemented with a simple script called ‘rc_fastq.pl’ (Appendix B) and 
quality trimmed to discard those with an excessive number of missing bases 
(N>5). >99% of sequences passed that filter in all samples. After a quality control 
certifying good quality scores along all base pairs of the read (Figure 4.5B) in 
most reads (Figure 4.5C) and a balanced GC content (Figure 4.5D), barcodes 
were extracted with a script called ‘extract_rt-pcr_barcodes.pl’, which, similarly 
to the script ‘extract_viral_insertion_barcodes.pl’, recognises 46 and 39nt LTR 
sequences flanking the barcode and extracts the barcode sequence. 
The number of barcodes after this step dropped to 60,000-185,000 depending on 
the dataset (Figure 4.6A); 2L reported only 5,878 barcodes. The number of 
unique variants found for 2HM5, MH4, 2M and 2L were 1561; 1,578; 1,691 and 
518, respectively, of which 477; 528; 605 and 107 were recurrent (Figure 4.6B). 
As shown in Figure 4.6C, the nucleotide composition is biased towards those 
variants retrieved in a major proportion. This trait is particularly strong in 2HM5, 
MH4, and 2L (Figure 4.6D). 
Despite the reduction in the number of barcodes variants retrieved, the peak in 
the number of dissimilarities is maintained at 11 nucleotides as seen in plasmid 
and vector libraries. Interestingly, the removal of false barcode variants 
originated as a result of sequencing errors can be seen in Figure 4.6E where the 
peak around 3 nucleotides disappears upon clustering correction.  
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Figure 4.6. Characteristics of the barcoded counts retrieved from the custom sequencing 
library and analysed by next-generation sequencing. 
(A) Frequency of barcodes after discarding and extracting barcodes using ‘extract_rt-
pcr_barcodes.pl’ custom script. (B) Frequency of unique barcode variants before and after 
clustering using Starcode. (C) Pictogram of relative frequencies of nucleotides in sequenced 
barcodes Resource available at: weblogo.berkeley.edu.logo.cgi704. Adenine (A) is shown in green; 
cytosine (C) in blue; thymidine (T) in blue and Guanine (G) in yellow. Pictograms from top to 
bottom corresponding to HM5, MH4, M, L. (D) Stacked bar plot showing the relative abundance of 
each barcode within the barcode population. (E) Barcode comparison plot showing the number 
of nucleotide differences between clustered (right) and non-clustered (left) 2MH4 RNA-Seq 
barcodes.  
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Subsequently, clustering correction was applied to retrieved barcodes using 
Starcode. The thresholds for number of mismatches and ‘size absorbing’ ratio 
(explained below) were optimised for 2HM5, 2MH4, 2M and 2L. In DNA 
barcoding, since incomplete barcodes are not tolerated, mismatches are 
understood as transversions or transitions (not indels), also known as edited 
nucleotides or Leveinshtein distance (-d –distance- parameter in the command 
line instruction). The ‘size absorbing’ (-r) ratio is the number of times a cluster 
has to be larger in number of barcodes than another to be considered a single 
node. Two clusters with the same number of barcodes separated by a distance 
superior than the higher will not be clustered together unless fold difference in 
the number of barcode sequences is higher than the ‘size absorbing’ ratio691.  
 
Figure 4.7. Effect of Starcode clustering parameters on frequency of barcode variants. 
Increasing ‘size absorbing’ ratios made the clustering conditions more stringent and thus less 
distinct barcodes variants are obtained. (Default value is ratio=5).  
 
 
 
Figure 4.7 shows a dramatic drop (8-12 fold) in the number of variants obtained 
allowing 3 mismatches. This number corresponds with the peak in the number of 
dissimilarities within the barcode sequence obtained cross comparing the 
different variants across themselves and confirms the noise-removal effect 
observed in Figure 4.6E around the 3 dissimilar nucleotides upon clustering 
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correction (14 variable positions – 3 mismatches allowed = 11 peak in the 
frequency of dissimilarities observed between barcodes). 
The number of variants was reduced around 5-fold after Starcode clustering 
(Figure 4.7). These results show a decrease of 3 orders of magnitude in the 
complexity of the barcoded library in transduced cells compared to values of 
barcodes and variants obtained in the plasmid and vector library 
(1,392,401/39,954 barcodes/clustered variants for pSYNT11 and 
5,061,108/88,052 barcodes/clustered variants for vSYNT11). The same 
phenomenon (also with similar frequencies depending on samples) was 
observed in the LM-PCR experiment (Figure 4.4), where a few variants were also 
retrieved in a relatively high proportion. Evidence from independent sources 
(DNA junctions and barcode-specific RNA) consistently indicates that barcode 
representation is biased towards a few overrepresented variants. The main 
reason could be that a few clones may have overgrown the population over 
several rounds of passaging. Another potential explanation could be preferential 
amplification of certain vector-host DNA junctions or barcoded RNAs.  
4.4.2 Primary sequence composition at chromosome-vector junctions 
HIV integration site selection is not thought to be exclusively sequence driven. 
However, several authors described a short palindromic weak consensus in the 
chromosomal primary sequence immediately upstream of the U3 region in the 
5’LTR (Table 4.2).  
 
Table 4.2. Favoured target primary DNA sequences for HIV integration. 
Publication Weak primary consensus sequence 
Carteau et al., 1998228 5’-TNG(GTNAC)’CAN-3’ 
Holman and Coffin 2005216 5’- TDG(GTWAC)’CHA-3’ 
Wu et al., 2005755 5’-TDG(GTNAC)’CHA-3’ 
Integration takes place in the position marked with (‘) on the top strand and the palindromic 
sequence in brackets is duplicated in the target site. 
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Chromosomal sequences at the integration site were analysed in HEK293 SA RIX 
reads. In HEK 293 SA RIX HM5, MH4 and 2M samples, the nucleotide pattern 
observed in Figure 4.8 (5’-TNGTAAH-3’) does not correlate to that described in 
the literature (Table 4.2), given that the TNG motif in the genomic DNA is located 
only 4 nucleotides from the vector sequence (instead of 5nt, as expected for HIV). 
In the 293 2M sample, the nucleotidic pattern is more random and does not follow 
the weak consensus sequence whereas. In 293L the nucleotide composition is 
strongly biased possibly due to a clone that outgrew the population in the rounds 
of passaging during the month the cells were kept in culture. In addition to that, 
the presence of a thymidine in the 5’ end of the integration site is not expected 
since it has been reported to cause steric hindering with the phosphate backbone 
of the newly made bond172.  
 
Figure 4.8. Pictogram showing relative frequencies of nucleotides on the 5'vector LTR-host 
chromosome junction in HEK 293 SA RIX transduced with vSYNT11. 
(A) Resource available at: weblogo.berkeley.edu.logo.cgi704. Adenine (A) is shown in green; 
cytosine (C) in blue; thymidine (T) in blue and Guanine (G) in yellow. (A) Primary sequences 
retrieved from HEK 293 SA RIX sorted subpopulations.  
 
4.3.5 Correlation of integration site analysis and RNA counts on HEK 293 
SA RIX data 
Barcode variants from the different groups (2HM5, 2MH4, M, L) were ranked 
based on their abundance of RNA counts after clustering correction. The top 10 
most expressed variants were interrogated to the LM-PCR dataset containing 
genomic positions associated with a particular barcode (Table 4.1). 
Although barcodes were clustered using Starcode, none of the top 10 barcodes 
changed in sequence or position (based on number of counts) compared to their 
position prior to clustering. These results indicate that pre-clustered variants 
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were distant in sequence similarity (at least >2 editing or Leveinshtein distance, 
the value of the parameter used in Starcode).  
From the correlation of both datasets, several integration sites were found to be 
associated with the same barcode variant. However, not all the genomic positions 
recovered by LM-PCR had the same number of reads. Some cases did not allow 
unique association of a barcode to a single integration site whereas in others, a 
particular integration site was substantially more represented than the rest of 
genomic positions. The threshold for establishing endposition_chr abundance 
obeys the following formula:  
#reads of the most represented genomic position
#reads of the 2nd mostrepresented genomic position
> 10 
A 10-fold threshold difference in the ratio between the first and second highest 
number of LM-PCR counts was established as a filter to consider the association 
a clear signal rather than background noise. The criterion to set to the ‘10-fold 
ratio’ threshold was based on the profile of signal/noise observed in different hits 
(linear increase for background noise versus logarithmic increase for real 
integration sites).  
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Table 4.3. Correlation of RNA counts with vector integration sites using the barcode. 
Barcodes present in >1 dataset are highlighted with the same colour. (*) Signal refers to the ratio 
between LM-PCR reads recovered between the first and the second genomic position with the 
same barcode. Column 1, sorted subpopulation of HEK 293 6E based on GFP intensity; column 2, 
position in the ranking of top expressed barcode variants; column 3, number of barcode counts 
per barcode variant retrieved by RT-PCR and NGS; column 4, variable nucleotides extracted from 
the whole barcode in this particular variant; column 5, number of reads retrieved by LM-PCR; 
column 6, Signal (ambiguity measurement) – ratio between the number of LM-PCR reads between 
the top two genomic positions associated with the same barcode variant; column 7, chromosomal 
position; column 8, chromosome; column 9, RefSeq gene associated with the genomic position. 
(**) Integration sites with a signal below the threshold (10-fold) were not mapped.   
Sub-
population 
Top # 
#RNA 
counts 
Barcode variant sequence 
#LM-PCR 
reads 
Signal* 
Genomic 
position 
Chr Gene 
2HM5 
1 80,324 ATG-TC-CA-TA-AT-TA-CCC 145 <10-fold **   
2 46,673 CAC-TC-TC-GT-GT-GC-TCA 314 <10-fold **   
3 25,523 ATG-TC-TT-CT-CA-AT-CGC none NA    
4 21,184 AAG-CG-AT-CT-GT-GT-TGT 29,717 11.3 88,071,769 5 MEF2C 
5 2,641 TAA-CG-AT-GC-CA-AC-AAC 144 <10-fold **   
6 2,178 ACA-AG-AG-CA-CA-AC-TTC 69 <10x    
7 1,184 TCA-GC-GT-TC-CA-AT-AAA 70,947 11.5 4,730,541 7 FOXK1 
8 1,045 AGA-TC-TT-TC-GA-CT-GCC none NA    
9 756 CGG-CC-TG-TT-AT-GA-CTA 5 <10-fold **   
10 554 TAG-CC-TT-AC-CT-AA-TCG none NA    
2MH4 
1 29,948 CAC-TC-TC-GT-GT-GC-TCA 146 <10-fold **   
2 17,670 ATG-TC-TT-CT-CA-AT-CGC none NA    
3 14,530 ATG-TC-CA-TA-AT-TA-CCC 16 <10-fold **   
4 12,351 AAG-CG-AT-CT-GT-GT-TGT 11,863 10.1 88,071,769 5 MEF2C 
5 4,457 CGA-AC-GT-GT-TT-TC-TAT none NA    
6 4,115 TAA-CG-AT-GC-CA-AC-AAC 267 <10-fold **   
7 3,992 CCC-GC-TC-GG-GA-CC-TAT 7,394 13.2 152,185,965 3  
8 3,664 ACA-AG-AG-CA-CA-AC-TTC 110 <10-fold **   
9 3,529 GTC-AG-TT-AT-TA-CC-GTT none NA    
10 2,188 CAA-AC-CT-TA-AT-AT-AAC none NA    
2M 
1 6,535 ATG-TC-CA-TA-AT-TA-CCC none NA    
2 6,046 TAG-CC-TT-AC-CT-AA-TCG none NA    
3 5,082 ACA-AG-AG-CA-CA-AC-TTC none NA    
4 3,582 CAC-TC-TC-GT-GT-GC-TCA none NA    
5 2,816 TCA-GC-GT-TC-CA-AT-AAA 6 <10-fold **   
6 2,581 AGA-TC-TT-TC-GA-CT-GCC none NA    
7 2,331 CCC-GC-TC-GG-GA-CC-TAT none NA    
8 2,265 CGA-AC-GT-GT-TT-TC-TAT none NA    
9 1,978 ACC-AC-AC-AT-AA-AA-AAA none NA    
10 1,866 CGG-CC-TG-TT-AT-GA-CTA none NA    
2L 
1 1,905 TCT-TG-CT-TA-AT-AA-AAG 2 <10-fold **   
2 748 CAT-GC-CT-TT-GT-AA-GAA none NA    
3 663 TGC-TG-AC-TT-AT-TG-AGT none NA    
4 426 CAC-TG-AT-TA-CA-AA-ATC none NA    
5 350 TTT-TC-GT-GC-TT-AT-TCG none NA    
6 334 ACA-TC-CC-GT-AT-CA-AAG none NA    
7 310 CCC-CC-GT-AG-GT-GA-AAT 9,718 1618.2 108,685,768 6 LACE1 
8 155 AAG-TC-TG-CG-TT-CT-GAT none NA    
9 150 TCT-CG-TC-CA-TT-TC-AAT 16 <10-fold **   
10 115 TAC-CC-CC-AC-GT-AA-AAT none NA    
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Association of RNA and LM-PCR barcodes derived from datasets 2HM5, 2MH4 
and 2L under the aforementioned premises resulted in 4 candidate genomic 
positions associated with different genes:  
- FOXK1 (also known as myocyte nuclear factor, MNF) stands for forkhead box 
protein K1 and is RNA polymerase II regulator that binds to the upstream 
enhancer region (CCAC box) of myoglobin gene. 
- MEF2C is a protein-coding gene whose position was retrieved from both 2HM5 
and 2MH4 datasets. MEF2C (myocyte specific-enhancer factor 2C) is a 
transcription factor, which binds to regulatory regions of muscle-specific genes. 
As well as FOXK1, it is involved in cardiac morphogenesis and myogenesis. It also 
plays a role in neuronal development and it is necessary for megakaryocytes, 
platelets, and B-cell lymphopoiesis.  
The third position (chr3:152,185,965) is not associated with a gene but it is 
located <3kb downstream of the human musclebind like splicing regulator 1 
(MBNL1) gene, a zinc-finger protein that participates in alternative splicing of 
myogenic pre-mRNAs. 
- LACE1, whose signal/noise ratio was 100 times higher than the rest of positions, 
stands for lactation-elevated protein 1 and is a protein-coding gene with a 
possible ATPase function.   
However, screening of 300-500 genomic positions/barcodes does not represent 
a significant improvement compared to current selection methods for high 
expressing clones. Due to the high degree of library complexity (throughput) lost 
over several weeks of culture, a new strategy was explored where integration 
sites were screened for expression 10 days post-transduction.  This strategy 
maximises the maintenance of entropy/complexity by transduction of the 
barcoded library in detriment of stability of gene expression. From a biological 
point of view, this strategy would present a problem if gamma-retroviral vectors 
were used to screen the genome for high expressing sites due to the gene silencing 
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associated with CpG islands, more predominant in the TSS, where gamma-
retroviral vector are more likely to integrate. However, since lentiviral vectors are 
being used in this study and these vectors tend to integrate along the 
transcription unit, this risk becomes minor. 
4.4 Integration site analysis and RNA expression on 
vSYNT-transduced HEK 293 6E  
4.3.4 Next-generation sequencing of integration sites in HEK 293 6E 
In addition to the modifications introduced in the last section, our Cell and Gene 
Therapy CMC group at GlaxoSmithKline switched from HEK 293 SA RIX to HEK 
293 6E cell lines.  This cell line is also suspension adapted, grows in serum-free 
media and according to the Biotechnology Research Institute of the National 
Research Council of Canada (NRC-BRI) allows for high yield production of viral 
vector and recombinant proteins374,721. The HEK 293 6E cell line expresses a 
truncated form of the Epstein Barr Virus (EBV) nuclear antigen (EBNA) 1 which 
enables episomal persistence and amplification of plasmids possessing the EBV 
oriP sequence with yields up to 10-fold higher for antibody production722. This 
feature together with a faster growth rate make this host cell line suitable for 
large-scale transfection and biomanufacturing376.  
Following the procedure described in Section 3.5.1, either 103, 104 or 105 HEK293 
6E cells were transduced with vSYNT11 at an MOI of 1 and cultured for a week 
before RNA and DNA harvest. Such numbers of cells respond to the expected 
library complexity and throughput that the barcode method is expected to reach 
given the results obtained in Table 3.1. pSYNT library size and diversity details 
pre- and post-Starcode clustering correction. The introduction of a known 
number of transducing units delivered to a known number of cells constitutes an 
internal control for recovery of integration sites. Genomic DNA from HEK 293 6E 
cells transduced with vSYNT11 (at a MOI of 1) was extracted and integration sites 
captured by ligation-mediated PCR (LM-PCR) as described in Section 4.3 for HEK 
293 SA RIX host cell lines. LM-PCR was performed using 4 restriction enzymes 
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(DraI, NlaIII BsuRI and HpyCH4v) to screen a higher proportion of sequences with 
different characteristics. 
 
Figure 4.9. Radar diagram showing the frequency of different 4-base cutters in the human 
genome (H. sapiens GRCh37/hg19). 
Enzyme sites labelled with an ‘m’ were discarded for being blocked by methylation or for being 
present in the LTR/ (labelled with ‘x’). All enzymes shown are palindromic (except SsiI) and thus 
are recognised in both strands of DNA. 
 
The choice of restriction enzymes was also optimised to maximise the access to 
genomic fragments with different GC content and cutting fashions and discarded 
those cutting within the LTR or linker sequence or blocked by methylation. 
Regarding the choice of restriction enzyme, NlaIII, BsuRI and HpyCH4v are the 4-
base cutters not present in the LTR and/or linker sequence with more 
representation in the human genome (Figure 4.9). Their recognition sequence is 
also different (CATG’, GG’CC and TG’CA, respectively), with different properties 
(blunt/sticky, GC/AT rich). Nonetheless, some studies showed no significant 
differences in integration preferences detected between restriction enzyme 
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compared to an in vitro integration control249 or cloning of integration sites using 
different restriction enzymes228,234,249.  
The presence of fixed nucleotides in the barcode stretch minimizes the number 
of restrictions sites randomly generated in barcodes potentially cleaved to 10 
combinations (using DraI, NlaIII, BsuRI and HpyCH4v) (Table 4.4). 
Table 4.4. LM-PCR restriction sites found in barcode sequence 
Restriction enzyme  Barcode sequence 
HpyCH4v (5’-TG’CA-3’)          TAatgcATCNSGATNNAAANNGGTNWAACNNTGANNNTGG 
          TAANNNATCNSGAtgcaAANNGGTNWAACNNTGANNNTGG 
DraI (5’-TTT’AAA-3’)          TAANNNATCNSGAtttaaaNNGGTNWAACNNTGANNNTGG 
NlaIII (5’-CATG’-3’)  
         TAANNNATCNSGATNNAAANNGGTNWAACcatgANNNTGG 
         TAANNNATCNSGATNNAAANNGGTNWAACNNTGANcatgG 
Original barcode          TAANNNATCNSGATNNAAANNGGTNWAACNNTGANNNTGG 
Sequences flanking the barcode and restriction sites are highlighted in bold and lowercase, 
respectively. 
 
 
Retrieval of integration sites by TOPO TA shotgun cloning prior to next-
generation sequencing was performed as described for HEK 293 SA RIX LM-PCR 
with DraI with similar recovery rates (data not shown). From the number of 
bands that can be seen in the electrophoresis gel (Figure 4.10A) the polyclonality 
of the samples seems to be higher than that of HEK 293 SA RIX samples (Figure 
4.2A). Even though a single junction would represent a minimal band in a DNA 
smear on the gel, the presence of several visible bands anticipates the recovery of 
more (and more diverse) IS. 
LM_PCR products from 103, 104, 105 cells transduced at a MOI of 1 were recovered 
by next-generation sequencing following the same strategy as in SA RIX 
integration sites (MiSeq 300bp PE). Around 1.7M reads R1 (left) and R2 (right) 
reads were obtained for each of the 3 samples (103, 104, 105 cells) and 4 
restriction enzymes (12 total). The same pipeline applied previously on 293SA 
RIX 2HM5, MH4, M, L fastq files was used to process from HEK 293 6E integration 
sites. R1 (left) and R2 (right) integration sites/barcodes retrieved from the same 
sample with different enzymes were collated together and trimmed to optimise 
merging and subsequently merged using Burrows-Wheeler Aligner (BWA) 
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pemerge tool. Around 3.4M out of 6.4M reads (53%) were successfully merged 
across samples.  
Quality control of the merged sequences for the ‘104 cells’ dataset revealed a 
balanced global GC content (Figure 4.10C) as well as good quality calls along the 
length of the read (Figure 4.10D). The frequency of reads increases exponentially 
beyond a mean sequence quality score of 30 (Figure 4.10 B) and the frequency in 
read length of the merged reads decreases between 150 and 290bp (Figure 
4.10E). Compared to SA RIX read lengths the presence of numerous band sizes 
observed in this HEK 293 6E LM-PCR anticipates a higher diversity of junction 
lengths (Figure 4.10A). These results were comparable for the other two datasets 
(103 cells and 105 cells).   
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Figure 4.10. Summary of quality control 
statistics by FastQC for LM-PCR on HEK 
293 6E4. 
DNA quality 
assessment of vector-chromosome junctions for HEK 293 6E 10e3 LM-PCR products digested 
with DraI by microchip-based capillary electrophoresis using Agilent Bioanalyzer; results given 
in fluorescent units (FU). Peaks at 35bp and 10,380bp are internal controls. (B) Mean sequence 
quality distribution over all sequences. (C) GC distribution (mean GC%) over all sequences. 
Similar results were obtained for LM-PCR6E3 and LM-PCR6E5, also sequenced using MiSeq 
300bp PE (data not shown). (D) Distribution of quality scores across all 100bp of the read 
(Sanger/Illumina 1.9 encoding). The yellow boxes represent the inter-quartile range (25-75% of 
the score values per bp). The upper and lower whiskers indicate the 10th and 90th percentiles; the 
blue line represents the mean quality. The background of the graph divides the y-axis into very 
good quality calls (green), calls of intermediate quality (orange) and calls of poor quality (red). 
(E) Frequency of read lengths after trimming 3´ends and merging with BWA pemerge. Results 
shown for LM-PCR6E3 and LM-PCR6E5 are comparable to the results shown.  
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After quality control, a custom script previously used in Section 4.3.2 was used to 
extract integration sites and barcode sequences. Around 2.4M (71%) IS/barcodes 
were successfully retrieved across the 3 samples. IS were mapped using Blat 
against the human genome (same version and parameters as described in Section 
4.3.2). Out of the 21,522,222; 32,644,849; and 30,650,729 raw alignments with 
various scores output by Blat, 807,411 (82%); 1,089,554 (87%) and 836,938 
(86%) non-ambiguous integration sites were retrieved for 103, 104, 105 HEK 293 
SA RIX cells, respectively (Figure 4.11.A).  
 
Figure 4.11. Barcode retrieval from LM-PCR reads using integration site processing 
pipeline 
(A) Frequency of sequences obtained throughout the integration site-processing pipeline.  (B) 
Correlation between the number of transducing units HEK 293 6E were transduced with vSYNT11 
at an MOI of 1 and the number of IS retrieved after the bioinformatics pipeline. (C) Barcode 
comparison plot showing the number of nucleotide differences between all the sequenced 
LMPCR4 barcodes. LMPCR3 and LMPCR show comparable profiles (data not shown).  
B 
A 
C 
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Since psl files contained repeated hits retrieved with different restriction 
enzymes, the different retrieved loci were counted based on the expression 
endposition_chr and 8,261 different IS were obtained out of the 1,089,554 
unambiguous sequences of the 104 psl file. These ~8,000 integration sites 
correspond to the 10,000 transducing units (TU) that were applied during 
transduction (Figure 4.11B).  The +1,700 missing IS could be partially justified by 
short junctions discarded in the PCR product purification prior to NGS 
submission. Another source of missing barcodes could be unbarcoded lentiviral 
vectors, which transduced cells but did not deliver a tag into their genome. 
Similarly 1,245 were retrieved in a sample transduced with 1,000 TU (103 
sample). However, the ‘105’ sample did not follow the expected number of 
transducing units (4,604 seen vs ~100,000 expected). A potential explanation 
could be that transduction was done in a 24-well plate format instead of 96-well 
plate as for 103 and 104, so the distribution of the viral vector over the cells was 
not uniform and consequently less TU were retrieved. The number of nucleotides 
dissimilarities in the barcodes of the viral and plasmid libraries is maintained at 
11 nucleotides in LM-PCR junctions (Figure 4.11C). 
4.4.2 Primary sequence composition at chromosome-vector junctions 
In HEK293 6E, all samples display a similar nucleotide composition compatible 
sequence with the reference pattern (summarised with the expression 
TDG(G)TAAC) although the proportion of the nucleotides is better balanced than 
those retrieved in HEK 293 SA RIX (Figure 4.12B). This result reinforces the 
observation that HEK 293 SA RIX junctions have less diversity and polyclonality 
than HEK 293 6E.  
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Figure 4.12. Pictogram showing relative frequencies of nucleotides on the 5'vector LTR-
host chromosome junction. 
Resource available at: weblogo.berkeley.edu.logo.cgi704. Adenine (A) is shown in green; cytosine 
(C) in blue; thymidine (T) in blue and Guanine (G) in yellow. (A) Primary sequences retrieved from 
HEK 293 SA RIX sorted subpopulations. Primary sequences retrieved from HEK 293 by LM-PCR 
with different enzymes. The 5’-TNG-3’ trinucleotide of the 5’-TNG’(GTNAC)CAN-3’ pattern of the is 
indicated in a square.  
 
4.4.3 Genomic distribution of lentiviral vector integration sites 
Integration sites were retrieved from HEK 293 6E 104 and 103 sample and plotted 
on chromosomes arranged in a karyotype-like fashion using the Galaxy karyotype 
plotting tool (Figure 4.13). In parallel, the same number of random genomic 
positions (8,261) were generated using VISA (Vector Integration Sites Analysis 
server, default filtering parameters)696 to use as a control and were processed in 
the same manner as HEK 293 NGS files.  
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Figure 4.13. Distribution of vSYNT integration sites in the human genome.  
Karyotype view of integration sites in the human genome. 104 HEK 293 6E cells were transduced 
with 104 LVV TU resulting in 8,261 and an equivalent amount of randomly generated sites 
represented in magenta and green, respectively. Random integration sites were generated using 
the online tool “Vector Integration Site Analysis” from Trobridge Lab at University of Washington, 
College of Pharmacy (https://visa.pharmacy.wsu.edu/bioinformatics)696. A similar profile is 
obtained when plotting 103 HEK 293 6E cells were transduced with 103 LVV TU (data not shown). 
Heterochromatic regions (displayed in yellow) were downloaded from the UCSC Table browser 
‘Gap’ database creating a filter “centromere telomere”. 
 
 
As can be seen in Figure 4.13, lentiviral vector integrations are less frequent in 
centromeric regions, rich in constitutive heterochromatin756, compared to a 
random integration profile. Figure 4.14 demonstrates that the frequency of 
lentiviral integration sites relative to random integration does not correlate with 
the chromosome size (Figure 4.14A) but with gene density. These results are 
consistent with the earliest models204–206 proposing chromatin conformation 
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playing a key role on integration site selection, disfavouring integration in 
heterochromatic regions (Figure 4.13) and displaying positive biasing towards 
RefSeq genes (Figure 4.14B). As more recently described by Wang et al., in 2009 
and Biffi et al., in 2011 lentiviral vectors tend to integrate into gene dense 
chromosomes such as chromosome 17, 19 (with >20genes/Mb), 3 and 22 (less 
gene dense) in comparison to a random integration pattern (Figure 4.14B)225,757. 
Figure 4.14. Integration sites relative to random displayed on genome content (A) or gene 
density (B) per chromosome.  
Chromosome base pairs and genome density per chromosome from NCBI GRCh37.p13 
(https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.25). Random integration sites were 
generated using the online tool “Vector Integration Site Analysis” from Trobridge laboratory at 
University of Washington, College of Pharmacy (https://visa.pharmacy.wsu.edu/ 
bioinformatics)696.  
B 
A 
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Bedtools was used to associate integration sites coordinated to different 
annotation features. Similarly to the rates described in the literature249,758,759, 
71% (p<0.0001) of the integrations (n=5,891) were found within genes (Figure 
4.15A), a percentage significantly higher than the frequency of randomly 
generated IS integrated within genes (35%, generated using VISA696). The latter 
is consistent with the proportion of transcription units in the human genome 
(33%)229. LVV IS hit 3,032 different genes, 17% of the 18,041 genes. Within the 
gene, integrations were predominantly located within the transcription unit (TU) 
(Figure 4.15D) evenly distributed along the length of the gene (Figure 4.15C) 
(p=0.318>0.05, null hypothesis). Such phenomenon is due to the tethering effect 
LEDGF/p75 protein. Depletion of this protein has been reported to reduce the 
preference towards transcription units243. 
When looking at integration within repetitive elements, LVV IS were found to be 
underrepresented compared to random (p<0.05) (Figure 4.15B) agreeing with 
Stevens and Griffith and Moiani et al.,251,760. Frequencies lower than random were 
observed in LINE, LTR and DNA elements and especially in Satellite DNA, 
predominantly found in centromeres and telomeres, theoretically disfavoured 
due to their heterochromatic conformation. On the contrary, IS located in short 
interspersed nuclear elements (SINEs) were more frequent when compared to 
random, as expected given their location close to RNA polymerase II promoters256. 
The same procedure was applied to compare the genomic positions retrieved 
from the HEK 293 6E 103 sample, which reported comparable results.  
Custom tracks containing annotation for repetitive elements were obtained from 
UCSC Table browser, which utilises data from ‘Repbase update library of repeats’ 
from the GIRI (Genetic Information Research Institute)695.  
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Figure 4.15. Distribution of vSYNT vector library IS compared to genomic annotation 
features. 
(A) Distribution of vector integration sites relative to RefSeq genes compared to random 
integration profile. (B) Distribution of vector IS relative to repetitive elements compared to a 
random integration profile (values in brackets show percentage, n=8,261). (C) Distribution of 
vector integrations along the length of the gene; length of the gene body was segmented into 8 
fragments. (D) Distribution of vector integrations relative to the transcription start site (TSS) of 
RefSeq genes relative to random. Chi-squared tests were performed to determine whether the 
probabilities are due to chance using the same number of random generated integrated sites. P-
values are determined from the Chi-square statistics; Yate’s correction was applied in the case of 
a 2x2 contingency table and 1 degree of freedom.  
Repetitive 
element 
Random IS (%) LVVvSYNT11 IS (%) 
SINE 14.32  16.21 (p=0.32) 
LINE 19.40  18.12 (p=0.61) 
LTR elements 10.43  4.19 (p=0.0002) 
DNA transposons 2.56  0.71 (p=0.001) 
Satellites 0.41  0.04 (p<0.0001) 
Others 4.67  4.8 (p=0.43) 
Total 51.79  44.07 (p<0.05) 
A 
C
B 
 D 
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4.4.4 Study of the barcode complexity and duplication across samples 
LMPCR6E integration sites from 10e3, 10e4 and 10e5 cells were cross-compared 
and <5% of them were found to be repeated in different samples (Figure 4.16A).  
Given that the chances of a viral vector genome independently integrating in the 
exact genomic position multiple times are extremely low, this phenomenon could 
be explained by the existence of cross-contamination between samples. 
LMPCR6E integration sites with multiple copies were discarded from the 
candidate list to avoid duplicities in the retrieval or correlation of barcode 
variants.  
Figure 4.16. Venn diagrams representing the number of overlapping integration sites 
found between samples.  
Percentage of total sequences per sample indicated in brackets. 
 
In the case of HEK293 SA RIX cells, sorted into 4 subset populations 30 days post-
transduction, MH4 and HM5 present the highest number of duplicities, which can 
be attributed to the fact that cells with the same origin were sorted into different 
subpopulation due to having similar fluorescence intensities. Percentages of 
integration site duplicities in the rest of groups are negligible (Figure 4.16B).   
A B
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4.5.2 Determination of the relative abundance of barcode in vSYNT11-
transduced HEK 293 6E cells 
In parallel to the DNA harvest of transduced (MOI of 1) 103, 104 and 105 samples 
and in order to perform integration site analysis, RNA was also extracted to 
quantify the expression of each barcode variant in that same sample. DNAseI was 
applied to 1μg of total RNA and the mixture was column-purified to avoid any 
amplification from DNA and conditions were optimised in order to synthesize 
cDNA and amplify a specific region of the RNA in a single reaction. RNA was 
reverse-transcribed and amplified with primers binding a region flanking the 
barcode. A band of the expected size (220bp) was observed in prior to next-
generation sequencing of cDNA (Figure 4.17A). Nomenclature adopted for these 
samples is RTPCR 3, 4 and 5 for specific PCR products amplified from reverse 
transcribed RNA. 
PCR reactions were purified and sent for sequencing at Genewiz using HiSeq 
2500 100bp PE sequencing strategy (custom-made libraries were not available). 
Close examination of reads from both orientations revealed barcodes that could 
successfully be extracted from R2 reads. Consequently, >10M input R2 reads per 
sample were reverse complemented with a simple script called ‘rc_fastq.pl’ 
(Appendix B) and quality trimmed to discard those with an excessive number of 
missing bases (N>5).  
Quality control of 100bp R2 reads showed base calls of good quality along the 
length of the read (Figure 4.17B) in most reads (Figure 4.17C) and the GC content 
was well balanced (Figure 4.17D).  
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Figure 4.17. Summary of quality control statistics by FastQC performed on RT-PCR6E4. 
(A) DNA quality assessment by micro chip-based capillary electrophoresis using Agilent 
Bioanalyzer showing a 220bp band corresponding to the barcoded band reverse transcribed from 
cellular RNA. On the right, peaks of DNA are given in fluorescent units (FU). Peaks at 35bp and 
10,380bp are internal controls. (B) Distribution of quality scores across all 100bp of the read 
(Sanger/Illumina 1.9 encoding). The yellow boxes represent the inter-quartile range (25-75% of 
the score values per bp). The upper and lower whiskers indicate the 10th and 90th percentiles; the 
blue line represents the mean quality. The background of the graph divides the y-axis into very 
good quality calls (green), calls of intermediate quality (orange) and calls of poor quality (red). 
(C) Mean sequence quality distribution over all sequences. (D) GC distribution (mean GC%) over 
all sequences. (E) Similar results were obtained for RT-PCR6E3 and RT-PCR6E3, also sequenced 
using HiSeq2500 100bpPE (data not shown).  
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After quality control, barcodes were extracted with a script called ‘extract_rt-
pcr_barcodes.pl’ (Appendix B) similar to the script ‘extract_viral_insertion 
_barcodes.pl’, which recognises 46 and 39nt LTR sequences flanking the barcode 
and extracts the barcode sequence. 
Out of >12M initial reads per sample, over 99% of the sequences passed the filter 
and yielded 4.8M, 4.8M and 4.9M successfully extracted barcodes (for RTPCR3, 4, 
5, respectively), which converged into 300,943; 385,927 and 408,338 variants 
(reduced to 1,398; 9,561 and 5,457 unique clustered variants, respectively). 
These values are in agreement with the expected number of variants considering 
the number of transducing units applied to the different samples (except in the 
RTPCR5). In addition, these results also correlate with the LM-PCR results shown 
in Section 4.4.1, which reinforces the robustness of this screening method at DNA 
and RNA level. 
As shown in Figure 4.18, the complexity of the retrieved barcode remained high, 
with no variants representing more than 5% of the whole barcode population.  
These results contrast with those obtained from transduced HEK 293 SA RIX 
(MOI of 1) where a few variants were retrieved in a relatively high proportion 
suggesting that a few clones might have overgrown the population. This might be 
attributed to the extended times of culture the transduced HEK 293 SA RIX were 
kept for, which contrasts with HEK 293 6E cells, harvested for NGS a week post-
transduction. The level of complexity and throughput of the barcoded library 
retrieved at a transcriptional level (104 barcodes variants) is compatible in order 
of magnitude with that of barcodes retrieved by integration site recovery 
techniques (104 unambiguous IS). An alternative method to assess clonal 
expansion would be to use a vector library consisting of different fluorescent 
markers in order to track the expansion of individual clones although the 
throughput of this approach is limited. 
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Figure 4.18. Characteristics of the barcode counts retrieved from reverse transcribed 
cellular RNA analysed by next-generation sequencing. 
(A) Number of R2 reads obtained by high-throughput sequencing using a HiSeq 2500 100bp 
paired-end (PE) strategy, successfully merged reads with less than 5N, extracted barcodes, unique 
barcode variants and clustered variants (using Starcode) present in the three samples analysed. 
(B) Pictogram of relative frequencies of nucleotides in sequenced barcodes Resource available at: 
weblogo.berkeley.edu.logo.cgi704. Adenine (A) is shown in green; cytosine (C) in blue; thymidine 
(T) in blue and Guanine (G) in yellow. Pictograms from top to bottom corresponding to RTPCR6E5, 
RTPCR6E4, RTPCR6E3; (C) Barcode comparison plot showing the number of nucleotide 
differences between all the sequenced barcodes of clustered RTPCR samples.  
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Clustering correction was applied to extracted barcodes RTPCR3 and RTPCR4 
different Leveinshtein distances (-d1 to -d5) as in Figure 4.7; RTPCR5 was 
discarded because its integration site counterpart file did not contain the 
expected number of IS. In both cases, top expressers remained in the same 
positions of the ranking and unclustered as separate nodes (or centroids), 
indicating they were significantly different below a threshold of –d=3, 
corresponding with the results seen in Figure 4.18C.  
All four nucleotides in Starcoded barcodes extracted from RNA counts were 
equally represented in variable positions of the barcodes in all samples (Figure 
4.18B). In conjunction with these results, the cumulative density demonstrates 
also a balanced profile. The profile and peak number of dissimilarities (at 11 
nucleotides) (Figure 4.18C) is maintained when the barcodes from RTPCR3, 
RTPCR4 and RTPCR5 samples are clustered confirming their variant proportions 
(data not shown). 
4.5.2 Correlation of retrieved integration sites - relative abundance via 
barcode 
In order to know the number of barcodes in the RNA-Seq analysis that could be 
mapped to LM-PCR reads, only one barcode variant per integration site should 
have been retrieved. However, from the 8,261 IS retrieved in the 6E4 dataset, the 
multiple barcode variants obtained per integration site make the total number of 
theoretical IS-variant combination rises up to 142,256. Of these, 85,157 would 
find correspondence in the RNA-Seq dataset. This association is not meaningful, 
as the element used to correlate both datasets (the barcode variants) is 
duplicated. Therefore, there are many barcode variants per integration site and 
also some of the variants are common in between different integration sites.  
Following the same procedure used with HEK 293 SA RIX (Section 4.3.5), a list of 
top 15 candidate positions with relatively high barcode expression and 
unambiguous correspondence in the host cell genome was generated for genome 
editing candidate selection in HEK 293 6E 104, 103 datasets (Table 4.5). 
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Table 4.5. Correlation of lentiviral integration sites with their derived RNA counts via 
barcode. 
 
Sample 
Top 
# 
#RNA 
counts 
Barcode variant sequence 
Number of 
containing 
this variant 
Signal? 
** 
#LM-PCR 
reads 
Genomic 
position 
Chr Gene 
6E4 
1 24,032 TTC-TC-CA-AT-TA-CG-ACT 254 <10-fold  ***   
2 20,017 AGC-TC-AA-AT-TT-AC-CAC 66 160 802 168,010,733 3 EGFEM1P 
3 19,928 GGT-AC-CA-AT-TA-CG-GTA 199 <10-fold  ***   
4 19,907 TCC-CC-CA-GT-GA-AC-TGT 96 255 1,529 80,591,158 17 WDR45B 
5 18,778 CTT-TG-AC-GC-CA-AG-ATA 58 <10-fold  ***   
6 17,028 AGG-CC-GT-AA-TA-TA-AAA 19 <10-fold  ***   
7 16,624 CAA-TC-AG-AA-AA-AT-CAT 2 <10-fold  ***   
8 16,001 TAA-TC-TT-AT-TT-TA-AAG 14 <10-fold  ***   
9 15,034 TGC-CG-CG-TG-TT-TA-TAC 185 14 361 107,887,987 11 CUL5 
10 14,242 TTC-TG-TA-TT-GT-GT-GCA 106 <10-fold  ***   
11 13,944 AAT-AC-CA-AA-TT-AT-GTT 193 <10-fold  ***   
12 12,605 GAC-AC-CA-CT-TT-TA-TAT 214 11 4,491 15,409,560 21 none 
13 12,556 ATA-AC-GC-TT-TA-TA-AAA 257 24 573 37,722,505 14 MIPOL1 
14 12,330 TGA-GC-GA-TT-TA-AT-TTG 74 15 511 151,738,902 4 LRBA 
15 12,311 TTA-TC-TA-GA-AA-GA-CTG 298 <10-fold  ***   
6E3 
1 72,976 ACA-TG-TA-CT-AA-GT-CTA none NA     
2 59,439 CTT-GG-AG-AT-AT-TG-TTT 11 <10-fold  ***   
3 47,243 GCA-CC-AA-TA-AT-AA-TAT none NA     
4 45,842 ATC-TC-AT-GT-CT-TC-TAC 5 <10-fold  ***   
5 44,350 TGT-TC-AT-GT-AT-TT-GGT none NA     
6 42,378 TCT-TG-TT-AT-TT-AT-GGT none NA     
7 38,362 AAT-TG-AA-TT-AT-AA-ACA none NA     
8 37,101 TTT-AC-TT-AA-GA-TT-GTT 25 <10-fold  ***   
9 35,877 ATG-GC-TT-CA-CT-GC-TTA none NA     
10 35,610 ATT-AC-TG-GA-GA-TG-ATG none NA     
11 34,181 AGC-TC-AA-AT-TT-AC-CAC none NA     
12 32,200 GAA-CG-AA-GC-AA-CC-ATT none NA     
13 31,784 ATT-TG-GA-TT-TT-TC-AAG 33 <10-fold  ***   
14 31,683 TCC-CC-CA-AA-GA-AT-GAC none NA     
15 28,180 CTA-CG-TT-CA-AA-TA-GCA none NA     
Column 5, number of IS containing this barcode variant, number of genomic positions correlated 
to a single barcode variant; column 6, signal (**), in the case of >1 IS per barcode variant, ratio  
between the 2 first genomic positions with more reads retrieved by LM-PCR and NGS. Candidate 
positions selected for genome editing of lentiviral transfer vector are highlighted in bold. 
Highlighted barcode sequences are common in both samples. (***) Integration sites with a signal 
below the threshold (10-fold) were not mapped.   
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Again, as shown in Table 4.5 column 5, there is more than one genomic locus 
retrieved per barcode variant. In this particular example, 66 different loci 
respond to the variant AGC-TC-AA-AT-TT-AC-CAC. However, the position with ID 
268 (chr3:168,010,733) displays a relatively high signal considering the number 
of times it was retrieved by LM-PCR. The term signal refers to a relatively 
abundant number of reads with the same end position compared to other 
positions that share the same barcode variant. As in HEK 293 SA RIX, if the ratio 
between the first and the second genomic position with more LM-PCR reads is 
greater than an order of magnitude of difference, it was considered for correlation 
with the barcoded RNA counts. Otherwise, positions were considered 
background noise originated due to cross-priming during PCR and were 
subsequently discarded. 
Alternatively to a cross-comparison of datasets, the top most expressed barcodes 
obtained by RNA-Seq were searched for a barcode counterpart in the LM-PCR 
dataset. This approach is suboptimal as a result duplicity in barcode assignation 
encountered in the LM-PCR. This limits the criteria to chose candidates for 
targeted integration and in order to make a decision, only integration sites with a 
high number of reads retrieved were considered for RNA-Seq barcode 
correlation. The threshold (or strength of signal) was defined as the ratio number 
of LM-PCR reads obtained between the IS-most_abundant_variant and the IS-
second_most_abundant_variant. Therefore, no integration sites were 
unambiguously retrieved as candidates with a higher transcription rate as a 
result of the integration of the lentiviral vector. 
No genomic positions were unambiguously retrieved from the 6E 103 dataset. 
RNA counts per variant are higher in 6E 103 dataset because fewer positions were 
amplified and thus the throughput is divided/shared between fewer reverse 
transcribed mRNA molecules. Only one barcode combination was found in both 
datasets minimising the effect of any potential contamination. This contrasts with 
the results obtained in the SA RIX analysis Table 4.3 where half of the barcodes 
were also found in other datasets.  
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Three candidate positions with relatively high expression (barcoded RNA counts) 
were chosen from the HEK 293 6E 104 dataset for site-specific integration of a 
lentiviral transfer vector using the CRISPR-Cas9 system.  
Loci 1 - Chr3:168,010,733  (EGFEM1P pseudogene) 
Loci 2 - Chr11:107,887,987  (in the first CUL5 intron) 
Loci 3 - Chr21:15,409,560  (intergenic position) 
Such positions were chosen from the HEK 293 6E 104 dataset because more 
univocal/unambiguous candidates were in the first 15 positions of RNA-Seq 
variant counts compared to the HEK 293 6E 103 sample. In the case where 
positions were found in both datasets, candidates would still have been chosen 
from 6E 104 dataset, since it is a 10-fold larger pool of IS. The HEK293 6E LM-PCR 
105 dataset did not show the expected number of integration sites providing the 
transducing units that were applied to the cells and thus was discarded. 
EGFEM1P was chosen as a first candidate because due to the abundance of RT-
PCR reads. EGFEM1P stands for EGF-like and EMI domain containing 1 and it is 
annotated as a pseudogene particularly expressed in the pituitary. Pseudogenes 
are vestigial, non-essential fragments of genes that have lost their ability to code 
for protein as a result of multiple mutations. However, pseudogenes can undergo 
transcription of non-coding RNA driven by a nearby promoter761. Their function 
is not totally understood although they might play a regulatory role similarly to 
other non-coding RNA762.  
The second candidate position (chr14:107,887,987) is located in cullin5 (CUL5). 
CUL5 inhibits cellular proliferation, potentially through its involvement in the 
SOCS/ BC-box/ eloBC/ cul5/ RING E3 ligase complex, which functions as part of 
the ubiquitin system for protein degradation763. Interestingly, CUL5 protein is 
also reported in the literature to interact with viral trans-activating regulatory 
protein tat and viral accessory protein vif (although they are not present in a 3rd 
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generation lentiviral vector). It might also play a role in the reelin signaling 
cascade764. In terms of tissue distribution, studies have shown that cullin5 is 
highly expressed in heart and skeletal tissue, and is specifically expressed in 
vascular endothelium and renal collecting tubules. The renal origin of the 
HEK293 cells could possibly explain observed expression levels765. 
The third position (chr21:15,409,560) was chosen for two reasons. Firstly, the 
LM-PCR signal is relatively high compared to other candidates; this integration 
site was clearly distinguishable from the background noise of genomic positions 
with the same barcode variant. Secondly, because this position does not 
correspond to a RefSeq gene; the ankyrin repeat domain 20 family member A11 
(ANKRD20A11P), a non-coding pseudogene RNA and the human phospholipase I 
(LIPI) are located more than 50kb upstream and downstream, respectively. 
Therefore, our intention was to assess titers resulting from targeting a genomic 
position that does not disrupt gene expression at all.  
Although WDR45 has a higher signal ratio than any of the other candidates, this 
genomic position was not chosen for genome editing because its function is not 
as critical in the biology of the cell as CUL5 and was found to be not as accurately 
annotated. WDR45 encodes a member of the WD40 repeat protein family and 
participates in cell progression, regulation and apoptosis (NCBI Gene ID: 11152).  
The following  two positions also present in Table 4.5 were not considered 
because presented a lower number of corresponding RNA variants. Time an 
resources were the main limitations to keep the number of candidate positions to 
test for genome editing to 3. However, the biological function of these loci is 
described below for interest. 
MIPOL1 stands for mirror-image polydactyly 1 and it is a protein-coding gene 
whose truncation is associated with the above mentioned syndrome (also known 
as Laurin-Sandrow Syndrome)766.  
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LRBA is LPS (lipopolysaccharide) responsive beige-like anchor protein and plays 
a role in secretion of vesicles containing immune effector molecules. 
4.5 Summary of results and concluding remarks 
- An integration site analysis technique (ligation-mediated PCR) was 
optimized for detection of vector-chromosome junctions. Ligation-
mediated PCR performed at the 5’ end of the junction allows for longer 
reads and avoids NGS amplification of the internal band (commonly used 
as a reaction control).  
- A bioinformatics pipeline was built and optimised to isolate integration 
sites and their associated barcodes. 
- Integration site preferences of barcoded lentiviral vectors confirmed their 
predisposition for transcription units, no TSS and allowed for weak 
consensus sequence 
- The amount and complexity of the barcodes retrieved by integration site 
analysis (LM-PCR) and expression analysis (RNA-Seq) were equivalent 
and sufficient to simultaneously screen more than 104 sites. 
- Three candidate loci unequivocally reporting a high number of barcoded 
RNA counts were chosen for subsequent targeted integration of a 
lentiviral transfer vector using CRISPR-Cas9 genome editing technology.  
In this chapter, a variation of the LM-PCR was performed to successfully retrieve 
lentiviral barcoded junctions. The variation comprises amplification of 5’ 
junctions (instead of the 3’ junction) with a vector primer annealing immediately 
downstream of the 5’LTR (and thus not amplifying the 3’LTR barcode). This 
impedes amplification of an internal control band typically used in conventional 
LM-PCR as a control of the technique. In addition, amplification of the barcode 
from the 5’LTR U3 allows for the recovery of longer and better quality reads. 
Following this procedure, integration site analysis was initially performed on HEK 
293 SA RIX cells that had been transduced at a low MOI and sorted into different 
populations based on GFP intensity. An integration site analysis pipeline was built 
in order to recover integration sites with high identity rates to the human genome 
and perfect matching with known flanking sequences (LTR and linker if present). 
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Out of the 104-105 positions recovered, only 102-103 distinct sites were unique. 
Such a reduction in the complexity of the IS-barcode system may be explained by 
(i) the effects of clonal dynamics after prolonged periods of culture (with the aim 
of preventing silencing of gene expression) and (ii) the generation of chimeric 
PCR products. As a result of these phenomenons, (i) fewer clones (and their 
respective barcodes) overgrew the population and (ii) different loci associated to 
the same barcode, which precluded any concluding remarks. While this measure 
aimed for selection of stably expressing sites, population dynamics and several 
rounds of passaging are factors that contribute to diminish initial entropy 
introduced by the barcode vector library. Nevertheless, lentiviral vectors 
naturally select for stably expressing sites and amplification and the screening of 
genome-edited clones for several weeks of growth in a later stage can anticipate 
and prevent eventual silencing. Additionally, balanced and low relative 
abundance of variants in all barcode formats/supports (oligonucleotide, plasmid 
but mainly vector library level prior to transduction) was demonstrated to 
contribute to bias minimisation. Finally, genomic positions that were extracted 
from HEK 293 SA RIX, were mostly transcription factors related with myogenic 
function. Nevertheless, their annotation did not reveal any link with the biological 
precedence or origin of HEK 293 cells unlike candidates selected from HEK 293 
6E. 
A second attempt using HEK 293 6E (which have a better yield in vector 
production) was then performed avoiding prolonged periods of culture. The 
choice of restriction sites was also optimised to avoid any bias and maximise 
genome accessibility. In this experiment, 1,245 and 8,261 unique integration sites 
were recovered by next-generation sequencing upon transduction of 1,000 and 
10,000 cells with an MOI of 1. The number of IS retrieved in this validation 
experiment supposed a considerable increase compared to the size of previous 
genome-wide massive parallel DNA sequencing experiments such as Schroder et 
al., in 2002 (524 sites)249; Cattoglio et al.  (849 sites)767 and Mitchell et al., in 2004 
(407-528 sites)231 but below Wang et al., in 2007 (40,596 sites)759. Lentiviral 
integration was found predominantly in gene rich areas and confirmed not 
obeying the integration into larger chromosomes (C-paradox). This agrees with 
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the currently accepted (though incomplete) model for retroviral site selection, in 
which chromatin openness (if not excessively) of actively transcribed genes 
located in regions proximal to the nuclear envelope promote accessibility to the 
viral/vector particles, that have evolved to target PolII transcribed genes that 
enhance transcription upon integration. Integration was also found throughout 
the length of the transcription unit and not only close to the TSS. A weak 
consensus in the primary sequence (TDG(G)TAAC) was found in the IS retrieved 
from HEK 293 6E cells. Taken together, barcoded lentiviral vector libraries 
completely follow the integration features and preferences described in the 
literature. 
However, a few technical complications related to the nature of this method have 
been identified and may skew the results and anticipate potential solutions: 
- The first amplification steps of PCR are characterised by stochastic fluctuations 
in priming, which can lead to a disproportion in frequency of (barcode) template 
and the amplified product, commonly known as PCR jackpotting. A potential 
future improvement could be the implementation of Unique Molecular 
Identifiers, a second set of DNA tags (with a large sample space and sufficient 
editing distance) that provide information about PCR dynamics during the first 
two rounds of amplification768. This way a barcode variant that contains the same 
tag are likely to be formed as a result of PCR mutation or a sequencing error and 
can be easily removed from the pool of real barcodes. 
- Secondly, unlike linear amplification of barcode molecules in plasmids, the size 
of the genome of mammalian host cell lines together with the difficulty of 
extracting barcodes require several rounds of amplification, which introduces 
differences in PCR bias. Isolation or enrichment of barcoded sequences could 
alternatively be achieved by restriction digestion and size exclusion. Other 
methods based on capture would involve DNA or RNA “hooks”769–771. 
- A different source of bias could be introduced by PCR purification methods. Most 
commonly used methods for purification of DNA fragments (silica columns or 
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AMPureXP beads) enable recovery of fragments greater than 100bp, excluding 
short junctions. That could explain the difference between the number of 
transducing units applied to 6E cells and the amount of sites recovered. Short 
junctions could have flowed through the purification columns reducing the 
number of IS retrieved. 
In parallel to the determination of vector integration sites, retrieval of barcodes 
by RNA-Seq can be achieved by biotinylated primer selection/pooling and whole 
transcriptome analysis (WTA). However, the retrieval efficiency (4x106 barcodes 
for WTA vs 105 biotinylated primer) of both methods could not be compared due 
to the variation on the experimental design. Read lengths and fragmentation 
times are very important factors for the latter strategy. In any case, the 
throughput values achieved with any of these two strategies can complement 
those obtained by LM-PCR, indicating that the lack of throughput is not a 
limitation in the rationale of this project. In addition, 1,398 and 9,561 different 
barcode variants were retrieved for 103 and 104 samples, respectively, which 
confirms the values obtained by LM-PCR (1,245 and 8,261, respectively).  
However, in order to study the impact of transcriptional activity of HEK 293 on 
integration preferences, whole transcriptome (or microarray) analysis could have 
been performed on untransduced host cells. While in general terms, integration 
is favoured in actively transcribed genes, some studies show that the highest 
expressed genes report low levels of integration supporting what was suggested 
by Weidhaas et al., in 2000254. Schroder revealed that the correlation between 
integration and transcriptional activity already existing in non-transduced cells 
becomes stronger in transduced cells249. This analysis would have contributed to 
confirm lentiviral integration active sites and also to understand the extent to 
which barcode counts observed in genes at a local level correlate with global 
transcriptional activity assigned to a gene. This could help provide insight to 
establish a background noise threshold or a normalisation for basal level of 
activity associated to a gene. However, another way to discriminate between 
background noise and real low frequency barcodes could be to evaluate the 
consistency of variant representation over time. Population dynamics should be 
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evaluated to examine the model they follow (stochastic, stable, etc.). Once 
identified their trend in a particular cell line (exposed to stimuli different from 
hematopoietic stem cells, where this experiments are typically performed) their 
general contribution could be assessed and that could allow exclusion of outliers 
or artefacts generated at any stage of the process.  
An important aspect to consider is the fact that barcoded RNA transcripts will be 
mainly driven by the internal lentiviral vector promoter. Once integrated the 
5’LTR contains the SIN U3 and thus the enhancer/enhancer promoter activity is 
supressed. The influence of the chromatin environment and neighbouring genes 
to the barcode expression is questionable and limited given the position of the 
barcode in the 3’LTR.  
 
Figure 4.19. Schematics illustrating the role of different hypothetical promoter regions on 
the expression of barcode 
The viral transcript containing the barcode is represented by a black line below the integrated 
vector. Promoters are represented as angled arrows. LTR, HIV-1 long terminal repeat; Ψ, HIV-1 
RNA packaging signal; SIN, self-inactivating (U3-deleted) HIV-1 long terminal repeat; cPPT, central 
polypurine tract; Gag, HIV Gag gene; RRE, Rev responsive element; eGFP, enhanced green 
fluorescent protein; WPRE, woodchuck posttranscriptional regulatory element;  
 
In the event of evaluating the promoter that drives the expression of the whole 
transfer vector, this should be the same as the internal promoter; otherwise the 
difference between promoters (in this study EFS internal and RSV driving the 
transfer vector genome) can lead to inconclusive results.  
In this study, the barcode system is postulated as an alternative selection method 
with a screening capacity of 104 integration sites at a bp precision and such 
simplicity represents a major improvement compared to high-throughput 
systems, which need costly antibodies or sophisticated automated closed 
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systems. Although the libraries presented in this project could theoretically 
handle a few million cells with their >105 barcode variants and the majority of 
cells will receive unique barcodes, with larger transductions, the same barcode 
could be delivered to more than one cell more frequently. In addition, successful 
IS retrieval has not been validated with 105 cells. Other potential concerns like 
the loss of complexity in the number of dissimilarities were discarded as 11bp 
harbour enough variants to meet any throughput need. Elimination of 
overlapping integration sites attributable to contamination between samples 
represents <4% and is not a limitation either. 
The deletion of 400bp containing termination enhancer motifs in self-inactivating 
(SIN) retroviral vectors enhanced the leakiness of 3’LTR transcriptional 
termination (up to MLV levels), which results in read-through of vector 
transcripts into host genomic content772,773. This could be utilised to capture 
genomic position and expression derived from each integration event directly 
from a single RNA molecule avoiding any restriction or PCR bias. RNA molecules 
containing vector-host junctions could be selectively primed using a biotinylated 
primer that allows amplification of sequences downstream of the 3’LTR R region 
utilising a polyA signal instead of the conventional oligodT priming to synthesise 
the first strand of cDNA upstream of the polyA tail.  
No replicates were run in next-generation sequencing experiments. Due to the 
number of conditions to be tested in a single run and the sequence capacity of a 
flow cell, the presence of multiple replicates per condition would have 
compromised the sequencing depth. Introduction of technical replicates is critical 
in next-generation sequencing of rare single nucleotide variants774. In the case of 
small fragments of DNA with multiple variations, depth within a sample becomes 
a key component, especially if expected sample complexity raises up to 105 
distinct variants. Biological replicates imply separate experiments and 
sequencing runs, which suppose a limitation due to their elevated costs. The 
similarity of the results achieved between the HEK 293 6E 103, 104 and 105 
conditions (and also pSYNT and vSYNT 11 and 49 libraries in Chapter 3) indicates 
significant differences would not be expected among technical replicates. 
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In the next chapter, specific integration of a reporter gene into the positions 
discovered in this chapter will be tested in order to prove the hypothesis 
proposed in this study.   
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Chapter 5  
RESULTS: CRISPR-Cas9 knock-in of 
donor constructs in identified loci 
5.1 Introduction 
The traditional strategy for recombinant protein production typically involves the 
delivery of a gene of interest into the host cell lines followed by stable integration 
and selection and screening of multiple clones464. The lack of control of random 
integration of transfected plasmids often leads to phenotypic heterogeneity, also 
termed position effect variation775. This work presents an alternative, non-
random way to drive integration and reduce screening and selection timelines. 
Therefore, a controlled means of DNA insertion is required.  
CRISPR-Cas9 genome editing technology is quite recent and has not been fully 
explored for biopharmaceutical applications. In contrast, Lee et al., employed 
genome editing in CHO cells for protein production589. Site–specific integration of 
expression cassettes for protein production had only been seen in antibody 
production. In packaging cell line development, Sanber et al., used the integration 
preferences of MLV-derived vectors to stably drive the expression from highly 
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transcribing sites, although integration was not effectively site-specific. In their 
study, they tagged such sites with MLV and posteriorly introduced gag-pol genes 
via RMCE381. A similar strategy was used by Carrondo et al., to explore the impact 
in stoichiometry of Gibbon ape leukaemia virus env gene in combination with 
gag-pol on titers in the context of a packaging cell line431. To our knowledge, this 
is the first study in which CRISPR-Cas9 technology has been used to rationally 
integrate a lentiviral vector component with the objective of generating a 
packaging cell line. In addition, none of these studies rationally targeted 
integration to a specific locus based on their quantified expression. 
Several authors showed the expression of the transfer vector is the limiting factor 
for lentiviral vector production401,414,463. For this reason, the transfer vector 
constitutes the majority of the plasmid DNA in transient transfections. In order to 
simplify the project and demonstrate proof of concept in its limited timeline, a 
lentiviral transfer vector was introduced in the three different positions 
discovered in Chapter 4 instead of separately integrating vsv-g, gag-pol and rev. 
The remaining viral genes were then complemented in trans by transient 
transfection in order to assess titers. This constitutes the inverse approach to 
what is typically done (to keep the transfer vector flexible/modular) but allows 
effective screening and titration of functional titers by GFP fluorescence 
quantification. The fundamentals for this decision lie on the identification of the 
expression of the viral vector genome as one of the main limitations for a vector 
production in packaging cell lines420,430,776. In addition, transient expression of the 
remaining viral genes eliminates the consequences of gag-pol expression when 
not balanced with that of the envelope protein431,776.  
The three different positions discovered in Chapter 4 that were tested in Chapter 
5. Chr3:168,010,733 plus strand (EGFEM1P pseudogene), Chr11:107,887,987 
plus strand (located in the first intron of CUL5) and Chr21:15,409,560 minus 
strand (located in an intergenic position) show no disruption of the gene product. 
In this chapter, targeting efficiencies and efficacies of the CRISPR-Cas9 strategy 
were assessed and packaging cell lines containing transfer vectors integrated in 
high transcribing positions were produced and evaluated.  
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5.2 Aims 
The specific aims of this chapter were: 
- To demonstrate site-specific integration of a lentiviral transfer vector cassette 
>5kb fragment of DNA into a control position described in the literature and high 
transcribing positions discovered in Chapter 4 using genome editing techniques 
(CRISPR-Cas9).  
- To assess the efficiency and rates of recombination-mediated gene addition of the 
CRISPR-Cas9 genome editing technique.  
- To evaluate the titer of virus from a producer cell line containing a lentiviral 
backbone expressing GFP. 
5.3 Preparation of the CRISPR-Cas9 plasmids 
5.3.1 Cloning of donor construct (pRRL 2HA SIN cPPT EFS eGFP WPRE Zeo 
BFP) 
In order to explore the potential of CRISPR-Cas9 as a genome-editing tool, we 
tested the integration of a reporter system into a genomic position previously 
reported in the literature.  Insertion (knock-in) of a 1kb of foreign DNA into the 
EMX1 locus (Chr2: 73160998 - 73160999) has been previously reported by Cong 
et al., using 800bp homology regions777. Cong et al., (2013) used CRISPR-Cas9 
technology to site-specifically integrate a 1kb fragment into the EMX1 locus. Of 
relevance to this work, the size of our donor fragment is >5kb, which requires the 
optimization of delivery parameters (length of homology arms, number of cells 
per transfection, amount/ratio of plasmid DNA, transfection method, selection).  
Two components are necessary in order to specifically modify a sequence in a 
particular position of the genome via CRISPR-Cas9: (i) a guiding RNA containing 
the insertion or deletion at the loci of interest and (ii) a protein which catalyses 
the excision of a DNA strand (nuclease for double-strand break –DSB- or nickase 
for single strand cuts). If site-specific integration of a stretch of DNA is desired, 
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then a donor construct with homology arms is required to be added by 
homologous recombination.  
A donor plasmid containing homology arms flanking a lentiviral transfer vector 
containing a reporter gene was constructed (Figure 5.1). The lentiviral transfer 
vector comprised a 3rd generation lentiviral RRL backbone with the EFS promoter 
driving the expression of eGFP. The woodchuck hepatitis virus post-transcription 
regulatory element (WPRE) is located downstream of the eGFP reporter gene. 
The donor plasmid also contains an antibiotic resistance gene downstream of the 
transfer vector and within the homology arms, whose function is to act as a 
selectable marker in the presence of zeocin. The zeocin cassette consists of the 
resistance gene under the control of the SV40early promoter and upstream of the 
SV40 polyA signal from pcDNA4 TO (Figure 5.1B). The use of zeocin resistance as 
a selectable marker has reported higher and more stable GFP intensity in cell 
pools compared to other antibiotics778.  
In order to assemble the donor plasmid, the zeocin cassette was cloned 
downstream the 3’LTR of the original lentiviral transfer vector (Figure 5.1A). The 
1,145bp zeocin cassette was amplified from pcDNA 3.1 Zeo (+) (Invitrogen, V860-
20, Appendix A) with primers (NheI-SV40P-Zeo-fwd 5’-AGGATGCTAGC 
gaatgtgtgtcagttagggtg-3’ and Zeo-MCS-NheI-rev 5’-ATCGCGCTAGCACTAGTAC 
GCGTGGTCACCctagaggtcgacggtatacag-3’; NheI sites indicated in italics; 
overlapping base pairs in lowercase) including NheI sites and the PCR product 
was digested with NheI, column-purified prior to ligation of compatible ends to 
the AvrII site present in the lentiviral backbone (pRRL SIN cPPT EFS eGFP WPRE) 
giving rise to pRRL SIN cPPT EFS eGFP WPRE Zeo (Figure 5.1B). 
Next, the lentiviral backbone containing the zeocin resistance downstream the 
3´LTR (pRRL SIN cPPT EFS eGFP WPRE Zeo) was surrounded by several 
restriction sites in order to provide multiple options when incorporating the 
fragment into further constructs containing homology regions with potential 
conflicting sites. To achieve this, the lentiviral backbone + zeocin resistance 
cassette was amplified with primers containing MluI, BstBI, AscI and PacI, MreI, 
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AsiSI, NheI restriction sites on the 5’ and 3’ side, respectively, and topo-cloned into 
a pCR4 TOPO TA backbone (Figure 5.1B). 
MluI, BstBI, AscI T3promoter fwd primer sequence (MlBAT3_A1)                     
5’-AGCTAACGCGTATATATTCGAACGAATGGCGCGCCaattaaccctcactaaaggg-3 
T7promoter rev primer sequence with PacI, MreI, AsiSI, NheI (PMrAsINT7_A2) 
5’-TGATTTTAATTAAATTATGCGATCGCATTGCGCCGGCGAAGGCTAGCtaatacgac 
tcactatagg-3’ 
Restriction sites indicated in italics; overlapping base pairs in lowercase. 
Subsequently, 4 plasmids (pMS-RQ HA-MCS-HA2-BFP DCAF6, pMA-RQ HA-MCS-
HA2-BFP CUL5, pMK-RQ HA-MCS-HA2-BFP ‘inter’ and pMS-RQ HA-MCS-HA2 
EMX1) containing a 3,398bp fragment consisting of a multicloning site with the 
aforementioned restriction sites flanked by 800bp homology arms were ordered 
from GeneArt (Figure 5.1C). Homology sequences for the 3 candidate loci are: 
EGFEM1P (Chr3 Left:168009927–168010727; Right 168010731-168011531) 
CUL5 (Chr11 Left:107887184-107887984; Right 107887985 - 107888785) 
intergenic (Chr21 Left 15409567 -15410366; Right 15408767-15409566) 
A blue fluorescent marker (strongly enhanced blue fluorescent protein, seBFP, 
under the control of the SV40 promoter) was placed outside the homology arms 
(downstream the 3’ arm) to monitor integration not occurring via homologous 
recombination. In the event of a double recombination, the third generation 
transfer vector harboured in the donor construct together with the zeocin marker 
would be delivered to the host cell genome and cells would be exclusively GFP 
positive; otherwise, cells would be double positive for green and blue florescence. 
The choice of the BFP fluorochrome was based on excitation/emission 
wavelengths, sufficiently distinct from that of GFP (present in the transfer vector) 
and RFP (present in the Cas9/sgRNA vector for EGFEM1P, CUL5 and ‘intergenic’). 
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Assembly of pMK-RQ HA-MCS-HA2-BFP ‘inter’ could not be achieved by GeneArt 
after more than 20 cloning attempts and was thus dropped from our list of 
candidate positions due to limitations in our timelines. Both, TOPO TA vector 
backbone pCR4 containing pRRL SIN cPPT EFS eGFP WPRE Zeo flanked by NheI 
sites (insert) and GeneArt synthesised plasmids (backbone) containing a 
multicloning site flanked by the candidates’ respective homology arms (pMS-RQ 
HA-MCS-HA2-BFP EGFEM1P, pMA-RQ HA-MCS-HA2-BFP CUL5, and pMS-RQ HA-
MCS-HA2 EMX1) were digested with NheI and BstBI and ligated together 
resulting in the final donor constructs (Figure 5.1C). In all cases, DNA isolated 
from bacterial clones was tested by restriction digest analysis and confirmed by 
Sanger sequencing (data not shown). 
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Figure 5.1. Schematics of donor construct cloning procedure. 
(A) Original third generation pRRL SIN cPPT EFS eGFP WPRE transfer vector plasmid. (B) pRRL SIN cPPT EFS eGFP WPRE with zeocin resistance gene downstream 
the lentiviral transfer vector under the control the SV40 promoter and followed by a SV40polyA signal. (C) Backbone ordered from GeneArt containing a multicloning 
site (MCS) flanked by recombinase recognition sites (attB, loxP and FRT) and homology arms (right, R; left, L) upstream of a blue fluorescent protein gene under the 
control of the CMV promoter and upstream the SV40 early polyA signal. Distances are not to scale (D) Donor construct resulting from the cloning of pRRL SIN cPPT 
EFS eGFP WPRE Zeo into the pMS/K/A-RQ HA-MCS-HA2-BFP backbone containing homology arms and the BFP cassette. RSV Rous sarcoma virus; LTR, long terminal 
repeat; eGFP, enhanced green fluorescent protein; WPRE, woodchuck posttranscriptional regulatory element; CMV, cytomegalovirus; SV40pA, simian virus 40 polyA 
signal; seBFP, strongly enhanced blue fluorescent protein. (*) CMV-seBFP-SV40pA not present in the EMX1 donor. 
pRRL SIN cPPT EFS eGFP WPRE 
pRRL SIN cPPT EFS eGFP WPRE Zeo 
pMS/K/A-RQ HA-MCS-HA2-BFP 
Donor construct    
____________*___________ 
A 
B 
D 
C 
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5.3.2 Description of Cas9 and sgRNA plasmids 
Two separate plasmids containing the Cas9 nuclease under the control of the CMV 
promoter and the U6 promoter driving the expression of 20bp EMX-1 sgRNA 
sequence (5’-GAGTCCGAGCAGAAGAAGAA-3’) prior to the S. pyogenes protospacer 
adjacent motif (PAM, NGG in the genomic sequence in S. pyogenes CRISPR system) 
described by Cong et al., were obtained from Sigma-Aldrich (Figure 5.2A and B). 
The U6 promoter is a RNApol III promoter that allows ubiquitous expression of 
the sgRNA in human cells and specific initiation and termination of 
transcription779. However, it requires a guanine immediately before the first 
sgRNA nucleotide. In the case of the three candidate genomic positions, the 
sgRNA sequences containing the PAM motif were chosen using the Zhang 
laboratory (http://crispr.mit.edu/) online tool according to the following criteria: 
minimum risk of off-target effect, minimum distance from a PAM motif to the 
candidate position selected in Chapter 4. 
A single vector including the Cas9 gene and the sgRNA was used instead of two 
separate plasmids for the knock-in into the 3 candidate positions (Figure 5.2C). 
The sgRNA sequences were 5’-TTAATGCTTATTTATTTTGT-3’, 5’-
TACCTGGGGGTGGTGGTGTA-3’ and 5’-TACCTTCTTCCCTACAGGTC-3’ for EMX1, 
EGFEM1P, CUL5 and ‘intergenic’, respectively. . Transfection using a 2-plasmid 
system (donor + sgRNA/Cas9) maximises the chances of successful cellular 
delivery. Additionally, a RFP gene is co-expressed from the same mRNA as the 
Cas9 protein via a 2A peptide linkage enabling tracking of transfection efficiency 
in cell populations via flow cytometry. A T7 promoter sequence is located 
immediately upstream the Cas9 cDNA sequence, allowing in vitro Cas9-RFP 
mRNA synthesis. 
The Cas9 protein implemented in these vectors contains both HNH and RuvC 
activities enabling the creation of double strand breaks. Cas9 is linked to 
EVROGENTM TagRFP fluorescent proteins. TagRFP is a monomeric red (orange) 
fluorescent protein generated from the wild-type RFP from sea 
anemone Entacmaea quadricolor780. It possesses bright fluorescence with 
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excitation/emission maxima at 555 and 584 nm, respectively. In both GFP and 
RFP vectors, the 2A-FP encoding sequence is flanked by two HpaI restriction sites, 
which allows removal or replacement of the 2A-FP element. The XbaI site can be 
used to linearise the vector for production of Cas9-FP mRNA via in vitro 
transcription using T7 RNA polymerase. 
 
Figure 5.2. Schematics of CRISPR-Cas9 plasmids used for knock-in of a donor construct on 
HEK 293 6E cell line genomic positions. 
(A) pCMV-Cas9 plasmid map. (B) pU6-sgRNA plasmid. (C) pCMV-Cas9-U6-sgRNA-RFP (sgRNA 
and Cas9 combined in the same plasmid). pCMV-Cas9 plasmid map and pU6-sgRNA plasmids 
were used for targeting the RRL SIN cPPT 2HA EEW Zeo transfer vector into the EMX1 locus. 
pCMV-Cas9-U6-sgRNA-RFP was used for targeting the RRL SIN cPPT 2HA EEW Zeo BFP transfer 
vector into the EGFEM1P, CUL5 and ‘intergenic’ locus.  
A B 
C 
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5.4 Delivery of CRISPR-Cas9 and donor plasmids and 
screening 
5.4.1 Validation of targeted integration into the genome of HEK293 6E 
In order to deliver the CRISPR-Cas9 plasmids, 2µg of each plasmid (Sigma U6-
sgRNA, CMV-Cas9 and EMX1 donor, Figure 5.2A, B and Figure 5.1D, respectively) 
were nucleofected into 2x106 cells per condition using the Amaxa Nucleofector 
2b and program S-018. Such conditions were previously optimised to maximise 
transfection efficiency (data not shown). In the case of the two genomic loci 
discovered in Chapter 4 (EGFEM1P Chr3: 168,010,733- 168,010,734 and CUL5 
Chr11:107,887,987-107,887,988), 2µg of each plasmid of each of the two 
plasmids (Figure 5.2C and Figure 5.1D, respectively) were co-transfected into 
HEK-293 6E adapted to adherent culture.  
Two days post-transfection, zeocin selection (500µg/mL) was applied to the cells 
for 14 days. 24 EMX1, 34 EGFEM1P and 24 CUL5 colonies were randomly 
selected, isolated and amplified separately in adherent conditions for 15 days 
prior to re-adaptation to suspension conditions; EMX1 colonies 18, 19 and 21 did 
not re-adapt to suspension conditions; all EGFEM1P and CUL5 colonies 
successfully re-adapted to suspension cultures. The CRISPR-Cas9 editing strategy 
and timelines are schematically represented in Figure 5.3A. 
Precise integration of donor constructs was assessed by PCR amplification of 
donor construct-host genome junctions. Genomic DNA was extracted from all cell 
clones and PCR analysis was performed to verify the integration of the lentiviral 
vector. 5 different sets of primers binding genomic regions outside homology 
arms and 2 sets of primers binding the internal lentiviral gag and zeocin cassette 
(for 5’ and 3’ ends, respectively) were tested for each candidate site in order to 
optimize the PCR conditions in Figure 5.3B. Eventually, EMX1 right/left, 
EGFEM1P junction and CUL5 right/left junction were screened with primer sets 
detailed in Materials and Methods 2.2.43.  
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Figure 5.3. CRISPR-Cas9 'knock-in' strategy and validation by junction PCR. 
(A) Overview of CRISPR-Cas9 genome editing strategy timelines. (B) Schematic illustrating 
integration of a donor fragment of DNA into the desired locus; primers for screening the junctions 
for correct HR are indicated with arrows. (C) Predicted band sizes of CRISPR-Cas9 junctions are 
comprised between 1.1kb, 850bp and 1.3kb for EMX1, EGFEM1P and CUL5,  respectively. L, 
ladder; C-, negative control. 
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11 of 21 EMX clones (52%) showed a band for specific integration of a donor 
construct. For EGFEM1P and CUL5 clones, targeting efficiencies (with selection) 
raised up to 76% (26 and 16 positive clones out of 34 and 21, respectively) 
(Figure 5.3C). The similarity in targeting efficiency shows consistency between 
different targeted genomic locations. The difference in the targeting efficiency 
between EGFEM1P/CUL5 and EMX1 could be explained by the fact that sgRNA 
and the Cas9 were co-delivered into HEK293 6E cells instead of using a 3 plasmids 
(donor + sgRNA + Cas9) system, which contributed to simplify the system and 
enhance transfection efficiency.   
PCR products resulting from the amplification of CRISPR junctions were ligation-
independently cloned into a pCR4 TOPO-TA vector backbone. Sanger sequencing 
analysis with the M13reverse primer (5’-CAGGAAACAGCTATGAC-3’) verified 
expected sequences demonstrated precise integration on both genome-donor 5’ 
and 3’ boundaries, proving HDR integration of donor plasmid DNA into the 
desired position (Chr2: 73160998 - 73160999) in the host cell line genome 
(verified using Blat). The PAM motif (GGG following the S.pyogenes pattern 5’-
NGG-3’) can be seen immediately downstream to the three last nucleotides of the 
EMX1 sgRNA (GAA) (Figure 5.3B and Figure 5.4). This confirms that the DSB took 
place at the expected position (between the 17th and 18th position of the EMX1 
sgRNA, right upstream the remaining GAA sequence) and also the correct 
directionality of the integration. DNA was harvested 37 days post-transfection so 
that potential amplification from residual transfected donor plasmid was not 
possible. 
Interestingly, Sanger sequencing of the DNA fragments displaying the bands (with 
expected DNA sizes) shown in Figure 1.3C revealed amplification of sequences 
located in Chr5:127,818,094 for EGFEM1P and  Chr12:103,973,128 for CUL5 
instead of their expected loci (Chr3:168,010,733 plus strand and 
Chr11:107,887,987 plus strand, respectively) and no trace of donor construct. No 
sequence homology was found within 20kb surrounding these loci, which 
indicates this result could be due to a PCR artefact. Analysis of sgRNA specificity 
shows that no off-target effects are expected in chromosome 5 and 12 with less 
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than 4 mismatches in the sgRNA (data not shown). In addition, the predicted 
potential positions in those chromosomes do not correspond with the amplified 
sequences. Therefore, no evidence of targeted integration was obtained from the 
amplification of EGFEM1P and CUL5 junctions. 
This result contrasts with the successful integration shown for the EMX1 position 
obtained following the same procedure. A reasonable complementary approach 
to confirm these results could be to attempt amplification of donor-genome 
junctions on the off-sites predicted by the sgRNA design tool 
(http://crispr.mit.edu/). 
 
 
 
 
Figure 5.4. Sanger sequencing results from integrated donor plasmid-host cell line 
chromosome 3’ junction amplified by PCR.  
(A) Trace containing the junction between the donor construct and the beginning of the homology 
arm. The highlighted area shows the last 3bp (GAA) of the EMX1 sgRNA followed by the S.pyogenes 
PAM pattern (NGG). (B) Comparable junctions were obtained for the remaining GFP positive 
clones screened.   
Human EMX1 locus (right HA) 
Donor construct PAM 
EMX1 (downstream HA) 
pCR4 TOPO-TA backbone 
B 
A 
Human EMX1 locus (right HA) 
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5.4.2 Assessment of GFP expression in CRISPR-Cas9-modified HEK 293 6E 
cell clones 
GFP expression from the integrated transfer vector was assessed by FACS 15 days 
after isolation of single colonies grown under zeocin selection. All clones were 
GFP+ and 16 of the 21 EMX1 clones (76%) presented a defined single GFP peak 
suggesting that the composition of cells in that clone is uniform. Interestingly, the 
viability of clones 8, 9, 14 and 20, some of them reporting high levels of GFP 
(Figure 5.5), dramatically dropped after 3-4 days of isolation (data not shown). 
This result agrees with that of Chapter 3 (Figure 3.13) suggesting that high levels 
of GFP expression are detrimental for cell viability. EGFEM1P and CUL5 GFP 
intensity was also assessed by flow cytometry. 100% of the EGFEM1P clones were 
GFP+ (presented ratios >1 compared to non-fluorescent cells) while in CUL5 this 
percentage was lower (76%) (Figure 5.5B, C). A single peak of GFP intensity 
indicating homogeneity in the composition of the clone was obtained in 30 (88%) 
and 16 (76%) of them, respectively. Clones showing 2 peaks of GFP intensity were 
excluded from the screening in order to discard heterogeneous 
signal/integration. 
Interestingly, while EMX1 stable clones with the highest ratios were close to 30 
times more fluorescent than control cells, the ratios of highest expressers for 
EGFEM1P and CUL5 resulted to be 2-3 times lower than EMX1 values. The 
presence of GFP in samples in which integration was not detected can be 
attributed to off-target integration.   
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Figure 5.5. Mean fluorescent intensity of CRISPR-Cas9-edited clones and confirmation by 
junction PCR. 
MFI values are expressed as fluorescence intensity relative to GFP-negative cells. Successful 
homologous recombination at the target sites (A) EMX1, (B) EGFEM1P and (C) CUL5 was 
confirmed by genomic PCR as described in Section 2.2.6. N (in the x-axis) stands for the clones 
that were extracted in a second batch, although all clones were treated equally.
B 
C 
A 
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5.4.3 Assessment of Cas9/sgRNA transfection efficiency 
 
Figure 5.6. Flow cytometry analysis of Cas9/sgRNA and donor construct co-expression in 
HEK 293 cells. 
Cells were transfected with pCMV-Cas9-U6-sgRNA-RFP plasmid and donor construct (Figure 5.2). 
Marker gene expression was determined by flow cytometry after 3 days post-transfection. GFP 
and RFP fluorescence indicates expression of transfer vector and Cas9, respectively. Results for 
sgRNA/EGFEM1P only are comparable to those of sgRNA/EGFEM1P.  
 
Cas9 plasmid transfection efficiency was confirmed by flow cytometry for RFP 
fluorescence 3 days post-transfection in EGFEM1P and CUL5 transfections. 
Transfection efficiency rose up to 75% for cells co-transfected with the 
sgRNA/Cas9 + donor plasmids and was 50% for cells transfected only with the 
donor construct. The latter could be attributed to non-specific integration as well 
as transient expression. 17% and 27% in HEK 293 cells co-transfected with 
sgRNA/Cas9 and donor plasmids were RFP and GFP positive, which indicates that 
both the nuclease proteins (fused to RFP with a 2A peptide) and the transfer 
vector (encoding for GFP) was being expressed in EGFEM1P and CUL5 clones (). 
RFP fluorescence was not detected in edited clones after 1-2 weeks post-
transfection by cell imaging indicating the expression was transient as expected 
(data not shown). pmaxGFP was used as a GFP single fluorochrome positive 
control and plasmids containing EGFEM1P and CUL5 pCMV-Cas9-U6-sgRNA-RFP 
were used as a RFP single fluorochrome positive control. Western Blot analysis of 
Cas9 expression on transfected cells would confirm these results.  
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5.5 Screening of specificity, copy number and titer on 
targeted packaging cell lines 
5.5.1 Assessment of background integration 
To evaluate the rate of non-HR mediated donor construct integration in EGFEM1P 
and CUL5 clones (EMX1 clones lack the BFP marker in the donor construct), the 
GFP and BFP fluorescence levels were measured on all clones using an IN Cell 
2000 imaging system. Successful homology directed repair would result in the 
integration of a GFP cassette only. In the case of a single random integration, cells 
are expected to appear double positive for green and blue fluorescent protein. 
pmaxGFP (supplied with the Invitrogen Nucleofection kit V, VCA-1003, Appendix 
A) and pMA-RQ HA-MCS-HA2-BFP plasmid (Appendix A) were used as green and 
blue single fluorescence controls. 
 A 
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Figure 5.7. Screening of successful homologous recombination integration events in 
EGFEM1P and CUL5 edited clones by cell imaging. 
(A) Quantification of the proportion of GFP+ve/BFP-ve cells within the total population of 
transduced cells using a custom script in Columbus imaging software (Section 2.2.42 and 
Appendix B). (B) Images were taken using a fluorescence confocal microscope at a 20x or 40x 
magnification. eGFP, enhanced green fluorescent protein (430-480nm); seBFP strongly enhanced 
blue fluorescent protein (510-600nm). No overlap between the detection spectra was observed 
between seBFP and eGFP. EGFEM1P clone 2 and CUL5 clone 2 are shown; results were comparable 
for all clones (data not shown). N (in the x-axis) stands for the clones that were extracted in a 
second batch, although all clones were treated equally.  
EGFEMP1 overlay 40x CUL5 overlay 40x 
Overlay Bright field eGFP seBFP 
EGFEMP1 
CUL5 
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Co-expression of BFP and GFP was observed in more than 95% of cells (higher in 
CUL5 clones) in all clones of EGFEM1P and CUL5 indicating random integration 
(Figure 5.7). No clone with high percentage of eGFP only was observed, indicating 
that homologous recombination at these loci did not occur. 
5.5.2 Lentiviral vector genome copy number of packaging cell lines 
Quantification of the number of copies of transfer vector was performed on all 
clones by qPCR. Absolute quantification accounting for the mass of a cell genome 
(based on an average number of chromosomes781) was used to normalize the 
number of copies obtained per number of cells (calculations explained in Section 
2.2.25).  
Most EMX1 clones harboured between 1 and 3 copies of the transfer lentiviral 
vector.  Clones 8, 13 and 14 reported up to 6 integrated copies of transfer vector, 
which resulted in proportionally increased GFP fluorescence. In EGFEM1P and 
CUL5 clones, most clones show around 1 copy and the highest expressers report 
up to 3 and 1.5-2, respectively.  
The presence of multiple copies of integrated lentiviral transfer vector can be 
explained either by off-target integration, variable penetrance of the insertion 
within the multiple potential alleles of HEK293 cell lines or the variability of the 
assay. The HEK 293 cell line is originally hypotriploid with a modal number of 64 
chromosomes occurring in 30% of the cells (ATCC® CRL-1573™); therefore, copy 
numbers greater than 2 are biologically possible. However, the rate of multiple 
HR events is expected to be lower than a single HR, which suggests off-target 
integration has occurred.  
As can be seen in Figure 5.5A, C and A, C, there is a strong correlation (Pearson’s 
R2=0.643) between GFP intensity and the number of integrated copies of 
lentiviral transfer vector in EMX1 clones (Figure 5.8D) unlike EGFEM1P and CUL5 
clones. 
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Figure 5.8. CRISPR-Cas9-integrated lentiviral vector copy number on clones and 
correlation with the fold MFI. 
(A, B and C) Vector copy number was assessed by RT-qPCR (2.2.25). Samples labelled N* indicate 
clones isolated without cloning rings but by pipetting after incubation with 10%(v/v) TrypLE 
dissociating agent in PBS.  NTC, non-template control 1. Results expressed as means ± SD. (D) 
Pearson’s correlation between qPCR vector copy number and fold MFI for the three genomic 
candidates 
  
D 
EMX1 
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5.5.3 Lentiviral vector titer of packaging cell lines 
EMX1 clones 2, 17 and 23 and the EGFEM1 and CUL5 polyclonal pools were 
chosen for lentiviral vector production. The criteria behind the choice of EMX1-
clone 2 and clone 17 comprised the detection of CRISPR-Cas9 mediated 
integration and a copy number of 1 indicating no off-target integration. EMX1-
clone 23 was chosen because it reported the highest MFI (within the clones that 
successfully readapted to suspencion culture) despite the copy number being 
greater than 1. Clones with different MFI values were chosen in order not to link 
the vector production yield to enhanced GFP expression driven by other reasons 
(interclonal intrinsic variation, clonal fitness). Vector titers from EMX1 clones 2 
and 17, EGFEM1P and CUL5 packaging cell lines were undetectable (Figure 5.9). 
HEK 293 6E cells transduced with viral supernatant from EMX1 clone 23 did 
show low levels of transduction, translated in titers of 104 TU/mL. However, titers 
were significantly lower compared to a standard lentiviral preparation (107 
TU/mL) using non-modified HEK293 6E cells cotransfected with a 4 plasmid 
system (gag-pol, rev, VSV-G and transfer vector). 
Figure 5.8. Functional lentiviral vector titration by flow cytometry on CRISPR-Cas9-
modified clones.  
Packaging cell lines were transiently co-transfected with gag-pol, rev and VSV-G for the production 
of lentiviral vectors using the calcium phosphate technique. Titers were calculated as indicated in 
Section 2.2.18. All results presented (means ± SD; * p<0.05, ** p<0.001, *** p<0.0001, grouped per 
cell type, Friedman’s test analysis of variance) correspond to 3 technical replicates. Titers were 
assessed on HEK 293 6E cells.   
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5.6 Summary of results and concluding remarks 
- A 5.5kb lentiviral transfer vector donor construct was specifically 
integrated into the expected loci at the EMX1 gene using CRISPR-Cas9 
genome editing technology.  
- Targeting efficiencies observed were high (57%) at the EMX1 locus. The 
integration of donor template was mediated via homologous directed 
repair pathway as the junction sequence (with no indels) indicates. 
- Random integration was detected when a donor plasmid containing a 
transfer vector was used to target EGFEM1P and CUL5 loci, indicating 
unsuccessful CRISPR-mediated homologous recombination. 
-  Functional lentiviral production titers derived from the integration of a 
transfer vector in the EMX1 loci reported 104 TU/mL. 
Successful targeting in EMX1 clones 
The results presented in this chapter provided evidence that CRISPR-Cas9 can be 
used as a genome editing tool to mediate knock-in of a >5kb functional transfer 
vector cassette into HEK 293 6E host cells.  A lentiviral transfer vector was 
integrated into the EMX1 gene, reporting a targeting efficiency of 57% (using a 3 
plasmid system). These targeting efficiencies are comparable to those reported 
in recent articles describing ‘knock-in’ strategies using antibiotic selection even 
though the size of the donor construct is relatively higher (see Appendix A). 
Successful integration was confirmed by Sanger sequencing of one of both 
junctions.  
Correlation between barcode counts and titer 
Although targeted integration of donor construct containing transfer lentiviral 
vectors was successful, transduction of HEK 293 6E cells with supernatant from 
EMX1 clones 2 and 17 resulted in no titers. Despite being undetectable, EMX1 
clone 23 (with a vector copy number of 4) showed low levels of transduction (10-
15% transduction in the 1/10 dilution). Taking into account that vector copy 
numbers of 14-59 reported by Hu et al.,463 or up 200 with the concatemeric 
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array292 are necessary to achieve 107 TU/mL titers, it is understandable that a 
vector copy number of 4 is not sufficient. In this study, individual loci were 
targeted with donor plasmid containing the transfer vector genome in order to 
test the hypothesis of the contribution of the a genomic environment  on the 
expression of a particular barcoded vector transcript. Targeting multiple genomic 
locations would have made more difficult to assign the contribution of a 
particular position to the overall expression of vector genome. 
Several factors could explain the lack of correlation between the high number of 
barcode counts associated to a particular locus and a low or inexistent vector titer 
from a transfer vector integrated in that position: 
- Firstly, the stable integration of a lentiviral transfer vector might compromise 
the stoichiometry of the 4 necessary components required to produce 3rd 
generation lentiviral vector. In EMX1, EGFEM1P and CUL5 clones, the remaining 
plasmids containing vsv-g, gag-pol and rev were provided following the 
stoichiometry used for transient transfection (Section 2.2.16). However, the 
number of mRNA molecules in cell cytoplasm was not analysed. RT-PCR of the 
viral transcripts could provide insights on the actual messenger ratios although 
amplification bias could skew the results. Transcriptomic analysis could 
contribute to optimise the stoichiometry in addition to help explain the 
differences seen between clones and copy numbers. 
- In line with the lentiviral integration preferences exploited in this work, Cas9 
activity was reported to be higher in open chromatin regions782. Nonetheless, 
efficiencies could substantially vary within a particular locus. The high-
transcribing position of vector integration retrieved by LM-PCR does not exactly 
correspond to the position where the nuclease excised the DNA. The DSB 
produced after the 17th base pair of the sgRNA and the choice of site of integration 
are subject to the presence of a PAM sequence (NGG) from S. pyogenes. Restriction 
to the S.pyogenes PAM limits genome accessibility to 1/42bp (the average 
frequency of a GG dinucleotide in a DNA sequence)782. The use of other PAM 
sequences such as NNAGAA and NGGNG for S. thermophiles459 or NNNNGATT for 
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N.meningiditis783,784 could answer that question although such systems are not 
standardised at a commercial level. Alternatively, targeting efficiencies could be 
tested using different sgRNA sequences (protospacers). 
- On a technical note, optimisation of co-transfection parameters showed that 
delivery of higher amounts of plasmid also contributes to increase the 
transfection efficiency. CRISPR-Cas9 is a relatively new genome editing 
technology and further investigation is required to determine the optimal 
parameters for addition of foreign DNA into cells. Although most studies use 
homology arms 500bp-1kb and repair templates of up to 6kb, the 
interdependencies of these characteristics and their direct effects on the 
targeting efficiency of the system remains to be explored. 
Transfection of linear plasmid DNA has been known to yield more stable clones 
compared to supercoiled circular plasmid501. In fact, PI-SceI yeast restriction sites 
had been designed opposite the exchangeable components of the donor plasmid 
in order to explore that possibility. However, despite being more recombinogenic, 
linearised plasmid DNA has also been described to be taken up less efficiently by 
the cell785. In addition, endogenous exonucleases could degrade linearised 
DNA785. Since, the delivery of the CRISPR-Cas9 plasmids did not become a 
limitation (as can be seen in ) and posterior selection was going to be applied to 
cells, this measure was not applied.  
Interclonal variation in mean fluorescence intensity and vector copy number  
We also observed variability in GFP expression and titer within clones with the 
same amount of vector copies. Interclonal variation is a common phenomenon 
observed in cell line development consisting in variability in the performance of 
clones that theoretically share the same genotype. This heterogeneity manifests 
in measurable variation in terms of cell densities, growth rate and protein 
secretion786. In 2005, Barnes et al., studied the causes of this phenotypic drift and 
demonstrated this phenomenon can be observed in the absence of selective 
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pressure787. In their study, they attributed interclonal divergence to intrinsic 
genetic differences due to the natural stability of mammalian cell lines. Random 
mutations in cell cycle-regulator or proteins involved in the nutrient uptake can 
affect the individual yield of each cell. They also showed phenotypic drift is more 
likely to occur if parental cell lines have been cultured for prolonged periods as 
accumulation of changes. However, it is unclear if this heterogeneity is intrinsic 
to the clone or arises after isolation of the single cell. Other factors such us 
epigenetics have been suggested to play a role in clonal variability through binary 
switching of endogenous metabolic genes. In addition, stochastic fluctuations of 
endogenous genes in cell cultures have been described622. Expression of p27 
protein, a member of the cyclin–dependent kinase family, is often screened as this 
protein cell cycle regulator inhibits cell cycle progression. High levels of p27 have 
been shown to correlate with decreased cell growth rates786. However, (and in 
order to understand the extent of this phenomenon) heterogeneous expression 
is not limited to different clones. Pilbrough et al., showed that expression noise 
can also occur within cells of the same clone788. Stochastic bursts of promoter 
activation linked with fluctuations in chromatin folding dynamics generates a 
graded repertoire of expressions789. This burst is then subject to amplification by 
protein and mRNA turnover in the timescale of hours for higher eukaryotes790.  
Acquired phenotypic drift has also been observed and could explain why the rate 
of variation for different parameters remains low (7% in Barnes et al.,) in early 
passages and increases over generations. In any case, Kim et al., remarked that 
the term ‘clones’ was not sufficiently accurate and instead the idea of a “clonally-
derived population” was more realistic791. Another source of acquired 
heterogeneity is the lack of control of the effects of integrated copies of donor 
plasmid in host chromosomes. Deregulation or disruption of endogenous genes 
can result in interclonal changes in response to environmental factors such as 
temperature or pH792,793. In this study, all clones had the same number of 
passages, which discards the accumulated drift hypothesis. Therefore, differences 
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in GFP expression of cell generated could be explained by intrinsic heterogeneity 
or as a result of the effect of random integration. Precisely because of this reason, 
clones displaying different levels of GFP (with low/no random integration and 
low copy number) were tested for lentiviral production.  
Targeting specificity 
Tightly coupled with the efficiency of the editing is the specificity of the DSB. In 
this study, we showed specific integration of a donor construct in the expected 
EMX1 loci. However, copy numbers higher than one (and especially higher than 
three, being HEK293 considered hypotriploid) observed in some clones do not 
allow discernment between off-target integration and targeted integration in 
other alleles. Contrarily, specificity results for EGFEM1P and CUL5 showed that 
integration of the transfer vector construct took place in a random manner. In 
order to complement the specificity results obtained by PCR and quantify the 
potential off-target integrations, lentiviral transfer vector copy number was 
analysed on selected/isolated/amplified/re-adapted clones. Its correlation with 
the GFP intensity (particularly seen in CUL5 and EMX1 clones) and also observed 
in Charrier et al.,724,  reinforces the consistency of the outcome. Donor copy 
numbers of EMX1 were found to be higher than those of EGFEM1P and CUL5 
(with values around 1 donor copy per cell). Nevertheless, values superior to 1 do 
not necessarily imply off-target integration events. Although it occurs less 
frequently, the integration of up to two separate copies (not in tandem) of donor 
plasmid could be explained by biallelic targeting (or even triallelic, given the 
hypotriploid nature of this cell line). Access to the karyotype of this particular cell 
line would provide insight into this aspect. As mentioned before, cell lines are 
known to undergo genomic rearrangements to overcome metabolic limitations 
and their genetic stability is compromised. Alternatively, the correct composition 
of the junctions and homology arms could be identified by Fluorescent In Situ 
Hibridisation (FISH)794. Next-generation sequencing executed with the MiSeq 
system (Illumina) would provide representativity of the rate of 
indels/integrations obtained although the read length could suppose a limitation 
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to identify junctions with long homology arms. Single-molecule real-time (SMRT) 
sequencing allows for read lengths of up to 3kb and has been used to screen 
edited human cells795. A reasonable complementary approach to confirm these 
results could be to attempt amplification of donor-genome junctions on the off-
sites predicted by the sgRNA design tool (http://crispr.mit.edu/)581. 
Possible explanations for random integration observed in EGFEM1P and CUL5 
candidate loci 
As previously stated, targeting efficiency and specificity are partly locus-
dependent factors. However, 57% on target efficiency obtained in EMX1 clones 
contrast with the results observed in other candidate loci (EGFEM1P and CUL5), 
where targeted integration was not observed. Despite different clones showed a 
correlation between level of GFP expression and vector copy number, they failed 
to show targeted integration by PCR of integration junctions from genomic DNA. 
Therefore, the positional effect of the viral integration could not be assessed in 
these candidate positions. Polyclonal pools heterogeneously expressing transfer 
vector were assessed for EGFEM1P and CUL5 but functional titers were not 
detected. Possible reasons for failure to target candidate loci may include: 
- The difference in targeting efficiency could be due to the co-transfection of a 
different number of plasmids. While EMX1 locus was targeted using 3 plasmids, 
EGFEM1P and CUL5 loci were targeted with 2 plasmids. Co-transfection of the 
EMX1 locus with the 2 plasmids system would answer that question. 
- The design of the sgRNA was also found to influence its targeting efficiency. A 
study by Wang et al., using a library of 73,000 sgRNAs and massive parallel 
sequencing helped determine the parameters for the design of effective sgRNA796. 
Purine rich sgRNA PAM-proximal regions as well as a balanced GC content and 
sgRNA were found to favour Cas9 activity.  Taking that into consideration, the 
composition of the sgRNA sequences utilized in this work (EGFEM1P 5’-
TACCTGGGGGTGGTGGTGTA-3’ 60% GC content and CUL5 5’-
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TACCTTCTTCCCTACAGGTC-3’ 50% GC content) would indicate that higher 
targeting efficiency should be expected in EGFEM1P and CUL5 loci. However, 
successful targeting was achieved in EMX1 clones with 15% GC content (EMX1 
sgRNA 5’-TTAATGCTTATTTATTTTGT-3’). Enhanced efficiency has also been 
reported if the sgRNA targets the transcribing strand. However, in this study, all 
three designed sgRNA targeted the non-transcribing strand where the closest 
PAM motif to the viral integration was.  
- Another aspect that might have contributed to non-specific integration is the 
application of increasing concentrations of antibiotic post-transfection. Although 
antibiotic selection can help reduce selection timelines, this might also exert a 
negative effect on the specificity of the integration and the donor copy number. 
Similarly to genomic amplification strategies (e.g. DHFR/MTX system624) used for 
biopharmaceutical protein production, the metabolic burden imposed by the 
presence of zeocin may promote random integration, amplification or even 
genomic rearrangement instead of HR to adapt to such conditions. For that reason 
and in order to assess the targeting efficiencies without selection, a non-selection 
control could be added to the study. 
In EGFEM1P and CUL5 clones, the occurrence of off-target effects might justify 
the presence of more copies and consequent higher reporter gene expression. A 
relatively high frequency (50%) of GFP+ cells was detected when transfecting 
donor construct (in absence of sgRNA/Cas9 plasmids). Besides transient GFP 
expression, screening of random integration was required to discern whether 
integration events were legitimate. The inclusion of a BFP selectable marker 
revealed that a large proportion of cells (>90%) had undergone random 
integration, independently of the locus. An alternative way to examine the off-
target integrations would be to amplify potential junctions of donor plasmid with 
regions with a certain number of mismatches in the sgRNA sequence (predicted 
by sgRNA design tools). Alternatively, other studies have used negative selectable 
markers (such as the HSV thymidine kinase or diphtheria toxin A) located outside 
the homology arms to kill cells with randomly integrated donor constructs797. 
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- Potential recombination between SV40 polyA. The donor plasmid harbours 
three SV40 polyadenylation signals that enable termination of the transcripts 
containing the gene of interest and zeocin and BFP selectable marker. Potential 
recombinations occurring between the three polyadenylation signals, which 
share exactly the same sequence, could explain the presence of a BFP marker 
between homology arms and thus its expression upon integration (either random 
or targeted). At a plasmid level, donor plasmids were completely sequenced 
before transfection. Therefore, in the event of a recombination within the donor 
plasmids, this must have occurred in the host cell line, not during the cloning 
process. However, successful targeted integration was achieved using the 3-
plasmid system with a donor plasmid containing two exact polyA sequences 
(devoid of the BFP marker).  
- The absence of integration of donor construct in the candidate loci might be 
explained by the lack of Cas9 cutting activity. An alternative approach to test this 
hypothesis could be to transfect cells with the plasmid containing the Cas9 and 
examine the cutting site with primers flanking it to see if there are any indels. 
Plasmid rescue is another alternative to retrieve bacterial backbone randomly 
integrated by digesting gDNA and circularising, transforming and selecting with 
the antibiotic resistance. However, although the fusion of RFP with a Cas9 is not 
sufficient to demonstrate cutting efficiency, it does confirm with the Cas9 
expression () and therefore weakens this theory. 
- Stoichiometry. The EMX1 locus was targeted using a 3-plasmid system 
(donor+sgRNA+Cas9) that worked compared to the 2-plasmid system 
(donor+Cas9/sgRNA) that did not work with EGFEM1P and CUL5. As a result, this 
might have implications on the stoichiometry of the system. The two-plasmid 
system drives expression of sgRNA and Cas9 from two different promoters within 
the same plasmid. As the same amount (in mass, 2μg) of each plasmid were used 
per single transfection in a single 6-well plate, the stoichiometry might be slightly 
different from a 8,236bp plasmid expressing both compared to two plasmids of 
7,037bp and 2,349bp (Figure 5.2). In line with the stoichiometry point, the 3-
plasmid system with a BFP marker was placed downstream of the homology arms 
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in order to detect non-specific integration.  That makes the donor construct larger 
(11.3kb vs 9.6kb), which means that with the same mass of plasmid DNA 
transfected there would be less molecules of plasmid vector. In order to test that 
hypothesis, the donor construct of EGFEM1P and CUL5 could be tested following 
the transfection conditions of EMX1 with the 3-plasmid system.  
- Compatible origin of replication. Firstly, HEK 2936E cells have the EBNA1 
antigen and can maintain expression of plasmids with an EBV origin of 
replication. Despite not possessing such origin of replication, donor plasmid 
sequences potentially similar to it could sustain stable episomal expression of the 
donor plasmid including transfer vector and the BFP selectable marker. However, 
no similarities were found between EBV origin of replication (GenBank: 
DQ279927.1) and any of the elements in the donor plasmid.  
- Lastly, low levels (17 and 27%) of co-transfection of donor construct and sgRNA-
Cas9 plasmid observed in  might explain the low targeting efficiencies observed 
in EGFEM1P and CUL5. However, EMX1 clones, which showed 57% efficiency, 
were transfected following the same procedure and in addition, sgRNA and Cas9 
were split in two different plasmids. 
As previously stated, to our knowledge this is the first approach that uses a 
genome editing technology for lentiviral packaging cell line development. This 
study opens the door to the introduction of packaging plasmids and transfer 
vectore genomes into optimal positions as opposed to integrated via random 
integration and also preventing any concerns arising from integrated viral 
sequences. 
A reasonable criticism to this work would be the limited number of sgRNAs tested 
for each genomic loci. Typically, three different sgRNAs targeting a particular 
region are designed in order to find the one that shows higher cutting efficiency. 
Due to the time limitation of the project, only one sgRNA per loci was tested. A 
relatively easy way of testing the cutting efficienty of several sgRNA would be to 
transfect the Cas9-sgRNA plasmid (and not the donor) and amplify expected 
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target sites in the genome seeking for double strand breaks resolved by NHEJ 
(with insertions and deletions in their sequence).  
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Chapter 6  
DISCUSSION 
Typical strategies for the generation of lentiviral packaging cell lines are based on 
sequential stable transfection and selection for populations containing lentiviral 
packaging genes. The random and multi-step nature of this process requires 
arduous screening and limits the performance of higher producers, respectively. 
In the last 10-15 years, viral transduction was introduced as a means of delivery 
that can efficiently target actively transcribed sites with higher associated 
expression compared to conventional stable transfection. This represents a useful 
tool for the expression of packaging plasmids. However, state of the art transfer 
SIN LVV widely used in the clinic cannot be produced using non-SIN for safety 
reasons and are incompatible with SIN vector delivery systems. Although some 
solutions have been proposed (cSIN), titers are slightly lower and genotoxicity 
has not been extensively assessed401,463.  
The rationale behind this project lies on the idea of optimising the screening 
capacity of a semi-random insertion of a lentiviral transfer vector based on viral 
integration preferences. However, citing the words of Prof David James 
(University of Sheffield – advance biomanufacturing centre) in an oral 
communication at GSK, “screening is the admission of cellular screening 
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incapability. Design, don’t screen”. He presented the rational design vs irrational 
screening paradigm and claims that while the engineering or analytical tools to 
analyse phenotype (bioinformatics, genome editing, synthetic biology, “-omics”) 
are available, efforts still needs to be made in understanding the biological 
mechanism and interactions that govern production systems such as lentiviral 
production so that we can develop predictive models. These predictive models 
would then serve to iteratively test (design-build-validate) different expression 
configurations. Although this strategy was thought and executed for the previous 
wave of therapeutic products in the 1980s-2000s (hybridomas, recombinant 
proteins in E.coli and mammalian cell lines, protein engineering), it is reasonable 
to think that gene and cell therapies and regenerative medicine follow a similar 
path now that academic clinical trials meet industrial production. This project 
aimed to use irrational screening of integration sites to allow rational design of 
PCLs in the future. 
Following a similar rationale to Sanber et al.,381 lentiviral targeting of actively 
transcribed sites and nucleased-based genome editing (instead of retargeting via 
recombinase-mediated cassette exchange) could present a solution to that issue 
and is explored in this project. In addition, a barcode system was implemented to 
quantitatively evaluate the expression derived from each integration site and 
enhance the screening of naturally actively expressed sites. 
Key findings and observations 
The lentiviral barcoded library 
In this study, we developed a simple and cost effective method that allows 
simultaneous genetic cell marking and screening of thousands of integration sites 
for cell line development. This is the first example of barcoding applied in 
lentiviral packaging cell line development. Apart from the aforementioned 
advantages, the barcode system offers attractive features summarised below: 
The titers of the lentiviral vector library (vSYNT) are comparable to standard 
lentiviral preparations, indicating incorporation of a 70nt fragment of DNA 
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containing a genetic tag is not deleterious for viral replication. Low 109 TU/mL 
titers were achieved after ultracentrifugation, which established the first 
empirical threshold in the maximum library complexity (414 x 22 = 1,073,741,824 
~109).  
During the library construction process, the scale up of the ligation reaction 
reported the highest improvement in cloning efficiency. Around 120,000 colonies 
were obtained from a single ligation experiment. 90% of them contained a 
barcode and NGS sequencing revealed the library composition was balanced, with 
no predominant clones/variants outgrowing the population. Experimental 
optimization of the oligonucleotide cloning was critical and minimised the impact 
of backbone re-ligation, backbone:insert ratios, ligation temperature/time 
conditions and oligonucleotide annealing mismatches in the overall cloning 
efficiency . 
The applicability of this barcode method lies in the ability of the vector library to 
transduce cells. However, this is not a limiting factor since VSV-G pseudotype can 
efficiently transduce a wide range of cell types to meet different applications. On 
a different level, host cell line restriction factors dictate its permissiveness to the 
vector library. The versatility of this method allows assessment of the 
(therapeutic) transgene of interest driven by a promoter of choice and thus does 
not require a reporter gene. Another advantage is that selection does not need to 
be applied to maintain the cell tag. In addition and contrary to antibody/secretion 
selection methods, genetic marking allows for cells to be manipulated (passaged, 
frozen, thawed) and high transcribing integration sites will still be tagged. 
Integration site analysis and barcode abundance 
Notably, a modification of LM-PCR was used to retrieve integration sites; instead 
of being performed in the 3’LTR, primers were designed to anneal sequences 
immediately downstream the 5’LTR U3 region, allowing higher read lengths and 
thus longer junctions. 
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Integration preferences did not diverge from those reported in lentiviruses232. 
Integration sites were found to be more abundant in gene-rich regions and 
chromosomes and LEDGF/p75 protein tethered insertions along the 
transcription unit798 of the gene as opposed to gamma-retroviral vector 
preferences (TSS). Primary weak consensus sequences799 in the integration 
junctions were also identified. 
The system is also compatible to any sequencing platform. Although analysis was 
performed with Illumina using a 300bp PE, retrieval of longer integration 
junctions would benefit from techniques that push NGS read length to 
2x500bp800. Similarly, single molecule real time sequencing technology such as 
PacBio (that offers 100,000 reads of >1kb) or Roche 454 newest system (GS FLX 
Titanium XL that allows for sequencing of 1,000bp for 700,000reads) could 
help801,802. 
In order to process LM-PCR and RNA-Seq reads into annotated barcoded 
integration sites and sorted barcode counts, respectively, bioinformatics 
pipelines were designed. For LM-PCR custom scripts were written to filter 
sequences >20nt with high homology with the linker (mainly in the last 5 bases) 
and map them using BLAT692 against the hg19 genome taking into account that 
indels and gaps are not expected, discarding ambiguous alignments and 
promoting regions with a high degree of intensity. Although the RNA-Seq 
processing pipeline was simpler, the RNA-Seq protocol itself was also optimised 
by extending fragmentation times and thus enabling synthesis of longer RNA –
seq libraries, identified as critical factors for barcode retrieval. Out of the top 15 
barcode variants with a higher number of barcode counts, 6 and 0 variants for 
104-cell and 103-cell transductions were found to have a correspondence with a 
genomic position. The difference could be explained due to the fact that ten times 
more potentially high expressing positions are screened with the 104 TU library. 
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The complexity challenge 
The complexity of the library reached 4x105 barcode variants according to the 
Lincoln-Petersen estimate709. In a single aliquot, 5x104 different barcodes were 
retrieved and 10% of them were overlapping events. Sequencing errors account 
for false barcode generated as misread events. In order to quantify their 
contribution to the library diversity, Starcode clustering analysis was performed 
throughout all the steps of this project691. Conversely, mean number of 11bp 
dissimilarities among barcodes was found to correlate with a dramatic increase 
of the library complexity if more than 3bp (out of the 14 nucleotides of the 
barcode) are edited.  
The diversity of the library dictates the throughput of the system. Accordingly, the 
complexity observed at a plasmid and vector level, 103, 104 and 105 integration 
sites were screened using the lentiviral barcoded library method.  1,245 (for 103 
TU applied) and 8,261 (for 104 TU applied) integration sites with distinct barcode 
variants were identified by high-throughput sequencing of LM-PCR reads. 
Therefore, the system presents an adequate scalability to a number of clones 
greater than current screening platforms. The lack of correlation between 105 TU 
applied and the IS retrieved was likely due to a change in the culture format. 
Besides that, the limiting factor in the screening capacity could be attributed to 
the complexity of the library. The 105 barcode variants threshold achieved during 
the library construction process is below the theoretical sampling space of the 
barcode design (109 variants) the 109 TU/mL of a lentiviral preparation and the 
2M reads/sample sequencing capacity of a MiSeq run (RNA-Seq capacity is 
higher), as long as the computational power/time is not a limitation. 
CRISPR-Cas9 Genome editing for packaging cell line development 
Once EGFEM1P, CUL5 and ‘intergenic’ high-expressing positions were selected, 
site-specific integration of a transfer vector was attempted using the CRISPR-Cas9 
technology. Sanger sequencing confirmed the insertion of a 5.5kb donor construct 
containing a lentiviral transfer vector and a zeocin selectable marker into the 
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control EMX1 loci with a 57% targeting efficiency (similar to those reported in 
the literature with selection). Despite displaying Cas9 activity and the same 
protocol as the control position (although different CRISPR-Cas9 plasmids), 
EGFEM1P and CUL5 (‘intergenic’ was discarded) showed off-target integration. 
Among the targeted EMX1 clones, only EMX1 clone 23 with vector copy number 
of 4 reported measurable titers (104 TU/mL), highlighting the importance of the 
expression of transfer vector for the stoichiometry of lentiviral vector production. 
Criticisms and potential improvements 
The barcode system also presents some intrinsic limitations. Beyond technical 
difficulties related to library generation, including the cloning bottleneck to 
library diversity and the possibility of introducing multiple copies per cell 
(already discussed in Chapter 3 and 4), sequencing errors may become a problem 
for the library complexity and thus the throughput of the approach or application. 
False barcodes can be generated as a result of misreading events or amplification 
of those generated by the polymerases’ biases. In order to control that variable, 
and apart from barcode clustering, future work should be oriented towards 
calibration of the library to compensate for those biases and accurately predict 
the library size. An internal control library with known number of manually 
cloned variants could help to improve the accuracy of library complexity 
determination. The downside of this would be the throughput of the library since 
the cloning process would be laborious and time-consuming. An alternative to 
this could be to use spike-in controls as in Brugman et al735. Different proportions 
(i.e. 1%, 5%, 10%, 50% and 100%) of a plasmid with a known variant (or another 
distinguishable sequence tag) could be added into the library plasmid pool to 
normalise the barcode counts by the number of molecules present in the library. 
 However, this is time-consuming and may be only feasible for low complexity 
libraries.  To avoid enzyme bias, heat and divalent metal cation803, acoustic and 
hydrodynamic DNA shearing804 as well as sonication or DNaseI non-specific 
nuclease805, phage Mu (Buschman’s laboratory)806 or nrLM-PCR (Schmidt’s 
laboratory)807 can be used as alternatives to fragment DNA. 
Chapter 6. Discussion  
 268 
Linked to the complexity of the library, a balance needs to be found between the 
throughput requirements and Leveinshtein or editing distance for each individual 
application. A high complexity library is not always recommended as it can 
compromise the accuracy of its variant distinction; it depends on the complexity 
required or the proportion of the theoretical space occupied by the actual library. 
Library complexity is a critical parameter in studies involving barcoded 
experiments. However, a uniform criteria does not exist for the estimation of 
library complexities; diversity indexes such as the Schnabel, Lincoln Petersen 
(used in this study), Shannon-Weaver (used in Porter et al.,)736, Simpson, Berger 
Parker and their respective modifications contrast with descriptive frequency 
plots or simply no control over this variable. 
Another potential major objection to this novel marking approach might be its 
inability to screen for genomic positions with high associated expression due to 
post-translational modifications. Therefore, this system would not be sensitive 
enough to detect epigenetic changes that could affect clonal fitness understood as 
growth rate, sensitivity to lactate/ammonia and tolerance to the heterologous 
expression burden. However, environmental factors are not the only parameters 
to affect expression. Internal processes like mRNA export and its processing 
(capping, splicing and polyadenylation) regulate the stability and decay of the 
mRNA. Translation regulation mechanisms include the availability of eIF2-GTP-
Met-tRNAiMet  ternary complexes (necessary for translation initiation)94, 
upregulation by upstream ORFs (uORFS)808, AU-rich elements809, or 
downregulation by interference RNAs or inhibitory proteins (or combinations of 
them). In the context of lentiviral vectors there are other steps in assembly and 
budding that can influence the infectivity of the vector. However, the main 
objective of this project was to increase the transcription of viral genome and thus 
post-transcriptional modifications are not critical. In the event of using this 
system to improve the expression of packaging genes, post-transcriptional 
modifications should be considered. 
While analysis of clonal dynamics is critical for the characterisation of different 
lineages, in this study barcode proportions are analysed at a particular time point 
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(cells are harvested one week after transduction). However, expression dynamics 
could be assessed to determine whether barcode abundance (and thus gene 
expression) is stable over time and also to discard false barcodes (background 
sequencing noise). A potential alternative method to be explored to determine 
site-specific expression would be to examine read through barcoded transcripts 
that have extended into the genome from RNA-Seq and have not terminated at the 
polyadenylation site. Another advantage of tracking clonal dynamics of a 
particular barcode variant would be the information provided about the stability 
of transgene expression. In this study, despite being cultured for 4-5 weeks and 
during the genome editing process, the lack of stability assessment could be a 
possible criticism to the strategy followed. 
As a quantitative method for transcript expression, the random integration events 
observed in the candidate positions preclude drawing any conclusions about the 
correlation between the barcode counts obtained in EGFEM1P and CUL5 
positions with their basal expression and eventually the titers resulting from the 
integration of the transfer vector. Noise discrimination experiments should be 
planned to determine its specificity, recovery rate, precision (repeatability) and 
establish a linearity range in which the method is fit for purpose. 
One of the objectives pursued with the barcode screening was the reduction of 
cell line development timelines. However, the intrinsic variability in phenotype 
(copy number and consequently GFP intensity) observed between clones after 
the genome edition process and the need for screening questions that argument. 
In that matter, the advantage of the CRISPR-Cas9 technology compared to other 
editing technologies is that several positions can be targeted at the same time in 
the event of simultaneous integration of several lentiviral components.   
A further criticism is that transcription was measured from the internal EFS 
promoter instead of the 5’LTR promoter, which might be more predictive of a 
producer cell line. To explore that possibility, the barcode should have been 
located immediately downstream of the RSV promoter, which might be 
Chapter 6. Discussion  
 270 
incompatible with the sequencing of vector-host DNA junctions for integration 
site analysis. 
Overall, despite the criticisms, the described method could represent an 
improved method of cell line development in terms of screening and 
amplification, decreasing time lines and adjusting costs. In addition, the 
application of these findings would not only be limited to seek high-producers. 
Low-producer clones could be used to identify where to integrate host-cell 
modifying enzymes that might confer a faster growth, increased protein 
production and secretion, lower rates of cell death (apoptosis resistance), 
resistance to any toxicity observed from overexpression of proteins (or viral 
vectors), serum independence or an innate resistance to bacterial or fungal 
contamination. In this way, these factors could be constitutively expressed in 
packaging cell lines at a level that is not toxic to the cells and would not reduce 
vector production. 
Viral integration and packaging/producer cell line development 
An alternative approach to the rational screening strategy described in this study 
could employ viral transduction as opposed to random transfection for the 
separate delivery of lentiviral components and has been used by several authors 
in the last years385,395,396,398,400,456,460. Separate delivery of the packaging 
constructs (gag-pol, rev, VSV-G) into the host cell line is advised to avoid 
generation of RCL. Providing that selection and screening needs to be performed 
in any case to select for successful integration events, viral delivery provides an 
efficient means of delivery and semi-random integration into actively transcribed 
regions. MOI can be adjusted if more copies of the gene are required (Figure 3.11). 
Integration profiles (alpha, gamma- lenti-), other elements (WPRE, S/MARs) as 
well as different promoters can help modulate expression of the transgene.  
In terms of envelope proteins, although an eventual lentiviral platform should be 
open to accommodate different envelope proteins, the wide usage and multiple 
advantages of VSV-G makes it a good candidate for an inducible PCL. 
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Among inducible systems, “inducer-on” present advantages over “inducer-off”  
(explained in Section 1.1.6) and in particular double switch systems such as the 
cumate switch reported by Broussau et al., have demonstrated relatively high 
titers (107 TU/mL) and sustained expression for 18 weeks. 
The delivery of the SIN lentiviral transfer vector is a more cumbersome aspect. As 
highlighted in the introduction of this study, stoichiometric limitation of transfer 
vector is a critical factor for lentiviral production776. In this study, that 
requirement was confirmed by the fact that only measurable titers from cells with 
>1 proviral copies/cell were obtained. Production of clinical grade SIN lentiviral 
transfer vectors would benefit from stable PCL that enable generation of large 
volumes of vector. Viral delivery of transfer vectors enable generation of 
populations with stable expression derived from actively transcribed sites, which 
offers advantages compared to stable transfection. However, SIN LVV cannot be 
delivered using SIN-LVV due to the inactivated U3 in the 3’LTR (one round of 
replication). Initial attempts of lentiviral delivery of transfer vectors such as Kafri 
et al., Klages et al., or Kuate et al., used non-SIN vectors tat dependent (similar to 
Ikeda et al., and Ni et al., 385,400), chimeric tat independent LTRs (HIV R and U5 and 
RSV U3/CMV promoter in 5’/3’ LTR) or LTR from other species (SIV), 
respectively398,399,459. However, mobilisation of vector into RCL in target cells 
upon delivery of gag-pol and env genes supposes a safety concern811,812. Although 
this problem was partly solved with cSIN vectors (with TRE regulatory regions in 
the 3’LTR U3 region), the genotoxicity of these vectors have not been extensively 
tested401,463. The alternative is stable co-transfection of SIN transfer vectors 
although further optimisation of the method is required and productivity drops 
40-fold385. In 2015, Sanber et al., used a two-step approach to target recombinase 
recognition sites into actively transcribed regions using viral transduction and 
subsequently induce recombination of transfected transfer vector constructs381. 
However, that strategy involves two more rounds of selection, which might delay 
production timelines.  
Delivery of full SIN vectors using SIN (non-cSIN) LVV transduction remains a 
challenge. SIN lenti-delivery of SIN vectors could provide a more efficient, stable 
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and reproducible way to increase transfer vector expression than Throm’s 
concatemeric array (currently the approach of sustained production with higher 
titers). Integration preferences of lentiviral vectors would offer a one-step delivery 
of the vector into a stable, high-expressing locus and would also meet all the safety 
requirements. The eventual design should overcome the limitations of inactivated 
vectors encountered during reverse transcription and enable two rounds of 
replication.  
The promising results of gene therapy using lentiviral vectors as a safe integrating 
transgene delivery method envisage a future requirement for larger volumes of 
vector when the treatment of diseases with increasing incidences are developed as 
commercial biopharmaceutical products. The generation of lentiviral producer cell 
lines that yield high titers is thus crucial to enable efficient, long-lasting and 
accesible therapies to the patients. 
 
  273 
References 
1. International Congress of Genetics. Proceedings of the Sixth International Congress of 
Genetics. (1932). 
2. McCarty, M. & Avery, O. T. STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE 
INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : II. EFFECT OF 
DESOXYRIBONUCLEASE ON THE BIOLOGICAL ACTIVITY OF THE TRANSFORMING 
SUBSTANCE. J. Exp. Med. 83, 89–96 (1946). 
3. WATSON, J. D. & CRICK, F. H. Genetical implications of the structure of deoxyribonucleic 
acid. Nature 171, 964–967 (1953). 
4. Franklin RE, G. R. Molecular structure of nucleic acids. Molecular configuration in sodium 
thymonucleate. Nature 171, 740–741 (1953). 
5. ZINDER, N. D. & LEDERBERG, J. Genetic exchange in Salmonella. J. Bacteriol. 64, 679–699 
(1952). 
6. Rogers, S., Lowenthal, A., Terheggen, H. G. & Columbo, J. P. Induction of arginase activity 
with the Shope papilloma virus in tissue culture cells from an argininemic patient. J. Exp. 
Med. 137, 1091–1096 (1973). 
7. Friedmann, T. & Roblin, R. Gene Therapy for Human Genetic Disease? Science 175, 949–
955 (1972). 
8. Terheggen, H. G., Lowenthal, A., Lavinha, F., Colombo, J. P. & Rogers, S. Unsuccessful trial of 
gene replacement in arginase deficiency. Z. Kinderheilkd. 119, 1–3 (1975). 
9. Graham, F. L. & van der Eb, A. J. A new technique for the assay of infectivity of human 
adenovirus 5 DNA. Virology 52, 456–467 (1973). 
10. Mulligan, R. C. & Berg, P. Selection for animal cells that express the Escherichia coli gene 
coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. U. S. A. 78, 
2072–2076 (1981). 
11. Anderson, W. F. & Fletcher, J. C. Sounding boards. Gene therapy in human beings: when is 
it ethical to begin? N. Engl. J. Med. 303, 1293–1297 (1980). 
12. Cline, M. J. et al. Gene transfer in intact animals. Nature 284, 422–425 (1980). 
13. Wade, N. UCLA gene therapy racked by friendly fire. Science (New York, N.Y.) 210, 509–511 
(1980). 
14. Wade, N. Gene therapy caught in more entanglements. Science (New York, N.Y.) 212, 24–25 
(1981). 
15. Baltimore, D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 
226, 1209–1211 (1970). 
16. Temin, H. M. & Mizutani, S. RNA-dependent DNA polymerase in virions of Rous sarcoma 
virus. Nature 226, 1211–1213 (1970). 
17. Willis, R. C. et al. Partial phenotypic correction of human Lesch-Nyhan (hypoxanthine-
guanine phosphoribosyltransferase-deficient) lymphoblasts with a transmissible 
retroviral vector. J. Biol. Chem. 259, 7842–7849 (1984). 
18. Miller, A. D., Jolly, D. J., Friedmann, T. & Verma, I. M. A transmissible retrovirus expressing 
human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells 
obtained from humans deficient in HPRT. Proc. Natl. Acad. Sci. U. S. A. 80, 4709–4713 
(1983). 
19. Kantoff, P. W. et al. Correction of adenosine deaminase deficiency in cultured human T and 
B cells by retrovirus-mediated gene transfer. Proc. Natl. Acad. Sci. U. S. A. 83, 6563–6567 
(1986). 
20. Rosenberg, S. A. et al. Gene transfer into humans--immunotherapy of patients with 
advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene 
transduction. N. Engl. J. Med. 323, 570–578 (1990). 
21. Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results 
after 4 years. Science (New York, N.Y.) 270, (1995). 
22. Bordignon, C. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for 
ADA- immunodeficient patients. Science 270, 470–475 (1995). 
23. Fox, J. L. Gene-therapy death prompts broad civil lawsuit. Nature biotechnology 18, 1136 
(2000). 
24. Hacein-Bey-Abina, S. et al. Efficacy of gene therapy for X-linked severe combined 
immunodeficiency. N. Engl. J. Med. 363, 355–364 (2010). 
  274 
25. Gaspar, H. B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of 
a pseudotyped gammaretroviral vector. Lancet (London, England) 364, 2181–2187 
(2004). 
26. Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with 
nonmyeloablative conditioning. Science 296, 2410–2413 (2002). 
27. Aiuti, A. et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. 
The New England journal of medicine 360, (2009). 
28. Gaspar, H. B. et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene 
therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 14, 
505–513 (2006). 
29. Ott, M. G. et al. Correction of X-linked chronic granulomatous disease by gene therapy, 
augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 
401–409 (2006). 
30. Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked 
adrenoleukodystrophy. Science 326, 818–823 (2009). 
31. Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-
Aldrich syndrome. Science 341, 1233151 (2013). 
32. Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic 
leukodystrophy. Science 341, 1233158 (2013). 
33. Bartus, R. T., Weinberg, M. S. & Samulski, R. J. Parkinson’s disease gene therapy: success by 
design meets failure by efficacy. Mol. Ther. 22, 487–97 (2014). 
34. Schimmer, J. & Breazzano, S. Investor Outlook: Rising from the Ashes; GSK’s European 
Approval of Strimvelis for ADA-SCID. Hum. Gene Ther. Clin. Dev. 27, 57–61 (2016). 
35. Deev, R. V et al. pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of 
Treatment for  Patients With Chronic Lower Limb Ischemia. J. Cardiovasc. Pharmacol. Ther. 
20, 473–482 (2015). 
36. Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555 (2014). 
37. Putnam, D. Polymers for gene delivery across length scales. Nat. Mater. 5, 439–451 (2006). 
38. Yeh, P. & Perricaudet, M. Advances in adenoviral vectors: from genetic engineering to their 
biology. FASEB J. 11, 615–623 (1997). 
39. Raper, S. E. et al. Developing adenoviral-mediated in vivo gene therapy for ornithine 
transcarbamylase deficiency. in Journal of Inherited Metabolic Disease 21, 119–137 (1998). 
40. Kim, M. Replicating poxviruses for human cancer therapy. J. Microbiol. 53, 209–218 (2015). 
41. Breitbach, C. J., Thorne, S. H., Bell, J. C. & Kirn, D. H. Targeted and armed oncolytic 
poxviruses for cancer: the lead example of JX-594. Curr. Pharm. Biotechnol. 13, 1768–1772 
(2012). 
42. Boehmer, P. E. & Lehman, I. R. Herpes simplex virus DNA replication. Annu. Rev. Biochem. 
66, 347–384 (1997). 
43. Miller, A. D. Identi cation and Elimination of Replication-Competent Adeno-Associated 
Virus (AAV) That Can Arise by Nonhomologous Recombination during AAV Vector 
Production. Microbiology 71, 6816–6822 (1997). 
44. Flotte, T. R. et al. Phase I trial of intranasal and endobronchial administration of a 
recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis 
patients: a two-part clinical study. Human gene therapy 14, (2003). 
45. Simonelli, F. et al. Gene therapy for Leber’s congenital amaurosis is safe and effective through 
1.5 years after vector administration. Molecular therapy : the journal of the American Society 
of Gene Therapy 18, (2010). 
46. MacLaren, R. E. et al. Retinal gene therapy in patients with choroideremia: initial findings 
from a phase 1/2 clinical trial. Lancet 383, 1129–37 (2014). 
47. Hasbrouck, N. C. & High, K. A. AAV-mediated gene transfer for the treatment of hemophilia 
B: problems and prospects. Gene Ther. 15, 870–875 (2008). 
48. Louis Jeune, V., Joergensen, J. A., Hajjar, R. J. & Weber, T. Pre-existing anti-adeno-associated 
virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67 
(2013). 
49. Nault, J.-C. et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular 
carcinomas. Nat. Genet. 47, 1–15 (2015). 
50. Kraunus, J. et al. Murine leukemia virus regulates alternative splicing through sequences 
upstream of the 5??? splice site. J. Biol. Chem. 281, 37381–37390 (2006). 
  275 
51. Pessel-Vivares, L., Houzet, L., Laine , S. & Mougel, M. Insights into the nuclear export of 
murine leukemia virus intron-containing RNA. RNA Biol. 12, 942–9 (2015). 
52. Cavazza, A., Moiani, A. & Mavilio, F. Mechanisms of retroviral integration and mutagenesis. 
Hum. Gene Ther. 24, 119–31 (2013). 
53. Li, C. L., Xiong, D., Stamatoyannopoulos, G. & Emery, D. W. Genomic and functional assays 
demonstrate reduced gammaretroviral vector genotoxicity associated with use of the 
cHS4 chromatin insulator. Mol. Ther. 17, 716–724 (2009). 
54. Meiering, C. D. & Linial, M. L. Historical perspective of foamy virus epidemiology and 
infection. Clin. Microbiol. Rev. 14, 165–76 (2001). 
55. Jackson, D. L., Lee, E.-G. & Linial, M. L. Expression of prototype foamy virus pol as a Gag-
Pol fusion protein does not change the timing of reverse transcription. J. Virol. 87, 1252–4 
(2013). 
56. Trobridge, G. & Russell, D. W. Cell cycle requirements for transduction by foamy virus 
vectors compared to those of oncovirus and lentivirus vectors. J. Virol. 78, 2327–35 (2004). 
57. Bodem, J., Schied, T., Gabriel, R., Rammling, M. & Rethwilm, A. Foamy virus nuclear RNA 
export is distinct from that of other retroviruses. J Virol 85, 2333–2341 (2011). 
58. Lo chelt, M. et al. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus 
accessory Bet protein. Proc. Natl. Acad. Sci. U. S. A. 102, 7982–7 (2005). 
59. Venkatesh, L. K., Theodorakis, P. A. & Chinnadurai, G. Distinct cis-acting regions in U3 
regulate trans-activation of the human spumaretrovirus long terminal repeat by the viral 
bel1 gene product. Nucleic Acids Res. 19, 3661–3666 (1991). 
60. Olszko, M. E. & Trobridge, G. D. Foamy virus vectors for HIV gene therapy. Viruses 5, 2585–
600 (2013). 
61. Trobridge, G., Josephson, N., Vassilopoulos, G., Mac, J. & Russell, D. W. Improved foamy virus 
vectors with minimal viral sequences. Mol.Ther 6, 321–328 (2002). 
62. Suerth, J. D., Maetzig, T., Galla, M., Baum, C. & Schambach, A. Self-inactivating 
alpharetroviral vectors with a split-packaging design. J. Virol. 84, 6626–35 (2010). 
63. Stewart, H. J., Leroux-Carlucci, M. a, Sion, C. J. M., Mitrophanous, K. a & Radcliffe, P. a. 
Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. 
Gene Ther. 16, 805–814 (2009). 
64. Leroux, C., Cadore , J. L. & Montelaro, R. C. Equine Infectious Anemia Virus (EIAV): What 
has HIV’s country cousin got tell us? Veterinary Research 35, 485–512 (2004). 
65. Shimojima, M. et al. Use of CD134 as a primary receptor by the feline immunodeficiency 
virus. Science 303, 1192–5 (2004). 
66. Oberste, M. S., Greenwood, J. D. & Gonda, M. A. Analysis of the transcription pattern and 
mapping of the putative rev and env splice junctions of bovine immunodeficiency-like 
virus. J Virol 65, 3932–7. (1991). 
67. Dietrich, I. et al. Feline tetherin efficiently restricts release of feline immunodeficiency 
virus but not spreading of infection. J. Virol. 85, 5840–5852 (2011). 
68. De Rijck, J. & Debyser, Z. The central DNA flap of the human immunodeficiency virus type 
1 is important for viral replication. Biochem. Biophys. Res. Commun. 349, 1100–1110 
(2006). 
69. Mamede, J. I., Sitbon, M., Battini, J.-L. & Courgnaud, V. Heterogeneous susceptibility of 
circulating SIV isolate capsids to HIV-interacting factors. Retrovirology 10, p1–15. 15p. 
(2013). 
70. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a 
lentiviral vector. Science 272, 263–7 (1996). 
71. Naldini, L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. 
Opin. Biotechnol. 9, 457–63 (1998). 
72. Coffin, J. M., Hughes, S. H. & Varmus, H. E. in Retroviruses (1997). 
73. Huthoff, H., Bugala, K., Barciszewski, J. & Berkhout, B. On the importance of the primer 
activation signal for initiation of tRNA(lys3)-primed reverse transcription of the HIV-1 
RNA genome. Nucleic Acids Res. 31, 5186–94 (2003). 
74. Verma, I. M., Meuth, N. L., Bromfeld, E., Manly, K. F. & Baltimore, D. Covalently linked RNA-
DNA molecule as initial product of RNA tumour virus DNA polymerase. Nat. New Biol. 233, 
131–4 (1971). 
75. Dahlberg, J. E. et al. Transcription of DNA from the 70S RNA of Rous sarcoma virus. I. 
Identification of a specific 4S RNA which serves as primer. J. Virol. 13, 1126–1133 (1974). 
  276 
76. Mann, R. & Baltimore, D. Varying the position of a retrovirus packaging sequence results 
in the encapsidation of both unspliced and spliced RNAs. J. Virol. 54, 401–7 (1985). 
77. Charneau, P. et al. HIV-1 reverse transcription. A termination step at the center of the 
genome. Journal of molecular biology 241, 651–662 (1994). 
78. Finston, W. I. & Champoux, J. J. RNA-primed initiation of Moloney murine leukemia virus 
plus strands by reverse transcriptase in vitro. J. Virol. 51, 26–33 (1984). 
79. Emerman, M. & Malim, M. H. HIV-1 regulatory/accessory genes: keys to unraveling viral 
and host cell biology. Science 280, 1880–4 (1998). 
80. Frankel, A. D. & Young, J. A. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67, 1–
25 (1998). 
81. Zhou, M. et al. The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal 
domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc. Natl. Acad. Sci. U. S. A. 
100, 12666–71 (2003). 
82. Varmus H, S. R. Replication of retroviruses. Tumour Viruses: Molecular Biology of Tumor 
Viruses. (Cold Spring Harbor Laboratory, 1984). 
83. Van Lint, C., Bouchat, S. & Marcello, A. HIV-1 transcription and latency: an update. 
Retrovirology 10, 67 (2013). 
84. Pierson, T. C. et al. Molecular Characterization of Preintegration Latency in Human 
Immunodeficiency Virus Type 1 Infection. J. Virol. 76, 8518–8531 (2002). 
85. Mbonye, U. & Karn, J. Control of HIV latency by epigenetic and non-epigenetic mechanisms. 
Curr. HIV Res. 9, 554–67 (2011). 
86. Gilmartin, G. M., Fleming, E. S., Oetjen, J. & Graveley, B. R. CPSF recognition of an HIV-1 
mRNA 3′-processing enhancer: Multiple sequence contacts involved in poly(A) site 
definition. Genes Dev. 9, 72–83 (1995). 
87. Das, A. T., Klaver, B. & Berkhout, B. A hairpin structure in the R region of the human 
immunodeficiency virus type 1 RNA genome is instrumental in polyadenylation site 
selection. J Virol 73, 81–91 (1999). 
88. Ashe, M. P., Furger, A. & Proudfoot, N. J. Stem-loop 1 of the U1 snRNP plays a critical role in 
the suppression of HIV-1 polyadenylation. RNA 6, 170–7 (2000). 
89. Cullen, B. R. Mechanism of action of regulatory proteins encoded by complex retroviruses. 
Microbiol. Rev. 56, 375–394 (1992). 
90. Cullen, B. R. Nuclear mRNA export: insights from virology. Trends Biochem. Sci. 28, 419–24 
(2003). 
91. Fritz, C. C. & Green, M. R. HIV Rev uses a conserved cellular protein export pathway for the 
nucleocytoplasmic transport of viral RNAs. Curr. Biol. 6, 848–54 (1996). 
92. Elfgang, C. et al. Evidence for specific nucleocytoplasmic transport pathways used by 
leucine-rich nuclear export signals. Proc. Natl. Acad. Sci. U. S. A. 96, 6229–34 (1999). 
93. Malim, M. H., Hauber, J., Le, S. Y., Maizel, J. V & Cullen, B. R. The HIV-1 rev trans-activator 
acts through a structured target sequence to activate nuclear export of unspliced viral 
mRNA. Nature 338, 254–257 (1989). 
94. Jackson, R. J., Hellen, C. U. T. & Pestova, T. V. The mechanism of eukaryotic translation 
initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 11, 113–127 (2010). 
95. Chamond, N., Locker, N. & Sargueil, B. The different pathways of HIV genomic RNA 
translation. Biochem. Soc. Trans. 38, 1548–52 (2010). 
96. de Breyne, S., Soto-Rifo, R., Lo pez-Lastra, M. & Ohlmann, T. Translation initiation is driven 
by different mechanisms on the HIV-1 and HIV-2 genomic RNAs. Virus Research (2012). 
doi:10.1016/j.virusres.2012.10.006 
97. Willey, R. L., Shibata, R., Freed, E. O., Cho, M. W. & Martin, M. A. Differential glycosylation, 
virion incorporation, and sensitivity to neutralizing antibodies of human 
immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte 
and macrophage cultures. J. Virol. 70, 6431–6 (1996). 
98. Brierley, I. & Dos Ramos, F. J. Programmed ribosomal frameshifting in HIV-1 and the SARS-
CoV. Virus Res. 119, 29–42 (2006). 
99. Cassan, M., Delaunay, N., Vaquero, C. & Rousset, J. P. Translational frameshifting at the gag-
pol junction of human immunodeficiency virus type 1 is not increased in infected T-
lymphoid cells. J. Virol. 68, 1501–1508 (1994). 
100. Shehu-xhilaga, M. & Crowe, S. M. Maintenance of the Gag / Gag-Pol Ratio Is Important for 
Human Immunodeficiency Virus Type 1 RNA Dimerization and Viral Infectivity. 75, 1834–
  277 
1841 (2001). 
101. Miller, J. H., Presnyak, V. & Smith, H. C. The dimerization domain of HIV-1 viral infectivity 
factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4, 81 
(2007). 
102. Fujita, M., Nomaguchi, M., Adachi, A. & Otsuka, M. SAMHD1-Dependent and -Independent 
Functions of HIV-2/SIV Vpx Protein. Front. Microbiol. 3, 297 (2012). 
103. Bukrinsky, M. & Adzhubei, A. Viral protein R of HIV-1. Rev. Med. Virol. 9, 39–49 
104. Bour, S., Schubert, U. & Strebel, K. The human immunodeficiency virus type 1 Vpu protein 
specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of 
degradation. J. Virol. 69, 1510–20 (1995). 
105. Das, S. R. & Jameel, S. Biology of the HIV Nef protein. Indian Journal of Medical Research 
121, 315–332 (2005). 
106. Douglas, J. L. et al. Vpu directs the degradation of the human immunodeficiency virus 
restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 83, 
7931–47 (2009). 
107. Ivanchenko, S. et al. Dynamics of HIV-1 assembly and release. PLoS Pathog. 5, (2009). 
108. Go ttlinger, H. G., Sodroski, J. G. & Haseltine, W. a. Role of capsid precursor processing and 
myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 
1. Proc. Natl. Acad. Sci. U. S. A. 86, 5781–5785 (1989). 
109. Jin, J., Sturgeon, T., Weisz, O. A., Mothes, W. & Montelaro, R. C. HIV-1 matrix dependent 
membrane targeting is regulated by Gag mRNA trafficking. PLoS One 4, (2009). 
110. Sundquist, W. I. & Kra usslich, H. G. HIV-1 assembly, budding, and maturation. Cold Spring 
Harbor Perspectives in Medicine 2, (2012). 
111. Bryant, M. & Ratner, L. Myristoylation-dependent replication and assembly of human 
immunodeficiency virus 1. Proc. Natl. Acad. Sci. U. S. A. 87, 523–7 (1990). 
112. Huang, Y. et al. Incorporation of excess wild-type and mutant tRNA(3Lys) into human 
immunodeficiency virus type 1. J. Virol. 68, 7676–83 (1994). 
113. Cen, S. et al. Retrovirus-specific packaging of aminoacyl-tRNA synthetases with cognate 
primer tRNAs. J. Virol. 76, 13111–5 (2002). 
114. Paxton, W., Connor, R. I. & Landau, N. R. Incorporation of Vpr into human 
immunodeficiency virus type 1 virions: requirement for the p6 region of gag and 
mutational analysis. J. Virol. 67, 7229–37 (1993). 
115. Abeydeera, N. D. et al. Evoking picomolar binding in RNA by a single phosphorodithioate 
linkage. Nucleic Acids Res. 44, 8052–8064 (2016). 
116. Wyatt, R. T. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and 
immunogens. Science (80-. ). 280, 1884–1888 (1998). 
117. Arthos, J. et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, 
the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301–309 (2008). 
118. Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that 
enhances trans-infection of T cells. Cell 100, 587–97 (2000). 
119. Chen, B. et al. Structure of an unliganded simian immunodeficiency virus gp120 core. 
Nature 433, 834–841 (2005). 
120. Rizzuto, C. D. et al. A conserved HIV gp120 glycoprotein structure involved in chemokine 
receptor binding. Science 280, 1949–1953 (1998). 
121. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope 
glycoprotein. Cell 89, 263–73 (1997). 
122. Fassati, A. & Goff, S. P. Characterization of intracellular reverse transcription complexes of 
human immunodeficiency virus type 1. J. Virol. 75, 3626–35 (2001). 
123. Hulme, A. E., Perez, O. & Hope, T. J. Complementary assays reveal a relationship between 
HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. U. S. A. 108, 9975–80 
(2011). 
124. Rasaiyaah, J. et al. HIV-1 evades innate immune recognition through specific cofactor 
recruitment. Nature 503, 402–5 (2013). 
125. Lahaye, X. et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral 
cDNA by the innate sensor cGAS in dendritic cells. Immunity 39, 1132–42 (2013). 
126. Peng, K. et al. Quantitative microscopy of functional HIV post-entry complexes reveals 
association of replication with the viral capsid. Elife 3, e04114 (2014). 
127. Hatziioannou, T., Perez-Caballero, D., Cowan, S. & Bieniasz, P. D. Cyclophilin interactions 
  278 
with incoming human immunodeficiency virus type 1 capsids with opposing effects on 
infectivity in human cells. J. Virol. 79, 176–83 (2005). 
128. Lukacs, G. L. et al. Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 
275, 1625–1629 (2000). 
129. Vaughan, J. C., Brandenburg, B., Hogle, J. M. & Zhuang, X. Rapid actin-dependent viral 
motility in live cells. Biophys. J. 97, 1647–1656 (2009). 
130. McDonald, D. et al. Visualization of the intracellular behavior of HIV in living cells. J. Cell 
Biol. 159, 441–52 (2002). 
131. Suikkanen, S. et al. Exploitation of microtubule cytoskeleton and dynein during parvoviral 
traffic toward the nucleus. J. Virol. 77, 10270–9 (2003). 
132. Ward, B. M. Visualization and characterization of the intracellular movement of vaccinia 
virus intracellular mature virions. J. Virol. 79, 4755–63 (2005). 
133. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. Crystal structure at 3.5 
A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (80-. ). 
256, 1783–1790 (1992). 
134. Telesnitsky, A. & Goff, S. P. Two defective forms of reverse transcriptase can complement 
to restore retroviral infectivity. EMBO J 12, 4433–4438 (1993). 
135. Hu, W.-S. & Hughes, S. H. HIV-1 reverse transcription. Cold Spring Harb. Perspect. Med. 2, 
a006882- (2012). 
136. Kovaleski, B. J. et al. In vitro characterization of the interaction between HIV-1 Gag and 
human Lysyl-tRNA synthetase. J. Biol. Chem. 281, 19449–19456 (2006). 
137. Fuentes, G. M., Rodriguez-Rodriguez, L., Fay, P. J. & Bambara, R. A. Use of an 
oligoribonucleotide containing the polypurine tract sequence as a primer by HIV reverse 
transcriptase. J. Biol. Chem. 270, 28169–28176 (1995). 
138. Smith, C. M., Potts, W. B., Smith, J. S. & Roth, M. J. RNase H cleavage of tRNAPro mediated 
by M-MuLV and HIV-1 reverse transcriptases. Virology 229, 437–46 (1997). 
139. Shaharabany, M., Rice, N. R. & Hizi, A. Expression and mutational analysis of the reverse 
transcriptase of the lentivirus equine infectious anemia virus. Biochem Biophys Res 
Commun 196, 914–920 (1993). 
140. Renda, M. J. et al. Mutation of the methylated tRNA(Lys)(3) residue A58 disrupts reverse 
transcription and inhibits replication of human immunodeficiency virus type 1. J. Virol. 75, 
9671–8 (2001). 
141. Woodward, C. L., Prakobwanakit, S., Mosessian, S. & Chow, S. a. Integrase interacts with 
nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus 
type 1. J. Virol. 83, 6522–6533 (2009). 
142. Bouyac-Bertoia, M. et al. HIV-1 Infection Requires a Functional Integrase NLS. Mol. Cell 7, 
1025–1035 (2001). 
143. Jenkins, Y., McEntee, M., Weis, K. & Greene, W. C. Characterization of HIV-1 Vpr nuclear 
import: Analysis of signals and pathways. J. Cell Biol. 143, 875–885 (1998). 
144. Haffar, O. K. et al. Two nuclear localization signals in the HIV-1 matrix protein regulate 
nuclear import of the HIV-1 pre-integration complex. J. Mol. Biol. 299, 359–68 (2000). 
145. Zennou, V. et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 
173–185 (2000). 
146. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. 
Virol. 72, 8463–8471 (1998). 
147. Rivie re, L., Darlix, J.-L. & Cimarelli, A. Analysis of the viral elements required in the nuclear 
import of HIV-1 DNA. J. Virol. 84, 729–39 (2010). 
148. Yamashita, M. & Emerman, M. The cell cycle independence of HIV infections is not 
determined by known karyophilic viral elements. PLoS Pathog. 1, 0170–0178 (2005). 
149. Yamashita, M. & Emerman, M. Capsid Is a Dominant Determinant of Retrovirus Infectivity 
in Nondividing Cells. J. Virol. 78, 5670–5678 (2004). 
150. Krishnan, L. et al. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during 
infection maps to human immunodeficiency virus type 1 capsid and not integrase. J. Virol. 
84, 397–406 (2010). 
151. Yamashita, M., Perez, O., Hope, T. J. & Emerman, M. Evidence for direct involvement of the 
capsid protein in HIV infection of nondividing cells. PLoS Pathog. 3, 1502–1510 (2007). 
152. Gallay, P., Stitt, V., Mundy, C., Oettinger, M. & Trono, D. Role of the karyopherin pathway in 
human immunodeficiency virus type 1 nuclear import. J. Virol. 70, 1027–32 (1996). 
  279 
153. Zaitseva, L. et al. HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome. 
Retrovirology 6, 11 (2009). 
154. Christ, F. et al. Transportin-SR2 Imports HIV into the Nucleus. Curr. Biol. 18, 1192–1202 
(2008). 
155. Schaller, T. et al. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, 
integration targeting and replication efficiency. PLoS Pathog. 7, (2011). 
156. Zhang, Z. H. et al. A comparative study of techniques for differential expression analysis on 
RNA-seq data. PLoS One 9, (2014). 
157. Ocwieja, K. E. et al. HIV integration targeting: A pathway involving transportin-3 and the 
nuclear pore protein RanBP2. PLoS Pathog. 7, (2011). 
158. Engelman, A. & Cherepanov, P. The structural biology of HIV-1: mechanistic and 
therapeutic insights. Nat. Rev. Microbiol. 10, 279–290 (2012). 
159. Fitzgerald, M. L., Vora,  a C., Zeh, W. G. & Grandgenett, D. P. Concerted integration of viral 
DNA termini by purified avian myeloblastosis virus integrase. J. Virol. 66, 6257–6263 
(1992). 
160. Quinn, T. P. & Grandgenett, D. P. Genetic evidence that the avian retrovirus DNA 
endonuclease domain of pol is necessary for viral integration. J. Virol. 62, 2307–2312 
(1988). 
161. Schiff, R. D. & Grandgenett, D. P. Virus-coded origin of a 32,000-dalton protein from avian 
retrovirus cores: structural relatedness of p32 and the beta polypeptide of the avian 
retrovirus DNA polymerase. J. Virol. 28, 279–291 (1978). 
162. Rice, P., Craigie, R. & Davies, D. R. Retroviral integrases and their cousins. Current Opinion 
in Structural Biology 6, 76–83 (1996). 
163. Eijkelenboom, A. P. et al. The solution structure of the amino-terminal HHCC domain of 
HIV-2 integrase: a three-helix bundle stabilized by zinc. Curr. Biol. 7, 739–746 (1997). 
164. Cai, M. et al. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase 
[published erratum appears in Nat Struct Biol 1997 Oct;4(10):839-40]. Nat. Struct. Biol. 
42854, 567–577 (1997). 
165. Dyda, F. et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to 
other polynucleotidyl transferases. Science 266, 1981–1986 (1994). 
166. Kulkosky, J., Jones, K. S., Katz, R. A., Mack, J. P. & Skalka, A. M. Residues critical for retroviral 
integrative recombination in a region that is highly conserved among 
retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol. 
Cell. Biol. 12, 2331–2338 (1992). 
167. Calmels, C. et al. Biochemical and random mutagenesis analysis of the region carrying the 
catalytic E152 amino acid of HIV-1 integrase. Nucleic Acids Res. 32, 1527–1538 (2004). 
168. Lodi, P. J. et al. Solution structure of the DNA binding domain of HIV-1 integrase. 
Biochemistry 34, 9826–9833 (1995). 
169. Eijkelenboom, A. P. et al. The DNA-binding domain of HIV-1 integrase has an SH3-like fold. 
Nat. Struct. Biol. 2, 807–810 (1995). 
170. van Gent, D. C., Vink, C., Groeneger, A. A. & Plasterk, R. H. Complementation between HIV 
integrase proteins mutated in different domains. EMBO J. 12, 3261–7 (1993). 
171. Engelman, A., Bushman, F. D. & Craigie, R. Identification of discrete functional domains of 
HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 12, 
3269–75 (1993). 
172. Maertens, G. N., Hare, S. & Cherepanov, P. The mechanism of retroviral integration from X-
ray structures of its key intermediates. Nature 468, 326–9 (2010). 
173. Bukrinsky, M. I. et al. Association of integrase, matrix, and reverse transcriptase antigens 
of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. 
Proc. Natl. Acad. Sci. U. S. A. 90, 6125–6129 (1993). 
174. Lee, Y. M. & Coffin, J. M. Relationship of avian retrovirus DNA synthesis to integration in 
vitro. Mol. Cell. Biol. 11, 1419–1430 (1991). 
175. Lapadat-tapolsky, M. et al. Interactions between HIV-1 nucleocapsid protein and viral DNA 
may have important functions in the viral life cycle. Nucleic Acids Research 21, 2024 
(1993). 
176. Lee, M. S. & Craigie, R. Protection of retroviral DNA from autointegration: involvement of a 
cellular factor. Proc. Natl. Acad. Sci. U. S. A. 91, 9823–9827 (1994). 
177. Farnet, C. M. & Bushman, F. D. HIV-1 cDNA integration: Requirement of HMG I(Y) protein 
  280 
for function of preintegration complexes in vitro. Cell 88, 483–492 (1997). 
178. Farnet, C. M. & Haseltine, W. A. Integration of human immunodeficiency virus type 1 DNA 
in vitro. Proc Natl Acad Sci U S A 87, 4164–4168 (1990). 
179. Brown, P. O., Bowerman, B., Varmus, H. E. & Bishop, J. M. Correct integration of retroviral 
DNA in vitro. Cell 49, 347–356 (1987). 
180. Bushman, F. D. & Craigie, R. Activities of human immunodeficiency virus (HIV) integration 
protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. U. S. A. 
88, 1339–1343 (1991). 
181. Katzman, M., Katz, R. A., Skalka, A. M. & Leis, J. The avian retroviral integration protein 
cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration. J. Virol. 
63, 5319–5327 (1989). 
182. Sherman, P. A. & Fyfe, J. A. Human immunodeficiency virus integration protein expressed 
in Escherichia coli possesses selective DNA cleaving activity. Proc. Natl. Acad. Sci. U. S. A. 
87, 5119–5123 (1990). 
183. Farnet, C. M. & Haseltine, W. A. Determination of viral proteins present in the human 
immunodeficiency virus type 1 preintegration complex. J. Virol. 65, 1910–1915 (1991). 
184. Katz, R. A., Gravuer, K. & Skalka, A. M. A preferred target DNA structure for retroviral 
integrase in vitro. J. Biol. Chem. 273, 24190–24195 (1998). 
185. Bor, Y. C., Miller, M. D., Bushman, F. D. & Orgel, L. E. Target-sequence preferences of HIV-1 
integration complexes in vitro. Virology 222, 283–288 (1996). 
186. Fujiwara, T. & Craigie, R. Integration of mini-retroviral DNA: a cell-free reaction for 
biochemical analysis of retroviral integration. Proc. Natl. Acad. Sci. U. S. A. 86, 3065–3069 
(1989). 
187. Kukolj, G., Katz, R. A. & Skalka, A. M. Characterization of the nuclear localization signal in 
the avian sarcoma virus integrase. Gene 223, 157–163 (1998). 
188. von Schwedler, U., Kornbluth, R. S. & Trono, D. The nuclear localization signal of the matrix 
protein of human immunodeficiency virus type 1 allows the establishment of infection in 
macrophages and quiescent T lymphocytes. Proc.Natl.Acad.Sci. 91, 6992–6996 (1994). 
189. Lobel, L. I., Murphy, J. E. & Goff, S. P. The palindromic LTR-LTR junction of Moloney murine 
leukemia virus is not an efficient substrate for proviral integration. J. Virol. 63, 2629–2637 
(1989). 
190. Misra, T. K., Grandgenett, D. P. & Parsons, J. T. Avian retrovirus pp32 DNA-binding protein. 
I. Recognition of specific sequences on retrovirus DNA terminal repeats. J. Virol. 44, 330–
343 (1982). 
191. Knaus, R. J. et al. Avian retrovirus pp32 DNA binding protein. Preferential binding to the 
promoter region of long terminal repeat DNA. Biochemistry 23, 350–359 (1984). 
192. Heuer, T. S. & Brown, P. O. Photo-cross-linking studies suggest a model for the architecture 
of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 
37, 6667–6678 (1998). 
193. Colicelli, J. & Goff, S. P. Sequence and spacing requirements of a retrovirus integration site. 
J. Mol. Biol. 199, 47–59 (1988). 
194. Duyk, G., Leis, J., Longiaru, M. & Skalka, A. M. Selective cleavage in the avian retroviral long 
terminal repeat sequence by the endonuclease associated with the alpha beta form of 
avian reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 80, 6745–6749 (1983). 
195. Farnet, C. M. & Haseltine, W. A. Circularization of human immunodeficiency virus type 1 
DNA in vitro. J. Virol. 65, 6942–6952 (1991). 
196. Engelman, A., Mizuuchi, K. & Craigie, R. HIV-1 DNA integration: mechanism of viral DNA 
cleavage and DNA strand transfer. Cell 67, 1211–1221 (1991). 
197. Vink, C., van Gent, D. C., Elgersma, Y. & Plasterk, R. H. Human immunodeficiency virus 
integrase protein requires a subterminal position of its viral DNA recognition sequence for 
efficient cleavage. J. Virol. 65, 4636–4644 (1991). 
198. Patel, P. H. & Preston, B. D. Marked infidelity of human immunodeficiency virus type 1 
reverse transcriptase at RNA and DNA template ends. Proc. Natl. Acad. Sci. U. S. A. 91, 549–
553 (1994). 
199. Ellison, V. & Brown, P. O. A stable complex between integrase and viral DNA ends mediates 
human immunodeficiency virus integration in vitro. Proc. Natl. Acad. Sci. U. S. A. 91, 7316–
7320 (1994). 
200. Li, L. et al. Role of the non-homologous DNA end joining pathway in the early steps of 
  281 
retroviral infection. EMBO J. 20, 3272–3281 (2001). 
201. Junghans, R. P., Boone, L. R. & Skalka,  a M. Products of reverse transcription in avian 
retrovirus analyzed by electron microscopy. J. Virol. 43, 544–554 (1982). 
202. Kilzer, J. M. et al. Roles of host cell factors in circularization of retroviral DNA. Virology 314, 
460–467 (2003). 
203. Lee, M. S. & Craigie, R. A previously unidentified host protein protects retroviral DNA from 
autointegration. Proc. Natl. Acad. Sci. U. S. A. 95, 1528–1533 (1998). 
204. Panet, A. & Cedar, H. Selective degradation of integrated murine leukemia proviral DNA by 
deoxyribonucleases. Cell 11, 933–940 (1977). 
205. Vijaya, S., Steffen, D. L. & Robinson, H. L. Acceptor sites for retroviral integrations map near 
DNase I-hypersensitive sites in chromatin. J. Virol. 60, 683–692 (1986). 
206. Rohdewohld, H., Weiher, H., Reik, W., Jaenisch, R. & Breindl, M. Retrovirus integration and 
chromatin structure: Moloney murine leukemia proviral integration sites map near DNase 
I-hypersensitive sites. J. Virol. 61, 336–343 (1987). 
207. Marini, B. et al. Nuclear architecture dictates HIV-1 integration site selection. Nature 
(2015). doi:10.1038/nature14226 
208. Chubb, J. R. & Bickmore, W. A. Considering nuclear compartmentalization in the light of 
nuclear dynamics. Cell 112, 403–406 (2003). 
209. Bushman, F. D. & Miller, M. D. Tethering human immunodeficiency virus type 1 
preintegration complexes to target DNA promotes integration at nearby sites. J. Virol. 71, 
458–464 (1997). 
210. Ciuffi, A. et al. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 11, 1287–
1289 (2005). 
211. Brady, T. et al. Quantitation of HIV DNA integration: effects of differential integration site 
distributions on Alu-PCR assays. J. Virol. Methods 189, 53–7 (2013). 
212. Serrao, E. et al. Integrase residues that determine nucleotide preferences at sites of HIV-1 
integration: Implications for the mechanism of target DNA binding. Nucleic Acids Res. 42, 
5164–5176 (2014). 
213. Withers-Ward, E. S., Kitamura, Y., Barnes, J. P. & Coffin, J. M. Distribution of targets for avian 
retrovirus DNA integration in vivo. Genes Dev. 8, 1473–1487 (1994). 
214. Shih, C. C., Stoye, J. P. & Coffin, J. M. Highly preferred targets for retrovirus integration. Cell 
53, 531–537 (1988). 
215. Pryciak, P. M. & Varmus, H. E. Nucleosomes, DNA-binding proteins, and DNA sequence 
modulate retroviral integration target site selection. Cell 69, 769–780 (1992). 
216. Alexander G. Holman and John M. Coffin. Symmetrical base preferences surrounding HIV-
1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. 102, 6103–
6107 (2005). 
217. Sna sel, J., Rosenberg, I., Paces, O. & Pichova , I. Mapping of HIV-1 integrase preferences for 
target site selection with various oligonucleotides. Arch. Biochem. Biophys. 488, 153–62 
(2009). 
218. Jiang, C. & Pugh, B. F. Nucleosome positioning and gene regulation: advances through 
genomics. Nat. Rev. Genet. 10, 161–172 (2009). 
219. Osipov, S. A., Preobrazhenskaia, O. V & Karpov, V. L. [Chromatin structure and transcription 
regulation in Saccharomyces cerevisiae]. Mol Biol 44, 966–979 (2010). 
220. Schones, D. E. et al. Dynamic regulation of nucleosome positioning in the human genome. 
Cell 132, 887–898 (2008). 
221. Segal, E. et al. A genomic code for nucleosome positioning. Nature 442, 772–778 (2006). 
222. Pruss, D., Bushman, F. D. & Wolffe, A. P. Human immunodeficiency virus integrase directs 
integration to sites of severe DNA distortion within the nucleosome core. Proc. Natl. Acad. 
Sci. U. S. A. 91, 5913–5917 (1994). 
223. Mu ller, H. P. & Varmus, H. E. DNA bending creates favored sites for retroviral integration: 
an explanation for preferred insertion sites in nucleosomes. EMBO J. 13, 4704–4714 
(1994). 
224. Pruss, D., Reeves, R., Bushman, F. D. & Wolffe, A. P. The influence of DNA and nucleosome 
structure on integration events directed by HIV integrase. J. Biol. Chem. 269, 25031–25041 
(1994). 
225. Wang, G. P. et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving 
autologous infusions of gene modified CD4+ T cells. Mol. Ther. 17, 844–850 (2009). 
  282 
226. Wang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C. & Bushman, F. D. HIV integration site selection: 
Analysis by massively parallel pyrosequencing reveals association with epigenetic 
modifications. Genome Res. 17, 1186–1194 (2007). 
227. Brady, T. et al. HIV integration site distributions in resting and activated CD4+ T cells 
infected in culture. AIDS 23, 1461–1471 (2009). 
228. Carteau, S., Hoffmann, C. & Bushman, F. Chromosome structure and human 
immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a 
disfavored target. J. Virol. 72, 4005–4014 (1998). 
229. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–
921 (2001). 
230. Felice, B. et al. Transcription factor binding sites are genetic determinants of retroviral 
integration in the human genome. PLoS One 4, (2009). 
231. Mitchell, R. S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target 
site preferences. PLoS Biol. 2, E234 (2004). 
232. Schro der, A. R. W. et al. HIV-1 integration in the human genome favors active genes and 
local hotspots. Cell 110, 521–9 (2002). 
233. Deichmann, A. et al. Vector integration is nonrandom and clustered and influences the fate 
of lymphopoiesis in SCID-X1 gene therapy. 117, (2007). 
234. Xiaolin Wu, Yuan Li, Bruce Crise, S. M. B. Transcription Start Regions in the Human Genome 
Are Favored Targets for MLV Integration. Science (80-. ). 300, 1749–1751 (2003). 
235. Kim, S. et al. Fidelity of Target Site Duplication and Sequence Preference during Integration 
of Xenotropic Murine Leukemia Virus-Related Virus. PLoS One 5, (2010). 
236. Kim, S. et al. Integration site preference of xenotropic murine leukemia virus-related virus, 
a new human retrovirus associated with prostate cancer. J. Virol. 82, 9964–9977 (2008). 
237. Cattoglio, C. et al. High-definition mapping of retroviral integration sites identifies active 
regulatory elements in human multipotent hematopoietic progenitors. Blood 116, 5507–
17 (2010). 
238. Narezkina, A. et al. Genome-Wide Analyses of Avian Sarcoma Virus Integration Sites 
Genome-Wide Analyses of Avian Sarcoma Virus Integration Sites. 78, 11656–11663 
(2004). 
239. Moiani, A. et al. Genome-wide analysis of alpharetroviral integration in human 
hematopoietic stem/progenitor cells. Genes (Basel). 5, 415–429 (2014). 
240. Ustek, D. et al. A genome-wide analysis of lentivector integration sites using targeted 
sequence capture and next generation sequencing technology. Infect. Genet. Evol. 12, 
1349–1354 (2012). 
241. Roth, S. L., Malani, N. & Bushman, F. D. Gammaretroviral integration into nucleosomal 
target DNA in vivo. J. Virol. 85, 7393–7401 (2011). 
242. Wang, G. P. et al. DNA bar coding and pyrosequencing to analyze adverse events in 
therapeutic gene transfer. Nucleic Acids Res. 36, 1–12 (2008). 
243. Marshall, H. M. et al. Role of PSIP 1/LEDGF/p75 in lentiviral infectivity and integration 
targeting. PLoS One 2, (2007). 
244. Berry, C. C. et al. Estimating abundances of retroviral insertion sites from DNA fragment 
length data. Bioinformatics 28, 755–762 (2012). 
245. Lewinski, M. K. et al. Retroviral DNA integration: viral and cellular determinants of target-
site selection. PLoS Pathog. 2, e60 (2006). 
246. Ciuffi, A. & Telenti, A. State of genomics and epigenomics research in the perspective of 
HIV cure. Curr. Opin. HIV AIDS 8, 176–81 (2013). 
247. Barr, S. D. et al. HIV Integration Site Selection: Targeting in Macrophages and the Effects of 
Different Routes of Viral Entry. Mol. Ther. 14, 218–225 (2006). 
248. Ferris, A. L. et al. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 
DNA integration. Proc. Natl. Acad. Sci. U. S. A. 107, 3135–3140 (2010). 
249. Schro der,  a. R. W. et al. HIV-1 integration in the human genome favors active genes and 
local hotspots. Cell 110, 521–529 (2002). 
250. Lewinski, M. K. & Bushman, F. D. Retroviral DNA Integration-Mechanism and 
Consequences. Adv. Genet. 55, 147–181 (2005). 
251. Stevens, S. W. & Griffith, J. D. Human immunodeficiency virus type 1 may preferentially 
integrate into chromatin occupied by L1Hs repetitive elements. Proc. Natl. Acad. Sci. U. S. 
A. 91, 5557–5561 (1994). 
  283 
252. Stevens, S. W. & Griffith, J. D. Sequence analysis of the human DNA flanking sites of human 
immunodeficiency virus type 1 integration. J. Virol. 70, 6459–6462 (1996). 
253. Leclercq, I. et al. Host sequences flanking the human T-cell leukemia virus type 1 provirus 
in vivo. J. Virol. 74, 2305–2312 (2000). 
254. Weidhaas, J. B., Angelichio, E. L., Fenner, S. & Coffin, J. M. Relationship between retroviral 
DNA integration and gene expression. J. Virol. 74, 8382–8389 (2000). 
255. Lunyak, V. V et al. Developmentally regulated activation of a SINE B2 repeat as a domain 
boundary in organogenesis. Science 317, 248–251 (2007). 
256. Ferrigno, O. et al. Transposable B2 SINE elements can provide mobile RNA polymerase II 
promoters. Nat. Genet. 28, 77–81 (2001). 
257. Cherepanov, P. et al. HIV-1 integrase forms stable tetramers and associates with 
LEDGF/p75 protein in human cells. J. Biol. Chem. 278, 372–381 (2003). 
258. Llano, M., Delgado, S., Vanegas, M. & Poeschla, E. M. Lens epithelium-derived growth 
factor/p75 prevents proteasomal degradation of HIV-1 integrase. J. Biol. Chem. 279, 
55570–55577 (2004). 
259. Cherepanov, P. et al. Solution structure of the HIV-1 integrase-binding domain in 
LEDGF/p75. Nat. Struct. Mol. Biol. 12, 526–532 (2005). 
260. Maertens, G. et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-
1 integrase in human cells. J. Biol. Chem. 278, 33528–39 (2003). 
261. Busschots, K. et al. The interaction of LEDGF/p75 with integrase is lentivirus-specific and 
promotes DNA binding. J. Biol. Chem. 280, 17841–17847 (2005). 
262. Llano, M. et al. Identification and Characterization of the Chromatin-binding Domains of 
the HIV-1 Integrase Interactor LEDGF/p75. J. Mol. Biol. 360, 760–773 (2006). 
263. Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T. & Engelman, A. Structural 
basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. 
Proc. Natl. Acad. Sci. U. S. A. 102, 17308–17313 (2005). 
264. Shun, M. C. et al. LEDGF/p75 functions downstream from preintegration complex 
formation to effect gene-specific HIV-1 integration. Genes Dev. 21, 1767–1778 (2007). 
265. Meehan, A. M. et al. LEDGF/p75 proteins with alternative chromatin tethers are functional 
HIV-1 cofactors. PLoS Pathog. 5, (2009). 
266. Shun, M.-C. et al. Identification and characterization of PWWP domain residues critical for 
LEDGF/p75 chromatin binding and human immunodeficiency virus type 1 infectivity. J. 
Virol. 82, 11555–67 (2008). 
267. Eidahl, J. O. et al. Structural basis for high-affinity binding of LEDGF PWWP to 
mononucleosomes. Nucleic Acids Res. 41, 3924–3936 (2013). 
268. Biasco, L. et al. Integration profile of retroviral vector in gene therapy treated patients is 
cell-specific according to gene expression and chromatin conformation of target cell. 
EMBO Mol. Med. 3, 89–101 (2011). 
269. Bannister, A. J. et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 
chromo domain. Nature 410, 120–124 (2001). 
270. Sharma, A. et al. BET proteins promote efficient murine leukemia virus integration at 
transcription start sites. Proc. Natl. Acad. Sci. U. S. A. 110, 12036–41 (2013). 
271. El Ashkar, S. et al. BET-independent MLV-based Vectors Target Away From Promoters and 
Regulatory Elements. Mol. Ther. Nucleic Acids 3, e179 (2014). 
272. Kalpana, G. V, Marmon, S., Wang, W., Crabtree, G. R. & Goff, S. P. Binding and stimulation of 
HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 266, 
2002–2006 (1994). 
273. Miller, M. D. & Bushman, F. D. Inil for integration ? The newly discovered Inil cellular 
protein binds HIV-1 integrase and is. 5, (1995). 
274. Bushman, F. et al. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 
3, 848–58 (2005). 
275. Bartholomae, C. C. et al. Lentiviral vector integration profiles differ in rodent postmitotic 
tissues. Mol. Ther. 19, 703–10 (2011). 
276. Bartholomae, C. C. et al. Lentiviral vector integration profiles differ in rodent postmitotic 
tissues. Mol. Ther. 19, 703–710 (2011). 
277. Poeschla, E. et al. Identification of a human immunodeficiency virus type 2 (HIV-2) 
encapsidation determinant and transduction of nondividing human cells by HIV-2-based 
lentivirus vectors. J. Virol. 72, 6527–6536 (1998). 
  284 
278. Kim, S. S. et al. Generation of replication-defective helper-free vectors based on simian 
immunodeficiency virus. Virology 282, 154–67 (2001). 
279. Curran, M. A., Kaiser, S. M., Achacoso, P. L. & Nolan, G. P. Efficient transduction of 
nondividing cells by optimized feline immunodeficiency virus vectors. Mol.Ther. 1, 31–38 
(2000). 
280. Berkowitz, R. D., Ilves, H., Plavec, I. & Veres, G. Gene transfer systems derived from Visna 
virus: analysis of virus production and infectivity. Virology 279, 116–129 (2001). 
281. Mselli-Lakhal, L., Guiguen, F., Greenland, T., Mornex, J. F. & Chebloune, Y. Gene transfer 
system derived from the caprine arthritis-encephalitis lentivirus. J. Virol. Methods 136, 
177–184 (2006). 
282. Mitrophanous, K. et al. Stable gene transfer to the nervous system using a non-primate 
lentiviral vector. Gene Ther. 6, 1808–1818 (1999). 
283. Burns, J. C., Friedmann, T., Drievert, W., Burrascano, M. & Yee, J.-K. Vesicular stomatitis virus 
G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and 
efficient gene transfer into mammalian and nonmammalian cells (gene 
therapy/zebrafish). Genetics 90, 8033–8037 (1993). 
284. Kahl, C. a, Marsh, J., Fyffe, J., Sanders, D. a & Cornetta, K. Human immunodeficiency virus 
type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from 
Ross River virus and Semliki Forest virus. J. Virol. 78, 1421–1430 (2004). 
285. Trabalza,  a et al. Venezuelan equine encephalitis virus glycoprotein pseudotyping confers 
neurotropism to lentiviral vectors. Gene Ther. 20, 723–32 (2013). 
286. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral 
vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871–875 (1997). 
287. Otto, E. et al. Characterization of a replication-competent retrovirus resulting from 
recombination of packaging and vector sequences. Hum. Gene Ther. 5, 567–75 (1994). 
288. Zufferey, R. et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene 
Delivery. J. Virol. 72, 9873–9880 (1998). 
289. Yu, S. F. et al. Self-inactivating retroviral vectors designed for transfer of whole genes into 
mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 83, 3194–8 (1986). 
290. Miyoshi, H., Blo mer, U., Takahashi, M., Gage, F. H. & Verma, I. M. Development of a self-
inactivating lentivirus vector. J. Virol. 72, 8150–7 (1998). 
291. Schambach, A., Swaney, W. P. & van der Loo, J. C. M. Design and production of retro- and 
lentiviral vectors for gene expression in hematopoietic cells. Methods Mol. Biol. 506, 191–
205 (2009). 
292. Throm, R. E. et al. Efficient construction of producer cell lines for a SIN lentiviral vector for 
SCID-X1 gene therapy by concatemeric array transfection. Blood 113, 5104–5110 (2009). 
293. Iglesias, C. et al. Residual HIV-1 DNA Flap-independent nuclear import of cPPT/CTS double 
mutant viruses does not support spreading infection. Retrovirology 8, 92 (2011). 
294. Huang, J. & Liang, T. J. A novel hepatitis B virus (HBV) genetic element with Rev response 
element-like properties that is essential for expression of HBV gene products. Mol. Cell. 
Biol. 13, 7476–7486 (1993). 
295. Donello, J. E., Beeche, A. A., Smith, G. J., Lucero, G. R. & Hope, T. J. The hepatitis B virus 
posttranscriptional regulatory element is composed of two subelements. J. Virol. 70, 
4345–4351 (1996). 
296. Higashimoto, T. et al. The woodchuck hepatitis virus post-transcriptional regulatory 
element reduces readthrough transcription from retroviral vectors. Gene Ther. 14, 1298–
1304 (2007). 
297. Donello, J. E., Loeb, J. E. & Hope, T. J. Woodchuck hepatitis virus contains a tripartite 
posttranscriptional regulatory element. J. Virol. 72, 5085–5092 (1998). 
298. Zufferey, R., Donello, J. E., Trono, D. & Hope, T. J. Woodchuck hepatitis virus 
posttranscriptional regulatory element enhances expression of transgenes delivered by 
retroviral vectors. J. Virol. 73, 2886–92 (1999). 
299. Schambach,  a et al. Woodchuck hepatitis virus post-transcriptional regulatory element 
deleted from X protein and promoter sequences enhances retroviral vector titer and 
expression. Gene Ther. 13, 641–645 (2006). 
300. Kingsman, S. M., Mitrophanous, K. & Olsen, J. C. Potential oncogene activity of the 
woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene therapy 12, 
3–4 (2005). 
  285 
301. Flajolet, M., Tiollais, P., Buendia, M. A. & Fourel, G. Woodchuck hepatitis virus enhancer I 
and enhancer II are both involved in N-myc2 activation in woodchuck liver tumors. J. Virol. 
72, 6175–6180 (1998). 
302. Nash, K. L., Jamil, B., Maguire, A. J., Alexander, G. J. M. & Lever, A. M. L. Hepatocyte-specific 
gene expression from integrated lentiviral vectors. J. Gene Med. 6, 974–983 (2004). 
303. Sirma, H. et al. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue 
abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 18, 4848–
4859 (1999). 
304. Tu, H. et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X 
protein in hepatocellular carcinoma tissues. Cancer Res. 61, 7803–7810 (2001). 
305. Terradillos, O. et al. The hepatitis B virus X gene potentiates c-myc-induced liver 
oncogenesis in transgenic mice. Oncogene 14, 395–404 (1997). 
306. Zanta-Boussif, M. a et al. Validation of a mutated PRE sequence allowing high and 
sustained transgene expression while abrogating WHV-X protein synthesis: application to 
the gene therapy of WAS. Gene Ther. 16, 605–619 (2009). 
307. Swanstrom, R. & Wills, J. W. Synthesis, Assembly, and Processing of Viral Proteins. 
Retroviruses 263–334 (1997). 
308. Wagner, R. et al. Rev-independent expression of synthetic gag-pol genes of human 
immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the 
safety of lentiviral vectors. Hum. Gene Ther. 11, 2403–2413 (2000). 
309. Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M. & Mitrophanous, K. a. A Rev-
Independent Human Immunodeficiency Virus Type 1 ( HIV-1 ) -Based Vector That Exploits 
a A Rev-Independent Human Immunodeficiency Virus Type 1 ( HIV-1 ) -Based Vector That 
Exploits a Codon-Optimized HIV-1 gag-pol Gene. J. Virol. 74, 4839–4852 (2000). 
310. Nappi, F. et al. Identification of a novel posttranscriptional regulatory element by using a 
rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a 
molecular trap. J. Virol. 75, 4558–69 (2001). 
311. Zolotukhin, A., Valentin, A., Pavlakis, G. & Felber, B. Continuous propagation of RRE(-) and 
Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-
acting element of simian retrovirus type 1 in human peripheral blood lymphocytes. J. Virol. 
68, 7944–7952 (1994). 
312. Kim, V. N., Mitrophanous, K., Kingsman, S. M. & Kingsman,  a J. Minimal requirement for a 
lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72, 811–816 
(1998). 
313. Takara, C.-. Fourth Generation Lentiviral Packaging Systems. Available at: 
http://www.clontech.com/US/Products/Viral_Transduction/Lentiviral_Packaging/Lenti
viral_Packaging_Overview.  
314. Urano, E. et al. Substitution of the myristoylation signal of human immunodeficiency virus 
type 1 Pr55Gag with the phospholipase C-??1 pleckstrin homology domain results in 
infectious pseudovirion production. J. Gen. Virol. 89, 3144–3149 (2008). 
315. Hong, S. et al. Functional analysis of various promoters in lentiviral vectors at different 
stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther 15, 1630–1639 
(2007). 
316. Hanawa, H., Yamamoto, M., Zhao, H., Shimada, T. & Persons, D. a. Optimized lentiviral vector 
design improves titer and transgene expression of vectors containing the chicken beta-
globin locus HS4 insulator element. Mol. Ther. 17, 667–674 (2009). 
317. Uchida, N., Washington, K. N., Lap, C. J., Hsieh, M. M. & Tisdale, J. F. Chicken HS4 insulators 
have minimal barrier function among progeny of human hematopoietic cells transduced 
with an HIV1-based lentiviral vector. Mol. Ther. 19, 133–139 (2011). 
318. Real, G., Monteiro, F., Burger, C. & Alves, P. M. Improvement of lentiviral transfer vectors 
using cis-acting regulatory elements for increased gene expression. Appl. Microbiol. 
Biotechnol. 91, 1581–1591 (2011). 
319. Leavitt,  a D., Robles, G., Alesandro, N. & Varmus, H. E. Human immunodeficiency virus type 
1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA 
efficiently during infection. J. Virol. 70, 721–728 (1996). 
320. Cornu, T. I. & Cathomen, T. Targeted genome modifications using integrase-deficient 
lentiviral vectors. Mol. Ther. 15, 2107–2113 (2007). 
321. Miller, D. G., Petek, L. M. & Russell, D. W. Adeno-associated virus vectors integrate at 
  286 
chromosome breakage sites. Nat. Genet. 36, 767–773 (2004). 
322. Ma trai, J. et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors 
induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53, 1696–
1707 (2011). 
323. Mates, L. et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase 
enables robust stable gene transfer in vertebrates. Nat. Genet. 41, 753–761 (2009). 
324. Staunstrup, N. H. et al. Hybrid lentivirus-transposon vectors with a random integration 
profile in human cells. Mol. Ther. 17, 1205–14 (2009). 
325. Li, L. et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and 
progenitor cells using zinc finger nucleases. Mol. Ther. 21, 1259–69 (2013). 
326. Kochenderfer, J. N. & Rosenberg, S. A. Treating B-cell cancer with T cells expressing 
anti-CD19 chimeric antigen receptors. Nat. Publ. Gr. 10, 267–276 (2013). 
327. Kumar, M., Keller, B., Makalou, N. & Sutton, R. E. Systematic determination of the packaging 
limit of lentiviral vectors. Hum. Gene Ther. 12, 1893–1905 (2001). 
328. Segura, M. M., Mangion, M., Gaillet, B. & Garnier, A. New developments in lentiviral vector 
design, production and purification. Expert Opin. Biol. Ther. 13, 987–1011 (2013). 
329. Pichlmair, A. et al. Tubulovesicular structures within vesicular stomatitis virus G protein-
pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses 
via Toll-like receptor 9. J. Virol. 81, 539–547 (2007). 
330. Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene 
therapy of human β-thalassaemia. Nature 467, 318–322 (2010). 
331. Cartier, N. et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked 
Adrenoleukodystrophy. Science (80-. ). 326, 818–823 (2009). 
332. Merten, O.-W., Hebben, M. & Bovolenta, C. Production of lentiviral vectors. Mol. Ther. 
Methods Clin. Dev. 3, 16017 (2016). 
333. Slepushkin, V., Chang, N., Cohen, R., G. & Y., Jiang, B., Deausen, E. Large-scale purification of 
a lentiviral vector by size exclusion chromatography or Mustang Q ion exchange 
chromatography. Bioprocess. J. 89–95 (2003). 
334. Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nat. 
Protoc. 1, 241–245 (2006). 
335. Giry-Laterriere, M., Verhoeyen, E. & Salmon, P. Lentiviral vectors. Methods Mol Biol 737, 
183–209 (2011). 
336. Kuroda, H., Marino, M. P., Kutner, R. H. & Reiser, J. Production of lentiviral vectors in 
protein-free media. Curr. Protoc. Cell Biol. (2011). doi:10.1002/0471143030.cb2608s50 
337. Segura, M. M., Mangion, M., Gaillet, B. & Garnier, A. New developments in lentiviral vector 
design , production and purification. 1–25 (2013). 
338. Broussau, S. et al. Inducible packaging cells for large-scale production of lentiviral vectors 
in serum-free suspension culture. Mol. Ther. 16, 500–507 (2008). 
339. Co te , J., Garnier, A., Massie, B. & Kamen, A. Serum-free production of recombinant proteins 
and adenoviral vectors by 293SF-3F6 cells. Biotechnol. Bioeng. 59, 567–575 (1998). 
340. Ansorge, S. et al. Development of a scalable process for high-yield lentiviral vector 
production by transient transfection of HEK293 suspension cultures. J. Gene Med. 11, 868–
876 (2009). 
341. PUCK, T. T. The genetics of somatic mammalian cells. Adv. Biol. Med. Phys. 5, 75–101 (1957). 
342. Jayapal, K., Wlaschin, K., Hu, W. & Yap, G. Recombinant protein therapeutics from CHO 
cells-20 years and counting. Chem. Eng. Prog. 103, 40–47 (2007). 
343. Chu, L. & Robinson, D. K. Industrial choices for protein production by large-scale cell 
culture. Current Opinion in Biotechnology 12, 180–187 (2001). 
344. Fan, L., Frye, C. C. & Racher, A. J. The use of glutamine synthetase as a selection marker: 
recent advances in Chinese hamster ovary cell line generation processes. Pharm. 
Bioprocess. 1, 487–502 (2013). 
345. Hossler, P., Khattak, S. F. & Li, Z. J. Optimal and consistent protein glycosylation in 
mammalian cell culture. Glycobiology 19, 936–49 (2009). 
346. Shulman, M., Wilde, C. D. & Ko hler, G. A better cell line for making hybridomas secreting 
specific antibodies. Nature 276, 269–270 (1978). 
347. Bebbington, C. R. et al. High-level expression of a recombinant antibody from myeloma 
cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology. 
(N. Y). 10, 169–175 (1992). 
  287 
348. Macpherson, I. & Stoker, M. Polyoma transformation of hamster cell clones--an 
investigation of genetic factors affecting cell competence. Virology 16, 147–151 (1962). 
349. Boeger, H. et al. Structural basis of eukaryotic gene transcription. in FEBS Letters 579, 899–
903 (2005). 
350. Viruses, A. Viral Vectors for Gene Therapy. Viral Vectors for gene therapy: Methods and 
Protocols 737, (2011). 
351. Takeuchi, Y. et al. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by 
galactosyl(alpha1-3)galactosylation. J Virol 71, 6174–6178 (1997). 
352. Pensiero, M. N., Wysocki, C. A., Nader, K. & Kikuchi, G. E. Development of amphotropic 
murine retrovirus vectors resistant to inactivation by human serum. Hum. Gene Ther. 7, 
1095–1101 (1996). 
353. Davis, J. L. et al. Retroviral particles produced from a stable human-derived packaging cell 
line transduce target cells with very high efficiencies. Hum Gene Ther 8, 1459–1467 
(1997). 
354. Mason, J. M. et al. Human serum-resistant retroviral vector particles from galactosyl 
(alpha1-3) galactosyl containing nonprimate cell lines. Gene Ther. 6, 1397–1405 (1999). 
355. Jones, D. et al. High-level expression of recombinant IgG in the human cell line per.c6. 
Biotechnol Prog 19, 163–168 (2003). 
356. Kirschweger, G. Crucell: biopharmaceuticals--as human as they get. Mol. Ther. 7, 5–6 
(2003). 
357. Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line 
transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–74 (1977). 
358. Graham, F. L. & van der Eb, A. J. A new technique for the assay of infectivity of human 
adenovirus 5 DNA. Virology 52, 456–67 (1973). 
359. Louis, N., Evelegh, C. & Graham, F. L. Cloning and sequencing of the cellular-viral junctions 
from the human adenovirus type 5 transformed 293 cell line. Virology 233, 423–9 (1997). 
360. Lin, Y.-C. et al. Genome dynamics of the human embryonic kidney 293 lineage in response 
to cell biology manipulations. Nat. Commun. 5, 4767 (2014). 
361. Park, M., Lee, M., Kim, S., Jo, E.-C. & Lee, G. Influence of culture passages on growth kinetics 
and adenovirus vector production for gene therapy in monolayer and suspension cultures 
of HEK 293 cells. Appl. Microbiol. Biotechnol. 65, (2004). 
362. Shen, C. et al. The tumorigenicity diversification in human embryonic kidney 293 cell line 
cultured in vitro. Biologicals 36, 263–268 (2008). 
363. Shaw, G., Morse, S., Ararat, M. & Graham, F. L. Preferential transformation of human 
neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 16, 869–
71 (2002). 
364. Merten, O.-W. et al. Large-scale manufacture and characterization of a lentiviral vector 
produced for clinical ex vivo gene therapy application. Hum. Gene Ther. 22, 343–56 (2011). 
365. DuBridge, R. B. et al. Analysis of mutation in human cells by using an Epstein-Barr virus 
shuttle system. Mol. Cell. Biol. 7, 379–87 (1987). 
366. Rio, D. C., Clark, S. G. & Tjian, R. A mammalian host-vector system that regulates expression 
and amplification of transfected genes by temperature induction. Science 227, 23–8 
(1985). 
367. Wu, X. et al. SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes 
Dev. 18, 1305–1316 (2004). 
368. Gama-Norton, L. et al. Lentivirus Production Is Influenced by SV40 Large T-Antigen and 
Chromosomal Integration of the Vector in HEK293 Cells. Hum. Gene Ther. 22, 1269–1279 
(2011). 
369. Barbanti-Brodano, G. et al. Simian virus 40 infection in humans and association with 
human diseases: Results and hypotheses. Virology 318, 1–9 (2004). 
370. Manilla, P. et al. Regulatory considerations for novel gene therapy products: a review of 
the process leading to the first clinical lentiviral vector. Hum. Gene Ther. 16, 17–25 (2005). 
371. Engels, E. a et al. Cancer incidence in Denmark following exposure to poliovirus vaccine 
contaminated with simian virus 40. J. Natl. Cancer Inst. 95, 532–539 (2003). 
372. Reisman, D. & Sugden, B. trans activation of an Epstein-Barr viral transcriptional enhancer 
by the Epstein-Barr viral nuclear antigen 1. Mol. Cell. Biol. 6, 3838–3846 (1986). 
373. Young, J. M., Cheadle, C., Foulke, J. S., Drohan, W. N. & Sarver, N. Utilization of an Epstein-
Barr virus replicon as a eukaryotic expression vector. Gene 62, 171–185 (1988). 
  288 
374. Durocher, Y., Perret, S. & Kamen, A. High-level and high-throughput recombinant protein 
production by transient transfection of suspension-growing human 293-EBNA1 cells. 
Nucleic Acids Res. 30, E9 (2002). 
375. Lambert, P. F., Baker, C. C. & Howley, P. M. The Genetics of Bovine Papillomavirus Type 1. 
Annu. Rev. Genet. 22, 235–258 (1988). 
376. National Research Council of Canada. HEK 293 expression platform (L-10894 / 11266 / 
11565). 
377. Yves Durocher. Expression vectors for enhanced transient gene expression and 
mammalian cells expressing them. (2009). 
378. Poeschla, E., Corbeau, P. & Wong-Staal, F. Development of HIV vectors for anti-HIV gene 
therapy. Proc. Natl. Acad. Sci. U. S. A. 93, 11395–11399 (1996). 
379. Corbeau, P., Kraus, G. & Wong-Staal, F. Efficient gene transfer by a human 
immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell 
line. Proc. Natl. Acad. Sci. U. S. A. 93, 14070–14075 (1996). 
380. Srinivasakumar, N. et al. The effect of viral regulatory protein expression on gene delivery 
by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. 
J. Virol. 71, 5841–5848 (1997). 
381. Sanber, K. S. et al. Construction of stable packaging cell lines for clinical lentiviral vector 
production. Sci. Rep. 5, 9021 (2015). 
382. Marin, V. et al. RD-MolPack technology for the constitutive production of self-inactivating 
lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope. Mol. Ther. — 
Methods Clin. Dev. 3, 16033 (2016). 
383. Humbert, O. et al. Development of Third-generation Cocal Envelope Producer Cell Lines 
for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. Mol. Ther. 
(2016). doi:10.1038/mt.2016.70 
384. Sandrin, V. et al. Lentiviral vectors pseudotyped with a modified RD114 envelope 
glycoprotein show increased stability in sera and augmented transduction of primary 
lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100, 
823–32 (2002). 
385. Relander, T. et al. Gene transfer to repopulating human CD34+ cells using amphotropic-, 
GALV-, or RD114-pseudotyped HIV-1-Based vectors from stable producer cells. Mol. Ther. 
11, 452–459 (2005). 
386. von Kalle, C. et al. Increased gene transfer into human hematopoietic progenitor cells by 
extended in vitro exposure to a pseudotyped retroviral vector. Blood 84, 2890–7 (1994). 
387. Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M. & Morgan, R. A. High-efficiency 
retroviral-mediated gene transfer into human and nonhuman primate peripheral blood 
lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 92, 7739–43 (1995). 
388. Mukherjee, S. & Thrasher, A. J. Gene therapy for PIDs: Progress, pitfalls and prospects. Gene 
525, 174–181 (2013). 
389. Ikeda, Y. et al. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21, 569–572 
(2003). 
390. Carrondo, M. et al. Integrated strategy for the production of therapeutic retroviral vectors. 
Hum. Gene Ther. 22, 370–379 (2011). 
391. Schucht, R. et al. A New Generation of Retroviral Producer Cells: Predictable and Stable 
Virus Production by Flp-Mediated Site-Specific Integration of Retroviral Vectors. Mol. Ther. 
14, 285–292 (2006). 
392. Coroadinha, A. S. et al. The use of recombinase mediated cassette exchange in retroviral 
vector producer cell lines: Predictability and efficiency by transgene exchange. J. 
Biotechnol. 124, 457–468 (2006). 
393. Stornaiuolo, A. et al. RD2-MolPack-Chim3, a Packaging Cell Line for Stable Production of 
Lentiviral Vectors for Anti-HIV Gene Therapy. Hum. Gene Ther. Methods 24, 228–40 (2013). 
394. Manilla, P. et al. Regulatory considerations for novel gene therapy products: a review of 
the process leading to the first clinical lentiviral vector. Hum. Gene Ther. 16, 17–25 (2005). 
395. Rogel, M. E., Wu, L. I. & Emerman, M. The human immunodeficiency virus type 1 vpr gene 
prevents cell proliferation during chronic infection. J. Virol. 69, 882–888 (1995). 
396. Jowett, J. B. et al. The human immunodeficiency virus type 1 vpr gene arrests infected T 
cells in the G2 + M phase of the cell cycle. J. Virol. 69, 6304–13 (1995). 
397. Kaplan,  a H. & Swanstrom, R. Human immunodeficiency virus type 1 Gag proteins are 
  289 
processed in two cellular compartments. Proc. Natl. Acad. Sci. U. S. A. 88, 4528–4532 
(1991). 
398. Kafri, T., van Praag, H., Ouyang, L., Gage, F. H. & Verma, I. M. A packaging cell line for 
lentivirus vectors. J. Virol. 73, 576–584 (1999). 
399. Klages, N., Zufferey, R. & Trono, D. A stable system for the high-titer production of multiply 
attenuated lentiviral vectors. Mol. Ther. 2, 170–176 (2000). 
400. Farson, D. et al. A new-generation stable inducible packaging cell line for lentiviral vectors. 
Hum. Gene Ther. 12, 981–997 (2001). 
401. Cockrell, A. S., Ma, H., Fu, K., McCown, T. J. & Kafri, T. A trans-lentiviral packaging cell line 
for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther. 14, 276–284 (2006). 
402. Kaul, M., Yu, H., Ron, Y. & Dougherty, J. P. Regulated lentiviral packaging cell line devoid of 
most viral cis-acting sequences. Virology 249, 167–174 (1998). 
403. Ni, Y. et al. Generation of a packaging cell line for prolonged large-scale production of high-
titer HIV-1-based lentiviral vector. J. Gene Med. 7, 818–834 (2005). 
404. Xu, K., Ma, H., McCown, T. J., Verma, I. M. & Kafri, T. Generation of a stable cell line producing 
high-titer self-inactivating lentiviral vectors. Mol. Ther. 3, 97–104 (2001). 
405. Pacchia,  a L., Adelson, M. E., Kaul, M., Ron, Y. & Dougherty, J. P. An inducible packaging cell 
system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory 
proteins. Virology 282, 77–86 (2001). 
406. Sparacio, S., Pfeiffer, T., Schaal, H. & Bosch, V. Generation of a flexible cell line with 
regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-
derived vectors. Mol. Ther. 3, 602–612 (2001). 
407. Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by 
tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 89, 5547–5551 (1992). 
408. Yu, H., Rabson,  a B., Kaul, M., Ron, Y. & Dougherty, J. P. Inducible human immunodeficiency 
virus type 1 packaging cell lines. J. Virol. 70, 4530–4537 (1996). 
409. Kafri, T., Blo mer, U., Peterson, D. a, Gage, F. H. & Verma, I. M. Sustained expression of genes 
delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17, 314–317 
(1997). 
410. Westerman, K. a, Ao, Z., Cohen, E. a & Leboulch, P. Design of a trans protease lentiviral 
packaging system that produces high titer virus. Retrovirology 4, 96 (2007). 
411. Bestor, T. H. Gene silencing as a threat to the success of gene therapy. J. Clin. Invest. 105, 
409–411 (2000). 
412. Garrick, D., Fiering, S., Martin, D. I. & Whitelaw, E. Repeat-induced gene silencing in 
mammals. Nat. Genet. 18, 56–9 (1998). 
413. McBurney, M. W., Mai, T., Yang, X. & Jardine, K. Evidence for repeat-induced gene silencing 
in cultured Mammalian cells: inactivation of tandem repeats of transfected genes. Exp. Cell 
Res. 274, 1–8 (2002). 
414. Ikeda, Y. et al. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21, 569–572 
(2003). 
415. Stewart, H. J. et al. A stable producer cell line for the manufacture of a lentiviral vector for 
gene therapy of Parkinson’s disease. Hum. Gene Ther. 22, 357–369 (2011). 
416. Hillen, W. & Berens, C. Mechanisms underlying expression of Tn10 encoded tetracycline 
resistance. Annu. Rev. Microbiol. 48, 1–25 (1994). 
417. Heinz, N. et al. Retroviral and transposon-based tet-regulated all-in-one vectors with 
reduced background expression and improved dynamic range. Hum. Gene Ther. 22, 166–
176 (2011). 
418. No, D., Yao, T. P. & Evans, R. M. Ecdysone-inducible gene expression in mammalian cells and 
transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 93, 3346–51 (1996). 
419. Transfiguracion, J., Jaalouk, D. E., Ghani, K., Galipeau, J. & Kamen, A. Size-exclusion 
chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-
pseudotyped retrovectors for cell and gene therapy applications. Hum. Gene Ther. 14, 
1139–1153 (2003). 
420. Sheridan, P. L. et al. Generation of retroviral packaging and producer cell lines for large-
scale vector production and clinical application: improved safety and high titer. Mol. Ther. 
2, 262–75 (2000). 
421. Shimizu-Sato, S., Huq, E., Tepperman, J. M. & Quail, P. H. A light-switchable gene promoter 
system. Nat. Biotechnol. 20, 1041–4 (2002). 
  290 
422. Liu, M., Komiyama, M. & Asanuma, H. Design of light-switchable phage promoter for 
efficient photo-regulation of gene-expression. Nucleic Acids Symp. Ser. (Oxf). 283–284 
(2005). doi:10.1093/nass/49.1.283 
423. Martí nez-Garcí a, J. F., Huq, E. & Quail, P. H. Direct targeting of light signals to a promoter 
element-bound transcription factor. Science 288, 859–863 (2000). 
424. No Title. 
425. Greene, M. R. et al. Transduction of human CD34+ repopulating cells with a SIN-lentiviral 
vector for SCID-X1 produced at clinical scale by a stable cell line. Hum. Gene Ther. Methods 
308, 121022094731004 (2012). 
426. Katz, R. A., Kotler, M. & Skalka, A. M. cis-acting intron mutations that affect the efficiency 
of avian retroviral RNA splicing: implication for mechanisms of control. J. Virol. 62, 2686–
2695 (1988). 
427. Oppermann, H., Bishop, J. M., Varmus, H. E. & Levintow, L. A joint product of the genes gag 
and pol of Avian Sarcoma Virus: a possible precursor of reverse transcriptase. Cell 12, 993–
1005 (1977). 
428. Matano, T., Odawara, T., Ohshima, M., Yoshikura, H. & Iwamoto,  a. trans-dominant 
interference with virus infection at two different stages by a mutant envelope protein of 
Friend murine leukemia virus. J. Virol. 67, 2026–33 (1993). 
429. Odawara, T., Oshima, M., Doi, K., Iwamoto, A. & Yoshikura, H. Threshold number of provirus 
copies required per cell for efficient virus production and interference in moloney murine 
leukemia virus-infected NIH 3T3 cells. J. Virol. 72, 5414–24 (1998). 
430. Lei, P. & Andreadis, S. T. Stoichiometric limitations in assembly of active recombinant 
retrovirus. Biotechnol. Bioeng. 90, 781–792 (2005). 
431. Carrondo, M. J. T., Merten, O.-W., Haury, M., Alves, P. M. & Coroadinha, A. S. Impact of 
retroviral vector components stoichiometry on packaging cell lines: effects on 
productivity and vector quality. Hum. Gene Ther. 19, 199–210 (2008). 
432. O’Brien, J. A. & Lummis, S. C. R. Biolistic transfection of neuronal cultures using a hand-
held gene gun. Nat. Protoc. 1, 977–81 (2006). 
433. Shirahata, Y., Ohkohchi, N., Itagak, H. & Satomi, S. New technique for gene transfection 
using laser irradiation. J. Investig. Med. 49, 184–90 (2001). 
434. Plank, C. et al. The magnetofection method: Using magnetic force to enhance gene delivery. 
Biological Chemistry 384, 737–747 (2003). 
435. Neumann, E., Schaefer-Ridder, M., Wang, Y. & Hofschneider, P. H. Gene transfer into mouse 
lyoma cells by electroporation in high electric fields. EMBO J. 1, 841–5 (1982). 
436. Rols, M. P., Coulet, D. & Teissie , J. Highly efficient transfection of mammalian cells by electric 
field pulses. Application to large volumes of cell culture by using a flow system. Eur. J. 
Biochem. 206, 115–21 (1992). 
437. Li, L.-H. et al. Highly efficient, large volume flow electroporation. Technol. Cancer Res. Treat. 
1, 341–350 (2002). 
438. Coleman, J. E. et al. Efficient large-scale production and concentration of HIV-1-based 
lentiviral vectors for use in vivo. Physiol. Genomics 12, 221–8 (2003). 
439. Reed, S. E., Staley, E. M., Mayginnes, J. P., Pintel, D. J. & Tullis, G. E. Transfection of 
mammalian cells using linear polyethylenimine is a simple and effective means of 
producing recombinant adeno-associated virus vectors. J. Virol. Methods 138, 85–98 
(2006). 
440. Vandermeulen, G., Marie, C., Scherman, D. & Pre at, V. New generation of plasmid backbones 
devoid of antibiotic resistance marker for gene therapy trials. Mol. Ther. 19, 1942–9 
(2011). 
441. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20, 
709–760 (2002). 
442. Garnier, A., Co te , J., Nadeau, I., Kamen, A. & Massie, B. Scale-up of the adenovirus expression 
system for the production of recombinant protein in human 293S cells. Cytotechnology 15, 
145–55 (1994). 
443. Kartenbeck, J., Schmid, E., Franke, W. W. & Geiger, B. Different modes of internalization of 
proteins associated with adhaerens junctions and desmosomes: experimental separation 
of lateral contacts induces endocytosis of desmosomal plaque material. EMBO J. 1, 725–32 
(1982). 
444. Merten, O.-W. et al. Large-scale manufacture and characterization of a lentiviral vector 
  291 
produced for clinical ex vivo gene therapy application. Hum. Gene Ther. 22, 343–356 
(2011). 
445. Kutner, R. H., Puthli, S., Marino, M. P. & Reiser, J. Simplified production and concentration 
of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange 
membrane chromatography. BMC Biotechnol. 9, 10 (2009). 
446. Wu, S. C., Huang, G. Y. L. & Liu, J. H. Production of Retrovirus and Adenovirus Vectors for 
Gene Therapy: A Comparative Study Using Microcarrier and Stationary Cell Culture. 
Biotechnol. Prog. 18, 617–622 (2002). 
447. Segura, M. M., Garnier, A., Durocher, Y., Coelho, H. & Kamen, A. Production of lentiviral 
vectors by large-scale transient transfection of suspension cultures and affinity 
chromatography purification. Biotechnol. Bioeng. 98, 789–799 (2007). 
448. Witting, S. R. et al. Efficient Large Volume Lentiviral Vector Production Using Flow 
Electroporation. Hum. Gene Ther. 23, 243–249 (2012). 
449. Olsen, J. C. & Sechelski, J. Use of sodium butyrate to enhance production of retroviral 
vectors expressing CFTR cDNA. Hum. Gene Ther. 6, 1195–202 (1995). 
450. Wade, P. a., Pruss, D. & Wolffe, A. P. Histone acetylation: Chromatin in action. Trends 
Biochem. Sci. 22, 128–132 (1997). 
451. Sena-Esteves, M., Tebbets, J. C., Steffens, S., Crombleholme, T. & Flake, A. W. Optimized 
large-scale production of high titer lentivirus vector pseudotypes. J. Virol. Methods 122, 
131–139 (2004). 
452. Luthman, H. & Magnusson, G. High efficiency polyoma DNA transfection of chloroquine 
treated cells. Nucleic Acids Res. 11, 1295–1308 (1983). 
453. Ellis, B. L., Potts, P. R. & Porteus, M. H. Creating higher titer lentivirus with caffeine. Hum. 
Gene Ther. 22, 93–100 (2011). 
454. Kuroda, H., Kutner, R. H., Bazan, N. G. & Reiser, J. Simplified lentivirus vector production in 
protein-free media using polyethylenimine-mediated transfection. J. Virol. Methods 157, 
113–121 (2009). 
455. Vogt, B. et al. Lack of superinfection interference in retroviral vector producer cells. Hum. 
Gene Ther. 12, 359–365 (2001). 
456. Brandtner, E. M. et al. Quantification and characterization of autotransduction in retroviral 
vector producer cells. Hum. Gene Ther. 19, 97–102 (2008). 
457. Carroll, R. et al. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector 
system utilizing stable HIV-1 packaging cell lines. J. Virol. 68, 6047–6051 (1994). 
458. Haselhorst, D., Kaye, J. F. & Lever,  a M. Development of cell lines stably expressing human 
immunodeficiency virus type 1 proteins for studies in encapsidation and gene transfer. J. 
Gen. Virol. 79 ( Pt 2), 231–7 (1998). 
459. Kuate, S., Wagner, R. & U berla, K. Development and characterization of a minimal inducible 
packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J. Gene 
Med. 4, 347–355 (2002). 
460. Strang, B. L. et al. Human Immunodeficiency Virus Type 1 Vectors with Alphavirus 
Envelope Glycoproteins Produced from Stable Packaging Cells Human Immunodeficiency 
Virus Type 1 Vectors with Alphavirus Envelope Glycoproteins Produced from Stable 
Packaging Cells. 79, 1765–1771 (2005). 
461. Muratori, C. et al. Generation and characterization of a stable cell population releasing 
fluorescent HIV-1-based Virus Like Particles in an inducible way. BMC Biotechnol. 6, 52 
(2006). 
462. Lee, C. L., Chou, M., Dai, B., Xiao, L. & Wang, P. Construction of stable producer cells to make 
high-titer lentiviral vectors for dendritic cell-based vaccination. Biotechnol. Bioeng. 109, 
1551–1560 (2012). 
463. Hu, P., Li, Y., Sands, M. S., McCown, T. & Kafri, T. Generation of a stable packaging cell line 
producing high-titer PPT-deleted integration-deficient lentiviral vectors. Mol. Ther. — 
Methods Clin. Dev. 2, 15025 (2015). 
464. Wurm, F. M. Production of recombinant protein therapeutics in cultivated mammalian 
cells. Nat. Biotechnol. 22, 1393–8 (2004). 
465. Ringold, G., Dieckmann, B. & Lee, F. Co-expression and amplification of dihydrofolate 
reductase cDNA and the Escherichia coli XGPRT gene in Chinese hamster ovary cells. J. Mol. 
Appl. Genet. 1, 165–75 (1981). 
466. Le Hir, H., Nott, A. & Moore, M. J. How introns influence and enhance eukaryotic gene 
  292 
expression. Trends Biochem. Sci. 28, 215–20 (2003). 
467. Makrides, S. C. Components of vectors for gene transfer and expression in mammalian 
cells. Protein Expr. Purif. 17, 183–202 (1999). 
468. Kalwy, S., Rance, J. & Young, R. Toward more efficient protein expression: keep the message 
simple. Mol. Biotechnol. 34, 151–156 (2006). 
469. Balland, A. et al. Characterisation of two differently processed forms of human 
recombinant factor IX synthesised in CHO cells transformed with a polycistronic vector. 
572, 565–572 (1988). 
470. Ryan, M. D., King, A. M. & Thomas, G. P. Cleavage of foot-and-mouth disease virus 
polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. 
72 ( Pt 11, 2727–32 (1991). 
471. Bestor, T. H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 9, 2395–2402 
(2000). 
472. Cosset, F. L., Takeuchi, Y., Battini, J. L., Weiss, R. a & Collins, M. K. High-titer packaging cells 
producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430–7436 
(1995). 
473. Girod, P. A., Zahn-Zabal, M. & Mermod, N. Use of the chicken lysozyme 5??? matrix 
attachment region to generate high producer CHO cell lines. Biotechnol. Bioeng. 91, 1–11 
(2005). 
474. Kim, J.-M. et al. Improved recombinant gene expression in CHO cells using matrix 
attachment regions. J. Biotechnol. 107, 95–105 (2004). 
475. Zahn-Zabal, M. et al. Development of stable cell lines for production or regulated 
expression using matrix attachment regions. J. Biotechnol. 87, 29–42 (2001). 
476. Barnes, L. M. & Dickson, A. J. Mammalian cell factories for efficient and stable protein 
expression. Curr. Opin. Biotechnol. 17, 381–6 (2006). 
477. Mirkovitch, J., Mirault, M. E. & Laemmli, U. K. Organization of the higher-order chromatin 
loop: specific DNA attachment sites on nuclear scaffold. Cell 39, 223–232 (1984). 
478. Bell, A. C., West, A. G. & Felsenfeld, G. The protein CTCF is required for the enhancer 
blocking activity of vertebrate insulators. Cell 98, 387–396 (1999). 
479. Girod, P.-A. et al. Genome-wide prediction of matrix attachment regions that increase gene 
expression in mammalian cells. Nat. Methods 4, 747–753 (2007). 
480. Antoniou, M. et al. Transgenes encompassing dual-promoter CpG islands from the human 
TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 
82, 269–279 (2003). 
481. Benton, T. et al. The use of UCOE vectors in combination with a preadapted serum free, 
suspension cell line allows for rapid production of large quantities of protein. 
Cytotechnology 38, 43–6 (2002). 
482. Zhang, F. et al. Lentiviral vectors containing an enhancer-less ubiquitously acting 
chromatin opening element (UCOE) provide highly reproducible and stable transgene 
expression in hematopoietic cells. Blood 110, 1448–1457 (2007). 
483. Ye, J. et al. Rapid protein production using CHO stable transfection pools. Biotechnol. Prog. 
26, 1431–1437 (2010). 
484. Mallik A, Pinkus G, S. S. Biopharma’s capacity crunch. McKinsey Q. 2002 Spec. Ed. Risk 
Resilience. McKinsey Co. 9–11 (2002). 
485. Adams, J. M. & Cory, S. Life-or-death decisions by the Bcl-2 protein family. Trends in 
Biochemical Sciences 26, 61–66 (2001). 
486. Kim, Y. G., Kim, J. Y., Mohan, C. & Lee, G. M. Effect of Bcl-xL overexpression on apoptosis and 
autophagy in recombinant Chinese hamster ovary cells under nutrient-deprived 
condition. Biotechnol. Bioeng. 103, 757–766 (2009). 
487. Hwang, S. O. & Lee, G. M. Effect of Akt overexpression on programmed cell death in 
antibody-producing Chinese hamster ovary cells. J. Biotechnol. 139, 89–94 (2009). 
488. Sunley, K. & Butler, M. Strategies for the enhancement of recombinant protein production 
from mammalian cells by growth arrest. Biotechnol. Adv. 28, 385–394 (2010). 
489. Lao, M. S. & Toth, D. Effects of ammonium and lactate on growth and metabolism of a 
recombinant Chinese hamster ovary cell culture. Biotechnol. Prog. 13, 688–691 (1997). 
490. Zhang, F., Sun, X., Yi, X. & Zhang, Y. Metabolic characteristics of recombinant Chinese 
hamster ovary cells expressing glutamine synthetase in presence and absence of 
glutamine. Cytotechnology 51, 21–28 (2006). 
  293 
491. Kim, S. H. & Lee, G. M. Functional expression of human pyruvate carboxylase for reduced 
lactic acid formation of Chinese hamster ovary cells (DG44). Appl. Microbiol. Biotechnol. 
76, 659–665 (2007). 
492. Zhou, M. et al. Decreasing lactate level and increasing antibody production in Chinese 
Hamster Ovary cells (CHO) by reducing the expression of lactate dehydrogenase and 
pyruvate dehydrogenase kinases. J. Biotechnol. 153, 27–34 (2011). 
493. Lin, C. Y. et al. Enhancing protein expression in HEK-293 cells by lowering culture 
temperature. PLoS One 10, (2015). 
494. Garcia-Ruiz, E., Gonzalez-Perez, D., Ruiz-Duen as, F. J., Martí nez, A. T. & Alcalde, M. Directed 
evolution of a temperature-, peroxide- and alkaline pH-tolerant versatile peroxidase. 
Biochem. J. 441, 487–98 (2012). 
495. Gorman, C., Padmanabhan, R. & Howard, B. H. High efficiency DNA-mediated 
transformation of primate cells. Science 221, 551–553 (1983). 
496. Orrantia, E. & Chang, P. L. Intracellular distribution of DNA internalized through calcium 
phosphate precipitation. Exp. Cell Res. 190, 170–174 (1990). 
497. Vaughan, E. E. & Dean, D. A. Intracellular trafficking of plasmids during transfection is 
mediated by microtubules. Mol. Ther. 13, 422–428 (2006). 
498. Potter, H. & Heller, R. Transfection by Electroporation. Curr. Protoc. Neurosci. (2011). 
doi:10.1002/0471142301.nsa01es57 
499. Grosjean, F., Batard, P., Jordan, M. & Wurm, F. M. S-phase synchronized CHO cells show 
elevated transfection efficiency and expression using CaPi. in Cytotechnology 38, 57–62 
(2002). 
500. Weber, M., Mo ller, K., Welzeck, M. & Schorr, J. Short technical reports. Effects of 
lipopolysaccharide on transfection efficiency in eukaryotic cells. Biotechniques 19, 930–40 
(1995). 
501. Stuchbury, G. & Mu nch, G. Optimizing the generation of stable neuronal cell lines via pre-
transfection restriction enzyme digestion of plasmid DNA. Cytotechnology 62, 189–194 
(2010). 
502. Ivics, Z., Hackett, P. B., Plasterk, R. H. & Izsva k, Z. Molecular Reconstruction of Sleeping 
Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells. Cell 91, 
501–510 (1997). 
503. Kawakami, K. & Shima, A. Identification of the Tol2 transposase of the medaka fish Oryzias 
latipes that catalyzes excision of a nonautonomous Tol2 element in zebrafish Danio rerio. 
Gene 240, 239–44 (1999). 
504. Fraser, M. J., Ciszczon, T., Elick, T. & Bauser, C. Precise excision of TTAA-specific 
lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus 
genome in cell lines from two species of Lepidoptera. Insect Mol. Biol. 5, 141–51 (1996). 
505. Vink, C. A Hybrid Lentivirus-Transposon Vector for Safer Gene Therapy. (2009). 
506. Matasci, M., Baldi, L., Hacker, D. L. & Wurm, F. M. The PiggyBac transposon enhances the 
frequency of CHO stable cell line generation and yields recombinant lines with superior 
productivity and stability. Biotechnol. Bioeng. 108, 2141–2150 (2011). 
507. Balasubramanian, S. et al. Rapid recombinant protein production from piggyBac 
transposon-mediated stable CHO cell pools. J. Biotechnol. 200, 61–69 (2015). 
508. Li, Z., Michael, I. P., Zhou, D., Nagy, A. & Rini, J. M. Simple piggyBac transposon-based 
mammalian cell expression system for inducible protein production. Proc. Natl. Acad. Sci. 
U. S. A. 110, 5004–9 (2013). 
509. Ley, D. et al. MAR Elements and Transposons for Improved Transgene Integration and 
Expression. PLoS One 8, (2013). 
510. Howe, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations 
causes leukemogenesis following gene therapy of SCID-X1 patients. 118, (2008). 
511. Smith, K. Theoretical mechanisms in targeted and random integration of transgene DNA. 
Reprod. Nutr. Dev. 41, 465–485 (2002). 
512. Wong, E. A. & Capecchi, M. R. Analysis of homologous recombination in cultured 
mammalian cells in transient expression and stable transformation assays. Somat. Cell Mol. 
Genet. 12, 63–72 (1986). 
513. Calos, M. P., Lebkowski, J. S. & Botchan, M. R. High mutation frequency in DNA transfected 
into mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 80, 3015–9 (1983). 
514. Burdon, T. G. & Wall, R. J. Fate of microinjected genes in preimplantation mouse embryos. 
  294 
Mol. Reprod. Dev. 33, 436–442 (1992). 
515. Chen, C. & Chasin, L. A. Cointegration of DNA molecules introduced into mammalian cells 
by electroporation. Somat. Cell Mol. Genet. 24, 249–256 (1998). 
516. Covarrubias, L., Nishida, Y., Terao, M., D’Eustachio, P. & Mintz, B. Cellular DNA 
rearrangements and early developmental arrest caused by DNA insertion in transgenic 
mouse embryos. Mol. Cell. Biol. 7, 2243–7 (1987). 
517. Covarrubias, L., Nishida, Y. & Mintz, B. Early postimplantation embryo lethality due to DNA 
rearrangements in a transgenic mouse strain. Proc.Natl.Acad.Sci.U.S.A. 83, 6020–6024 
(1986). 
518. Milot E, Belmaaza A, Wallenburg JC, Gusew N, Bradley WE and Chartrand, P. Chromosomal 
illegitimate recombination in mammalian cells is associated with intrinsically bent DNA 
elements. EMBO J. 11, 5063–5070 (1992). 
519. Robins, D. M., Ripley, S., Henderson, A. S. & Axel, R. Transforming DNA integrates into the 
host chromosome. Cell 23, 29–39 (1981). 
520. Murnane, J. P. & Yu, L. C. Acquisition of telomere repeat sequences by transfected DNA 
integrated at the site of a chromosome break. Mol. Cell. Biol. 13, 977–983 (1993). 
521. Bestor, T. H. The host defence function of genomic methylation patterns. Novartis Found. 
Symp. 214, 187-189-232 (1998). 
522. Heartlein, M. W., Knoll, J. H. & Latt, S. a. Chromosome instability associated with human 
alphoid DNA transfected into the Chinese hamster genome. Mol. Cell. Biol. 8, 3611–8 
(1988). 
523. Murnane, J. P. & Young, B. R. Nucleotide sequence analysis of novel junctions near an 
unstable integrated plasmid in human cells. Gene 84, 201–205 (1989). 
524. Merrihew, R. V, Marburger, K., Pennington, S. L., Roth, D. B. & Wilson, J. H. High-frequency 
illegitimate integration of transfected DNA at preintegrated target sites in a mammalian 
genome. Mol. Cell. Biol. 16, 10–18 (1996). 
525. Perez, E. E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using 
zinc-finger nucleases. Nat. Biotechnol. 26, 808–16 (2008). 
526. Festenstein, R. et al. Locus control region function and heterochromatin-induced position 
effect variegation. Science 271, 1123–5 (1996). 
527. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target 
base in genomic DNA without double-stranded DNA cleavage. Nature 61, 5985–91 (2016). 
528. He, X. et al. Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced 
homology-dependent and independent DNA repair. Nucleic Acids Res. gkw064- (2016). 
doi:10.1093/nar/gkw064 
529. Goncz, K. K., Prokopishyn, N. L., Chow, B. L., Davis, B. R. & Gruenert, D. C. Application of 
SFHR to gene therapy of monogenic disorders. Gene Ther 9, 691–694 (2002). 
530. ACG, P. Designer Genomes. Techniques 53–65 (1989). 
531. Porteus, M. Using homologous recombination to manipulate the genome of human 
somatic cells. Biotechnol. Genet. Eng. Rev. 24, 195–212 (2007). 
532. O’Driscoll, M. & Jeggo, P. a. The role of double-strand break repair - insights from human 
genetics. Nat Rev Genet. 7, 45–54 (2006). 
533. Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 
461, 1071–8 (2009). 
534. Doyon, J. B. et al. Rapid and efficient clathrin-mediated endocytosis revealed in genome-
edited mammalian cells. Nat. Cell Biol. 13, 331–337 (2011). 
535. Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE 
nucleases. Nat. Biotechnol. 29, 731–4 (2011). 
536. Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. 
Nature 475, 217–221 (2011). 
537. Maresca, M., Lin, V. G., Guo, N. & Yang, Y. Obligate ligation-gated recombination (ObLiGaRe): 
Custom-designed nuclease-mediated targeted integration through nonhomologous end 
joining. Genome Res. 23, 539–546 (2013). 
538. Ran, F. A. et al. Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing 
specificity. Cell 154, 1380–1389 (2013). 
539. Chen, F. et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-
finger nucleases. Nat Methods 8, 753–755 (2011). 
540. Choi, P. S. & Meyerson, M. Targeted genomic rearrangements using CRISPR/Cas 
  295 
technology. Nat. Commun. 5, 3728 (2014). 
541. Lee, H. J., Kweon, J., Kim, E., Kim, S. & Kim, J. S. Targeted chromosomal duplications and 
inversions in the human genome using zinc finger nucleases. Genome Res. 22, 539–548 
(2012). 
542. Khanna, K. K. & Jackson, S. P. DNA double-strand breaks: signaling, repair and the cancer 
connection. Nat. Genet. 27, 247–54 (2001). 
543. Chappel, S. C. Method for the modification of the expression characteristics of an 
endogenous gene of a given cell line. (1990). 
544. Yutaka, K. et al. Comparison of cell lines for stable production of fucose-negative 
antibodies with enhanced ADCCYutaka Kanda and Naoko Yamane-Ohnuki contributed 
equally to this work. Biotechnol. Bioeng. 94, 680–688 (2006). 
545. Grandjean, M. et al. High-level transgene expression by homologous recombination-
mediated gene transfer. Nucleic Acids Res. 39, (2011). 
546. Capecchi, M. R. Altering the genome by homologous recombination. Science 244, 1288–92 
(1989). 
547. Chapman, J. R., Sossick, A. J., Boulton, S. J. & Jackson, S. P. BRCA1-associated exclusion of 
53BP1 from DNA damage sites underlies temporal control of DNA repair. J. Cell Sci. 125, 
3529–34 (2012). 
548. Bunting, S. F. et al. 53BP1 inhibits homologous recombination in brca1-deficient cells by 
blocking resection of DNA breaks. Cell 141, 243–254 (2010). 
549. Helmink, B. A. et al. H2AX prevents CtIP-mediated DNA end resection and aberrant repair 
in G1-phase lymphocytes. Nature 469, 245–249 (2011). 
550. Rouet, P., Smih, F. & Jasin, M. Introduction of double-strand breaks into the genome of 
mouse cells by expression of a rare-cutting endonuclease. Mol. Cell. Biol. 14, 8096–106 
(1994). 
551. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with 
engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636–46 (2010). 
552. Wolfe, S. A., Nekludova, L. & Pabo, C. O. DNA recognition by Cys2His2 zinc finger proteins. 
Annu Rev Biophys Biomol Struct 29, 183–212 (2000). 
553. Silva, G. et al. Meganucleases and other tools for targeted genome engineering: 
perspectives and challenges for gene therapy. Curr. Gene Ther. 11, 11–27 (2011). 
554. Cabaniols, J.-P. et al. Meganuclease-driven targeted integration in CHO-K1 cells for the fast 
generation of HTS-compatible cell-based assays. J. Biomol. Screen. 15, 956–67 (2010). 
555. Sun, N. & Zhao, H. Transcription activator-like effector nucleases (TALENs): A highly 
efficient and versatile tool for genome editing. Biotechnol. Bioeng. 110, 1811–1821 (2013). 
556. Santiago, Y. et al. Targeted gene knockout in mammalian cells by using engineered zinc-
finger nucleases. Proc. Natl. Acad. Sci. U. S. A. 105, 5809–5814 (2008). 
557. Liu, P. et al. Generation of a triple-gene knockout mammalian cell line using engineered 
zinc-finger nucleases. Biotechnol. Bioeng. 106, 97–105 (2010). 
558. Cost, G. J. et al. BAK and BAX deletion using zinc-finger nucleases yields apoptosis-
resistant CHO cells. Biotechnol. Bioeng. 105, 330–40 (2010). 
559. Li, J. et al. Multiplexed, targeted gene editing in Nicotiana benthamiana for glyco-
engineering and monoclonal antibody production. Plant Biotechnol J (2015). 
doi:10.1111/pbi.12403 
560. Kim, H. & Kim, J.-S. A guide to genome engineering with programmable nucleases. Nat. Rev. 
Genet. 15, 321–34 (2014). 
561. Carroll, D. Genome engineering with targetable nucleases. Annu. Rev. Biochem. 83, 409–39 
(2014). 
562. Marraffini, L. A. & Sontheimer, E. J. CRISPR interference: RNA-directed adaptive immunity 
in bacteria and archaea. Nat. Rev. Genet. 11, 181–90 (2010). 
563. Koonin, E. V & Makarova, K. S. CRISPR-Cas: evolution of an RNA-based adaptive immunity 
system in prokaryotes. RNA Biol. 10, 679–86 (2013). 
564. Barrangou, R. & Marraffini, L. A. CRISPR-cas systems: Prokaryotes upgrade to adaptive 
immunity. Molecular Cell 54, 234–244 (2014). 
565. Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. 
Science 327, 167–170 (2010). 
566. Wiedenheft, B., Sternberg, S. H. & Doudna, J. a. RNA-guided genetic silencing systems in 
bacteria and archaea. Nature 482, 331–338 (2012). 
  296 
567. Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas Systems in Bacteria and Archaea: 
Versatile Small RNAs for Adaptive Defense and Regulation. Annu. Rev. Genet. 45, 273–297 
(2011). 
568. Terns, M. P. & Terns, R. M. CRISPR-based adaptive immune systems. Current Opinion in 
Microbiology 14, 321–327 (2011). 
569. Haurwitz, R. E., Jinek, M., Wiedenheft, B., Zhou, K. & Doudna, J. A. Sequence- and structure-
specific RNA processing by a CRISPR endonuclease. Science 329, 1355–8 (2010). 
570. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor 
RNase III. Nature 471, 602–607 (2011). 
571. Gesner, E. M., Schellenberg, M. J., Garside, E. L., George, M. M. & Macmillan, A. M. 
Recognition and maturation of effector RNAs in a CRISPR interference pathway. Nat. 
Struct. Mol. Biol. 18, 688–692 (2011). 
572. Sashital, D. G., Jinek, M. & Doudna, J. a. An RNA-induced conformational change required 
for CRISPR RNA cleavage by the endoribonuclease Cse3. Nat. Struct. Mol. Biol. 18, 680–7 
(2011). 
573. Lintner, N. G. et al. The structure of the CRISPR-associated protein csa3 provides insight 
into the regulation of the CRISPR/Cas system. J. Mol. Biol. 405, 939–955 (2011). 
574. Makarova, K. S., Wolf, Y. I. & Koonin, E. V. Comparative genomics of defense systems in 
archaea and bacteria. Nucleic Acids Res. 41, 4360–4377 (2013). 
575. Makarova, K. S. et al. An updated evolutionary classification of CRISPR-Cas systems. Nat. 
Rev. Microbiol. 13, 722–736 (2015). 
576. Makarova, K. S. & Koonin, E. V. Annotation and classification of CRISPR-Cas systems. 
Methods Mol. Biol. 1311, 47–75 (2015). 
577. Marraffini, L. A. & Sontheimer, E. J. CRISPR interference limits horizontal gene transfer in 
staphylococci by targeting DNA. Science (80-. ). 322, 1843–1845 (2008). 
578. Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides 
immunity in Escherichia coli. Nucleic Acids Res. 39, 9275–9282 (2011). 
579. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial 
immunity. Science 337, 816–21 (2012). 
580. Makarova, K. S., Grishin, N. V, Shabalina, S. A., Wolf, Y. I. & Koonin, E. V. A putative RNA-
interference-based immune system in prokaryotes: computational analysis of the 
predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and 
hypothetical mechanisms of action. Biol. Direct 1, 7 (2006). 
581. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 
31, 827–32 (2013). 
582. Zhou, Y. et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics 
in human cells. Nature 509, 487–91 (2014). 
583. Ma, H. et al. Multiplexed labeling of genomic loci with dCas9 and engineered sgRNAs using 
CRISPRainbow. Nat. Biotechnol. 34, 528–530 (2016). 
584. Kimura, Y. et al. CRISPR/Cas9-mediated reporter knock-in in mouse haploid embryonic 
stem cells. Sci. Rep. 5, 10710 (2015). 
585. Krentz, N. a. J., Nian, C. & Lynn, F. C. TALEN/CRISPR-Mediated eGFP Knock-In Add-On at 
the OCT4 Locus Does Not Impact Differentiation of Human Embryonic Stem Cells towards 
Endoderm. PLoS One 9, e114275 (2014). 
586. Wang, L. et al. Large genomic fragment deletion and functional gene cassette knock-in via 
Cas9 protein mediated genome editing in one-cell rodent embryos. Sci. Rep. 5, 17517 
(2015). 
587. Chu, V. T. et al. Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in 
C57BL/6 zygotes. BMC Biotechnol. 16, 4 (2016). 
588. Kimura, Y., Hisano, Y., Kawahara, A. & Higashijima, S. Transgenic Zebrafish Carrying 
Reporter /. 1–7 (2014). doi:10.1038/srep06545 
589. Lee, J. S., Kallehauge, T. B., Pedersen, L. E. & Kildegaard, H. F. Site-specific integration in 
CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair pathway. Sci. Rep. 
5, 8572 (2015). 
590. Wang, Z. et al. CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and 
Accelerate Viral Escape. Cell Rep. 15, 481–489 (2016). 
591. Reardon, S. First CRISPR clinical trial gets green light from US panel. Nature (2016). 
doi:10.1038/nature.2016.20137 
  297 
592. WuXi Biologics. Case Study: FUT8 KO using CRISPR/Cas9 Technology. Available at: 
http://www.wuxibiologics.com/client-support-resources-2/case-studies-for-
development-services/.  
593. Grindley, N. D. F., Whiteson, K. L. & Rice, P. a. Mechanisms of site-specific recombination. 
Annu. Rev. Biochem. 75, 567–605 (2006). 
594. Turan, S. & Bode, J. Site-specific recombinases: from tag-and-target- to tag-and-exchange-
based genomic modifications. FASEB J. 25, 4088–4107 (2011). 
595. Holliday, R. A mechanism for gene conversion in fungi. Genet. Res. 5, 282–304 (1964). 
596. Landy, A. Dynamic, Structural, and Regulatory Aspects of lambda Site-Specific 
Recombination. Annu. Rev. Biochem. 58, 913–941 (1989). 
597. Kuhstoss, S. & Rao, R. N. Analysis of the integration function of the streptomycete 
bacteriophage phi C31. Journal of molecular biology 222, 897–908 (1991). 
598. Groth,  a C., Olivares, E. C., Thyagarajan, B. & Calos, M. P. A phage integrase directs efficient 
site-specific integration in human cells. Proc. Natl. Acad. Sci. U. S. A. 97, 5995–6000 (2000). 
599. Ma, Q. wen et al. Identification of pseudo attP sites for phage ??{symbol}C31 integrase in 
bovine genome. Biochem. Biophys. Res. Commun. 345, 984–988 (2006). 
600. Bi, Y. et al. Pseudo attP sites in favor of transgene integration and expression in cultured 
porcine cells identified by streptomyces phage phiC31 integrase. BMC Mol. Biol. 14, 20 
(2013). 
601. Sternberg, N. & Hamilton, D. Bacteriophage P1 site-specific recombination. I. 
Recombination between loxP sites. J. Mol. Biol. 150, 467–486 (1981). 
602. Hoess, R. H., Ziese, M. & Sternberg, N. P1 site-specific recombination: nucleotide sequence 
of the recombining sites. Proc. Natl. Acad. Sci. U. S. A. 79, 3398–3402 (1982). 
603. Seibler, J., Sch??beler, D., Fiering, S., Groudine, M. & Bode, J. DNA cassette exchange in ES 
cells mediated by FLF recombinase: An efficient strategy for repeated modification of 
tagged loci by marker-free constructs. Biochemistry 37, 6229–6234 (1998). 
604. Verhoeyen, E., Hauser, H. & Wirth, D. Evaluation of retroviral vector design in defined 
chromosomal loci by Flp-mediated cassette replacement. Hum. Gene Ther. 12, 933–944 
(2001). 
605. Loonstra, A. et al. Growth inhibition and DNA damage induced by Cre recombinase in 
mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 98, 9209–14 (2001). 
606. Schmidt-Supprian, M. & Rajewsky, K. Vagaries of conditional gene targeting. Nat. Immunol. 
8, 665–668 (2007). 
607. Lee, G. & Saito, I. Role of nucleotide sequences of loxP spacer region in Cre-mediated 
recombination. Gene 216, 55–65 (1998). 
608. Lee, J. & Jayaram, M. Role of partner homology in DNA recombination: Complementary 
base pairing orients the 5???-hydroxyl for strand joining during Flp site-specific 
recombination. J. Biol. Chem. 270, 4042–4052 (1995). 
609. Umlauf, S. W. & Cox, M. M. The functional significance of DNA sequence structure in a site-
specific genetic recombination reaction. EMBO J. 7, 1845–52 (1988). 
610. Albert, H., Dale, E. C., Lee, E. & Ow, D. W. Site-specific integration of DNA into wild-type and 
mutant lox sites placed in the plant genome. Plant J. 7, 649–659 (1995). 
611. Araki, K., Araki, M. & Yamamura, K. Targeted integration of DNA using mutant lox sites in 
embryonic stem cells. Nucleic Acids Res. 25, 868–72 (1997). 
612. Hoess, R. H., Wierzbicki, A. & Abremski, K. The role of the loxP spacer region in P1 site-
specific recombination. Nucleic Acids Res. 14, 2287–300 (1986). 
613. Branda, C. S. & Dymecki, S. M. Talking about a revolution: The impact of site-specific 
recombinases on genetic analyses in mice. Developmental Cell 6, 7–28 (2004). 
614. Wiberg, F. C. et al. Production of target-specific recombinant human polyclonal antibodies 
in mammalian cells. Biotechnol. Bioeng. 94, 396–405 (2006). 
615. McLeod, M., Craft, S. & Broach, J. R. Identification of the crossover site during FLP-mediated 
recombination in the Saccharomyces cerevisiae plasmid 2 microns circle. Mol. Cell. Biol. 6, 
3357–67 (1986). 
616. Buchholz, F., Angrand, P. O. & Stewart,  a F. Improved properties of FLP recombinase 
evolved by cycling mutagenesis. Nat. Biotechnol. 16, 657–662 (1998). 
617. Schlake, T. & Bode, J. Use of mutated FLP recognition target (FRT) sites for the exchange of 
expression cassettes at defined chromosomal loci. Biochemistry 33, 12746–12751 (1994). 
618. Gaj, T. & Barbas, C. F. Genome engineering with custom recombinases. Methods Enzymol. 
  298 
546, 79–91 (2014). 
619. Gaj, T., Mercer, A. C., Sirk, S. J., Smith, H. L. & Barbas, C. F. A comprehensive approach to zinc-
finger recombinase customization enables genomic targeting in human cells. Nucleic Acids 
Res. 41, 3937–3946 (2013). 
620. Maeder, M. L., Thibodeau-Beganny, S., Sander, J. D., Voytas, D. F. & Joung, J. K. Oligomerized 
pool engineering (OPEN): an ‘open-source’ protocol for making customized zinc-finger 
arrays. Nat. Protoc. 4, 1471–501 (2009). 
621. Sander, J. D. et al. Selection-free zinc-finger-nuclease engineering by context-dependent 
assembly (CoDA). Nat. Methods 8, 67–9 (2011). 
622. Kaern, M., Elston, T. C., Blake, W. J. & Collins, J. J. Stochasticity in gene expression: from 
theories to phenotypes. Nat. Rev. Genet. 6, 451–464 (2005). 
623. Lai, T., Yang, Y. & Ng, S. K. Advances in Mammalian Cell Line Development Technologies. 
579–603 (2013). doi:10.3390/ph6050579 
624. Ng, S. K. Generation of high-expressing cells by methotrexate amplification of destabilized 
dihydrofolate reductase selection marker. Methods Mol. Biol. 801, 161–172 (2012). 
625. Westwood, A. D., Rowe, D. A. & Clarke, H. R. G. Improved recombinant protein yield using 
a codon deoptimized DHFR selectable marker in a CHEF1 expression plasmid. Biotechnol. 
Prog. 26, 1558–1566 (2010). 
626. Ho, S. C. L. et al. IRES-mediated Tricistronic vectors for enhancing generation of high 
monoclonal antibody expressing CHO cell lines. J. Biotechnol. 157, 130–139 (2012). 
627. Yenofsky, R. L., Fine, M. & Pellow, J. W. A mutant neomycin phosphotransferase II gene 
reduces the resistance of transformants to antibiotic selection pressure. Proc. Natl. Acad. 
Sci. U. S. A. 87, 3435–9 (1990). 
628. Chin, C. L. S. H. C. L., Chin, H. K., Chin, C. L. S. H. C. L., Lai, E. T. & Ng, S. K. Engineering selection 
stringency on expression vector for the production of recombinant human alpha1-
antitrypsin using Chinese Hamster ovary cells. BMC Biotechnol. 15, 44 (2015). 
629. Alt, F. W., Kellems, R. E. & Schimke, R. T. Synthesis and degradation of folate reductase in 
sensitive and methotrexate-resistant lines of S-180 cells. J Biol Chem 251, 3063–3074 
(1976). 
630. Gandor, C., Leist, C., Fiechter, A. & Asselbergs, F. A. M. Amplification and expression of 
recombinant genes in serum-independent Chinese hamster ovary cells. FEBS Lett. 377, 
290–294 (1995). 
631. Pallavicini, M. G., DeTeresa, P. S., Rosette, C., Gray, J. W. & Wurm, F. M. Effects of methotrexate 
on transfected DNA stability in mammalian cells. Mol. Cell. Biol. 10, 401–404 (1990). 
632. Simonsen, C. C. & Levinson,  a D. Isolation and expression of an altered mouse 
dihydrofolate reductase cDNA. Proc. Natl. Acad. Sci. U. S. A. 80, 2495–2499 (1983). 
633. Wirth, M., Bode, J., Zettlmeissl, G. & Hauser, H. Isolation of overproducing recombinant 
mammalian cell lines by a fast and simple selection procedure. Gene 73, 419–426 (1988). 
634. Kaufman, R. J., Murtha, P., Ingolia, D. E., Yeung, C. Y. & Kellems, R. E. Selection and 
amplification of heterologous genes encoding adenosine deaminase in mammalian cells. 
Proc. Natl. Acad. Sci. U. S. A. 83, 3136–3140 (1986). 
635. Fan, L. et al. Improving the efficiency of CHO cell line generation using glutamine 
synthetase gene knockout cells. Biotechnol. Bioeng. 109, 1007–15 (2012). 
636. Browne, S. M. & Al-Rubeai, M. Selection methods for high-producing mammalian cell lines. 
Trends Biotechnol. 25, 425–32 (2007). 
637. Barnes, L. M., Bentley, C. M. & Dickson, A. J. Molecular Definition of Predictive Indicators of 
Stable Protein Expression in Recombinant NSO Myeloma Cells. Biotechnol. Bioeng. 85, 
115–121 (2004). 
638. Gorman, C. M., Howard, B. H. & Reeves, R. Expression of recombinant plasmids in 
mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res 11, 7631–7648 
(1983). 
639. Mazur, X., Fussenegger, M., Renner, W. a & Bailey, J. E. Higher productivity of growth-
arrested Chinese hamster ovary cells expressing the cyclin-dependent kinase inhibitor 
p27. Biotechnol. Prog. 14, 705–13 (1998). 
640. Puck, T. T. & Marcus, P. I. A RAPID METHOD FOR VIABLE CELL TITRATION AND CLONE 
PRODUCTION WITH HELA CELLS IN TISSUE CULTURE: THE USE OF X-IRRADIATED CELLS 
TO SUPPLY CONDITIONING FACTORS. Proc. Natl. Acad. Sci. U. S. A. 41, 432–7 (1955). 
641. Anne Underwood, P. & Bean, P. A. Hazards of the limiting-dilution method of cloning 
  299 
hybridomas. J. Immunol. Methods 107, 119–128 (1988). 
642. Yang, G. & Withers, S. G. Ultrahigh-throughput FACS-based screening for directed enzyme 
evolution. ChemBioChem 10, 2704–2715 (2009). 
643. Marder, P., Maciak, R. S., Fouts, R. L., Baker, R. S. & Starling, J. J. Selective cloning of 
hybridoma cells for enhanced immunoglobulin production using flow cytometric cell 
sorting and automated laser nephelometry. Cytometry 11, 498–505 (1990). 
644. DeMaria, C. T. et al. Accelerated clone selection for recombinant CHO CELLS using a FACS-
based high-throughput screen. Biotechnol. Prog. 23, 465–472 (2007). 
645. Meng, Y. G., Liang, J., Lee, W. & Chisholm, V. Green fluorescent protein as a second selectable 
marker for selection of high producing clones from transfected CHO cells. 242, 201–207 
(2000). 
646. Mancia, F. et al. Optimization of protein production in mammalian cells with a coexpressed 
fluorescent marker. Structure 12, 1355–60 (2004). 
647. Yoshikawa, T. et al. Flow cytometry: an improved method for the selection of highly 
productive gene-amplified CHO cells using flow cytometry. Biotechnol. Bioeng. 74, 435–
442 (2001). 
648. Powell, K. T. & Weaver, J. C. Gel microdroplets and flow cytometry: rapid determination of 
antibody secretion by individual cells within a cell population. Biotechnol. (Nature Publ. 
Company) 8, 333–7 (1990). 
649. Weaver, J. C., McGrath, P. & Adams, S. Gel microdrop technology for rapid isolation of rare 
and high producer cells. Nat. Med. 3, 583–585 (1997). 
650. Borth, N., Zeyda, M., Kunert, R. & Katinger, H. Efficient selection of high-producing 
subclones during gene amplification of recombinant Chinese hamster ovary cells by flow 
cytometry and cell sorting. Biotechnol. Bioeng. 71, 266–273 (2001). 
651. Koller, M. R. et al. High-throughput laser-mediated in situ cell purification with high purity 
and yield. Cytom. Part A 61, 153–161 (2004). 
652. Hanania, E. G. et al. Automated in situ measurement of cell-specific antibody secretion and 
laser-mediated purification for rapid cloning of highly-secreting producers. Biotechnol. 
Bioeng. 91, 872–876 (2005). 
653. Lee, C., Ly, C. & Sauerwald, T. High-throughput screening of cell lines expressing 
monoclonal antibodies. Bioprocess Int. 32–35 (2006). 
654. Xu, X. et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat. 
Biotechnol. 29, 735–741 (2011). 
655. Baik, J. Y. et al. Initial transcriptome and proteome analyses of low culture temperature-
induced expression in CHO cells producing erythropoietin. Biotechnol. Bioeng. 93, 361–
371 (2006). 
656. Yee, J. C., Gerdtzen, Z. P. & Hu, W. S. Comparative transcriptome analysis to unveil genes 
affecting recombinant protein productivity in mammalian cells. Biotechnol. Bioeng. 102, 
246–263 (2009). 
657. Schepers, K. et al. Dissecting T cell lineage relationships by cellular barcoding. J. Exp. Med. 
205, 2309–18 (2008). 
658. van Heijst, J. W. J. et al. Recruitment of antigen-specific CD8+ T cells in response to infection 
is markedly efficient. Science 325, 1265–1269 (2009). 
659. Gerrits, A. et al. Cellular barcoding tool for clonal analysis in the hematopoietic system. 
Blood 115, 2610–8 (2010). 
660. Cheung, A. M. S. et al. Analysis of the clonal growth and differentiation dynamics of 
primitive barcoded human cord blood cells in NSG mice. Blood 122, 3129–37 (2013). 
661. Lu, R., Neff, N. F., Quake, S. R. & Weissman, I. L. Tracking single hematopoietic stem cells in 
vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat. 
Biotechnol. 29, 928–933 (2011). 
662. Gerlach, C. et al. Heterogeneous differentiation patterns of individual CD8+ T cells. Science 
340, 635–9 (2013). 
663. Livet, J. et al. Transgenic strategies for combinatorial expression of fluorescent proteins in 
the nervous system. Nature 450, 56–62 (2007). 
664. Naik, S. H., Schumacher, T. N. & Perie , L. Cellular barcoding: A technical appraisal. Exp. 
Hematol. 42, 598–608 (2014). 
665. Peikon, I. D., Gizatullina, D. I. & Zador, A. M. In vivo generation of DNA sequence diversity 
for cellular barcoding. Nucleic Acids Res. 42, 1–10 (2014). 
  300 
666. Maeda, N. et al. Development of a DNA barcode tagging method for monitoring dynamic 
changes in gene expression by using an ultra high-throughput sequencer. Biotechniques 
45, 95–97 (2008). 
667. Hoffmann, C. et al. DNA bar coding and pyrosequencing to identify rare HIV drug 
resistance mutations. Nucleic Acids Res. 35, e91–e91 (2007). 
668. Hillenmeyer, M. E. et al. The chemical genomic portrait of yeast: uncovering a phenotype 
for all genes. Science (80-. ). 320, 362–365 (2008). 
669. Smith, A. M. et al. Quantitative phenotyping via deep barcode sequencing. Genome Res. 19, 
1836–1842 (2009). 
670. Robinson, D. G., Chen, W., Storey, J. D. & Gresham, D. Design and analysis of Bar-seq 
experiments. G3 (Bethesda). 4, 11–8 (2014). 
671. Gresham, D. et al. System-level analysis of genes and functions affecting survival during 
nutrient starvation in Saccharomyces cerevisiae. Genetics 187, 299–317 (2011). 
672. Naik, S. H., Schumacher, T. N. & Perie , L. Cellular barcoding: A technical appraisal. Exp. 
Hematol. 42, 598–608 (2014). 
673. Filion, G. J. The TRiP technology. Available at: 
http://www.genomearchitecture.com/research-lines.  
674. Cellecta. CellTrackerTM Lentiviral Barcode Library. Available at: 
https://www.cellecta.com/products-services/cellecta-pooled-lentiviral-
libraries/celltracker-lentiviral-barcode-library/.  
675. Bhang, H. C. et al. Studying clonal dynamics in response to cancer therapy using high-
complexity barcoding. Nat. Med. 21, 440–8 (2015). 
676. Sancho, P. et al. MYC/PGC-1?? balance determines the metabolic phenotype and plasticity 
of pancreatic cancer stem cells. Cell Metab. 22, 590–605 (2015). 
677. Zufferey, R. et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene 
Delivery Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery. 72, 
(1998). 
678. ATCC. 293T (ATCC® CRL-3216TM) Available at: https://www.lgcstandards-
atcc.org/Products/All/CRL-3216.aspx?geo_country=gb.  
679. Lund, A. H., Duch, M. & Pedersen, F. S. Increased cloning efficiency by temperature-cycle 
ligation. Nucleic Acid Res. 24, 1996–1997 (1996). 
680. Inoue, H., Nojima, H., 0kayama, H. High efficiency transformation of Escherichia coli with 
plasmids. Gene 96, 23–28 (1990). 
681. Naldini, L., Blo mer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, 
and sustained long-term expression of the transgene in adult rat brains injected with a 
lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 93, 11382–8 (1996). 
682. Dull, T. et al. A Third-Generation Lentivirus Vector with a Conditional Packaging System A 
Third-Generation Lentivirus Vector with a Conditional Packaging System. 72, (1998). 
683. White, S. M. et al. Lentivirus vectors using human and simian immunodeficiency virus 
elements. J. Virol. 73, 2832–40 (1999). 
684. Shimada, H., Obayashi, T., Takahashi, N., Matsui, M. & Sakamoto, A. Normalization using 
ploidy and genomic DNA copy number allows absolute quantification of transcripts, 
proteins and metabolites in cells. Plant Methods 6, 9 (2010). 
685. Rand, K. N. et al. Headloop suppression PCR and its application to selective amplification 
of methylated DNA sequences. Nucleic Acids Res. 33, 1–11 (2005). 
686. Blankenberg, D. et al. Galaxy: A web-based genome analysis tool for experimentalists. Curr. 
Protoc. Mol. Biol. 1–21 (2010). doi:10.1002/0471142727.mb1910s89 
687. Afgan, E. et al. The Galaxy platform for accessible, reproducible and collaborative 
biomedical analyses: 2016 update. Nucleic Acids Res. gkw343 (2016). 
doi:10.1093/nar/gkw343 
688. Goecks, J., Nekrutenko, A. & Taylor, J. Galaxy: a comprehensive approach for supporting 
accessible, reproducible, and transparent computational research in the life sciences. 
Genome Biol. 11, R86 (2010). 
689. Blankenberg, D. et al. Manipulation of FASTQ data with galaxy. Bioinformatics 26, 1783–
1785 (2010). 
690. Andrews, S. FastQC: a quality control tool for high throughput sequence data. Available at: 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc.  
691. Zorita, E., Cusco, P. & Filion, G. J. Sequence analysis Starcode : sequence clustering based 
  301 
on all-pairs search. 31, 1913–1919 (2015). 
692. Kent, W. J. BLAT - The BLAST-like alignment tool. Genome Res. 12, 656–664 (2002). 
693. Kent, W. J. et al. The Human Genome Browser at UCSC. Genome Res. 12, 996–1006 (2002). 
694. Quinlan, A. R. & Hall, I. M. BEDTools: A flexible suite of utilities for comparing genomic 
features. Bioinformatics 26, 841–842 (2010). 
695. Jurka, J. Repbase Update: A database and an electronic journal of repetitive elements. 
Trends in Genetics 16, 418–420 (2000). 
696. Hocum, J. D. et al. VISA--Vector Integration Site Analysis server: a web-based server to 
rapidly identify retroviral integration sites from next-generation sequencing. BMC 
Bioinformatics 16, 212 (2015). 
697. Sinici, I., Zarghooni, M., Tropak, M. B., Mahuran, D. J. & O zkara, H. A. Comparison of HCMV 
IE and EF-1α promoters for the stable expression of β-subunit of hexosaminidase in CHO 
cell lines. Biochem. Genet. 44, 173–180 (2006). 
698. Schambach, A. et al. Equal potency of gammaretroviral and lentiviral SIN vectors for 
expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol. Ther. 
13, 391–400 (2006). 
699. Zychlinski, D. et al. Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene 
Vectors. Mol. Ther. 16, 718–725 (2008). 
700. Montiel-Equihua, C. a et al. The β-globin locus control region in combination with the EF1α 
short promoter allows enhanced lentiviral vector-mediated erythroid gene expression 
with conserved multilineage activity. Mol. Ther. 20, 1400–9 (2012). 
701. Avedillo Diez, I. et al. Development of novel efficient SIN vectors with improved safety 
features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol. Pharm. 8, 1525–
1537 (2011). 
702. Qin, J. Y. et al. Systematic comparison of constitutive promoters and the doxycycline-
inducible promoter. PLoS One 5, (2010). 
703. Somers, A., , A. Omari, C.C. Ford, J.A. Mills, L. Ying, A., Sommer Gianotti, J.M. Jean, B.W. Smith, 
R. Lafyatis, M.F. Demierre, D.J. Weiss, D. L. & French, P. Gadue, G.J. Murphy, G. M. and D. N. 
K. Generation of transgene-free lung disease-specific human iPS cells using a single 
excisable lentiviral stem cell cassette. Stem Cells 28, 1728–1740 (2010). 
704. Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: A sequence logo generator. 
Genome Res. 14, 1188–1190 (2004). 
705. Hayashi, K., Nakazawa, M., Ishizaki, Y., Hiraoka, N. & Obayashi, A. Regulation of inter- and 
intramolecular ligation with T4 DNA ligase in the presence of polyethylene glycol. Nucleic 
Acids Res. 14, 7617–7631 (1986). 
706. Bystrykh, L. V. Generalized DNA barcode design based on Hamming codes. PLoS One 7, 
e36852 (2012). 
707. Buschmann, T. & Bystrykh, L. V. Levenshtein error-correcting barcodes for multiplexed 
DNA sequencing. BMC Bioinformatics 14, 272 (2013). 
708. Levenshtein, V. I. Binary codes capable of correcting deletions, insertions, and reversals. 
Sov. Phys. Dokl. 10, 707–710 (1966). 
709. Chao, A., Pan, H. Y. & Chiang, S. C. The Petersen - Lincoln estimator and its extension to 
estimate the size of a shared population. Biometrical J. 50, 957–970 (2008). 
710. Chapman D.G. Some properties of the hypergeometric distribution with applications to 
zoological sample censuses. Publ. Stat. 131–160 (1951). 
711. Krebs, C. J. Ecological Methodology. Harper and Row (1989). doi:10.1007/s007690000247 
712. Seber, G. a F. The estimation of animal abundance and related parameters. New York 2, 654 
(1982). 
713. Feller, W. An Introduction to Probability Theory and Its Applications. Wiley 2, (1968). 
714. McInerney, P., Adams, P. & Hadi, M. Z. Error Rate Comparison during Polymerase Chain 
Reaction by DNA Polymerase. Mol. Biol. Int. 2014, 287430 (2014). 
715. Fehse, B., Kustikova, O. S., Bubenheim, M. & Baum, C. Pois(s)on – It’s a Question of Dose…. 
Gene Ther. 11, 879–881 (2004). 
716. Kustikova, O. S. et al. Dose finding with retroviral vectors: correlation of retroviral vector 
copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102, 
3934–7 (2003). 
717. Nolan-Stevaux, O. et al. Measurement of Cancer Cell Growth Heterogeneity through 
Lentiviral Barcoding Identifies Clonal Dominance as a Characteristic of In Vivo Tumor 
  302 
Engraftment. PLoS One 8, (2013). 
718. Boettcher, M. et al. Decoding pooled RNAi screens by means of barcode tiling arrays. BMC 
Genomics 11, 7 (2010). 
719. Zhang, B. et al. The significance of controlled conditions in lentiviral vector titration and 
in the use of multiplicity of infection (MOI) for predicting gene transfer events. Genet. 
Vaccines Ther. 2, 6 (2004). 
720. Ellis, J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene 
Ther. 16, 1241–6 (2005). 
721. La ngle-Rouault, F. et al. Up to 100-fold increase of apparent gene expression in the 
presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear 
import of plasmids. J. Virol. 72, 6181–5 (1998). 
722. Jager, V. et al. High level transient production of recombinant antibodies and antibody 
fusion proteins in HEK293 cells. BMC Biotechnol 13, (2013). 
723. Tsai, Y.-C. et al. Linear correlation between average fluorescence intensity of green 
fluorescent protein and the multiplicity of infection of recombinant adenovirus. J. Biomed. 
Sci. 22, 31 (2015). 
724. Charrier, S. et al. Quantification of lentiviral vector copy numbers in individual 
hematopoietic colony-forming cells shows vector dose-dependent effects on the 
frequency and level of transduction. Gene Ther. 18, 479–487 (2011). 
725. Bystrykh, L. V., de Haan, G. & Verovskaya, E. in Methods in Molecular Biology (ed. Qu, K. D. 
B. and C.-K.) 345–360 (2014). doi:10.1007/978-1-4939-1133-2_23 
726. Worthington, M. T., Pelo, J. & Luo, R. Q. Cloning of random oligonucleotides to create single-
insert plasmid libraries. Anal. Biochem. 294, 169–175 (2001). 
727. Watson, R. J., Schildraut, I., Qiang, B. Q., Martin, S. M. & Visentin, L. P. NdeI: a restriction 
endonuclease from Neisseria denitrificans which cleaves DNA at 5’-CATATG-3’ sequences. 
FEBS Lett. 150, 114–6 (1982). 
728. Wang, A. H. J., Hakoshima, T., van der Marel, G., van Boom, J. H. & Rich, A. AT base pairs are 
less stable than GC base pairs in Z-DNA: The crystal structure of d(m5CGTAm5CG). Cell 37, 
321–331 (1984). 
729. Gilles, A. et al. Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. 
BMC Genomics 12, 245 (2011). 
730. Cheung, A. M. S. et al. Analysis of the clonal growth and differentiation dynamics of 
primitive barcoded human cord blood cells in NSG mice. Blood 122, 3129–3137 (2013). 
731. Grosselin, J. et al. Arrayed lentiviral barcoding for quantification analysis of hematopoietic 
dynamics. Stem Cells 31, 2162–2171 (2013). 
732. Verovskaya, E. et al. Heterogeneity of young and aged murine hematopoietic stem cells 
revealed by quantitative clonal analysis using cellular barcoding. Blood 122, 523–32 
(2013). 
733. Cornils, K. et al. Multiplexing clonality: Combining RGB marking and genetic barcoding. 
Nucleic Acids Res. 42, (2014). 
734. Lu Rong, Neff Norma, Quake Stephen, W. I. Tracking single hematopoietic stem cells in vivo 
using high-throughput sequencing in conjunction with viral genetic barcoding. Nat. 
Biotechnol. 29, 928–933 (2012). 
735. Brugman, M. H. et al. Development of a diverse human T-cell repertoire despite stringent 
restriction of hematopoietic clonality in the thymus. Proc. Natl. Acad. Sci. U. S. A. 112, 
E6020-7 (2015). 
736. Porter, S. N., Baker, L. C., Mittelman, D. & Porteus, M. H. Lentiviral and targeted cellular 
barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo. Genome Biol. 
15, R75 (2014). 
737. Peshwa, M. V., Kyung, Y. S., McClure, D. B. & Hu, W. S. Cultivation of mammalian cells as 
aggregates in bioreactors: Effect of calcium concentration on spatial distribution of 
viability. Biotechnol. Bioeng. 41, 179–187 (1993). 
738. Wu, J., Rostami, M. R., Cadavid Olaya, D. P. & Tzanakakis, E. S. Oxygen transport and stem 
cell aggregation in stirred-suspension bioreactor cultures. PLoS One 9, (2014). 
739. Renner, W. A., Jordan, M., Eppenberger, H. M. & Leist, C. Cell-cell adhesion and aggregation: 
Influence on the growth behavior of CHO cells. Biotechnol. Bioeng. 41, 188–193 (1993). 
740. Grell, M. et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 
and CD30: A role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 
  303 
18, 3034–3043 (1999). 
741. Houtz B, Trotter J, S. Tips on Cell Preparation for Flow Cytometric Analysis and Sorting. BD 
FACService Technotes Vol.4. p 3 (2004). Available at: 
https://www.bdbiosciences.com/documents/BD_Research_Sorting_TechBulletin.pdf.  
742. Covault, J., Liu, Q. yang & El-Deeb, S. Calcium-activated proteolysis of intracellular domains 
in the cell adhesion molecules NCAM and N-cadherin. Mol. Brain Res. 11, 11–16 (1991). 
743. Oppenheimer-Marks, N. & Grinnell, F. Calcium ions protect cell-substratum adhesion 
receptors against proteolysis. Evidence from immunoabsorption and electroblotting 
studies. Exp. Cell Res. 152, 467–475 (1984). 
744. Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre reactors. 
Nature 437, 376–80 (2005). 
745. Dohm, J. C., Lottaz, C., Borodina, T. & Himmelbauer, H. Substantial biases in ultra-short read 
data sets from high-throughput DNA sequencing. Nucleic Acids Res. 36, e105–e105 (2008). 
746. Eid, J. et al. Real-time DNA sequencing from single polymerase molecules. Science 323, 
133–138 (2009). 
747. Liu, H. S., Jan, M. S., Chou, C. K., Chen, P. H. & Ke, N. J. Is green fluorescent protein toxic to 
the living cells? Biochem. Biophys. Res. Commun. 260, 712–7 (1999). 
748. Bartz, S. R. & Vodicka, M. a. Production of high-titer human immunodeficiency virus type 
1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12, 337–342 (1997). 
749. Appelt, J.-U. et al. QuickMap: a public tool for large-scale gene therapy vector insertion site 
mapping and analysis. Gene Ther. 16, 885–893 (2009). 
750. Huston, M. W. et al. Comprehensive investigation of parameter choice in viral integration 
site analysis and its effects on the gene annotations produced. Hum. Gene Ther. 23, 1209–
19 (2012). 
751. Calabria, A. et al. VISPA: a computational pipeline for the identification and analysis of 
genomic vector integration sites. Genome Med. 6, 67 (2014). 
752. Saiki, R. et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA 
polymerase. Science (80-. ). 239, 487–491 (1988). 
753. Ramsko ld, D. et al. Full-length mRNA-Seq from single-cell levels of RNA and individual 
circulating tumor cells. Nat. Biotechnol. 30, 777–82 (2012). 
754. Corney, D. C. RNA-seq Using Next Generation Sequencing. Mater. Methods 3, 203 (2013). 
755. Wu, X., Li, Y., Crise, B., Burgess, S. M. & Munroe, D. J. Weak palindromic consensus 
sequences are a common feature found at the integration target sites of many retroviruses. 
J Virol 79, 5211–5214 (2005). 
756. Bernard, P. & Allshire, R. C. Centromeres become unstuck without heterochromatin. Trends 
in Cell Biology 12, 419–424 (2002). 
757. Biffi, A. et al. Lentiviral vector common integration sites in preclinical models and a clinical 
trial reflect a benign integration bias and not oncogenic selection. Blood 117, 5332–9 
(2011). 
758. Mitchell, R. S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target 
site preferences. PLoS Biol. 2, (2004). 
759. Wang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C. & Bushman, F. D. HIV integration site selection : 
Analysis by massively parallel pyrosequencing reveals association with epigenetic 
modifications HIV integration site selection : Analysis by massively parallel 
pyrosequencing reveals association with epigenetic modificatio. 1186–1194 (2007). 
doi:10.1101/gr.6286907 
760. Moiani, A. et al. Genome-wide analysis of alpharetroviral integration in human 
hematopoietic stem/progenitor cells. Genes (Basel). 5, 415–429 (2014). 
761. Zheng, D. et al. Pseudogenes in the ENCODE regions: Consensus annotation, analysis of 
transcription, and evolution. Genome Res. 17, 839–851 (2007). 
762. Tutar, Y. Pseudogenes. Comparative and Functional Genomics 2012, (2012). 
763. Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. 
Nat. Rev. Mol. Cell Biol. 6, 9–20 (2005). 
764. Feng, L., Allen, N. S., Simo, S. & Cooper, J. A. Cullin 5 regulates Dab1 protein levels and 
neuron positioning during cortical development. Genes Dev. 21, 2717–2730 (2007). 
765. Burnatowska-Hledin, M. et al. VACM-1 receptor is specifically expressed in rabbit vascular 
endothelium and renal collecting tubule. Am J Physiol 276, F199–209. (1999). 
766. Kondoh, S. et al. A novel gene is disrupted at a 14q13 breakpoint of t(2;14) in a patient 
  304 
with mirror-image polydactyly of hands and feet. J. Hum. Genet. 47, 136–9 (2002). 
767. Hacein-bey-abina, S. & Schmidt, M. correspondence A Serious Adverse Event after 
Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency. 255–266 
(2003). 
768. Kivioja, T. et al. Counting absolute numbers of molecules using unique molecular 
identifiers. Nat. Methods 9, 72–74 (2011). 
769. Malausa, T. et al. High-throughput microsatellite isolation through 454 GS-FLX Titanium 
pyrosequencing of enriched DNA libraries. Mol. Ecol. Resour. 11, 638–644 (2011). 
770. Hodges, E. et al. Genome-wide in situ exon capture for selective resequencing. Nat. Genet. 
39, 1522–7 (2007). 
771. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively 
parallel targeted sequencing. Nat. Biotechnol. 27, 182–9 (2009). 
772. Gilmartin, G. M., Fleming, E. S. & Oetjen, J. Activation of HIV-1 pre-mRNA 3’ processing in 
vitro requires both an upstream element and TAR. EMBO J. 11, 4419–28 (1992). 
773. Zaiss, A.-K., Son, S. & Chang, L.-J. RNA 3’ readthrough of oncoretrovirus and lentivirus: 
implications for vector safety and efficacy. J. Virol. 76, 7209–7219 (2002). 
774. Robasky, K., Lewis, N. E. & Church, G. M. The role of replicates for error mitigation in next-
generation sequencing. Nat. Rev. Genet. 15, 56–62 (2014). 
775. Wilson, C., Bellen, H. J. & Gehring, W. J. Position effects on eukaryotic gene expression. 
Annu. Rev. Cell Biol. 6, 679–714 (1990). 
776. Yap, M. W., Kingsman, S. M. & Kingsman,  a. J. Effects of stoichiometry of retroviral 
components on virus production. J. Gen. Virol. 81, 2195–2202 (2000). 
777. Cong, L., Ran, F., Cox, D., Lin, S. & Barretto, R. Multiplex Genome Engineering Using CRISPR 
/ Cas Systems. Science (80-. ). 819, (2013). 
778. Lanza, A. M., Kim, D. S. & Alper, H. S. Evaluating the influence of selection markers on 
obtaining selected pools and stable cell lines in human cells. Biotechnol. J. 8, 811–821 
(2013). 
779. Ma, H. et al. Pol III Promoters to Express Small RNAs: Delineation of Transcription 
Initiation. Mol. Ther. Nucleic Acids 3, e161 (2014). 
780. Merzlyak, E. M. et al. Bright monomeric red fluorescent protein with an extended 
fluorescence lifetime. Nat Methods 4, 555–557 (2007). 
781. ECACC. ECACC Catalogue Entry for HEK 293. hpacultures.org.uk 
782. Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals 
characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32, 677–
683 (2014). 
783. Esvelt, K. M. et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. 
Nat Methods 10, 1116–1121 (2013). 
784. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–
2308 (2013). 
785. von Groll, A., Levin, Y., Barbosa, M. C. & Ravazzolo, A. P. Linear DNA low efficiency 
transfection by liposome can be improved by the use of cationic lipid as charge neutralizer. 
Biotechnol. Prog. 22, 1220–4 
786. Barnes, L. M., Bentley, C. M. & Dickson, A. J. Characterization of the stability of recombinant 
protein production in the GS-NS0 expression system. Biotechnol. Bioeng. 73, 261–70 
(2001). 
787. Barnes, L. M., Moy, N. & Dickson, A. J. Phenotypic variation during cloning procedures: 
analysis of the growth behavior of clonal cell lines. Biotechnol. Bioeng. 94, 530–537 (2006). 
788. Pilbrough, W., Munro, T. P. & Gray, P. Intraclonal protein expression heterogeneity in 
recombinant CHO cells. PLoS One 4, (2009). 
789. Cai, L., Friedman, N. & Xie, X. S. Stochastic protein expression in individual cells at the 
single molecule level. Nature 440, 358–362 (2006). 
790. Raj, A., Peskin, C. S., Tranchina, D., Vargas, D. Y. & Tyagi, S. Stochastic mRNA synthesis in 
mammalian cells. PLoS Biol. 4, 1707–1719 (2006). 
791. Kim, N. S., Kim, S. J. & Lee, G. M. Clonal variability within dihydrofolate reductase-mediated 
gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure. 
Biotechnol. Bioeng. 60, 679–688 (1998). 
792. Sung, K. Y., Sun, O. H. & Gyun, M. L. Enhancing effect of low culture temperature on specific 
antibody productivity of recombinant Chinese hamster ovary cells: Clonal variation. 
  305 
Biotechnol. Prog. 20, 1683–1688 (2004). 
793. Kim, S. H. & Lee, G. M. Differences in optimal pH and temperature for cell growth and 
antibody production between two Chinese hamster ovary clones derived from the same 
parental clone. J. Microbiol. Biotechnol. 17, 712–720 (2007). 
794. Yang, Y. & Seed, B. Site-specific gene targeting in mouse embryonic stem cells with intact 
bacterial artificial chromosomes. Nat. Biotechnol. 21, 447–51 (2003). 
795. Hendel, A. et al. Quantifying genome-editing outcomes at endogenous loci with SMRT 
sequencing. Cell Rep. 7, 293–305 (2014). 
796. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the 
CRISPR-Cas9 system. Science 343, 80–4 (2014). 
797. Merkle, F. T. et al. Efficient CRISPR-Cas9-Mediated Generation of Knockin Human 
Pluripotent Stem Cells Lacking Undesired Mutations at the Targeted Locus. Cell Rep. 11, 
875–883 (2015). 
798. Marshall, H. M. et al. Role of PSIP 1/LEDGF/p75 in lentiviral infectivity and integration 
targeting. PLoS One 2, (2007). 
799. Wu, X., Li, Y., Crise, B., Burgess, S. M. & Munroe, D. J. Weak Palindromic Consensus 
Sequences Are a Common Feature Found at the Integration Target Sites of Many 
Retroviruses Weak Palindromic Consensus Sequences Are a Common Feature Found at the 
Integration Target Sites of Many Retroviruses. 79, 5211–5214 (2005). 
800. Birol, I. et al. Assembling the 20 Gb white spruce (Picea glauca) genome from whole-
genome shotgun sequencing data. Bioinformatics 29, 1492–1497 (2013). 
801. Roberts, R. J., Carneiro, M. O. & Schatz, M. C. The advantages of SMRT sequencing. Genome 
Biol. 14, 405 (2013). 
802. Trachtenberg, E. A. & Holcomb, C. L. Next-generation HLA sequencing using the 454 GS 
FLX system. Methods Mol. Biol. 1034, 197–219 (2013). 
803. Hengen, P. N. Shearing DNA for genomic library construction. Trends Biochem Sci 22, 273–
274 (1997). 
804. Thorstenson, Y. R., Hunicke-Smith, S. P., Oefner, P. J. & Davis, R. W. An automated 
hydrodynamic process for controlled, unbiased DNA shearing. Genome Res. 8, 848–855 
(1998). 
805. Knierim, E., Lucke, B., Schwarz, J. M., Schuelke, M. & Seelow, D. Systematic comparison of 
three methods for fragmentation of long-range PCR products for next generation 
sequencing. PLoS One 6, (2011). 
806. Brady, T. et al. A method to sequence and quantify DNA integration for monitoring outcome 
in gene therapy. Nucleic Acids Res. 39, 1–8 (2011). 
807. Paruzynski, A. et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR 
and next-generation sequencing. Nat. Protoc. 5, 1379–1395 (2010). 
808. Barbosa, C., Peixeiro, I. & Roma o, L. Gene Expression Regulation by Upstream Open 
Reading Frames and Human Disease. PLoS Genetics 9, (2013). 
809. Ng, S. K., Wang, D. I. C. & Yap, M. G. S. Application of destabilizing sequences on selection 
marker for improved recombinant protein productivity in CHO-DG44. Metab. Eng. 9, 304–
316 (2007). 
810. Ikeda, Y. et al. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21, 569–572 
(2003). 
811. Bukovsky,  a a, Song, J. P. & Naldini, L. Interaction of human immunodeficiency virus-
derived vectors with wild-type virus in transduced cells. J. Virol. 73, 7087–7092 (1999). 
812. Lucke, S., Grunwald, T. & Uberla, K. Reduced mobilization of Rev-responsive element-
deficient lentiviral vectors. J. Virol. 79, 9359–62 (2005). 
813. Donnelly, M. L. L. et al. Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ 
mechanism indicates not a proteolytic reaction, but a novel translational effect: A putative 
ribosomal ‘skip’. J. Gen. Virol. 82, 1013–1025 (2001). 
  
  306 
Appendix 
A. Plasmids 
 
 
Plasmid map of pRRL SIN cPPT PGK eGFP WPRE 
 
Plasmid map of pCCLSIN hIDUA 
  307 
 
 
Plasmid map of pRRL SIN Synthetic LTR cPPT EFS eGFP WPRE + barcoded library 
(pSYNT) 
 
 
 
Plasmid map of pTELO 
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Plasmid map of pMKRQ BTW2R (positive control for qPCR) 
 
 
 
 
Plasmid map of pcDNA 3.1/Zeo from Thermo Fisher Scientific (Cat no. V86020)  
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Plasmid map of pU6-sgRNA EMX1 20nt position from Cong et al., from Sigma (Cat 
no.CRISPR01). 
 
 
Plasmid map of pCMV-Cas9 from Sigma (CAS9P)  
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Plasmid map of pCMV-Cas9 U6-sgRNA from Sigma (CUL 5 sgRNA) 
 
 
Plasmid map of pmax GFP (Nucleofection Kit V. Lonza  VCA-1003)  
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Plasmid Map of CellTracker® Lentiviral Barcode Library Vector (Cellecta) 
 
Plasmid map of GeneArt HA1-MCS-HA2 (Cong et al., EMX1) 
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Bioinformatic scripts 
Extract_barcode_library 
 
use warnings; 
 
$five_prime = "GACAAGATCCATATGAGTAA"; 
$N = qr/[ACGT]/; 
$W = qr/[AT]/; 
$S = qr/[GC]/; 
$barcode = qr/($N$N$N)ATC($N$S)GAT($N$N)AAA($N$N)GGT($N$W)AAC($N$N)TGA($N$N$N)/; 
$three_prime  = "TGGTAACACCGACTAGGATC"; 
 
$matched = 0; 
while (<>) { 
    /^@/ or die; 
    chomp; 
    /^\S+/; 
    $read_name = $&; 
    chomp($read = <>); 
    <>; 
    <>; 
 
    if (@barcode = ($read =~ /$five_prime$barcode$three_prime/)) { 
        print "$read_name\t" . join("-", @barcode) . "\n"; 
        $matched++; 
    } 
} 
 
print STDERR "Found $matched read (pairs) with a barcode.\n"; 
 
 
Extract_viral_insertion_barcodes 
 
use warnings; 
$input_file = shift; 
 
$MIN_LINKER_SCORE = 40; 
$MIN_LTR_SCORE = 60; 
$MIN_LTR2_SCORE = 30; 
$N = qr/[ACGT]/; 
$W = qr/[AT]/; 
$S = qr/[GC]/; 
$barcode_pattern = 
qr/($N$N$N)ATC($N$S)GAT($N$N)AAA($N$N)GGT($N$W)AAC($N$N)TGA($N$N$N)/; 
 
if (-e "$input_file.vs_linker") { 
    print STDERR "Skipping alignment to linker sequence as file '$input_file.vs_linker' 
already exists.\n"; 
} 
else { 
    print STDERR "Aligning merged sequences against Linker...\n"; 
    system "./ssearch36 -3 -m 8 $input_file linker.fa > $input_file.vs_linker"; 
} 
 
if (-e "$input_file.vs_ltr") { 
    print STDERR "Skipping alignment to ltr sequence as file '$input_file.vs_ltr' 
already exists.\n"; 
} 
else { 
    print STDERR "Aligning merged sequences against LTR1...\n"; 
    system "./ssearch36 -3 -m 8 $input_file ltr.fa > $input_file.vs_ltr"; 
} 
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if (-e "$input_file.vs_ltr2") { 
    print STDERR "Skipping alignment to ltr2 sequence as file '$input_file.vs_ltr2' 
already exists.\n"; 
} 
else { 
    print STDERR "Aligning merged sequences against LTR2...\n"; 
    system "./ssearch36 -3 -m 8 $input_file ltr2.fa > $input_file.vs_ltr2"; 
} 
 
print STDERR "Collecting alignment coordinates...\n"; 
open LINKER, "$input_file.vs_linker" or die $!; 
open LTR,    "$input_file.vs_ltr" or die $!; 
open LTR2,   "$input_file.vs_ltr2" or die $!; 
open SEQ,    $input_file or die $!; 
 
$matched = $total = 0; 
while ($linker = <LINKER>) { 
    $ltr = <LTR>; 
    $ltr2 = <LTR2>; 
    <SEQ>; 
    $seq = <SEQ>; 
    chomp $seq; 
    $total++; 
 
    @L1 = split /\t/, $linker; 
    @L2 = split /\t/, $ltr; 
    @L3 = split /\t/, $ltr2; 
 
    # Sanity check 
    if ($L1[0] ne $L2[0] || $L1[0] ne $L3[0]) { 
        die; 
    } 
 
    # A read that passes must align to linker and both LTRs. 
    # In this case extract barcode and host sequence.  
    # Finally make sure that the barcode is of right length and pattern. 
    if ($L1[11] < $MIN_LINKER_SCORE) { next; } 
    if ($L2[11] < $MIN_LTR_SCORE) { next; } 
    if ($L3[11] < $MIN_LTR2_SCORE) { next; } 
 
    # Extract the host sequence and the potential barcode sequence 
    if ($L2[6] <= $L1[7]) { 
        $host_seq = ""; 
    } 
    else { 
        $host_seq = substr($seq, $L1[7], $L2[6] - $L1[7] - 1); 
    } 
    if ($L3[6] <= $L2[7]) { 
        $barcode = ""; 
    } 
    else { 
        $barcode = substr($seq, $L2[7], $L3[6] - $L2[7] - 1); 
    } 
 
    # Barcode must match the expected pattern 
    if (@barcode = ($barcode =~ $barcode_pattern)) { 
        print join( 
            "\t", 
            $L1[0], 
            join("-", @barcode), 
            $host_seq, 
        ) . "\n"; 
 
        $matched++; 
    } 
} 
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print STDERR "Found $matched/$total read pairs with a barcode and host sequence.\n"; 
 
 
fastq_to_fasta 
 
use warnings; 
 
while ($name = <>) { 
    $name =~ s/^\@/>/ or die; 
    $seq = <>; 
    <>; 
    <>; 
 
    print $name; 
    print $seq; 
} 
 
 
extract_rt-pcr_barcodes.pl 
 
use warnings; 
$input_file = shift; 
 
$MIN_LTR_SCORE = 60; 
$MIN_LTR2_SCORE = 30; 
$N = qr/[ACGT]/; 
$W = qr/[AT]/; 
$S = qr/[GC]/; 
$barcode_pattern = 
qr/($N$N$N)ATC($N$S)GAT($N$N)AAA($N$N)GGT($N$W)AAC($N$N)TGA($N$N$N)/; 
 
if (-e "$input_file.vs_ltr") { 
    print STDERR "Skipping alignment to ltr sequence as file 
'$input_file.vs_ltr' already exists.\n"; 
} 
else { 
    print STDERR "Aligning merged sequences against LTR1...\n"; 
    system "./ssearch36 -3 -m 8 $input_file ltr.fa > $input_file.vs_ltr"; 
} 
 
if (-e "$input_file.vs_ltr2") { 
    print STDERR "Skipping alignment to ltr2 sequence as file 
'$input_file.vs_ltr2' already exists.\n"; 
} 
else { 
    print STDERR "Aligning merged sequences against LTR2...\n"; 
    system "./ssearch36 -3 -m 8 $input_file ltr2.fa > $input_file.vs_ltr2"; 
} 
 
print STDERR "Collecting alignment coordinates...\n"; 
open LTR,    "$input_file.vs_ltr" or die $!; 
open LTR2,   "$input_file.vs_ltr2" or die $!; 
open SEQ,    $input_file or die $!; 
 
$matched = $total = 0; 
while ($ltr = <LTR>) { 
    $ltr2 = <LTR2>; 
    <SEQ>; 
    $seq = <SEQ>; 
    chomp $seq; 
    $total++; 
 
    @L1 = split /\t/, $ltr; 
    @L2 = split /\t/, $ltr2; 
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    # Sanity check 
    if ($L1[0] ne $L2[0]) { 
        die; 
    } 
 
    # A read that passes must align both LTRs. 
    # Extract barcode and host sequence.  
    # Finally make sure that the barcode is of right length and pattern. 
    if ($L1[11] < $MIN_LTR_SCORE) { next; } 
    if ($L2[11] < $MIN_LTR2_SCORE) { next; } 
 
    # Extract the barcode sequence 
    if ($L2[6] <= $L1[7]) { 
        $barcode = ""; 
    } 
    else { 
        $barcode = substr($seq, $L1[7], $L2[6] - $L1[7] - 1); 
    } 
 
    # Barcode must match the expected pattern 
    if (@barcode = ($barcode =~ $barcode_pattern)) { 
        print join( 
            "\t", 
            $L1[0], 
            join("-", @barcode), 
        ) . "\n"; 
 
        $matched++; 
    } 
} 
 
print STDERR "Found $matched/$total read pairs with a barcode and host 
sequence.\n"; 
 
  
get_best_hit_from_psl 
 
use warnings; 
 
$MIN_ID_THRESHOLD = 0.999; 
 
# Parse first line 
chomp($_ = <>); 
@F = split /\t/; 
if ( 
    $F[10] != $F[12] ||  # Last base of the host sequence was aligned? 
    !last_base_is_a_match($F[8], $F[21], $F[22])  # The last base of the host sequence 
was a match? 
) { 
    $last_read = ""; 
} 
else { 
    $last_read = $F[9]; 
    $last_score = get_identity($F[10], $F[1], $F[5], $F[7]); 
    $last_strand = $F[8]; 
    $last_chr = $F[13]; 
    $last_start = $F[15]; 
    $last_end = $F[16]; 
    $last_length = $F[10]; 
    $multi_best_hit = 1; 
} 
 
while (<>) { 
    chomp; 
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    @F = split /\t/; 
 
    # As above, only accept host sequence alignments where the final base 
    # was part of the alignment and aligned to the reference as a match.  
    if ( 
        $F[10] != $F[12] || 
        !last_base_is_a_match($F[8], $F[21], $F[22]) 
    ) { 
        next; 
    } 
 
    $cur_score = get_identity($F[10], $F[1], $F[5], $F[7]); 
 
    # If we encountered a new host sequence, then print the best alignment 
    # of the previous host sequence (if identity threshold is exceeded). 
    # If we are still traversing the alignments of the current host sequence, 
    # then just keep colleting alignments.  
    if ($F[9] ne $last_read) { 
        # Print only if score/length >= identity 
        if ( 
            $last_read ne "" && 
            $last_score > $MIN_ID_THRESHOLD 
        ) { 
            print join( 
                "\t", 
                $last_chr, 
                $last_start-1,  # BED format start is 0-based 
                $last_end, 
                $last_read, 
                $last_score, 
                $last_strand, 
                $multi_best_hit 
            ) . "\n"; 
        } 
 
        $last_read = $F[9]; 
        $last_score = $cur_score; 
        $last_strand = $F[8]; 
        $last_chr = $F[13]; 
        $last_start = $F[15]; 
        $last_end = $F[16]; 
        $last_length = $F[10]; 
        $multi_best_hit = 1; 
    } 
    else { 
        if ($cur_score > $last_score) { 
            $last_read = $F[9]; 
            $last_score = $cur_score; 
            $last_strand = $F[8]; 
            $last_chr = $F[13]; 
            $last_start = $F[15]; 
            $last_end = $F[16]; 
            $last_length = $F[10]; 
            $multi_best_hit = 1; 
        } 
        elsif ($cur_score == $last_score) { 
            $multi_best_hit++; 
        } 
    } 
} 
 
if ( 
    $last_read ne "" && 
    $last_score > $MIN_ID_THRESHOLD 
) { 
    print join( 
  317 
        "\t", 
        $last_chr, 
        $last_start-1,  # BED format start is 0-based 
        $last_end, 
        $last_read, 
        $last_score, 
        $last_strand, 
        $multi_best_hit 
    ) . "\n"; 
} 
 
 
sub last_base_is_a_match { 
    if ($_[0] eq "+") { 
        return substr($_[1], -2, 1) eq substr($_[2], -2, 1); 
    } 
    else { 
        return substr($_[1], 0, 1) eq substr($_[2], 0, 1); 
    } 
} 
 
sub get_identity { 
    ($length, $mismatches, $insertions, $deletions) = @_; 
    return(1 - ($mismatches + $insertions + $deletions) / ($length + $insertions + 
$deletions)); 
} 
 
 
plot_plasmid_library_distributions.R 
 
library(stringdist) 
 
files = c( 
    # "PlasmidPCR_11.barcodes.txt", 
    # "PlasmidPCR_49.barcodes.txt" 
    "PlasmidPCR_11.starcode_barcodes.txt", 
    "PlasmidPCR_49.starcode_barcodes.txt" 
) 
minimum_frequency = 2 
 
cat("Running plot_plasmid_library_distributions.R...\n", file = stderr()) 
cat("Parameters:\n", file = stderr()) 
cat(paste("Input files: ", paste(files, collapse = " "), "\n", sep = ""), file 
= stderr()) 
cat(paste("Minimum frequency: ", minimum_frequency, "\n", sep = ""), file = 
stderr()) 
 
for (f in files) { 
    cat(paste("Analysing file ", f, "...\n", sep = ""), file = stderr()) 
    sample = sub("\\..+", "", f) 
    d = read.table(f, header = F, sep = "\t", stringsAsFactors = F) 
    c = table(d[,2]) 
    c.f = c[c>1] 
 
    pdf(paste(sample, ".clustering.pdf", sep = ""), w = 20, h = 8) 
    par(mfrow = c(2, 1), mar = c(0, 4, 4, 2) + .1) 
 
    hclust_res = hclust(as.dist(stringdistmatrix(names(c.f), names(c.f), method 
= "hamming"))) 
    plot(hclust_res, ylab = "Number of differences", xlab = "", sub = 
paste("Minimum frequency: ", minimum_frequency, sep = ""), labels = F, main = 
sample, lwd = 0.5) 
 
    par(mar = c(5, 4, 0, 2) + .1) 
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    plot(hclust_res$order, c.f, type = "h", bty = "n", ylim = c(3000, 0), xlab 
= "Barcodes", ylab = "Frequency", lwd = 0.5, xaxt = "n") 
    dev.off() 
 
    pdf(paste(sample, ".distribution.pdf", sep = "")) 
    plot(sort(c.f), (1:length(c.f))/length(c.f), type = "l", main = sample, 
xlab = "Frequency of barcode", ylab = "Cumulative density") 
    dev.off() 
} 
 
Barcode_error_correction.R 
#Determine dissimilarity between barcodes 
#create a results set, which is as long as the number of barcodes. 
results <- matrix(data=NA,nrow=dim(vals)[1],ncol=dim(vals)[1]) 
 
# Split the barcode string and compare the barcodes one by one, this is embarrasingly 
parallel  
# and could be done much faster (in a little bit more complicated way) than shown here. 
system.time( 
 for (i in 1:dim(dat)[1]) { 
  for (j in 1:dim(dat)[1]) { 
   results[i,j] <- sum(unlist(strsplit(rownames(dat)[i], split="")) 
!=  unlist(strsplit(rownames(dat)[j], split=""))) 
  } 
 }  
) 
 
#The results matrix now contains the number of bases that differ between each barcode 
#A histogram of the dissimilarity between the codes. 
pdf("Dissimillarity histogram.pdf") 
hist(results, main="Histogram of barcode dissimilarities") 
dev.off() 
 
# now threshold on the allowed number of mismatches (here 2) 
results2 <- results 
results2[results2 > 2 ] <- 0 
 
# load the igraph library and generate an graph based on the adjacency matrix we made 
library(igraph) 
g1 <- graph.adjacency(results2) 
 
 
# now can we use the cluster membership from the graph to determine which barcodes are  
# similar and sum all rows that belong to the same cluster.  
processed.dat <- rowsum(dat, clusters(g1)$membership) 
 
 
# Normalize the counts by the sum of the column to get a matrix of error-corrected, 
normalized  
# counts. 
normvals <- processed.dat/colSums(processed.dat)[col(processed.dat)] 
 
# Sort the matrix from highest to lowest number of normalized counts 
sums <- apply(normvals, 1, sum) 
sorter <- order(sums, decreasing=TRUE) 
normvals <- normvals[sorter,] 
 
# plot the data 
 
library(plotrix) 
plot.colors<- 
c("#004586FF","#FF420eFF","#FFD320FF","#579D1CFF","#7e0021ff","#83caffff","#314004ff"
,"#aecf00ff","#4b1f6fff","#ff950eff","#c5000bff","#0084d1ff") 
stackpoly(t(normvals), stack=TRUE, col=plot.colors, xaxlab=colnames(normvals)) 
 
 
 
MHB08-059_check_and_assign_pSYNT 
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#! /usr/bin/perl 
 
# Creative Commons Attribution-Share Alike 3.0 Netherlands License 
# 21 March 2013, . 
# use lib '/home/mhb/Desktop/ensembl/Ensembl/ensembl/modules'; 
 
use warnings; 
use strict; 
use Cwd; 
use Bio::SeqIO; 
 
 
 
if ($#ARGV+1 == 0) {die "Please call with directory name\n"}; 
print "Called with ",$#ARGV+1," parameters which ", 
        @ARGV == 1 ? "was" : "were" ,"\n"; 
 
print ("$_\n") foreach (@ARGV) ; 
 
#The OUTPUT FILE goes here 
my $outfile = "$ARGV[0]" . ".txt"; 
open OUT, ">$outfile" || die "cannot open $outfile\n"; 
 
sleep 1; 
 
my $dir = $ARGV[0]; 
opendir DIR, $dir || die "Cannot open $dir\n"; 
 
 
#Put files in an array 
my @files = grep { !/^\./ && -f "$dir/$_" }readdir DIR; 
print "FILES: @files\n"; 
sleep 1; 
 
my %samplehash; 
my %filehash; 
my %barcodestore; 
  
# using hot pipe 
$|=1; 
 
foreach my $testfile (sort @files) { 
 my $infile = "$dir/$testfile"; 
 #$testfile =~ /(PTGZ_\d{3}.)/; 
 #$testfile =~ /(V11/; 
 my $filename_for_hash = $testfile; 
 $filehash{$filename_for_hash}++; 
 my $seqio_object = Bio::SeqIO->new(-file => "<$infile"); 
 #hash to store barcodes in 
  
 my $missed=0; 
 my $counter=0; 
 
 print "Performing Sample Barcode lookup... $infile\n";  
 while (my $seq_object = $seqio_object->next_seq()) { 
  $counter++; 
  my $test = $seq_object -> seq(); 
  my $id = $seq_object -> display_id() ; 
  my $seq = $seq_object -> seq(); 
  my $length = $seq_object-> length(); 
 
  my $samplecode=0; 
  # match either seed code in front or after the barcode 
  #if ($test =~ /ACAAGTAAGG(.{33})/){  #MATCH 33 bp after the key sequence 
  # $samplecode=$1; 
  #} 
  #elsif ($test =~ /(.{33})GACGGCCAGTG/){ 
  # $samplecode=$1;#put barcode in hash 
  #} 
 
  #or match the barcode 
  #if($test =~ /(GG.{3}AC.{3}GT.{3}CG.{3}TA.{3}CA.{3}TG.{3}GA)/) {  #PTGZ 
  if($test =~ /(.{3}ATC.{2}GAT.{2}AAA.{2}GGT.{2}AAC.{2}TGA.{3})/) { 
#PSYNT 
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   $samplecode=$1; 
   #print "$samplecode\n"; 
  } 
  else { 
   $missed++; 
   #print "Not matched, $missed\n"; 
   next; 
  } 
  # store barcode, then filename, then value 
  $samplehash{$filename_for_hash}{$samplecode}++; 
 
  # also keep a record of all barcodes we've encountered 
  $barcodestore{$samplecode}++; 
 } 
} 
 
 
print "Reporting:\n"; 
 
# print a tab for good alignment in R: IS THIS NEEDED? 
#print OUT "\t"; 
foreach my $barcode (keys %barcodestore) { #code 
  print OUT "$barcode\t"; 
} 
print OUT "\n"; 
 
foreach my $sample (sort keys %samplehash) { #25mar added sort here 
 print OUT "$sample\t"; 
 foreach my $barcode2 (keys %barcodestore) { #code 
  if (exists $samplehash{$sample}->{$barcode2}) { print OUT 
$samplehash{$sample}->{$barcode2} . "\t" } else {print OUT "0\t"}; 
   
 } 
 print OUT "\n"; 
} 
 
exit; 
 
 
make_ucsc_gene_txs.sh. 
tail -n +2 ensembl_hg19_protein_coding_genes_with_ccds_id.txt | cut -f1-6 | sort -u | 
perl -aF/\\t/ -ne '$F[3]--; print join("\t", @F[0,3,4,1,2], ($F[5] == -1 ? "-" : "+")) 
. "\n"' > hg19_genes.bed 
tail -n +2 ensembl_hg19_protein_coding_genes_with_ccds_id.txt | cut -f1-2,6-9 | perl -
aF/\\t/ -ne 'chomp @F; $F[4]--; print join("\t", @F[0,4,5,1,3], ($F[2] == -1 ? "-" : 
"+")) . "\n"' > hg19_txs.bed 
perl -aF/\\t/ -ne 'chomp @F; if ($F[5] eq "+") { print join("\t", $F[0], $F[1], $F[1]+1, 
$F[3], $F[4], $F[5]) . "\n" } else { print join("\t", $F[0], $F[2]-1, $F[2], @F[3..5]) 
. "\n" }' hg19_txs.bed > hg19_tss.bed 
 
gunzip -c hg19_cpg_islands.bed.gz | perl -pe 's/^chr//' | gzip -c > temp.gz 
mv temp.gz hg19_cpg_islands.bed.gz 
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Columbus Script: Off-target integration (% of BFP out of GFP+ cells) 
 
 
Thermo Fisher Scientific, 1kb plus DNA ladder (Cat no. 10787018) 
Analysis Sequence "% green cells"
Input
Image
Stack Processing :
Individual Planes
Flatfield Correction : None
Calculate
Image
(2)
Method : By Formula
Formula : A-B
Channel A : FITC
Channel B : DAPI
Negative Values : Set to Zero
Undefined Values : Set to
Local Average
Output Image : Green only
Find
Cells
Channel : Green only
ROI : None
Method : M
Diameter : 40 µm
Splitting Coefficient : 0.4
Common Threshold : 0.4
Output Population : Green
only cells
Calculate
Image
Method : By Formula
Formula : A+B
Channel A : DAPI
Channel B : FITC
Negative Values : Set to Zero
Undefined Values : Set to
Local Average
Output Image : Blue and
Green
Find
Cells
(3)
Channel : Blue and Green
ROI : None
Method : M
Diameter : 40 µm
Splitting Coefficient : 0.4
Common Threshold : 0.4
Output Population : Total
cells
Define
Results
Method : List of Outputs
Population : Green only
cells
Number of Objects
Apply to All : None
Population : Total cells
Number of Objects
Apply to All : None
Method : Formula Output
Formula : a/b*100
Population Type : Objects
Variable A : Green only cells
- Number of Objects
Variable B : Total cells -
Number of Objects
Output Name : % green only
Population : Green only
cells : None
Population : Total cells :
None
% green cells http://columbus-stv.gsk.com/tmp/6c7428725e6911b336866ced84d4a9...
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